0001014739-24-000052.txt : 20241030 0001014739-24-000052.hdr.sgml : 20241030 20241030160049 ACCESSION NUMBER: 0001014739-24-000052 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Option Care Health, Inc. CENTRAL INDEX KEY: 0001014739 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 050489664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11993 FILM NUMBER: 241410181 BUSINESS ADDRESS: STREET 1: 3000 LAKESIDE DR STREET 2: SUITE 300N CITY: BANNOCKBURN STATE: IL ZIP: 60015 BUSINESS PHONE: 312 940 2443 MAIL ADDRESS: STREET 1: 3000 LAKESIDE DR STREET 2: SUITE 300N CITY: BANNOCKBURN STATE: IL ZIP: 60015 FORMER COMPANY: FORMER CONFORMED NAME: BioScrip, Inc. DATE OF NAME CHANGE: 20050314 FORMER COMPANY: FORMER CONFORMED NAME: MIM CORP DATE OF NAME CHANGE: 19960516 10-Q 1 bios-20240930.htm 10-Q bios-20240930
000101473912/312024Q3FALSExbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbios:pharmacybios:suitebios:segmentxbrli:pure00010147392024-01-012024-09-3000010147392024-10-2800010147392024-09-3000010147392023-12-3100010147392024-07-012024-09-3000010147392023-07-012023-09-3000010147392023-01-012023-09-3000010147392022-12-3100010147392023-09-300001014739us-gaap:PreferredStockMember2022-12-310001014739us-gaap:CommonStockMember2022-12-310001014739us-gaap:TreasuryStockCommonMember2022-12-310001014739us-gaap:AdditionalPaidInCapitalMember2022-12-310001014739us-gaap:RetainedEarningsMember2022-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001014739us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100010147392023-01-012023-03-310001014739us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001014739us-gaap:RetainedEarningsMember2023-01-012023-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001014739us-gaap:PreferredStockMember2023-03-310001014739us-gaap:CommonStockMember2023-03-310001014739us-gaap:TreasuryStockCommonMember2023-03-310001014739us-gaap:AdditionalPaidInCapitalMember2023-03-310001014739us-gaap:RetainedEarningsMember2023-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100010147392023-03-310001014739us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000010147392023-04-012023-06-300001014739us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001014739us-gaap:RetainedEarningsMember2023-04-012023-06-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001014739us-gaap:PreferredStockMember2023-06-300001014739us-gaap:CommonStockMember2023-06-300001014739us-gaap:TreasuryStockCommonMember2023-06-300001014739us-gaap:AdditionalPaidInCapitalMember2023-06-300001014739us-gaap:RetainedEarningsMember2023-06-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000010147392023-06-300001014739us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001014739us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001014739us-gaap:RetainedEarningsMember2023-07-012023-09-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001014739us-gaap:PreferredStockMember2023-09-300001014739us-gaap:CommonStockMember2023-09-300001014739us-gaap:TreasuryStockCommonMember2023-09-300001014739us-gaap:AdditionalPaidInCapitalMember2023-09-300001014739us-gaap:RetainedEarningsMember2023-09-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001014739us-gaap:PreferredStockMember2023-12-310001014739us-gaap:CommonStockMember2023-12-310001014739us-gaap:TreasuryStockCommonMember2023-12-310001014739us-gaap:AdditionalPaidInCapitalMember2023-12-310001014739us-gaap:RetainedEarningsMember2023-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001014739us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100010147392024-01-012024-03-310001014739us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001014739us-gaap:RetainedEarningsMember2024-01-012024-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001014739us-gaap:PreferredStockMember2024-03-310001014739us-gaap:CommonStockMember2024-03-310001014739us-gaap:TreasuryStockCommonMember2024-03-310001014739us-gaap:AdditionalPaidInCapitalMember2024-03-310001014739us-gaap:RetainedEarningsMember2024-03-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100010147392024-03-310001014739us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000010147392024-04-012024-06-300001014739us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001014739us-gaap:RetainedEarningsMember2024-04-012024-06-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001014739us-gaap:PreferredStockMember2024-06-300001014739us-gaap:CommonStockMember2024-06-300001014739us-gaap:TreasuryStockCommonMember2024-06-300001014739us-gaap:AdditionalPaidInCapitalMember2024-06-300001014739us-gaap:RetainedEarningsMember2024-06-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000010147392024-06-300001014739us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001014739us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001014739us-gaap:RetainedEarningsMember2024-07-012024-09-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001014739us-gaap:PreferredStockMember2024-09-300001014739us-gaap:CommonStockMember2024-09-300001014739us-gaap:TreasuryStockCommonMember2024-09-300001014739us-gaap:AdditionalPaidInCapitalMember2024-09-300001014739us-gaap:RetainedEarningsMember2024-09-300001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001014739bios:LegacyHealthSystemsMember2024-09-300001014739us-gaap:CorporateJointVentureMember2024-07-012024-09-300001014739us-gaap:CorporateJointVentureMember2024-01-012024-09-300001014739us-gaap:CorporateJointVentureMember2023-07-012023-09-300001014739us-gaap:CorporateJointVentureMember2023-01-012023-09-300001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberbios:AccountsReceivableBenchmarkMember2024-01-012024-09-300001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberbios:AccountsReceivableBenchmarkMember2023-01-012023-12-310001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2024-07-012024-09-300001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2024-01-012024-09-300001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2023-01-012023-09-300001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2023-07-012023-09-300001014739bios:CommercialCustomerMember2024-07-012024-09-300001014739bios:CommercialCustomerMember2023-07-012023-09-300001014739bios:CommercialCustomerMember2024-01-012024-09-300001014739bios:CommercialCustomerMember2023-01-012023-09-300001014739bios:GovernmentCustomerMember2024-07-012024-09-300001014739bios:GovernmentCustomerMember2023-07-012023-09-300001014739bios:GovernmentCustomerMember2024-01-012024-09-300001014739bios:GovernmentCustomerMember2023-01-012023-09-300001014739bios:PatientCustomerMember2024-07-012024-09-300001014739bios:PatientCustomerMember2023-07-012023-09-300001014739bios:PatientCustomerMember2024-01-012024-09-300001014739bios:PatientCustomerMember2023-01-012023-09-300001014739us-gaap:StateAndLocalJurisdictionMember2024-01-012024-09-300001014739bios:AmedisysIncMember2023-06-262023-06-260001014739us-gaap:StateAndLocalJurisdictionMember2023-09-012023-09-300001014739us-gaap:StateAndLocalJurisdictionMember2024-09-300001014739us-gaap:StockOptionMember2024-07-012024-09-300001014739us-gaap:StockOptionMember2023-07-012023-09-300001014739us-gaap:StockOptionMember2024-01-012024-09-300001014739us-gaap:StockOptionMember2023-01-012023-09-300001014739bios:RestrictedStockAwardMember2024-07-012024-09-300001014739bios:RestrictedStockAwardMember2023-07-012023-09-300001014739bios:RestrictedStockAwardMember2024-01-012024-09-300001014739bios:RestrictedStockAwardMember2023-01-012023-09-300001014739bios:PerformanceStockUnitMember2024-07-012024-09-300001014739bios:PerformanceStockUnitMember2023-07-012023-09-300001014739bios:PerformanceStockUnitMember2024-01-012024-09-300001014739bios:PerformanceStockUnitMember2023-01-012023-09-300001014739bios:AmedisysIncMember2023-01-012023-09-300001014739bios:InfusionPumpsMember2024-09-300001014739bios:InfusionPumpsMember2023-12-310001014739bios:EquipmentFurnitureAndOtherMember2024-09-300001014739bios:EquipmentFurnitureAndOtherMember2023-12-310001014739us-gaap:LeaseholdImprovementsMember2024-09-300001014739us-gaap:LeaseholdImprovementsMember2023-12-310001014739us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-300001014739us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001014739us-gaap:AssetUnderConstructionMember2024-09-300001014739us-gaap:AssetUnderConstructionMember2023-12-310001014739us-gaap:CostOfSalesMember2024-07-012024-09-300001014739us-gaap:CostOfSalesMember2023-07-012023-09-300001014739us-gaap:CostOfSalesMember2024-01-012024-09-300001014739us-gaap:CostOfSalesMember2023-01-012023-09-300001014739us-gaap:OperatingExpenseMember2024-07-012024-09-300001014739us-gaap:OperatingExpenseMember2023-07-012023-09-300001014739us-gaap:OperatingExpenseMember2024-01-012024-09-300001014739us-gaap:OperatingExpenseMember2023-01-012023-09-300001014739us-gaap:CustomerListsMember2024-09-300001014739us-gaap:CustomerListsMember2023-12-310001014739us-gaap:TrademarksAndTradeNamesMember2024-09-300001014739us-gaap:TrademarksAndTradeNamesMember2023-12-310001014739us-gaap:OtherIntangibleAssetsMember2024-09-300001014739us-gaap:OtherIntangibleAssetsMember2023-12-310001014739us-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2024-09-300001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-09-300001014739bios:SecondLienTermLoanMemberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-12-310001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2023-12-310001014739bios:SecondLienTermLoanMemberus-gaap:SeniorNotesMember2023-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-05-072024-05-070001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-05-082024-05-080001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-05-080001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-07-012024-09-300001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-01-012024-09-300001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-07-012023-09-300001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-01-012023-09-300001014739us-gaap:JuniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-12-310001014739us-gaap:JuniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:JuniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-07-012024-09-300001014739us-gaap:JuniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-01-012024-09-300001014739us-gaap:JuniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-01-012023-09-300001014739us-gaap:JuniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-07-012023-09-300001014739us-gaap:SeniorLienMemberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-01-012024-09-300001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-01-012024-09-300001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-05-080001014739us-gaap:FairValueInputsLevel1Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:FairValueInputsLevel2Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:FairValueInputsLevel3Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:SeniorNotesMember2024-09-300001014739us-gaap:FairValueInputsLevel1Memberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:FairValueInputsLevel3Memberus-gaap:SeniorNotesMember2024-09-300001014739us-gaap:FairValueInputsLevel1Member2024-09-300001014739us-gaap:FairValueInputsLevel2Member2024-09-300001014739us-gaap:FairValueInputsLevel3Member2024-09-300001014739bios:SecondLienCreditAgreementMemberMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-12-070001014739bios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2024-09-300001014739bios:SecondLienCreditAgreementMemberMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2024-09-300001014739bios:FirstLienTermLoanMemberus-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-10-310001014739bios:FirstLienTermLoanMemberus-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-10-012021-10-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001014739us-gaap:InterestRateCapMember2024-07-012024-09-300001014739us-gaap:InterestRateCapMember2023-07-012023-09-300001014739us-gaap:InterestRateCapMember2024-01-012024-09-300001014739us-gaap:InterestRateCapMember2023-01-012023-09-300001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2024-07-012024-09-300001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2023-07-012023-09-300001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2024-01-012024-09-300001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2023-01-012023-09-300001014739bios:A2018PlanMember2021-05-310001014739bios:A2018PlanMember2024-05-012024-05-3100010147392024-05-310001014739bios:HCIIncentiveUnitsMemberbios:A2018PlanMember2024-07-012024-09-300001014739bios:HCIIncentiveUnitsMemberbios:A2018PlanMember2024-01-012024-09-300001014739bios:HCIIncentiveUnitsMemberbios:A2018PlanMember2023-07-012023-09-300001014739bios:HCIIncentiveUnitsMemberbios:A2018PlanMember2023-01-012023-09-300001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2024-07-012024-09-300001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2024-01-012024-09-300001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2023-01-012023-09-300001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2023-07-012023-09-300001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2023-12-310001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2024-09-300001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2024-01-012024-09-300001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2024-07-012024-09-300001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2023-07-012023-09-300001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2023-01-012023-09-300001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2024-09-300001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2023-12-310001014739bios:CommonStockRepurchaseProgramMember2024-09-300001014739us-gaap:CommonStockMember2024-01-012024-03-310001014739us-gaap:CommonStockMember2023-01-012023-03-310001014739us-gaap:CommonStockMember2024-04-012024-06-300001014739us-gaap:CommonStockMember2023-04-012023-06-300001014739us-gaap:CommonStockMember2024-07-012024-09-300001014739us-gaap:CommonStockMember2023-07-012023-09-300001014739us-gaap:CorporateJointVentureMember2024-09-300001014739us-gaap:CorporateJointVentureMember2023-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from     to             
Commission file number: 001-11993
OPCH_Logo.jpg
OPTION CARE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware05-0489664
(State of incorporation)(I.R.S. Employer Identification No.)
3000 Lakeside Dr.Suite 300N, Bannockburn, IL60015
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
312-940-2443
Securities registered pursuant to Section 12(b) of the Act:
Title of each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareOPCHNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑     No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☑     Accelerated filer ☐     Non-accelerated filer ☐      Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐     No ☑  

On October 28, 2024, there were 170,181,238 shares of the registrant’s Common Stock outstanding.







1


TABLE OF CONTENTS
2

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to "Option Care Health," the “Company,” “we,” “us” and “our” refer to Option Care Health, Inc. and its consolidated subsidiaries.
Forward-Looking Statements
This Form 10-Q includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning our expectations regarding industry and macroeconomic trends and our operating performance. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. If any of these risks materialize, or if any of our assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2023 (our “Form 10-K”) filed with the U.S. Securities and Exchange Commission (the “SEC”). Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this Form 10-Q. Any forward-looking statement made by us in this Form 10-Q speaks only as of the date hereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
3
PART I
FINANCIAL INFORMATION
Item 1.     Financial Statements
4
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)
September 30, 2024December 31, 2023
(unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$483,026 $343,849 
Accounts receivable, net428,951 377,658 
Inventories310,599 274,004 
Prepaid expenses and other current assets98,798 98,744 
Total current assets1,321,374 1,094,255 
 
NONCURRENT ASSETS:
Property and equipment, net125,911 120,630 
Operating lease right-of-use asset89,210 84,159 
Intangible assets, net17,768 20,092 
Referral sources, net291,839 315,304 
Goodwill1,540,246 1,540,246 
Other noncurrent assets41,379 42,349 
Total noncurrent assets2,106,353 2,122,780 
TOTAL ASSETS $3,427,727 $3,217,035 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
CURRENT LIABILITIES:  
Accounts payable$591,971 $426,513 
Accrued compensation and employee benefits60,835 92,508 
Accrued expenses and other current liabilities81,893 75,010 
Current portion of operating lease liability22,013 18,278 
Current portion of long-term debt6,512 6,000 
Total current liabilities763,224 618,309 
 
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion1,105,106 1,056,650 
Operating lease liability, net of current portion87,879 85,484 
Deferred income taxes45,008 34,920 
Other noncurrent liabilities279 — 
Total noncurrent liabilities1,238,272 1,177,054 
Total liabilities2,001,496 1,795,363 
 
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of September 30, 2024 and December 31, 2023
— — 
Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,793,536 shares issued and 170,146,331 shares outstanding as of September 30, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December 31, 2023
18 18 
Treasury stock; 13,647,205 and 8,330,022 shares outstanding, at cost, as of September 30, 2024 and December 31, 2023, respectively
(416,552)(255,107)
Paid-in capital1,224,059 1,204,270 
Retained earnings609,203 457,513 
Accumulated other comprehensive income9,503 14,978 
Total stockholders’ equity1,426,231 1,421,672 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$3,427,727 $3,217,035 
The notes to unaudited condensed consolidated financial statements are an integral part of these statements.
5
OPTION CARE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
NET REVENUE$1,278,546 $1,093,014 $3,651,784 $3,177,934 
COST OF REVENUE1,021,797 838,748 2,907,170 2,443,834 
GROSS PROFIT256,749 254,266 744,614 734,100 
 
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses156,999 158,214 465,524 459,644 
Depreciation and amortization expense14,659 15,005 44,294 44,417 
Total operating expenses171,658 173,219 509,818 504,061 
OPERATING INCOME85,091 81,047 234,796 230,039 
 
OTHER INCOME (EXPENSE):
Interest expense, net(12,345)(11,786)(38,150)(38,816)
Equity in earnings of joint ventures1,391 1,273 3,921 4,107 
Other, net(583)(449)1,983 84,487 
Total other (expense) income(11,537)(10,962)(32,246)49,778 
 
INCOME BEFORE INCOME TAXES73,554 70,085 202,550 279,817 
INCOME TAX EXPENSE19,698 13,783 50,860 69,904 
NET INCOME$53,856 $56,302 $151,690 $209,913 
 
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit of $1,998, $8, $1,785 and $57, respectively
$(6,127)$53 $(5,475)$(99)
OTHER COMPREHENSIVE (LOSS) INCOME (6,127)53 (5,475)(99)
NET COMPREHENSIVE INCOME $47,729 $56,355 $146,215 $209,814 
 
EARNINGS PER COMMON SHARE:
Earnings per share, basic$0.32 $0.31 $0.88 $1.17 
Earnings per share, diluted$0.31 $0.31 $0.87 $1.16 
 
Weighted average common shares outstanding, basic170,636 178,826 172,490 179,956 
Weighted average common shares outstanding, diluted171,941 180,528 173,848 181,286 
The notes to unaudited condensed consolidated financial statements are an integral part of these statements.
6
OPTION CARE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
Nine Months Ended September 30,
 20242023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income$151,690 $209,913 
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization expense46,029 46,423 
Non-cash operating lease costs17,892 14,610 
Deferred income taxes - net10,088 11,767 
Loss on extinguishment of debt377 — 
Amortization of deferred financing costs3,465 3,312 
Equity in earnings of joint ventures(3,921)(4,107)
Stock-based incentive compensation expense27,620 22,908 
Capital distribution from equity method investments1,250 4,000 
Other adjustments(1,845)1,769 
Changes in operating assets and liabilities:
Accounts receivable, net(51,293)(5,075)
Inventories(36,595)(28,362)
Prepaid expenses and other current assets(3,175)3,197 
Accounts payable164,754 50,726 
Accrued compensation and employee benefits(31,673)4,197 
Accrued expenses and other current liabilities5,560 9,829 
Operating lease liabilities(16,833)(13,019)
Other noncurrent assets and liabilities3,880 (11,762)
Net cash provided by operating activities287,270 320,326 
 
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment(25,266)(21,981)
Business acquisitions, net of cash acquired— (12,855)
Other investing activities — (5,889)
Net cash used in investing activities(25,266)(40,725)
 
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock-based compensation tax withholdings(11,235)(1,940)
Repayments of debt principal(4,756)(4,500)
Proceeds from issuance of debt49,959 — 
Deferred financing costs(77)— 
Purchase of company stock(160,122)(175,108)
Other financing activities3,404 (5,750)
Net cash used in financing activities(122,827)(187,298)
NET INCREASE IN CASH AND CASH EQUIVALENTS139,177 92,303 
Cash and cash equivalents - beginning of the period343,849 294,186 
CASH AND CASH EQUIVALENTS - END OF PERIOD$483,026 $386,489 
 
Supplemental disclosure of cash flow information:
Cash paid for interest$48,666 $46,377 
Cash paid for income taxes$45,258 $53,699 
Cash paid for operating leases$21,861 $20,272 
The notes to unaudited condensed consolidated financial statements are an integral part of these statements.
7
OPTION CARE HEALTH, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(IN THOUSANDS)
Preferred StockCommon StockTreasury StockPaid-in CapitalRetained Earnings Accumulated Other Comprehensive Income (Loss)Total Stockholders’ Equity
Balance - December 31, 2022$— $18 $(2,403)$1,176,906 $190,423 $21,159 $1,386,103 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (1,902)— — (1,902)
Stock-based incentive compensation— — — 5,988 — — 5,988 
Purchase of company stock— — (75,735)— — — (75,735)
Net income— — — — 39,208 — 39,208 
Other comprehensive loss— — — — — (3,443)(3,443)
Balance - March 31, 2023$— $18 $(78,138)$1,180,992 $229,631 $17,716 $1,350,219 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (247)— — (247)
Stock-based incentive compensation— — — 7,685 — — 7,685 
Purchase of company stock, and related tax effects— — 32 — — — 32 
Net income— — — — 114,403 — 114,403 
Other comprehensive income— — — — — 3,291 3,291 
Balance - June 30, 2023$— $18 $(78,106)$1,188,430 $344,034 $21,007 $1,475,383 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — 209 — — 209 
Stock-based incentive compensation— — — 9,235 — — 9,235 
Purchase of company stock, and related tax effects— — (101,099)— — — (101,099)
Net income— — — — 56,302 — 56,302 
Other comprehensive income— — — — — 53 53 
Balance - September 30, 2023$— $18 $(179,205)$1,197,874 $400,336 $21,060 $1,440,083 
 
Balance - December 31, 2023$— $18 $(255,107)$1,204,270 $457,513 $14,978 $1,421,672 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (8,182)— — (8,182)
Stock-based incentive compensation— — — 9,605 — — 9,605 
Purchase of company stock, and related tax effects— — (40,289)— — — (40,289)
Net income— — — — 44,791 — 44,791 
Other comprehensive income— — — — — 1,551 1,551 
Balance - March 31, 2024$— $18 $(295,396)$1,205,693 $502,304 $16,529 $1,429,148 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — 1,299 — — 1,299 
Stock-based incentive compensation— — — 7,608 — — 7,608 
Purchase of company stock, and related tax effects— — (78,768)— — — (78,768)
Net income— — — — 53,043 — 53,043 
Other comprehensive loss— — — — — (899)(899)
Balance - June 30, 2024$— $18 $(374,164)$1,214,600 $555,347 $15,630 $1,411,431 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (948)— — (948)
Stock-based incentive compensation— — — 10,407 — — 10,407 
Purchase of company stock, and related tax effects— — (42,388)— — — (42,388)
Net income— — — — 53,856 — 53,856 
Other comprehensive loss— — — — — (6,127)(6,127)
Balance - September 30, 2024$— $18 $(416,552)$1,224,059 $609,203 $9,503 $1,426,231 
The notes to unaudited condensed consolidated financial statements are an integral part of these statements.
8
OPTION CARE HEALTH, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
Corporate Organization and Business — Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 92 full service pharmacies and 93 stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company’s stock is listed on the Nasdaq Global Select Market as of September 30, 2024.
Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.
Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.
9
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of September 30, 2024, cash equivalents consisted of money market funds.
Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $45.9 million and $52.0 million as of September 30, 2024 and December 31, 2023, respectively.
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the balance of the investments was $23.6 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $3.9 million for the three and nine months ended September 30, 2024, respectively. The Company’s proportionate share of earnings was $1.3 million and $4.1 million for the three and nine months ended September 30, 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively. See Note 15, Related-Party Transactions, for discussion of related-party transactions with these investees.
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% for the three and nine months ended September 30, 2024. Revenue related to the Company’s largest payer was approximately 14% for the three and nine months ended September 30, 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.
For the three and nine months ended September 30, 2024, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2023, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of September 30, 2024 and December 31, 2023, approximately 10% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the three and nine months ended September 30, 2024, approximately 68% and 67%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. For the three and nine months ended September 30, 2023, approximately 73% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery, losses in revenue or decreased gross profit dollars, which could adversely affect the Company’s financial condition or operating results.
10
3. REVENUE
The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Commercial payers$1,109,971 $957,601 $3,160,490 $2,765,513 
Government payers147,005 124,122 424,033 370,648 
Patients21,570 11,291 67,261 41,773 
Net revenue$1,278,546 $1,093,014 $3,651,784 $3,177,934 
4. INCOME TAXES
During the three and nine months ended September 30, 2024, the Company recorded tax expense of $19.7 million and $50.9 million, respectively, which represents an effective tax rate of 26.8% and 25.1%, respectively. The variance in the Company’s effective tax rate of 26.8% and 25.1% for the three and nine months ended September 30, 2024, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the nine months ended September 30, 2024, the Company released $2.2 million of state valuation allowance. On June 26, 2023, the Company entered into an agreement to terminate the merger agreement (the “Mutual Termination Agreement”) with Amedisys, Inc. (“Amedisys”). Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys (“Termination Fee”). During the three months ended September 30, 2023, the Company recorded tax expense of $13.8 million. During the nine months ended September 30, 2023, the Company recorded tax expense of $69.9 million, which includes $22.1 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. The tax expense for the three and nine months ended September 30, 2023 represents an effective tax rate of 19.7% and 25.0%, respectively. The variance in the Company’s effective tax rate of 19.7% and 25.0% for the three and nine months ended September 30, 2023, respectively, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 26.8% for the three months ended September 30, 2024, compared to 19.7% for the three months ended September 30, 2023 was primarily due to change in state valuation allowance. In September 2023, the Company released $5.8 million of state valuation allowance.
The Company maintains a valuation allowance of $4.2 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.
The Company’s tax expense of $19.7 million and $50.9 million for the three and nine months ended September 30, 2024, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense. The Company’s tax expense of $13.8 million and $69.9 million for the three and nine months ended September 30, 2023, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.
The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (“Code”) Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses.
11
5. EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three and nine months ended September 30, 2024 and 2023 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock option awards779,876 984,567 855,323 1,180,376 
Restricted stock awards324,877 16,564 365,835 569,831 
Performance stock unit awards— — 257,735 288,680 
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net income (1)$53,856 $56,302 $151,690 $209,913 
Denominator:
Weighted average number of common shares outstanding170,636 178,826 172,490 179,956 
Earnings per common share:
Earnings per common share, basic$0.32 $0.31 $0.88 $1.17 
(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Numerator:
Net income (1)$53,856 $56,302 $151,690 $209,913 
Denominator:
Weighted average number of common shares outstanding170,636 178,826 172,490 179,956 
Effect of dilutive securities1,305 1,702 1,358 1,330 
Weighted average number of common shares outstanding, diluted171,941 180,528 173,848 181,286 
Earnings per common share:
Earnings per common share, diluted$0.31 $0.31 $0.87 $1.16 
(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.
12
6. LEASES
During the three and nine months ended September 30, 2024, the Company incurred operating lease expenses of $8.6 million and $25.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2023, the Company incurred operating lease expenses of $7.8 million and $22.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of September 30, 2024, the weighted-average remaining lease term was 6.5 years and the weighted-average discount rate was 6.49%.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2024$7,464 
202528,646 
202625,880 
202720,554 
202813,517 
Thereafter43,813 
Total lease payments139,874 
Less: interest(29,982)
Present value of lease liabilities$109,892 
During the nine months ended September 30, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $23.0 million related to increases in the operating lease right-of-use assets and operating lease liabilities. During the nine months ended September 30, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $26.1 million related to increases in the operating lease right-of-use assets and operating lease liabilities. As of September 30, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.
13
7. PROPERTY AND EQUIPMENT
Property and equipment was as follows as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Infusion pumps$36,476 $36,943 
Equipment, furniture and other30,124 23,593 
Leasehold improvements117,827 99,725 
Computer software, purchased and internally developed52,513 50,572 
Assets under development26,007 33,668 
262,947 244,501 
Less: accumulated depreciation(137,036)(123,871)
Property and equipment, net$125,911 $120,630 
Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Depreciation expense in cost of revenue$568 $616 $1,735 $2,006 
Depreciation expense in operating expenses6,063 6,365 18,485 18,665 
Total depreciation expense$6,631 $6,981 $20,220 $20,671 
8. GOODWILL AND OTHER INTANGIBLE ASSETS
There was no change in the carrying amount of goodwill for the three and nine months ended September 30, 2024.
The carrying amount and accumulated amortization of intangible assets consist of the following as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Gross intangible assets:
Referral sources$514,388 $514,388 
Trademarks/names39,136 39,136 
Other amortizable intangible assets985 995 
Total gross intangible assets554,509 554,519 
Accumulated amortization:
Referral sources(222,549)(199,084)
Trademarks/names(21,874)(19,698)
Other amortizable intangible assets(479)(341)
Total accumulated amortization(244,902)(219,123)
Total intangible assets, net$309,607 $335,396 
Amortization expense for intangible assets was $8.6 million and $25.8 million for the three and nine months ended September 30, 2024, respectively. Amortization expense for intangible assets was $8.6 million and $25.6 million for the three and nine months ended September 30, 2023, respectively.
14
9. INDEBTEDNESS
Long-term debt consisted of the following as of September 30, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan633,244 (5,885)(8,030)619,329 
Senior Notes500,000 — (7,711)492,289 
$1,133,244 $(5,885)$(15,741)1,111,618 
Less: current portion(6,512)
Total long-term debt$1,105,106 
Long-term debt consisted of the following as of December 31, 2023 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan588,000 (6,974)(9,678)571,348 
Senior Notes500,000 — (8,698)491,302 
$1,088,000 $(6,974)$(18,376)1,062,650 
Less: current portion(6,000)
Total long-term debt$1,056,650 
On May 8, 2024, the Company entered into the third amendment to the amended and restated First Lien Credit Agreement (the “Third Amendment”). The Third Amendment, among other things, reduces the interest rate on the First Lien Term Loan from Term Secured Overnight Financing Rate (“SOFR”) (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25%, increases borrowings by $50.0 million, and removes the credit spread adjustment with respect to such First Lien Term Loan.
The interest rate on the First Lien Term Loan was 7.50% and 8.21% as of September 30, 2024 and December 31, 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.56% and 7.84% for the three and nine months ended September 30, 2024, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 8.11% and 7.71% for the three and nine months ended September 30, 2023, respectively. The interest rate on the Senior Notes was 4.375% as of September 30, 2024 and December 31, 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three and nine months ended September 30, 2024. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three and nine months ended September 30, 2023.
The Company assessed whether the repayment of the First Lien Term Loan indebtedness resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the First Lien Term Loan and Senior Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $0.4 million of the First Lien Term Loan was extinguished. The First Lien Term Loan had insubstantial modifications for lenders that participated in both debt instruments, which resulted in a cash inflow from financing activities of $50.0 million in the unaudited condensed consolidated statements of cash flows. The Company incurred $1.6 million in fees, of which $0.1 million was capitalized, relative to the First Lien Term Loan and an immaterial amount of the total fees incurred was netted against the $50.0 million of debt proceeds as financing activities within the unaudited condensed consolidated statements of cash flows.
The Company recognized a loss on extinguishment of debt of $0.4 million included in the line entitled “Other, net” in the unaudited condensed consolidated statements of comprehensive income.
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2024$1,628 
20256,512 
20266,512 
20276,512 
2028612,080 
Thereafter500,000 
Total$1,133,244 
During the three and nine months ended September 30, 2024 and 2023, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 10, Derivative Instruments, for further discussion.
The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2024 (in thousands):
Financial Instrument
Carrying Value as of September 30, 2024
Markets for Identical Item (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
First Lien Term Loan$619,329 $— $634,827 $— 
Senior Notes492,289 — 475,000 — 
Total debt instruments$1,111,618 $— $1,109,827 $— 
See Note 11, Fair Value Measurements, for further discussion.
On December 7, 2023, the Company entered into the second amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (the “Second Amendment”). The Second Amendment, among other things, provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of $400.0 million (the “Revolver Facility”), pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company. As of September 30, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million.
15
10. DERIVATIVE INSTRUMENTS
The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.
In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a 5-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.
The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionSeptember 30, 2024December 31, 2023
Interest rate cap designated as cash flow hedgePrepaid expenses and other current assets$7,223 $9,746 
Interest rate cap designated as cash flow hedgeOther noncurrent assets5,446 10,183 
Total derivative assets$12,669 $19,929 
The (loss) gain associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
Derivative2024202320242023
Interest rate cap designated as cash flow hedge$(8,125)$45 $(7,260)$(156)
The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
DerivativeIncome Statement Caption2024202320242023
Interest rate cap designated as cash flow hedgeInterest expense, net$3,056 $2,931 $9,005 $8,002 
16
11. FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:
•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).
There were no other material assets or liabilities measured at fair value at September 30, 2024 and December 31, 2023.
12. COMMITMENTS AND CONTINGENCIES
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.
The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.
However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
17
13. STOCK-BASED INCENTIVE COMPENSATION
Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip, Inc. (“BioScrip”) stockholders on May 3, 2018 and amended and restated on May 19, 2021 and May 15, 2024, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. As of May 2021, a total of 9,101,734 shares of common stock were authorized for issuance under the 2018 Plan. In May 2024, an additional 4,000,000 shares were authorized for issuance under the 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of September 30, 2024 and 2023. During the three and nine months ended September 30, 2024, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $10.4 million and $27.6 million, respectively. During the three and nine months ended September 30, 2023, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $9.2 million and $22.9 million, respectively.
14. STOCKHOLDERS’ EQUITY
2017 Warrants — During the three and nine months ended September 30, 2024, warrant holders did not elect to exercise any warrants to purchase shares of common stock. During the three and nine months ended September 30, 2023, warrant holders elected to exercise 188,350 warrants to purchase shares of common stock. As of September 30, 2024 and December 31, 2023, the remaining warrant holders are entitled to purchase 51,838 shares of common stock.
2015 Warrants — During the three and nine months ended September 30, 2024, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. During the three and nine months ended September 30, 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. As of September 30, 2024 and December 31, 2023, the remaining warrant holders are entitled to purchase 11,775 and 13,888 shares of common stock, respectively.
Share Repurchase Program — The Company’s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.
During the three and nine months ended September 30, 2024, the Company purchased 1,399,674 and 5,317,183 shares of common stock for an average share price of $29.97 and $30.09, totaling $41.9 million and $160.0 million, respectively. During the three and nine months ended September 30, 2023, the Company purchased 2,913,520 and 5,388,686 shares of common stock for an average share price of $34.32 and $32.48, totaling $100.0 million and $175.0 million, respectively. All repurchased shares became treasury stock. As of September 30, 2024, the Company is authorized to repurchase up to a remaining $90.0 million of common stock of the Company.
Shares Outstanding — The following table shows the Company’s changes in shares of common stock for the three and nine months ended September 30, 2024 and 2023 (in thousands):
20242023
Balance, beginning of the year174,576 181,958 
Equity award issuances492 274 
Share repurchases(1,252)(2,475)
Balance March 31,173,816 179,757 
Equity award issuances261 114 
Share repurchases(2,666)— 
Balance June 30,171,411 179,871 
Equity award issuances135 172 
Share repurchases(1,400)(2,914)
Balance September 30,170,146 177,129 
18
15. RELATED-PARTY TRANSACTIONS
Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.6 million and $4.5 million for the three and nine months ended September 30, 2024, respectively. The Company recorded management fee income of $1.3 million and $3.9 million for the three and nine months ended September 30, 2023, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively.
The Company had amounts due from its joint ventures of $0.6 million and due to its joint ventures of $0.8 million as of September 30, 2024. The Company had amounts due from its joint ventures of $0.1 million and due to its joint ventures of $0.5 million as of December 31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.
19
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Unless the context requires otherwise, references in this report to "Option Care Health," the “Company,” “we,” “us” and “our” refer to Option Care Health, Inc. and its consolidated subsidiaries. Management’s discussion and analysis of financial condition and results of operations (“MD&A”) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial condition. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and the related notes thereto included in Item 1 of Part I of this Quarterly Report on Form 10-Q (this “Form 10-Q”). Certain statements in this Item 2 of Part I of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2023 (our “Form 10-K”), may cause our actual results, financial position, and cash and cash equivalents generated from operations to differ materially from these forward-looking statements.
Business Overview
Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 185 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Our services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, and dietitians work with the physician to develop a plan of care suited to each patient’s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions.
Update on the Impact of the Change Healthcare Cybersecurity Incident
As previously disclosed, Change Healthcare, a subsidiary of UnitedHealth Group, experienced an incident on February 21, 2024, in which a cybersecurity threat actor gained access to some of its information technology systems (“Change Healthcare Cybersecurity Incident”). Since the time of the system disruption, Option Care Health has worked continuously to find alternative processes to help maintain patient care and overall operations.
As of September 30, 2024, the Company has not identified any compromise or unauthorized access of its systems or networks due to this third party incident. As of the end of the second quarter of 2024, the Company reconnected to key applications maintained by Change Healthcare and as of the end of the third quarter of 2024, the Company has substantially recovered operationally. The Company continues to work through accumulated patient payment obligations and to establish full recovery from the Change Healthcare Cybersecurity Incident.
During the third quarter of 2024, the Company did not experience a material financial impact from the Change Healthcare Cybersecurity Incident on the financial results as reported. The Company continues to maintain strong liquidity and, having resumed submission of a majority of claims to payers, has determined that the Change Healthcare Cybersecurity Incident is not reasonably likely to materially impact the Company, including its business operations, financial condition or results of operations.
20
Composition of Results of Operations
The following results of operations include the accounts of Option Care Health and our subsidiaries for the three and nine months ended September 30, 2024 and 2023.
Gross Profit
Gross profit represents our net revenue less cost of revenue.
Net Revenue. Infusion and related health care services revenue is reported at the estimated net realizable amounts from third-party payers and patients for goods sold and services rendered. When pharmaceuticals are provided to a patient, revenue is recognized upon delivery of the goods. When nursing services are provided, revenue is recognized when the services are rendered.
Due to the nature of the health care industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded.
Cost of Revenue. Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients. In addition to product costs, cost of revenue includes warehousing costs, purchasing costs, depreciation expense relating to revenue-generating assets, such as infusion pumps, shipping and handling costs, and wages and related costs for the pharmacists, nurses, and all other employees and contracted workers directly involved in providing service to the patient.
The Company receives volume-based rebates and prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These payments are recorded as a reduction of inventory and are accounted for as a reduction of cost of revenue when the related inventory is sold.
Operating Costs and Expenses
Selling, General and Administrative Expenses. Selling, general and administrative expenses consist principally of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.
Depreciation and Amortization Expense. Depreciation within this caption relates to fixed assets and amortization relates to intangibles. Depreciation of revenue-generating assets, such as infusion pumps, is included in cost of revenue.
Other Income (Expense)
Interest Expense, Net. Interest expense consists principally of interest and fee payments on the Company’s outstanding borrowings under the First Lien Term Loan, Revolver Facility, Senior Notes, amortization of discount and deferred financing fees, payments associated with the interest rate cap, and interest income earned on cash and cash equivalents. Refer to the “Liquidity and Capital Resources” section below for further discussion of these outstanding borrowings.
Equity in Earnings of Joint Ventures. Equity in earnings of joint ventures consists of our proportionate share of equity earnings or losses from equity investments in two infusion joint ventures with health systems.
Other, Net. Other income (expense) primarily includes activity related to non-operating income and expenses.
Income Tax Expense. The Company is subject to taxation in the United States and various states. The Company’s income tax expense is reflective of the current federal and state tax rates.
Change in Unrealized (Loss) Gain on Cash Flow Hedge, Net of Income Tax Benefit. Change in unrealized (loss) gain on cash flow hedge, net of income tax benefit, consists of the (loss) gain associated with the changes in the fair value of derivatives designated as hedging instruments related to the interest rate cap hedge, net of income taxes.
21
Results of Operations
The following table presents Option Care Health’s consolidated results of operations for the three and nine months ended September 30, 2024 and 2023 (in thousands, except for percentages):
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Amount% of RevenueAmount% of RevenueAmount% of RevenueAmount% of Revenue
NET REVENUE$1,278,546 100.0 %$1,093,014 100.0 %$3,651,784 100.0 %$3,177,934 100.0 %
COST OF REVENUE1,021,797 79.9 %838,748 76.7 %2,907,170 79.6 %2,443,834 76.9 %
GROSS PROFIT256,749 20.1 %254,266 23.3 %744,614 20.4 %734,100 23.1 %
 
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses156,999 12.3 %158,214 14.5 %465,524 12.7 %459,644 14.5 %
Depreciation and amortization expense14,659 1.1 %15,005 1.4 %44,294 1.2 %44,417 1.4 %
Total operating expenses171,658 13.4 %173,219 15.8 %509,818 14.0 %504,061 15.9 %
OPERATING INCOME85,091 6.7 %81,047 7.4 %234,796 6.4 %230,039 7.2 %
 
OTHER INCOME (EXPENSE):
Interest expense, net(12,345)(1.0)%(11,786)(1.1)%(38,150)(1.0)%(38,816)(1.2)%
Equity in earnings of joint ventures1,391 0.1 %1,273 0.1 %3,921 0.1 %4,107 0.1 %
Other, net(583)— %(449)— %1,983 0.1 %84,487 2.7 %
Total other (expense) income(11,537)(0.9)%(10,962)(1.0)%(32,246)(0.9)%49,778 1.6 %
 
INCOME BEFORE INCOME TAXES73,554 5.8 %70,085 6.4 %202,550 5.5 %279,817 8.8 %
INCOME TAX EXPENSE19,698 1.5 %13,783 1.3 %50,860 1.4 %69,904 2.2 %
NET INCOME$53,856 4.2 %$56,302 5.2 %$151,690 4.2 %$209,913 6.6 %
 
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit of $1,998, $8, $1,785 and $57, respectively(6,127)(0.5)%53 — %(5,475)(0.1)%(99)— %
OTHER COMPREHENSIVE (LOSS) INCOME (6,127)(0.5)%53 — %(5,475)(0.1)%(99)— %
NET COMPREHENSIVE INCOME $47,729 3.7 %$56,355 5.2 %$146,215 4.0 %$209,814 6.6 %
22
Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023
The following tables present selected consolidated comparative results of operations from Option Care Health’s unaudited condensed consolidated financial statements for the three months ended September 30, 2024 and 2023.
Gross Profit
 Three Months Ended September 30,
20242023Variance
(in thousands, except for percentages)
Net revenue$1,278,546 $1,093,014 $185,532 17.0 %
Cost of revenue1,021,797 838,748 183,049 21.8 %
Gross profit$256,749 $254,266 $2,483 1.0 %
Gross profit margin20.1 %23.3 %
The increase in net revenue was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that had single-digit growth relative to the prior year while chronic revenue grew in the low-twenties. The increase in cost of revenue was primarily driven by the growth in revenue and therapy mix, as well as the comparable impact of certain temporary favorable therapy procurement dynamics in the prior year. The decrease in gross profit margin was primarily due to the launch of certain new higher cost therapies included within chronic growth (including rare and orphan therapies) and to the same comparable impact of certain temporary favorable procurement dynamics in the prior year that did not continue into 2024. Future revenue and gross profit may be impacted by the supply chain disruption in the availability of certain IV fluids in the near term. Additionally, management anticipates that 2025 gross profit will be negatively impacted due to a manufacturer’s proposed significant reduction in the spread at which the Company procures a key therapy relative to drug reference prices beginning in early 2025.
Operating Expenses
 Three Months Ended September 30,
 20242023Variance
(in thousands, except for percentages)
Selling, general and administrative expenses$156,999 $158,214 $(1,215)(0.8)%
Depreciation and amortization expense14,659 15,005 (346)(2.3)%
Total operating expenses$171,658 $173,219 $(1,561)(0.9)%
Selling, general and administrative expenses during the three months ended September 30, 2024 was relatively consistent with prior year; however, these expenses have declined as a percentage of revenue to 12.3% for the three months ended September 30, 2024 compared to 14.5% for the three months ended September 30, 2023, due to the Company’s focus on leveraging existing infrastructure to control spending.
23
Other Income (Expense)
 Three Months Ended September 30,
 20242023Variance
(in thousands, except for percentages)
Interest expense, net$(12,345)$(11,786)$(559)4.7 %
Equity in earnings of joint ventures1,391 1,273 118 9.3 %
Other, net(583)(449)(134)29.8 %
Total other (expense) income$(11,537)$(10,962)$(575)5.2 %
The increase in interest expense, net during the three months ended September 30, 2024 was primarily attributable to an increase in the Company’s First Lien Term Loan principal balance, compared to the three months ended September 30, 2023. See Note 9, Indebtedness, of the unaudited condensed consolidated financial statements for further information.
Income Tax Expense
 Three Months Ended September 30,
 20242023Variance
(in thousands, except for percentages)
Income tax expense$19,698 $13,783 $5,915 42.9 %
The Company recorded income tax expense of $19.7 million and $13.8 million for the three months ended September 30, 2024 and 2023, respectively, which represents an effective tax rate of 26.8% and 19.7%, respectively. The variance in the Company’s effective tax rate of 26.8% for the three months ended September 30, 2024, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 19.7% for the three months ended September 30, 2023, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 26.8% for the three months ended September 30, 2024, compared to 19.7% for the three months ended September 30, 2023 was primarily due to change in state valuation allowance. In September 2023, the Company released $5.8 million of state valuation allowance.
24
Net Income and Other Comprehensive Income (Loss)
 Three Months Ended September 30,
 20242023Variance
(in thousands, except for percentages)
Net income$53,856 $56,302 $(2,446)(4.3)%
Other comprehensive (loss) income, net of tax:
Changes in unrealized (loss) gain on cash flow hedges, net of income taxes(6,127)53 (6,180)
NM(1)
Other comprehensive (loss) income(6,127)53 (6,180)
NM(1)
Net comprehensive income$47,729 $56,355 $(8,626)(15.3)%
(1) Not meaningful
The change in net income was attributable to the factors described in the above sections.
For the three months ended September 30, 2024 and 2023, the change in unrealized (loss) gain on cash flow hedges, net of income taxes was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021.
Net comprehensive income decreased to $47.7 million for the three months ended September 30, 2024, compared to net comprehensive income of $56.4 million for the three months ended September 30, 2023, primarily as a result of the changes in net income discussed above as well as the change in the fair market value of the cash flow hedge.
25
Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023
The following tables present selected consolidated comparative results of operations from Option Care Health’s unaudited condensed consolidated financial statements for the nine months ended September 30, 2024 and 2023.
Gross Profit
Nine Months Ended September 30,
20242023Variance
(in thousands, except for percentages)
Net revenue$3,651,784 $3,177,934 $473,850 14.9 %
Cost of revenue2,907,170 2,443,834 463,336 19.0 %
Gross profit$744,614 $734,100 $10,514 1.4 %
Gross profit margin20.4 %23.1 %
The increase in net revenue was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that had single-digit growth relative to the prior year while chronic revenue grew in the mid-teens. The increase in cost of revenue was primarily driven by the growth in revenue, therapy mix, and acute drug supply chain disruption, as well as the comparable impact of certain temporary favorable therapy procurement dynamics in the prior year. The decrease in gross profit margin was primarily due to the launch of certain new higher cost therapies included within chronic growth (including rare and orphan therapies) and to the same comparable impact of certain temporary favorable procurement dynamics in the prior year that did not continue into 2024. Future revenue and gross profit may be impacted by the supply chain disruption in the availability of certain IV fluids in the near term. Additionally, management anticipates that 2025 gross profit will be negatively impacted due to a manufacturer’s proposed significant reduction in the spread at which the Company procures a key therapy relative to drug reference prices beginning in early 2025.
Operating Expenses
Nine Months Ended September 30,
20242023Variance
(in thousands, except for percentages)
Selling, general and administrative expenses$465,524 $459,644 $5,880 1.3 %
Depreciation and amortization expense44,294 44,417 (123)(0.3)%
Total operating expenses$509,818 $504,061 $5,757 1.1 %
The increase in selling, general and administrative expenses during the nine months ended September 30, 2024 was primarily due to an increase in salaries, benefits, and equity compensation; however, these expenses have declined as a percentage of revenue to 12.7% for the nine months ended September 30, 2024 compared to 14.5% for the nine months ended September 30, 2023, due to the Company’s focus on leveraging existing infrastructure to control spending.
26
Other Income (Expense)
Nine Months Ended September 30,
20242023Variance
(in thousands, except for percentages)
Interest expense, net$(38,150)$(38,816)$666 (1.7)%
Equity in earnings of joint ventures3,921 4,107 (186)(4.5)%
Other, net1,983 84,487 (82,504)(97.7)%
Total other (expense) income$(32,246)$49,778 $(82,024)(164.8)%
The decrease in interest expense, net during the nine months ended September 30, 2024 was primarily attributable to additional interest income generated from our cash and cash equivalents, partially offset by an increase in the Company’s First Lien Term Loan principal balance, compared to the nine months ended September 30, 2023. See Note 9, Indebtedness, of the unaudited condensed consolidated financial statements for further information.
The decrease in Other, net during the nine months ended September 30, 2024 was due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the nine months ended September 30, 2023. There was no comparable activity during the nine months ended September 30, 2024.
Income Tax Expense
Nine Months Ended September 30,
20242023Variance
(in thousands, except for percentages)
Income tax expense$50,860 $69,904 $(19,044)(27.2)%
The Company recorded income tax expense of $50.9 million and $69.9 million for the nine months ended September 30, 2024 and 2023, respectively, which represents an effective tax rate of 25.1% and 25.0%, respectively. The income tax expense for the nine months ended September 30, 2023 includes $22.1 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. The variance in the Company’s effective tax rate of 25.1% for the nine months ended September 30, 2024, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 25.0% for the nine months ended September 30, 2023, compared to the federal statutory rate of 21%, was primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance.
27
Net Income and Other Comprehensive Income (Loss)
Nine Months Ended September 30,
20242023Variance
(in thousands, except for percentages)
Net income$151,690 $209,913 $(58,223)(27.7)%
Other comprehensive loss, net of tax:
Changes in unrealized loss on cash flow hedges, net of income taxes(5,475)(99)(5,376)
NM(1)
Other comprehensive loss(5,475)(99)(5,376)
NM(1)
Net comprehensive income$146,215 $209,814 $(63,599)(30.3)%
(1) Not meaningful
The change in net income was attributable to the factors described in the above sections in addition to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the nine months ended September 30, 2023. There was no comparable activity during the nine months ended September 30, 2024.
For the nine months ended September 30, 2024 and 2023, the change in unrealized loss on cash flow hedges, net of income taxes was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021.
Net comprehensive income decreased to $146.2 million for the nine months ended September 30, 2024, compared to net comprehensive income of $209.8 million for the nine months ended September 30, 2023, primarily as a result of the changes in net income discussed above as well as the change in the fair market value of the cash flow hedge.
28
Liquidity and Capital Resources
For the nine months ended September 30, 2024 and the twelve months ended December 31, 2023, the Company’s primary sources of liquidity were cash and cash equivalents of $483.0 million and $343.8 million, respectively. As of September 30, 2024, the Company had $395.9 million of borrowings available under its credit facilities (net of $4.1 million undrawn letters of credit issued and outstanding). As of December 31, 2023, the Company had $394.7 million of borrowings available under its credit facilities (net of $5.3 million undrawn letters of credit issued and outstanding). During the nine months ended September 30, 2024, the Company’s cash flows from operations were impacted by the Change Healthcare Cybersecurity Incident. See the caption “Update on the Impact of the Change Healthcare Cybersecurity Incident” included in this Form 10-Q for further discussion. During the nine months ended September 30, 2023, the Company’s cash flows from operations enabled investments in pharmacy, infusion suites, and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and share repurchases.
The Company’s primary uses of cash and cash equivalents include supporting our ongoing business activities, investment in capital expenditures in both facilities and technology, the pursuit of acquisitions, and share repurchases. Ongoing operating cash outflows are associated with procuring and dispensing drugs, personnel and other costs associated with servicing patients, as well as paying cash interest on outstanding debt and cash taxes. Ongoing investing cash flows are primarily associated with capital projects related to business acquisitions, the improvement and maintenance of our pharmacy facilities and investment in our information technology systems. Ongoing financing cash flows are primarily associated with the quarterly principal payments on our outstanding debt, along with potential future share repurchases.
Our business strategy includes the deployment of capital to pursue acquisitions that complement our existing operations. We continue to evaluate acquisition opportunities and view acquisitions as a key part of our growth strategy. The Company historically has funded its acquisitions with cash and cash equivalents with the exception of the BioScrip merger. The Company may require additional capital in excess of current availability in order to complete future acquisitions. It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on acceptable terms.
Short-Term and Long-Term Liquidity Requirements
The Company’s ability to make principal and interest payments on any borrowings under our credit facilities and our ability to fund planned capital expenditures will depend on our ability to generate cash and cash equivalents in the future, which to a certain extent, is subject to general economic, financial, competitive, regulatory and other conditions. Based on our current level of operations and planned capital expenditures, we believe that our existing cash and cash equivalents balances and expected cash flows generated from operations will be sufficient to meet our operating requirements over the next 12 months and beyond. We may require additional borrowings under our credit facilities and alternative forms of financings or investments to achieve our longer-term strategic plans.
29
Credit Facilities
The Company’s Revolver Facility provides for borrowings up to $400.0 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility will bear interest at a rate equal to, at the option of the Company, either (i) the Term SOFR applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the Second Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent compliance certificate received by the Administrative Agent pursuant to the terms of the credit agreement. As of September 30, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million.
In May 2024, the Company entered into the Third Amendment on the First Lien Term Loan. The Third Amendment, among other things, (i) provides for an additional $50.0 million of incremental First Lien Term Loan indebtedness and (ii) reduces the interest rate on the First Lien Term Loan from Term SOFR (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25% and removes the credit spread adjustment with respect to such First Lien Term Loan.
The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.6 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Under the Third Amendment, interest on the First Lien Term Loan is payable monthly on either (i) SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.25% for Term SOFR Loans (as such term is defined in the Third Amendment); or (ii) a base rate determined in accordance with the Third Amendment, plus 1.25% for Base Rate Loans (as such term is defined in the Third Amendment).
The Senior Notes bear interest at a rate of 4.375% per annum and are payable semi-annually in arrears on October 31 and April 30 of each year, which began on April 30, 2022. The Senior Notes mature on October 31, 2029.
Interest payments over the course of long-term debt obligations total an estimated $305.1 million based on final maturity dates of the Company’s credit facilities. Interest payments are calculated based on current rates as of September 30, 2024. Actual payments are based on changes in SOFR and exclude the interest rate cap derivative instrument.
30
Cash Flows
Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023
The following table presents selected data from Option Care Health’s unaudited condensed consolidated statements of cash flows:
 Nine Months Ended September 30,
 20242023Variance
(in thousands)
Net cash provided by operating activities$287,270 $320,326 $(33,056)
Net cash used in investing activities(25,266)(40,725)15,459 
Net cash used in financing activities(122,827)(187,298)64,471 
Net increase in cash and cash equivalents139,177 92,303 46,874 
Cash and cash equivalents - beginning of period343,849 294,186 49,663 
Cash and cash equivalents - end of period$483,026 $386,489 $96,537 
Cash Flows from Operating Activities
The decrease in cash provided in operating activities during the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023, was primarily due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, and changes in accounts receivable, accrued compensation and employee benefits, and changes in prepaid expenses, offset by changes in accounts payable.
Cash Flows from Investing Activities
The change in cash used in investing activities during the nine months ended September 30, 2023 was primarily due to prior year acquisition activity with no comparable activity within the nine months ended September 30, 2024.
Cash Flows from Financing Activities
The decrease in cash used in financing activities was primarily related to the Company’s debt refinancing in May 2024, in which $50.0 million in proceeds from issuance of debt was received, which partially offset $160.0 million in repurchase of common stock during the nine months ended September 30, 2024. The cash used in financing activities during the nine months ended September 30, 2023 was primarily related to the Company’s $175.0 million repurchase of common stock.
Critical Accounting Policies and Estimates
The Company prepares its unaudited condensed consolidated financial statements in accordance with GAAP, which requires the Company to make estimates and assumptions. The Company evaluates its estimates and assumptions on an ongoing basis. Estimates and assumptions are based on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making assumptions about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. The Company’s actual results may differ from these estimates, and different assumptions or conditions may yield different estimates.
There have been no material changes to the Company’s critical accounting policies and estimates as presented in our Form 10-K, which are hereby incorporated by reference.
31
Item 3.     Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes to our exposure to market risk from those included in our Form 10-K, which is hereby incorporated by reference.
Item 4.     Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures (as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer, management evaluated the effectiveness of the Company’s disclosure controls and procedures as of September 30, 2024. Based on that evaluation, the Company’s Chief Executive Officer and its Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2024.
Changes in Internal Controls over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
32
PART II
OTHER INFORMATION
Item 1.     Legal Proceedings
For a summary of legal proceedings, refer to Note 12, Commitments and Contingencies, of the unaudited condensed consolidated financial statements included in Item 1 of this Form 10-Q.
Item 1A.    Risk Factors
There have been no material changes to the risk factors affecting our business, financial condition or results of operations from those set forth in Part I, Item 1A. “Risk Factors” in our Form 10-K. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition and/or operating results, except for the updated risk factors below:
Delays in reimbursement may adversely affect our liquidity, cash flows and results of operations.
The reimbursement process for the services we provide is complex, resulting in delays between the time we bill for a service and receipt of payment that can be significant. Reimbursement and procedural issues often require us to resubmit claims multiple times and respond to multiple administrative requests before payment is remitted. The collection of accounts receivable is challenging and requires constant focus and involvement by management and ongoing enhancements to information systems and billing center operating procedures. While management believes that our controls and processes are satisfactory, there can be no assurance that collections of accounts receivable will continue at historical rates. The risks associated with third-party payers and the inability to collect outstanding accounts receivable could have a material adverse effect on our liquidity, cash flows, and results of operations. For example, in the first quarter of 2024, Change Healthcare, a subsidiary of UnitedHealth Group, experienced a cybersecurity incident that disrupted its operations, causing us to disconnect from certain Change Healthcare applications until the end of the quarter, preventing us from processing claims for services and reducing our cash flows from operations in the first quarter of 2024. The majority of previously unprocessed claims were recognized in the second quarter of 2024 and we continued to experience delays in certain patient payment obligations through the third quarter of 2024.
Changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing, could adversely affect our business and financial results.
We have contractual relationships with pharmaceutical manufacturers to purchase the pharmaceuticals that we dispense. In order to have access to these pharmaceuticals, and to be able to participate in the launch of new pharmaceuticals, we must maintain a good working relationship with these manufacturers. Most of the manufacturers of the pharmaceuticals we sell have the right to cancel their supply contracts with us without cause and after giving only minimal notice. Any changes to these relationships, including, but not limited to, the loss of a manufacturer relationship, drug shortages, or changes in pricing, could have an adverse effect on our business and financial results. For example, in October 2024, the Company received notice of a manufacturer’s intention to significantly reduce the spread at which the Company procures a certain therapy relative to drug reference prices beginning in early 2025, which is expected to negatively impact gross margins in 2025.
Some pharmaceutical manufacturers attempt to limit the number of preferred distributors that may market certain of their pharmaceutical products. We cannot provide assurance that we will be selected and retained as a preferred distributor or that we can remain a preferred distributor to market these products. Although we believe we can effectively meet our suppliers’ requirements, we cannot provide assurance that we will be able to compete effectively with other providers to retain our position as a distributor of each of our core products. Our failure to retain our position as a distributor of each of our core products could have a material adverse effect on our financial condition and results of operations.
Federal actions and legislation may reduce reimbursement rates from governmental payers and adversely affect our results of operations.
In recent years, Congress has passed legislation reducing payments to healthcare providers. The Budget Control Act of 2011, as amended, requires automatic spending reductions to reduce the federal deficit, including Medicare spending reductions of up to 2% per fiscal year that extend through 2027. The Center for Medicare & Medicaid Services (“CMS”) began imposing a 2% reduction on Medicare claims on April 1, 2013. The Affordable Care Act provides for material reductions in the growth of Medicare program spending. The 21st Century Cures Act (the “Cures Act”) significantly reduced the amount paid by Medicare for drug costs, while delaying the implementation of a clinical services payment, although Congress also passed a temporary transitional service payment that took effect January 1, 2019. In addition, from time to time, CMS revises the reimbursement systems used to reimburse healthcare providers, which may result in reduced Medicare payments. In addition, in August 2024, CMS announced the results of its negotiation with pharmaceutical manufacturers with respect to the inaugural 10 drugs covered under Medicare Part D for which CMS conducted drug price negotiations under the Inflation Reduction Act of 2022 (the “IRA”). CMS negotiated a 66% discount, applicable beginning in 2026, from the 2023 list price with the manufacturer on a certain drug within the Company’s portfolio of therapies, and the manufacturer notified us in October 2024 that it intends to significantly reduce the spread at which we procure this therapy relative to drug reference prices beginning in early 2025. The results of price negotiations between CMS and drug manufacturers pursuant to the IRA with respect to therapies that the Company dispenses is expected to negatively impact our results of operations.
For the year ended December 31, 2023, 12% of our revenue was derived from reimbursement by direct federal and state programs such as Medicare and Medicaid. Reimbursement from these and other government programs is subject to statutory and regulatory requirements, administrative rulings, interpretations of policy, implementation of reimbursement procedures, retroactive payment adjustments, governmental funding restrictions and changes to or new legislation, all of which may materially affect the amount and timing of reimbursement payments to us. Changes to the way Medicare pays for our services, including mandatory payment reductions, such as sequestration, may reduce our revenue and profitability on services provided to Medicare patients and increase our working capital requirements. In addition, we are sensitive to possible changes in state Medicaid programs.
Because most states must operate with balanced budgets and because the Medicaid program is often a state’s largest program, some states have enacted or may consider enacting legislation designed to reduce their Medicaid expenditures. Further, many states have taken steps to reduce coverage and/or enroll Medicaid recipients in managed care programs. The current economic environment has increased the budgetary pressures on many states, and these budgetary pressures have resulted, and likely will continue to result, in decreased spending, or decreased spending growth, for Medicaid programs and the Children’s Health Insurance Program in many states.
In some cases, Third-Party Payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from Third-Party Payers. Current or future healthcare reform and deficit reduction efforts, changes in other laws or regulations affecting government healthcare programs, changes in the administration of government healthcare programs and changes in payment rates by Third-Party Payers could have a material, adverse effect on our financial position and results of operations.
A disruption in pharmaceutical and medical supply could adversely impact our business.
For the year ended December 31, 2023, approximately 72% of our pharmaceutical and medical supply purchases were from four vendors. Most of the pharmaceuticals that we purchase are available from multiple sources, and we believe they are available in sufficient quantities to meet our needs and the needs of our patients. We keep safety stock to ensure continuity of service for reasonable, but limited, periods of time. Should a supply disruption result in our inability to obtain especially high margin drugs and compound components necessary for patient care, our consolidated financial statements could be negatively impacted. For example, Hurricane Helene caused significant damage late in the third quarter of 2024 to a certain manufacturer’s plant that produces intravenous solution bags that are used by the Company, which may impact our ability to service existing and onboard new patients. This disruption is expected to negatively impact our revenue and gross profit results until the supply situation improves.
33
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
The Company’s Board of Directors approved a share repurchase program of up to an aggregate $500 million of common stock of the Company. This program has no specified expiration date.
The following table provides certain information with respect to the Company’s repurchases of common stock from July 1, 2024 through September 30, 2024:
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
July 1, 2024 - July 31, 2024433,841 $27.54 433,841 $120,000,179 
August 1, 2024 - August 31, 2024771,471 30.73 771,471 96,295,151 
September 1, 2024 - September 30, 2024194,362 32.37 194,362 90,004,547 
1,399,674 $29.97 1,399,674 $90,004,547 
Item 5.    Other Information
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements
No director or officer of the Company has adopted, modified or terminated a Rule 10b5-1 plan or non-Rule 10b5-1 trading arrangement during the three months ended September 30, 2024.
34
Item 6.     Exhibits
(a) Exhibits.
Exhibit Number Description
3.1
31.1
31.2
32.1
32.2
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Labels Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104XBRL Formatted Cover Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 OPTION CARE HEALTH, INC.
 
Date: October 30, 2024
/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Executive Vice President (Principal Financial Officer and Duly Authorized Officer)
35
 EX-31.1 2 opch-ex311x2024093010xq.htm EX-31.1 Document

EXHIBIT 31.1 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John Rademacher, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 30, 2024


/s/ John Rademacher
John Rademacher
President, Chief Executive Officer and Principal Executive Officer


 EX-31.2 3 opch-ex312x2024093010xq.htm EX-31.2 Document

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Shapiro, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of Option Care Health, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 30, 2024

/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Principal Financial Officer


EX-32.1 4 opch-ex321x2024093010xq.htm EX-32.1 Document

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
    In connection with the Quarterly Report of Option Care Health, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Rademacher, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 30, 2024

/s/ John Rademacher
John Rademacher
President, Chief Executive Officer and Principal Executive Officer

    


 EX-32.2 5 opch-ex322x2024093010xq.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
    In connection with the Quarterly Report of Option Care Health, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Shapiro, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 30, 2024

/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Principal Financial Officer





EX-101.SCH 6 bios-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - INDEBTEDNESS link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - FAIR VALUE MEASURMENTS link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INDEBTEDNESS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - LEASES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - LEASES - Schedule of Operating Leases Mature (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - LEASES - Schedule of Operating Leases Mature (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - INDEBTEDNESS - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - INDEBTEDNESS - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - INDEBTEDNESS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - INDEBTEDNESS - Schedule of Long Term Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - INDEBTEDNESS - Schedule of Estimated Fair Values of Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Amount and Location of Derivatives in the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Pre-tax Gain (Loss) on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bios-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bios-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bios-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Minimum Payments Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Adjustments to reconcile net income to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Assets under development Asset under Construction [Member] Cover [Abstract] NET INCREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Maturities of Lease Liabilities, Operating Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] 2017 Warrants 2017 Warrants [Member] 2017 Warrants [Member] Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Trading Symbol Trading Symbol Ownership interest (as a percent) Equity Method Investment, Ownership Percentage All Trading Arrangements All Trading Arrangements [Member] Legacy Health Systems Legacy Health Systems [Member] Legacy Health Systems [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Cash paid for income taxes Income Taxes Paid, Net Investments in equity-method investees Equity Method Investments Cost of Goods and Service, Product and Service Benchmark Cost of Goods and Service, Product and Service Benchmark [Member] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Income Tax Examination [Line Items] Income Tax Examination [Line Items] Derivative [Table] Derivative [Table] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] First Lien Credit Agreement, Third Amendment First Lien Credit Agreement, Third Amendment [Member] First Lien Credit Agreement, Third Amendment Schedule of Amount and Location of Derivatives in the Balance Sheet Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Cash paid for operating leases Operating Lease, Payments, Use LEASES Lessee, Operating Leases [Text Block] Common stock, shares, outstanding (in shares) Balance, beginning of the year Balance, end of the period Common Stock, Shares, Outstanding Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Total noncurrent assets Assets, Noncurrent Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Total gross intangible assets Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Treasury stock, shares, acquired (in shares) Treasury Stock, Shares, Acquired Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Supplier [Domain] Supplier [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Treasury Stock Treasury Stock, Common [Member] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Number of warrants exercised (in shares) Class of Warrant or Right, Number of Securities Exercised Class of Warrant or Right, Number of Securities Exercised Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Performance stock unit awards Performance Stock Unit [Member] Performance Stock Unit Adjustment to Compensation, Amount Adjustment to Compensation Amount Paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Earnings per common share, diluted Earnings Per Share, Diluted [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Deferred financing costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Release of valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Purchase of company stock Stock Repurchased During Period, Value Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Antidilutive securities excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Operating lease cost Operating Lease, Expense Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents - beginning of the period CASH AND CASH EQUIVALENTS - END OF PERIOD Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Concentrations of Business Risk Concentration Risk, Business Risk, Policy [Policy Text Block] Concentration Risk, Business Risk, Policy [Policy Text Block] HC I Incentive Units HC I Incentive Units [Member] HC I Incentive Units [Member] CURRENT ASSETS: Assets, Current [Abstract] Goodwill Goodwill Stock-based compensation tax withholdings Payment, Tax Withholding, Share-Based Payment Arrangement OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX: Other Comprehensive Income (Loss), Net of Tax [Abstract] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Treasury stock, at cost (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Total depreciation expense Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other financing activities Proceeds from (Payments for) Other Financing Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] NET COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Attributable to Parent First Lien Term Loan First Lien Term Loan First Lien Term Loan [Member] First Lien Term Loan [Member] Preferred stock, shares, outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Debt instrument, basis spread (as a percent) Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] 2015 Warrants 2015 Warrants [Member] 2015 Warrants [Member] Earnings per common share, basic Earnings Per Share, Basic [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Repayments of debt principal Repayment of debt Repayments of Debt Total liabilities Liabilities Termination fee income Termination Fee Income, Tax Effect Termination Fee Income, Tax Effect Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Revolver Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current portion of operating lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares, issued (in shares) Common Stock, Shares, Issued Senior Notes Second Lien Term Loan [Member] Second Lien Term Loan [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration ​risk (as a percent) Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, gross Property, Plant and Equipment, Gross Interest rate cap designated as cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Exercise of stock options, vesting of restricted stock, and related tax withholdings Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Weighted average interest rate paid on term loans during period (as a percent) Long-Term Debt, Weighted Average Interest Rate, over Time Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted average number of common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Proceeds from issuance of debt Proceeds from Issuance of Debt Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Deferred income taxes - net Deferred Income Tax Expense (Benefit) Interest rate cap designated as cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Computer software, purchased and internally developed Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Equity in earnings of joint ventures Investment Income, Net Undrawn letters of credit issued and outstanding Letters of Credit Outstanding, Amount Selling, general and administrative expenses Selling, General and Administrative Expense OTHER COMPREHENSIVE (LOSS) INCOME Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Interest rate cap designated as cash flow hedge Interest Rate Cap [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Depreciation expense in cost of revenue Cost of Sales [Member] Governmental Healthcare Programs Government Contracts Concentration Risk [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Balance Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Intangible assets, net Finite-Lived Intangible Assets, Net, Excluding Customer Lists Finite-Lived Intangible Assets, Net, Excluding Customer Lists Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Effective rate on term loans at end of period (as a percent) Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Treasury stock acquired, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share OTHER INCOME (EXPENSE): Other Expense, Nonoperating [Abstract] Depreciation and amortization expense Depreciation, Amortization and Accretion, Net Amortization expense for intangible assets Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Total intangible assets, net Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Discount Debt Instrument, Unamortized Discount Leasehold improvements Leasehold Improvements [Member] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount NONCURRENT ASSETS: Assets, Noncurrent [Abstract] PEO Name PEO Name Class of warrant or right, outstanding (in shares) Class of Warrant or Right, Outstanding Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] INCOME BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Medical Supply Vendors Supplier Concentration Risk [Member] Non-PEO NEO Non-PEO NEO [Member] Purchase of company stock, and related tax effects Stock Repurchased During Period, Value, Including Related Tax Effects Stock Repurchased During Period, Value, Including Related Tax Effects Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Earnings per share, diluted (in dollars per share) Earnings per common share, diluted (in dollars per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Non-cash operating lease costs Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name State Jurisdiction State and Local Jurisdiction [Member] Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of operating segments Number of Operating Segments Customer [Axis] Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Accrued expenses and other current liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Accounts receivable, net Increase (Decrease) in Receivables Stock-based incentive compensation expense Share-Based Payment Arrangement, Noncash Expense INCOME TAX EXPENSE Income tax expense Income Tax Expense (Benefit) Notional amount of derivative Derivative, Notional Amount Total derivative assets Derivative Asset Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Depreciation expense in operating expenses Operating Expense [Member] NET REVENUE Net revenue Management fee income Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities OPERATING INCOME Operating Income (Loss) Interest expense, net Interest Expense, Operating and Nonoperating Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Equity -Method Investments Equity Method Investments [Policy Text Block] TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity Other adjustments Other Operating Activities, Cash Flow Statement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and employee benefits Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Hedging Designation [Axis] Hedging Designation [Axis] DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Total other (expense) income Interest Income (Expense), Nonoperating Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Number of infusion sites Number Of Infusion Sites Number Of Infusion Sites Schedule of Long-term Debt Maturities Schedule of Maturities of Long-Term Debt [Table Text Block] Increase in operating lease right-of-use asset and lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Inventories Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Equipment, furniture and other Equipment, Furniture, And Other [Member] Equipment, Furniture, And Other [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Due to joint ventures Accounts Payable, Other OPERATING COSTS AND EXPENSES: Operating Expenses [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Derivative, term of contract (in years) Derivative, Term of Contract Infusion pumps Infusion Pumps [Member] Infusion Pumps [Member] Second Lien Term Loan Junior Lien [Member] Restatement Determination Date Restatement Determination Date Common Stock Repurchase Program Common Stock Repurchase Program [Member] Common Stock Repurchase Program Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Due from joint ventures Other Receivables Related Party Transactions [Abstract] Related Party Transactions [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Concentration Risk [Table] Concentration Risk [Table] Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Principal Amount Total Long-Term Debt, Gross Exercise Price Award Exercise Price EARNINGS PER SHARE Earnings Per Share [Text Block] Accrued compensation and employee benefits Increase (Decrease) in Employee Related Liabilities Arrangement Duration Trading Arrangement Duration LEASES Lessee, Finance Leases [Text Block] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Accounts payable Increase (Decrease) in Accounts Payable, Trade All Individuals All Individuals [Member] Trademarks/names Trademarks and Trade Names [Member] PEO PEO [Member] Termination fee Termination fee Business Combination, Contingent Consideration, Asset, Termination Fee Business Combination, Contingent Consideration, Asset, Termination Fee Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Amedisys Amedisys, Inc. [Member] Amedisys, Inc. Name Trading Arrangement, Individual Name Other, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Equity in earnings of joint ventures Proportionate share of earnings in equity-method investees Income (Loss) from Equity Method Investments Treasury stock; 13,647,205 and 8,330,022 shares outstanding, at cost, as of September 30, 2024 and December 31, 2023, respectively Treasury Stock, Common, Value 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] First Lien Term Loan Senior Lien [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Total noncurrent liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restricted stock awards Restricted Stock Award [Member] Restricted Stock Award [Member] Local Phone Number Local Phone Number Number of shares authorized to be repurchased (in shares) Share Repurchase Program, Authorized, Number of Shares Four Vendors Four Vendors [Member] Four Vendors Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Supplier [Axis] Supplier [Axis] Accounts Receivable, Benchmark Accounts Receivable, Benchmark [Member] Accounts Receivable, Benchmark Valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Deferred income taxes Deferred Income Tax Liabilities, Net Number of service locations Number Of Service Locations Number Of Service Locations Interest expense, net Interest Expense [Member] Share repurchases Stock Repurchased During Period, Shares Rebate receivable Contract with Customer, Receivable, after Allowance for Credit Loss Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Change in unrealized (loss) gain on cash flow hedges, income tax benefit (expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Emerging Growth Company Entity Emerging Growth Company Income Tax Examination [Table] Income Tax, Examination [Table] Entity Central Index Key Entity Central Index Key Patients Patient Customer [Member] Patient Customer [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2018 Plan 2018 Plan [Member] 2018 Plan STOCKHOLDERS’ EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Current portion of long-term debt Less: current portion Long-Term Debt, Current Maturities Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based incentive compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Government Healthcare Programs Government Healthcare Programs [Member] Government Healthcare Programs SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] City Area Code City Area Code CURRENT LIABILITIES: Liabilities, Current [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Markets for Identical Item (Level 1) Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Preferred Stock Preferred Stock [Member] Purchase of company stock Payments for Repurchase of Common Stock 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, net of discount, deferred financing costs and current portion Total long-term debt Long-Term Debt, Excluding Current Maturities Other amortizable intangible assets Other Intangible Assets [Member] INCOME TAXES Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four EARNINGS PER COMMON SHARE: Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Lien Category [Axis] Lien Category [Axis] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories Increase (Decrease) in Inventories Legal fees Debt Issuance Costs, Gross Schedule of Debt Schedule of Debt [Table Text Block] 2026 Long-Term Debt, Maturity, Year Two Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate, operating leases (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Present value of lease liabilities Operating Lease, Liability Net cash used in financing activities Cash outflow from financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Total debt instruments Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization expense Depreciation, Depletion and Amortization GROSS PROFIT Gross Profit Fair Value as of Grant Date Award Grant Date Fair Value Company's Largest Payer Customer Concentration Risk [Member] Largest Payer Largest Payer [Member] Largest Payer Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Debt Issuance Costs Debt issuance costs Debt Issuance Costs, Net INDEBTEDNESS Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] STOCKHOLDERS’ EQUITY: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Schedule of Net Revenue Earned by Category of Payer Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Principles of Consolidation Consolidation, Policy [Policy Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,793,536 shares issued and 170,146,331 shares outstanding as of September 30, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December 31, 2023 Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other investing activities Payments for (Proceeds from) Other Investing Activities Other noncurrent assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Joint Venture Corporate Joint Venture [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Schedule of Changes in Shares of Common Stock Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Earnings per share, basic (in dollars per share) Earnings per common share, basic (in dollars per share) Earnings Per Share, Basic Operating lease liabilities Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Stock option awards Equity Option [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] TOTAL ASSETS Assets Capital distribution from equity method investments Distributions received from the investees Proceeds from Equity Method Investment, Distribution COST OF REVENUE Cost of Goods and Services Sold Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Government payers Government Customer [Member] Government Customer [Member] Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Other noncurrent assets and liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Long-Term Debt, Maturity, Year One STOCK-BASED INCENTIVE COMPENSATION Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Estimated Fair Values of Debt Obligations Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Share-based compensation expense Share-Based Payment Arrangement, Expense NET INCOME Net income Net income Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Available borrowing capacity Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number REVENUE Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Equity award issuances Shares Issued During Period, Shares Shares Issued During Period, Shares Shares repurchased Treasury Stock, Value, Acquired, Cost Method Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Name Forgone Recovery, Individual Name 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted-average remaining lease term, operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Commercial payers Commercial Customer [Member] Commercial Customer [Member] Document Period End Date Document Period End Date Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Insider Trading Arrangements [Line Items] Lien Category [Domain] Lien Category [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Second Lien Credit Agreement Second Lien Credit Agreement Member [Member] Second Lien Credit Agreement Member Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Referral sources Customer Lists [Member] Customer [Domain] Customer [Domain] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Referral sources, net Finite Lived Customer Lists, Net Finite Lived Customer Lists, Net Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Related Party [Axis] Related and Nonrelated Parties [Axis] Weighted average common shares outstanding, basic (in shares) Weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit of $1,998, $8, $1,785 and $57, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 bios-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 bios-20240930_g1.jpg GRAPHIC begin 644 bios-20240930_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#T17AI9@ 34T *@ @ ! $[ ( M . (2H=I 0 ! (6)R= $ < 0T.H< < @, /@ M FMC.60G/SX-"CQX.GAM M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS M.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z M#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5 M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @* M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@ K &K P$B (1 0,1 ?_$ !\ $% 0$! M 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" M P $$042(3%!!A-180'EZ@X2% MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ M ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,082 M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3 ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C MY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D&W8^7&?>EHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DSB@G%>9^-_ M'4HGDTS1I"H0[99UZY]!_C0=>$PE3%U/9TSK]8\8Z/HK&.ZN0TP_Y91_,P^O MI^-Q+@9KS$G(GY7'N/ZTTSEQ>04W'FP[L^S/H>BLCPYXAM?$6EK=VK -TDC)Y1O M2M?(]:H^/G"5.3C)6:"BBB@@**** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH CGFCMH7FGD6..-2SNQP% [DUXMXT_:!@LKB2R\)6Z7;J M2INYL^6#_LCO7/?'?XDSWNJ/X4T>=DM(#B]=#_K7_N?0?J:\=0LPWRX!\N3NK&N05]95AJ!E41S'YQT/K5LR5S6Y&:[O3/'VKV+ 7+K>1]Q)PWYBO*O,]ZZ:TE\ZTC?U45Y M./YZ352#L+ZO0Q*:J13/W&GW:7-I(8Y4 M.01_*O:?#^LQZYI,=W'\K'AU_NMW%:X3%>V7++<^0S7*W@WSPUB_P-2BBBN\ M\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ%J0T?PWJ&HMQ] MEMWEY]E)K2KEOB7$\WPS\0)$/F-C)C\JJ"O))B>Q\93W?'%0H1YI;E:TL+FZQY$ M+./7''YUM6_AB\?[\D4?XEJU[;"J /05IPMTKBF<\\YQ%_/A2]0922 M&3VR5/ZU0GL;BS;%S"T?N1D?G7J>D^&]1UB1$MH=H;^.3Y1CUKJO^%2M/#MN MM14YZJL61^IKCG*'5GH8+-\=>\H\R^X^?02C!EX(/&*U4GWQJWK77>.OA/?> M&;!M3LIEN[13^]55(:(?WL=Q_*N#M9/W)'H:RLFM#[C!XI58\T>I?WYKIM); M.G1?C7(;\GK7964?DV<2=PHS7EY@KTTCW<&W*39:!KN_AE?LE_ MXK@@:ZWX<*3XHX[0MFO(PR<:T;$YM!2P<[]CUNBBBOHC\U"BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ JMJ-FFH:;<6(+ZRNUQ+:S-&N?0'@_E6C;. U4KW4) M=3U.XO;ABTMQ(9&)/J&5C@CO=1CR[# M9=T%O\ .X/<]A7K\<@( KRL5-Q?*C?#P4M6=3X> MLUCM#.1\TG3V%;-<5X&UT3276FW#XD25FBR>HSR*[3(KR:=15(\R/K9X>6&? MLY$=S;QW=M)!.H>.12K*1P0:^5/%>@-X9\4W^F_P)+NB/JAY%?4VHW]OINGS M7EW((X84+LQ[ 5\P:SBKT _*NB#Y4VSU\IIU)S?*M# M/T:T-W?!F'[J/ECZGL*ZT&JMG:QV< BB& .I]35BO+Q,_:2OT/O<-1]C"SW) M :]'^&.FD+>V5K+>W*0PC);J?0>M>N^#PMI$;*/[BKD?7O7 MG4J].&*C3>[/'SVMRX9TX[O?T.HHHHKZ$^ "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ KF/B06'PWUWR\[OL4F,?2NGJEK%@NJ:-=V,G*W$+1G\ M1BJB[23)DKQ:/B>*2K4?\ BFE//L*[5+G'>N%\$W _X1FW [,V?SKI5N>.M>)6C>HR(5.7 M0SWGFL-7::V)S32U-&5;%V5HH=I6GQ6$>V,98_ M><]374^'<_VIQ_<-8<(KI/#5N3)).>F-HKR\OYZV.@WJ[W/F,?4O3DY=3HZ* M**_1#Y<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PSXX_# M*>\=O%.@PF215_TV!!RP'_+0#O[BO E?!YXQ7W>0&!!&0>QKS#QK\#M#\2RR MWFEN=*OGY)C7,;GW7_"O4PN,4%R5-C@Q&%YWS1/)?A]?B73)[8GYHGW#Z&NQ M$IK$T[X/^-O"^N)-!;V^H6C?)(UO. =OKM;!_G6H^Z*1HY 5=3A@1R#3JN$I MW@[GS^(H3I2U6Y,9,CGI21XSMJ O2%_>O-QF"ABH6>CZ,]+*,XKY95YH:Q>Z M-%$JS&E9<5\T>-XWC\JO0ZG:_P ;,GU&?Y5\;B1^E8?B+ XF-^? ME?9Z&E$O2K<2TND64VL([Z>GFJAPS= #^-=)9>$YB0;N14'=4Y->:L#BJDN5 M09=7'X?EYE-/T,ZPM);N98X1DGJ?2NWM+5+.V6*/HHZ^II+2Q@LHMD"!?4]S M5BOJ,MRU816FP4445[)Q!1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% 1FN)\7^"O[29[[2P%NNKQ]!)[_6NVHJHR<7 M=&5:C"M'ED?/EQ!/:3-#M>]W^CV.J)MO[6.88X++R/QK MD^'&A.^X1S)ST$G%=*KKJ>)/*ZB?N.YY#FM[P[X2O]?G5@AAM0?GF8:^!/"'B M[1/'.K:CKVJ_:+"X5@B><7WDME3M/W<"O2J "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ J*YN$M;66XESLB0NV/0#-2U1UO_D W M_P#U[2?^@F@"AX3\7:=XRTN2_P!(\WR8YC"WF+M.X '^M;M>4_L]_P#(AWO_ M &$9/_05KU:@ HHHH **** "BBB@ HHHH P/%OC'3?!MC!=ZOYOESS"%/*3< M=V"?Z5MP3+<6\4?M"?\BKI/_817_P! :O4=+_Y!%I_UP3_T M$4 0Q:[IDVL2:5%>PM?QKN>W#?.H]$+%=2UR7[P/*0_4#J>_H.]=_?W0LM/N+END,;.?P&:\@^!-J-5U'Q%X MFO!YEU/<^4CMR5!RS8_,?E0,NC2_C*4^UG6-,$G7[+M&/I]W'ZUI^!_B5=ZG MKTGAGQ?8KINN1YV!>$FP.V>AQS[UZ/7BWQUMO[)U3P]XGLOW=W!<>677C./F M&?U'XT =1\6_&FJ>#-)TZYT=H5:XN#'(98]PVXS6'_PEWCWQS+*W@2VM;+2X MFV"^NAS,PZD9S@9]JJ?'^7[9X-T*5/\ EM/N'XIG^M>J^&]-AT?PWI]C;($C MA@10 .^.3^= 'D]SXV^(GP_NH9?&MG;ZEI-_&MAX'T(W]\#+*[;+>W0_-*_I[# MU->?_"O_ )*YXT_WO_:AJOXK3_A*_P!H;2-%NOWEG81B5HCT.%+G]0* ZENR MN/BYXKMUU"VFL-#M91NBA=/F([=03^>*!\0/&'@/5;>V^(MI!=:=<-M74+0? MP^,FL_VAK-A):17]^EV;;3;6%"I8[B,L?0 "NF^! M^K2:G\-;>.9BS6/;D?UK9^''Q%N_$=_=Z#XELUL= +!=0U($K+.XRD1[X'3CN3Q5)M,^,\*?:UU73II!\WV M;Y>?;[N/UJ?X!Z*D/A2XUN8![O4)VW2'D[0>GYY->LT#/._A]\29O$6H7&@^ M([,:=KEKG=$,A9 .I /0^U/^(/Q$N?#VHVF@^'+-;_7+W_5QM]V,'N1W-=A_ MPC^E?VW_ &O]AA_M#;M^T;?GQ]:P9/ FF0^/SXRGO)A6HVXR/2@# MDQH?QBN!]I?Q!IT$AY%N%&![?=Q5GP?\0]>B\9'PAX\LXH=089@N81A9.,\C MH<]B*W]9^*_@[1':.XU>.:5>#':J96_3C]:\OU#QE9>,OC3X7O=,M+JWBA;R MM]P@4R?,3D#TH ]A\>:U=^'O!.HZIIQ07-O'N0NNX9SZ5YQI7Q*\9>+]+L[# MPC96\VHK%OO[Z5-L4+$\*!TSCZ_2NW^+'_)+]9_ZX?U%4/@GIT5C\,K&2-0) M+IFFD;'+$G _04 6_#EWXD\.Z%J5_P#$?4+1XX<2))!C"KCD< )4 6S;D@!8?[0UM+/7--C.9O*^ M\@]<@ CZX(KT[POXFT_Q;H4.J:6Y,4G#(WWHV[J?>N.E^-O@J>%XIFO'C<%6 M5K-B"#U%I7@-@<=N"* /=ZHZW_R +_\ Z]I/ M_035ZJ.M_P#( O\ _KVD_P#030(\ ^&GC+4]*\*/H/A33QJ&MW=])(%?_5P1 M[5&]OQ%=7<<'Z5L^+O%FG^# M=!DU/4V.U?ECB7[TK]E%>:?#I!9_'CQ;:0C9$8F;:/7S%_\ BC65\9-8M9OB M?HFG:P[C2K/9+.J*6)RSU;XK>.(?[0T=;+0]/DYA$OWF'KD@D_ M7 %$OC;Q[\/[J ^/+.'4=*D<(;NU W)[Y&,_0BMV/XW^"XHU2-[U%48519L M!69XF^+/@CQ#X:O]+G>]87,+(N;-N&Q\I_ XH ]2T_4+;5-.@OK&59K>= \; MKT8&O-O$_P 0]>U#Q?+X4^'UI#->6_%U=SX';CN3WJO^S]JL]WX.NM/N M"W^A3_N\CHK#./SS73^'_!NC> ]3U35SJ+_\3!M\K7;J OS%C@\>M '+/HGQ MBM$-U%K^GW,@&3;E1@^PRN*W/AM\1+GQ7->Z1KMFMEK.GG]\B9"N,X) /0@] M13]6^,_@S3)&B34'OI1QLLXC)S]>GZUPOPUUF'7_ ([:SJ=M;RVT5S:NXBF& M&'*=0* -S]H3_D5-)_["*_\ H#5T_B'_ (3/^QM(_P"$(^Q;O)'VC[5CIM7; MC]:YC]H3_D5-)_["*_\ H#5ZCIG_ "";3_K@G_H(H ^=M,_X3W_A<.H?9/[/ M_P"$A\@^?NQY6SCI[]*]:M?^$K_X0#7_ /A-?LGVK[--Y7V7&-GEGK[YKEM" M_P"3E]9_Z]#_ .RUZ9XI_P"10U?_ *\9O_0#0!X5\-?&6KV/@V'P[X/T];[6 M9YWD9I/]7;IQAFKJ+I/C-I,+ZBUUI]\L8WO;1JK<=P!@?H:D_9XTV&+P?=Z@ M$'G7%QL+8YVJ!Q^M>O'I0!R'PZ\>0^.M#>X:#[+?6S>7=09R%;U'L:S->\0: MB-01HIY8XY)I88HH6*[?+=5R2 ?F8MGYOE Q]:YOX4 6WQ:\:6<0VQ+,Y"CH M,2G_ !KTZ]\-6MW=2SK)- TPQ*(FP'Z!R/04 2^'[Z>^T]_M>#-!,\#N MHX@14U6U-]I%W:CK-"Z#\017DW[/UR+ M:UU_19CLN;6[#E#UP1M)_-:]DKRGQA\/]:T[Q9_PE_P_D1+YL_:;1SA9O7'; MGN*!GJU>,?'VZ%\^@:!:_/=W%SO"#K@_*/U/Z5:_X6)\1&A^S+X$E%WC'FDG M9GU]/UJYX*^'VKS>*3XO\>3+-JG_ "[VZ'*P<8S^ / H#8R/CU']B\&^'X^O MD7 7Z[4'^%>N:1=Q7VC6=U;N'CFA1U([@@5Y5^T.H;P]HRGH;P@_]\TR"#Q[ M\.XQ:Z!8#7M#;Y[="GILM[:,(H[GU)]R>: /+M4_Y.H]"#77^!=4\5ZP]]=^*M,73(#L6TM\_,. MNXG]* .+^%?_ "5SQI_O?^U#5?5Y!H'[36GWEW\D%_#Y:NW RR%>OU 'XUO_ M ^\+ZOH_P 1_%&I:C:&&TO6S!(6!W_.3_*MOXC> 8?'&CQK%+]FU&U;?:W' MH?[I]C0'4[+--0?XF8;0/S-!W)%5Y_#GC;XHZA;_ /"66XT31(9-YME/SR?AZ^YH W_@3ILE MC\-HY95*_:IWE4$=5X /Z5B_!7_D);G5K,P0WEP7@8L#O&]CGCV- 'IU>-:K_P G0V'_ M %Z)_P"@M7LM>8:CX6UB;X^6FOQV9;3([94:?<, A6&,=>] 'I]<_P".M/DU M7P'K-E ,R2VCA!ZG&1_*N@I",C!Y!H$>6_ /58[OP(^GY FL9V5T/4!N0:]3 MS7CVN> ?$GA'Q9-XD^'926.X):XT]S@-GD@#N._J*?)\0/B1VK736RW,)G49,0<;A^'6O%KR+4OBM\3-4T6XOY;/0](< MH\4+8,A!QS]3FNC^'?PYU#3-:N/%'B^=;G6KG. #D19Z\^O;VK+\1>$?%/A/ MQY=>*O \*WT5]EKJS8\DGK@=^>: .ST3X8>$M!53:Z3#)(O_ "UG'F-^M<#X MWO+23X^^%;*S,8-F%614 0LQ('Y?SJ])XK^*6O+]DTWPNFDLXVMK?!_7M+72];T&Z6_UZ"9I[QYGQYSDY&,]ATH ] ^*__),-9_ZX_P!13?A' M_P DNT;_ *XG^9K/U2W\5>*/A1JMIK&E1VVKRYCCMXI 0ZC&#G/UK<^'.DWF MB> =,T_4HO)N8(RLB9!PSM'CGA5U81*Q'N#S7DFGZ M=\1?ABSV6DV:^(-&#EHE!^=!].HH ]@_LG3?^?"V_P"_*_X5F:/KGAF^UF[T M_19K1KZT)6>.&,!E]><^)_BCXGB:PTKPV=%$HVOGY5V?PZ M\ V_@?1WC:3[1J%R=]S<8ZGT'M0!V-4=;_Y -_\ ]>TG_H)J]53587N-'O(8 M5W220.JCU)4@4"/-/V>_^1#O?^PC)_Z"M>K&O/?@UX;U3PQX1NK/6[;[-/)> MO*J;@'-:OD4V4Y1' M+C*\$J<_]] UTOA/PKK&G?&CQ#K=Y:&/3[R%EAFW [B70].O0&NH\=^"[/QO MX=;3[IO*F0^9;S@>(/%M]-]@CG,=O90OM48YQ[ #'UKUKPQX1T_P ,>%X]$M%WQ;") M78BW,OF)&#\R?AV../?% 'INC^ _#.@(/ M[.TBVC91_K'3(9K5U>(PR(K+T.TH./RJY/>?$_QNIL%T MR/PW8R_+-.[?O-O?'>J,OPV\2^ _%L&L> X8M0A^SB*6*=\,3CYLY]2,T :? M[0G_ "*FD_\ 817_ - :O4M+_P"03:?]<$_]!%>:_$S0/$?C#P+HB1::/[22 MY6:Y@5QB/Y2#R>O)KTRPC:'3;:.08=(E5AZ$ 4 >2Z#_ ,G+ZS_UZ'^2UZ9X MI_Y%#5_^O&;_ - ->7^*M&\6>&?BP_BOPWI)U2"ZBV/&AZ<8(/IT!S76Z,_B MS7/!>MGQ+8QVEW=12):6J$952A !]\T 8_[/_P#R3<_]?;_R%>HUP/P=\.ZG MX9\$?8=:MS;W'VAWV%@>"!Z5WU 'C'PP_P"2U>-O^NK_ /HVO9Z\Q\!>%-8T M?XH>*=5U"T\JSOI'-O)N!W@R9''TKTZ@ HHHH$%%%% !BBBB@#R']H-6?0=& MV*6_TT]!G^&O6+,?Z%#G_GFO\JD>*.0 2(K@=-PS3L4 &**** "BBB@ HHHH M ,4444 %%%% !1110 4444 %&*** "BBB@ Q1110 4444 %%%% !1110 444 M4 %%%% !1110 8HHHH *,444 %%%% !1110 4444 %%%% !1110 4444 ?_9 end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2024
Oct. 28, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-11993  
Entity Registrant Name OPTION CARE HEALTH, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 05-0489664  
Entity Address, Address Line One 3000 Lakeside Dr.  
Entity Address, Address Line Two Suite 300N,  
Entity Address, City or Town Bannockburn,  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60015  
City Area Code 312  
Local Phone Number 940-2443  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol OPCH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   170,181,238
Entity Central Index Key 0001014739  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
CURRENT ASSETS:    
Cash and cash equivalents $ 483,026 $ 343,849
Accounts receivable, net 428,951 377,658
Inventories 310,599 274,004
Prepaid expenses and other current assets 98,798 98,744
Total current assets 1,321,374 1,094,255
NONCURRENT ASSETS:    
Property and equipment, net 125,911 120,630
Operating lease right-of-use asset 89,210 84,159
Intangible assets, net 17,768 20,092
Referral sources, net 291,839 315,304
Goodwill 1,540,246 1,540,246
Other noncurrent assets 41,379 42,349
Total noncurrent assets 2,106,353 2,122,780
TOTAL ASSETS 3,427,727 3,217,035
CURRENT LIABILITIES:    
Accounts payable 591,971 426,513
Accrued compensation and employee benefits 60,835 92,508
Accrued expenses and other current liabilities 81,893 75,010
Current portion of operating lease liability 22,013 18,278
Current portion of long-term debt 6,512 6,000
Total current liabilities 763,224 618,309
NONCURRENT LIABILITIES:    
Long-term debt, net of discount, deferred financing costs and current portion 1,105,106 1,056,650
Operating lease liability, net of current portion 87,879 85,484
Deferred income taxes 45,008 34,920
Other noncurrent liabilities 279 0
Total noncurrent liabilities 1,238,272 1,177,054
Total liabilities 2,001,496 1,795,363
STOCKHOLDERS’ EQUITY:    
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of September 30, 2024 and December 31, 2023 0 0
Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,793,536 shares issued and 170,146,331 shares outstanding as of September 30, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December 31, 2023 18 18
Treasury stock; 13,647,205 and 8,330,022 shares outstanding, at cost, as of September 30, 2024 and December 31, 2023, respectively (416,552) (255,107)
Paid-in capital 1,224,059 1,204,270
Retained earnings 609,203 457,513
Accumulated other comprehensive income 9,503 14,978
Total stockholders’ equity 1,426,231 1,421,672
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 3,427,727 $ 3,217,035
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 12,500,000 12,500,000
Preferred stock, shares, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares, issued (in shares) 183,793,536 182,905,559
Common stock, shares, outstanding (in shares) 170,146,331 174,575,537
Treasury stock, at cost (in shares) 13,647,205 8,330,022
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
NET REVENUE $ 1,278,546 $ 1,093,014 $ 3,651,784 $ 3,177,934
COST OF REVENUE 1,021,797 838,748 2,907,170 2,443,834
GROSS PROFIT 256,749 254,266 744,614 734,100
OPERATING COSTS AND EXPENSES:        
Selling, general and administrative expenses 156,999 158,214 465,524 459,644
Depreciation and amortization expense 14,659 15,005 44,294 44,417
Total operating expenses 171,658 173,219 509,818 504,061
OPERATING INCOME 85,091 81,047 234,796 230,039
OTHER INCOME (EXPENSE):        
Interest expense, net (12,345) (11,786) (38,150) (38,816)
Equity in earnings of joint ventures 1,391 1,273 3,921 4,107
Other, net (583) (449) 1,983 84,487
Total other (expense) income (11,537) (10,962) (32,246) 49,778
INCOME BEFORE INCOME TAXES 73,554 70,085 202,550 279,817
INCOME TAX EXPENSE 19,698 13,783 50,860 69,904
NET INCOME 53,856 56,302 151,690 209,913
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:        
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit of $1,998, $8, $1,785 and $57, respectively (6,127) 53 (5,475) (99)
OTHER COMPREHENSIVE (LOSS) INCOME (6,127) 53 (5,475) (99)
NET COMPREHENSIVE INCOME $ 47,729 $ 56,355 $ 146,215 $ 209,814
EARNINGS PER COMMON SHARE:        
Earnings per share, basic (in dollars per share) $ 0.32 $ 0.31 $ 0.88 $ 1.17
Earnings per share, diluted (in dollars per share) $ 0.31 $ 0.31 $ 0.87 $ 1.16
Weighted average common shares outstanding, basic (in shares) 170,636 178,826 172,490 179,956
Weighted average common shares outstanding, diluted (in shares) 171,941 180,528 173,848 181,286
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Change in unrealized (loss) gain on cash flow hedges, income tax benefit (expense) $ 1,998 $ 8 $ 1,785 $ 57
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 151,690 $ 209,913
Adjustments to reconcile net income to net cash provided by operations:    
Depreciation and amortization expense 46,029 46,423
Non-cash operating lease costs 17,892 14,610
Deferred income taxes - net 10,088 11,767
Loss on extinguishment of debt 377 0
Amortization of deferred financing costs 3,465 3,312
Equity in earnings of joint ventures (3,921) (4,107)
Stock-based incentive compensation expense 27,620 22,908
Capital distribution from equity method investments 1,250 4,000
Other adjustments (1,845) 1,769
Changes in operating assets and liabilities:    
Accounts receivable, net (51,293) (5,075)
Inventories (36,595) (28,362)
Prepaid expenses and other current assets (3,175) 3,197
Accounts payable 164,754 50,726
Accrued compensation and employee benefits (31,673) 4,197
Accrued expenses and other current liabilities 5,560 9,829
Operating lease liabilities (16,833) (13,019)
Other noncurrent assets and liabilities 3,880 (11,762)
Net cash provided by operating activities 287,270 320,326
CASH FLOWS FROM INVESTING ACTIVITIES:    
Acquisition of property and equipment (25,266) (21,981)
Business acquisitions, net of cash acquired 0 (12,855)
Other investing activities 0 (5,889)
Net cash used in investing activities (25,266) (40,725)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Stock-based compensation tax withholdings (11,235) (1,940)
Repayments of debt principal (4,756) (4,500)
Proceeds from issuance of debt 49,959 0
Deferred financing costs (77) 0
Purchase of company stock (160,122) (175,108)
Other financing activities 3,404 (5,750)
Net cash used in financing activities (122,827) (187,298)
NET INCREASE IN CASH AND CASH EQUIVALENTS 139,177 92,303
Cash and cash equivalents - beginning of the period 343,849 294,186
CASH AND CASH EQUIVALENTS - END OF PERIOD 483,026 386,489
Supplemental disclosure of cash flow information:    
Cash paid for interest 48,666 46,377
Cash paid for income taxes 45,258 53,699
Cash paid for operating leases $ 21,861 $ 20,272
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Treasury Stock
Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2022 $ 1,386,103 $ 0 $ 18 $ (2,403) $ 1,176,906 $ 190,423 $ 21,159
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings (1,902)       (1,902)    
Stock-based incentive compensation 5,988       5,988    
Purchase of company stock (75,735)     (75,735)      
Net income 39,208         39,208  
Other comprehensive income (loss) (3,443)           (3,443)
Ending balance at Mar. 31, 2023 1,350,219 0 18 (78,138) 1,180,992 229,631 17,716
Beginning balance at Dec. 31, 2022 1,386,103 0 18 (2,403) 1,176,906 190,423 21,159
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 209,913            
Other comprehensive income (loss) (99)            
Ending balance at Sep. 30, 2023 1,440,083 0 18 (179,205) 1,197,874 400,336 21,060
Beginning balance at Mar. 31, 2023 1,350,219 0 18 (78,138) 1,180,992 229,631 17,716
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings (247)       (247)    
Stock-based incentive compensation 7,685       7,685    
Purchase of company stock, and related tax effects 32     32      
Net income 114,403         114,403  
Other comprehensive income (loss) 3,291           3,291
Ending balance at Jun. 30, 2023 1,475,383 0 18 (78,106) 1,188,430 344,034 21,007
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings 209       209    
Stock-based incentive compensation 9,235       9,235    
Purchase of company stock, and related tax effects (101,099)     (101,099)      
Net income 56,302         56,302  
Other comprehensive income (loss) 53           53
Ending balance at Sep. 30, 2023 1,440,083 0 18 (179,205) 1,197,874 400,336 21,060
Beginning balance at Dec. 31, 2023 1,421,672 0 18 (255,107) 1,204,270 457,513 14,978
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings (8,182)       (8,182)    
Stock-based incentive compensation 9,605       9,605    
Purchase of company stock, and related tax effects (40,289)     (40,289)      
Net income 44,791         44,791  
Other comprehensive income (loss) 1,551           1,551
Ending balance at Mar. 31, 2024 1,429,148 0 18 (295,396) 1,205,693 502,304 16,529
Beginning balance at Dec. 31, 2023 1,421,672 0 18 (255,107) 1,204,270 457,513 14,978
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 151,690            
Other comprehensive income (loss) (5,475)            
Ending balance at Sep. 30, 2024 1,426,231 0 18 (416,552) 1,224,059 609,203 9,503
Beginning balance at Mar. 31, 2024 1,429,148 0 18 (295,396) 1,205,693 502,304 16,529
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings 1,299       1,299    
Stock-based incentive compensation 7,608       7,608    
Purchase of company stock, and related tax effects (78,768)     (78,768)      
Net income 53,043         53,043  
Other comprehensive income (loss) (899)           (899)
Ending balance at Jun. 30, 2024 1,411,431 0 18 (374,164) 1,214,600 555,347 15,630
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options, vesting of restricted stock, and related tax withholdings (948)       (948)    
Stock-based incentive compensation 10,407       10,407    
Purchase of company stock, and related tax effects (42,388)     (42,388)      
Net income 53,856         53,856  
Other comprehensive income (loss) (6,127)           (6,127)
Ending balance at Sep. 30, 2024 $ 1,426,231 $ 0 $ 18 $ (416,552) $ 1,224,059 $ 609,203 $ 9,503
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
Corporate Organization and Business — Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 92 full service pharmacies and 93 stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company’s stock is listed on the Nasdaq Global Select Market as of September 30, 2024.
Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.
Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of September 30, 2024, cash equivalents consisted of money market funds.
Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $45.9 million and $52.0 million as of September 30, 2024 and December 31, 2023, respectively.
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the balance of the investments was $23.6 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $3.9 million for the three and nine months ended September 30, 2024, respectively. The Company’s proportionate share of earnings was $1.3 million and $4.1 million for the three and nine months ended September 30, 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively. See Note 15, Related-Party Transactions, for discussion of related-party transactions with these investees.
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% for the three and nine months ended September 30, 2024. Revenue related to the Company’s largest payer was approximately 14% for the three and nine months ended September 30, 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.
For the three and nine months ended September 30, 2024, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2023, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of September 30, 2024 and December 31, 2023, approximately 10% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the three and nine months ended September 30, 2024, approximately 68% and 67%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. For the three and nine months ended September 30, 2023, approximately 73% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery, losses in revenue or decreased gross profit dollars, which could adversely affect the Company’s financial condition or operating results.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Commercial payers$1,109,971 $957,601 $3,160,490 $2,765,513 
Government payers147,005 124,122 424,033 370,648 
Patients21,570 11,291 67,261 41,773 
Net revenue$1,278,546 $1,093,014 $3,651,784 $3,177,934 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
During the three and nine months ended September 30, 2024, the Company recorded tax expense of $19.7 million and $50.9 million, respectively, which represents an effective tax rate of 26.8% and 25.1%, respectively. The variance in the Company’s effective tax rate of 26.8% and 25.1% for the three and nine months ended September 30, 2024, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the nine months ended September 30, 2024, the Company released $2.2 million of state valuation allowance. On June 26, 2023, the Company entered into an agreement to terminate the merger agreement (the “Mutual Termination Agreement”) with Amedisys, Inc. (“Amedisys”). Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys (“Termination Fee”). During the three months ended September 30, 2023, the Company recorded tax expense of $13.8 million. During the nine months ended September 30, 2023, the Company recorded tax expense of $69.9 million, which includes $22.1 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. The tax expense for the three and nine months ended September 30, 2023 represents an effective tax rate of 19.7% and 25.0%, respectively. The variance in the Company’s effective tax rate of 19.7% and 25.0% for the three and nine months ended September 30, 2023, respectively, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 26.8% for the three months ended September 30, 2024, compared to 19.7% for the three months ended September 30, 2023 was primarily due to change in state valuation allowance. In September 2023, the Company released $5.8 million of state valuation allowance.
The Company maintains a valuation allowance of $4.2 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.
The Company’s tax expense of $19.7 million and $50.9 million for the three and nine months ended September 30, 2024, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense. The Company’s tax expense of $13.8 million and $69.9 million for the three and nine months ended September 30, 2023, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.
The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (“Code”) Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER SHARE
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three and nine months ended September 30, 2024 and 2023 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock option awards779,876 984,567 855,323 1,180,376 
Restricted stock awards324,877 16,564 365,835 569,831 
Performance stock unit awards— — 257,735 288,680 
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net income (1)$53,856 $56,302 $151,690 $209,913 
Denominator:
Weighted average number of common shares outstanding170,636 178,826 172,490 179,956 
Earnings per common share:
Earnings per common share, basic$0.32 $0.31 $0.88 $1.17 
(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Numerator:
Net income (1)$53,856 $56,302 $151,690 $209,913 
Denominator:
Weighted average number of common shares outstanding170,636 178,826 172,490 179,956 
Effect of dilutive securities1,305 1,702 1,358 1,330 
Weighted average number of common shares outstanding, diluted171,941 180,528 173,848 181,286 
Earnings per common share:
Earnings per common share, diluted$0.31 $0.31 $0.87 $1.16 
(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
LEASES LEASES
During the three and nine months ended September 30, 2024, the Company incurred operating lease expenses of $8.6 million and $25.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2023, the Company incurred operating lease expenses of $7.8 million and $22.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of September 30, 2024, the weighted-average remaining lease term was 6.5 years and the weighted-average discount rate was 6.49%.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2024$7,464 
202528,646 
202625,880 
202720,554 
202813,517 
Thereafter43,813 
Total lease payments139,874 
Less: interest(29,982)
Present value of lease liabilities$109,892 
During the nine months ended September 30, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $23.0 million related to increases in the operating lease right-of-use assets and operating lease liabilities. During the nine months ended September 30, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $26.1 million related to increases in the operating lease right-of-use assets and operating lease liabilities. As of September 30, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.
LEASES LEASES
During the three and nine months ended September 30, 2024, the Company incurred operating lease expenses of $8.6 million and $25.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2023, the Company incurred operating lease expenses of $7.8 million and $22.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of September 30, 2024, the weighted-average remaining lease term was 6.5 years and the weighted-average discount rate was 6.49%.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2024$7,464 
202528,646 
202625,880 
202720,554 
202813,517 
Thereafter43,813 
Total lease payments139,874 
Less: interest(29,982)
Present value of lease liabilities$109,892 
During the nine months ended September 30, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $23.0 million related to increases in the operating lease right-of-use assets and operating lease liabilities. During the nine months ended September 30, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow of $26.1 million related to increases in the operating lease right-of-use assets and operating lease liabilities. As of September 30, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3
PROPERTY AND EQUIPMENT
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
Property and equipment was as follows as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Infusion pumps$36,476 $36,943 
Equipment, furniture and other30,124 23,593 
Leasehold improvements117,827 99,725 
Computer software, purchased and internally developed52,513 50,572 
Assets under development26,007 33,668 
262,947 244,501 
Less: accumulated depreciation(137,036)(123,871)
Property and equipment, net$125,911 $120,630 
Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Depreciation expense in cost of revenue$568 $616 $1,735 $2,006 
Depreciation expense in operating expenses6,063 6,365 18,485 18,665 
Total depreciation expense$6,631 $6,981 $20,220 $20,671 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
There was no change in the carrying amount of goodwill for the three and nine months ended September 30, 2024.
The carrying amount and accumulated amortization of intangible assets consist of the following as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Gross intangible assets:
Referral sources$514,388 $514,388 
Trademarks/names39,136 39,136 
Other amortizable intangible assets985 995 
Total gross intangible assets554,509 554,519 
Accumulated amortization:
Referral sources(222,549)(199,084)
Trademarks/names(21,874)(19,698)
Other amortizable intangible assets(479)(341)
Total accumulated amortization(244,902)(219,123)
Total intangible assets, net$309,607 $335,396 
Amortization expense for intangible assets was $8.6 million and $25.8 million for the three and nine months ended September 30, 2024, respectively. Amortization expense for intangible assets was $8.6 million and $25.6 million for the three and nine months ended September 30, 2023, respectively.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3
INDEBTEDNESS
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
INDEBTEDNESS INDEBTEDNESS
Long-term debt consisted of the following as of September 30, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan633,244 (5,885)(8,030)619,329 
Senior Notes500,000 — (7,711)492,289 
$1,133,244 $(5,885)$(15,741)1,111,618 
Less: current portion(6,512)
Total long-term debt$1,105,106 
Long-term debt consisted of the following as of December 31, 2023 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan588,000 (6,974)(9,678)571,348 
Senior Notes500,000 — (8,698)491,302 
$1,088,000 $(6,974)$(18,376)1,062,650 
Less: current portion(6,000)
Total long-term debt$1,056,650 
On May 8, 2024, the Company entered into the third amendment to the amended and restated First Lien Credit Agreement (the “Third Amendment”). The Third Amendment, among other things, reduces the interest rate on the First Lien Term Loan from Term Secured Overnight Financing Rate (“SOFR”) (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25%, increases borrowings by $50.0 million, and removes the credit spread adjustment with respect to such First Lien Term Loan.
The interest rate on the First Lien Term Loan was 7.50% and 8.21% as of September 30, 2024 and December 31, 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.56% and 7.84% for the three and nine months ended September 30, 2024, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 8.11% and 7.71% for the three and nine months ended September 30, 2023, respectively. The interest rate on the Senior Notes was 4.375% as of September 30, 2024 and December 31, 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three and nine months ended September 30, 2024. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three and nine months ended September 30, 2023.
The Company assessed whether the repayment of the First Lien Term Loan indebtedness resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the First Lien Term Loan and Senior Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $0.4 million of the First Lien Term Loan was extinguished. The First Lien Term Loan had insubstantial modifications for lenders that participated in both debt instruments, which resulted in a cash inflow from financing activities of $50.0 million in the unaudited condensed consolidated statements of cash flows. The Company incurred $1.6 million in fees, of which $0.1 million was capitalized, relative to the First Lien Term Loan and an immaterial amount of the total fees incurred was netted against the $50.0 million of debt proceeds as financing activities within the unaudited condensed consolidated statements of cash flows.
The Company recognized a loss on extinguishment of debt of $0.4 million included in the line entitled “Other, net” in the unaudited condensed consolidated statements of comprehensive income.
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2024$1,628 
20256,512 
20266,512 
20276,512 
2028612,080 
Thereafter500,000 
Total$1,133,244 
During the three and nine months ended September 30, 2024 and 2023, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 10, Derivative Instruments, for further discussion.
The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2024 (in thousands):
Financial Instrument
Carrying Value as of September 30, 2024
Markets for Identical Item (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
First Lien Term Loan$619,329 $— $634,827 $— 
Senior Notes492,289 — 475,000 — 
Total debt instruments$1,111,618 $— $1,109,827 $— 
See Note 11, Fair Value Measurements, for further discussion.
On December 7, 2023, the Company entered into the second amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (the “Second Amendment”). The Second Amendment, among other things, provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of $400.0 million (the “Revolver Facility”), pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company. As of September 30, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS
 9 Months Ended
Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS DERIVATIVE INSTRUMENTS
The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.
In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a 5-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.
The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionSeptember 30, 2024December 31, 2023
Interest rate cap designated as cash flow hedgePrepaid expenses and other current assets$7,223 $9,746 
Interest rate cap designated as cash flow hedgeOther noncurrent assets5,446 10,183 
Total derivative assets$12,669 $19,929 
The (loss) gain associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
Derivative2024202320242023
Interest rate cap designated as cash flow hedge$(8,125)$45 $(7,260)$(156)
The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
DerivativeIncome Statement Caption2024202320242023
Interest rate cap designated as cash flow hedgeInterest expense, net$3,056 $2,931 $9,005 $8,002 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3
FAIR VALUE MEASURMENTS
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:
•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).
There were no other material assets or liabilities measured at fair value at September 30, 2024 and December 31, 2023.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.
The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.
However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3
STOCK-BASED INCENTIVE COMPENSATION
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED INCENTIVE COMPENSATION STOCK-BASED INCENTIVE COMPENSATION
Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip, Inc. (“BioScrip”) stockholders on May 3, 2018 and amended and restated on May 19, 2021 and May 15, 2024, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. As of May 2021, a total of 9,101,734 shares of common stock were authorized for issuance under the 2018 Plan. In May 2024, an additional 4,000,000 shares were authorized for issuance under the 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of September 30, 2024 and 2023. During the three and nine months ended September 30, 2024, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $10.4 million and $27.6 million, respectively. During the three and nine months ended September 30, 2023, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $9.2 million and $22.9 million, respectively.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
2017 Warrants — During the three and nine months ended September 30, 2024, warrant holders did not elect to exercise any warrants to purchase shares of common stock. During the three and nine months ended September 30, 2023, warrant holders elected to exercise 188,350 warrants to purchase shares of common stock. As of September 30, 2024 and December 31, 2023, the remaining warrant holders are entitled to purchase 51,838 shares of common stock.
2015 Warrants — During the three and nine months ended September 30, 2024, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. During the three and nine months ended September 30, 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. As of September 30, 2024 and December 31, 2023, the remaining warrant holders are entitled to purchase 11,775 and 13,888 shares of common stock, respectively.
Share Repurchase Program — The Company’s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.
During the three and nine months ended September 30, 2024, the Company purchased 1,399,674 and 5,317,183 shares of common stock for an average share price of $29.97 and $30.09, totaling $41.9 million and $160.0 million, respectively. During the three and nine months ended September 30, 2023, the Company purchased 2,913,520 and 5,388,686 shares of common stock for an average share price of $34.32 and $32.48, totaling $100.0 million and $175.0 million, respectively. All repurchased shares became treasury stock. As of September 30, 2024, the Company is authorized to repurchase up to a remaining $90.0 million of common stock of the Company.
Shares Outstanding — The following table shows the Company’s changes in shares of common stock for the three and nine months ended September 30, 2024 and 2023 (in thousands):
20242023
Balance, beginning of the year174,576 181,958 
Equity award issuances492 274 
Share repurchases(1,252)(2,475)
Balance March 31,173,816 179,757 
Equity award issuances261 114 
Share repurchases(2,666)— 
Balance June 30,171,411 179,871 
Equity award issuances135 172 
Share repurchases(1,400)(2,914)
Balance September 30,170,146 177,129 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3
RELATED-PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONS
Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.6 million and $4.5 million for the three and nine months ended September 30, 2024, respectively. The Company recorded management fee income of $1.3 million and $3.9 million for the three and nine months ended September 30, 2023, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively.
The Company had amounts due from its joint ventures of $0.6 million and due to its joint ventures of $0.8 million as of September 30, 2024. The Company had amounts due from its joint ventures of $0.1 million and due to its joint ventures of $0.5 million as of December 31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net income $ 53,856 $ 53,043 $ 44,791 $ 56,302 $ 114,403 $ 39,208 $ 151,690 $ 209,913
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.
Principles of Consolidation
Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
Cash and Cash Equivalents
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of September 30, 2024, cash equivalents consisted of money market funds.
Equity -Method Investments
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the balance of the investments was $23.6 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $3.9 million for the three and nine months ended September 30, 2024, respectively. The Company’s proportionate share of earnings was $1.3 million and $4.1 million for the three and nine months ended September 30, 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively. See Note 15, Related-Party Transactions, for discussion of related-party transactions with these investees.
Concentrations of Business Risk
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% for the three and nine months ended September 30, 2024. Revenue related to the Company’s largest payer was approximately 14% for the three and nine months ended September 30, 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.
For the three and nine months ended September 30, 2024, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2023, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. As of September 30, 2024 and December 31, 2023, approximately 10% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the three and nine months ended September 30, 2024, approximately 68% and 67%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. For the three and nine months ended September 30, 2023, approximately 73% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery, losses in revenue or decreased gross profit dollars, which could adversely affect the Company’s financial condition or operating results.
Fair Value Measurements FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:
•Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).
There were no other material assets or liabilities measured at fair value at September 30, 2024 and December 31, 2023.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Net Revenue Earned by Category of Payer
The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Commercial payers$1,109,971 $957,601 $3,160,490 $2,765,513 
Government payers147,005 124,122 424,033 370,648 
Patients21,570 11,291 67,261 41,773 
Net revenue$1,278,546 $1,093,014 $3,651,784 $3,177,934 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock option awards779,876 984,567 855,323 1,180,376 
Restricted stock awards324,877 16,564 365,835 569,831 
Performance stock unit awards— — 257,735 288,680 
Schedule of Basic and Diluted Earnings Per Share
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net income (1)$53,856 $56,302 $151,690 $209,913 
Denominator:
Weighted average number of common shares outstanding170,636 178,826 172,490 179,956 
Earnings per common share:
Earnings per common share, basic$0.32 $0.31 $0.88 $1.17 
(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended September 30,Nine Months Ended September 30,
 2024202320242023
Numerator:
Net income (1)$53,856 $56,302 $151,690 $209,913 
Denominator:
Weighted average number of common shares outstanding170,636 178,826 172,490 179,956 
Effect of dilutive securities1,305 1,702 1,358 1,330 
Weighted average number of common shares outstanding, diluted171,941 180,528 173,848 181,286 
Earnings per common share:
Earnings per common share, diluted$0.31 $0.31 $0.87 $1.16 
(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES (Tables)
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Schedule of Maturities of Lease Liabilities, Operating
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2024$7,464 
202528,646 
202625,880 
202720,554 
202813,517 
Thereafter43,813 
Total lease payments139,874 
Less: interest(29,982)
Present value of lease liabilities$109,892 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3
PROPERTY AND EQUIPMENT (Tables)
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment was as follows as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Infusion pumps$36,476 $36,943 
Equipment, furniture and other30,124 23,593 
Leasehold improvements117,827 99,725 
Computer software, purchased and internally developed52,513 50,572 
Assets under development26,007 33,668 
262,947 244,501 
Less: accumulated depreciation(137,036)(123,871)
Property and equipment, net$125,911 $120,630 
The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Depreciation expense in cost of revenue$568 $616 $1,735 $2,006 
Depreciation expense in operating expenses6,063 6,365 18,485 18,665 
Total depreciation expense$6,631 $6,981 $20,220 $20,671 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets
The carrying amount and accumulated amortization of intangible assets consist of the following as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Gross intangible assets:
Referral sources$514,388 $514,388 
Trademarks/names39,136 39,136 
Other amortizable intangible assets985 995 
Total gross intangible assets554,509 554,519 
Accumulated amortization:
Referral sources(222,549)(199,084)
Trademarks/names(21,874)(19,698)
Other amortizable intangible assets(479)(341)
Total accumulated amortization(244,902)(219,123)
Total intangible assets, net$309,607 $335,396 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3
INDEBTEDNESS (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
Long-term debt consisted of the following as of September 30, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan633,244 (5,885)(8,030)619,329 
Senior Notes500,000 — (7,711)492,289 
$1,133,244 $(5,885)$(15,741)1,111,618 
Less: current portion(6,512)
Total long-term debt$1,105,106 
Long-term debt consisted of the following as of December 31, 2023 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan588,000 (6,974)(9,678)571,348 
Senior Notes500,000 — (8,698)491,302 
$1,088,000 $(6,974)$(18,376)1,062,650 
Less: current portion(6,000)
Total long-term debt$1,056,650 
Schedule of Long-term Debt Maturities
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2024$1,628 
20256,512 
20266,512 
20276,512 
2028612,080 
Thereafter500,000 
Total$1,133,244 
Schedule of Estimated Fair Values of Debt Obligations
The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2024 (in thousands):
Financial Instrument
Carrying Value as of September 30, 2024
Markets for Identical Item (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
First Lien Term Loan$619,329 $— $634,827 $— 
Senior Notes492,289 — 475,000 — 
Total debt instruments$1,111,618 $— $1,109,827 $— 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS (Tables)
 9 Months Ended
Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Amount and Location of Derivatives in the Balance Sheet
The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionSeptember 30, 2024December 31, 2023
Interest rate cap designated as cash flow hedgePrepaid expenses and other current assets$7,223 $9,746 
Interest rate cap designated as cash flow hedgeOther noncurrent assets5,446 10,183 
Total derivative assets$12,669 $19,929 
Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss) The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
Derivative2024202320242023
Interest rate cap designated as cash flow hedge$(8,125)$45 $(7,260)$(156)
The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
DerivativeIncome Statement Caption2024202320242023
Interest rate cap designated as cash flow hedgeInterest expense, net$3,056 $2,931 $9,005 $8,002 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Changes in Shares of Common Stock The following table shows the Company’s changes in shares of common stock for the three and nine months ended September 30, 2024 and 2023 (in thousands):
20242023
Balance, beginning of the year174,576 181,958 
Equity award issuances492 274 
Share repurchases(1,252)(2,475)
Balance March 31,173,816 179,757 
Equity award issuances261 114 
Share repurchases(2,666)— 
Balance June 30,171,411 179,871 
Equity award issuances135 172 
Share repurchases(1,400)(2,914)
Balance September 30,170,146 177,129 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)
 9 Months Ended
Sep. 30, 2024
suite
segment
pharmacy
Business Acquisition [Line Items]  
Number of service locations | pharmacy 92
Number of infusion sites | suite 93
Number of operating segments | segment 1
Legacy Health Systems  
Business Acquisition [Line Items]  
Ownership interest (as a percent) 50.00%
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Concentration Risk [Line Items]          
Rebate receivable $ 45,900   $ 45,900   $ 52,000
Investments in equity-method investees 23,600   23,600   $ 20,900
Proportionate share of earnings in equity-method investees $ 1,400 $ 1,300 3,921 $ 4,107  
Distributions received from the investees     $ 1,250 $ 4,000  
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 11.00% 11.00% 12.00% 12.00%  
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent)     10.00%   12.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 68.00% 73.00% 67.00% 73.00%  
Largest Payer | Revenue from Contract with Customer Benchmark | Company's Largest Payer          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 15.00% 14.00% 15.00% 14.00%  
Joint Venture          
Concentration Risk [Line Items]          
Distributions received from the investees $ 500 $ 1,500 $ 1,300 $ 4,000  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Net revenue $ 1,278,546 $ 1,093,014 $ 3,651,784 $ 3,177,934
Commercial payers        
Disaggregation of Revenue [Line Items]        
Net revenue 1,109,971 957,601 3,160,490 2,765,513
Government payers        
Disaggregation of Revenue [Line Items]        
Net revenue 147,005 124,122 424,033 370,648
Patients        
Disaggregation of Revenue [Line Items]        
Net revenue $ 21,570 $ 11,291 $ 67,261 $ 41,773
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3
INCOME TAXES (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 26, 2023
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Examination [Line Items]            
Income tax expense     $ 19,698 $ 13,783 $ 50,860 $ 69,904
Effective tax rate (as a percent)     26.80% 19.70% 25.10% 25.00%
Termination fee income           $ 22,100
Amedisys            
Income Tax Examination [Line Items]            
Termination fee $ 106,000         $ 62,800
State Jurisdiction            
Income Tax Examination [Line Items]            
Release of valuation allowance   $ 5,800     $ 2,200  
Valuation allowance     $ 4,200   $ 4,200  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Stock option awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded (in shares) 779,876 984,567 855,323 1,180,376
Restricted stock awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded (in shares) 324,877 16,564 365,835 569,831
Performance stock unit awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded (in shares) 0 0 257,735 288,680
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3
EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Jun. 26, 2023
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:                  
Net income   $ 53,856 $ 53,043 $ 44,791 $ 56,302 $ 114,403 $ 39,208 $ 151,690 $ 209,913
Denominator:                  
Weighted average number of common shares outstanding (in shares)   170,636     178,826     172,490 179,956
Effect of dilutive securities (in shares)   1,305     1,702     1,358 1,330
Weighted average number of common shares outstanding, diluted (in shares)   171,941     180,528     173,848 181,286
Earnings per common share, basic                  
Earnings per common share, basic (in dollars per share)   $ 0.32     $ 0.31     $ 0.88 $ 1.17
Earnings per common share, diluted                  
Earnings per common share, diluted (in dollars per share)   $ 0.31     $ 0.31     $ 0.87 $ 1.16
Amedisys                  
Earnings per common share, diluted                  
Termination fee $ 106,000               $ 62,800
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Leases [Abstract]        
Operating lease cost $ 8.6 $ 7.8 $ 25.3 $ 22.3
Weighted-average remaining lease term, operating leases (in years) 6 years 6 months   6 years 6 months  
Weighted-average discount rate, operating leases (as a percent) 6.49%   6.49%  
Increase in operating lease right-of-use asset and lease liabilities     $ 23.0 $ 26.1
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3
LEASES - Schedule of Operating Leases Mature (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Minimum Payments  
2024 $ 7,464
2025 28,646
2026 25,880
2027 20,554
2028 13,517
Thereafter 43,813
Total lease payments 139,874
Less: interest (29,982)
Present value of lease liabilities $ 109,892
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 262,947   $ 262,947   $ 244,501
Less: accumulated depreciation (137,036)   (137,036)   (123,871)
Property and equipment, net 125,911   125,911   120,630
Total depreciation expense 6,631 $ 6,981 20,220 $ 20,671  
Depreciation expense in cost of revenue          
Property, Plant and Equipment [Line Items]          
Total depreciation expense 568 616 1,735 2,006  
Depreciation expense in operating expenses          
Property, Plant and Equipment [Line Items]          
Total depreciation expense 6,063 $ 6,365 18,485 $ 18,665  
Infusion pumps          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 36,476   36,476   36,943
Equipment, furniture and other          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 30,124   30,124   23,593
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 117,827   117,827   99,725
Computer software, purchased and internally developed          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 52,513   52,513   50,572
Assets under development          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 26,007   $ 26,007   $ 33,668
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3
GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]          
Total gross intangible assets $ 554,509   $ 554,509   $ 554,519
Total accumulated amortization (244,902)   (244,902)   (219,123)
Total intangible assets, net 309,607   309,607   335,396
Amortization expense for intangible assets 8,600 $ 8,600 25,800 $ 25,600  
Referral sources          
Finite-Lived Intangible Assets [Line Items]          
Total gross intangible assets 514,388   514,388   514,388
Total accumulated amortization (222,549)   (222,549)   (199,084)
Trademarks/names          
Finite-Lived Intangible Assets [Line Items]          
Total gross intangible assets 39,136   39,136   39,136
Total accumulated amortization (21,874)   (21,874)   (19,698)
Other amortizable intangible assets          
Finite-Lived Intangible Assets [Line Items]          
Total gross intangible assets 985   985   995
Total accumulated amortization $ (479)   $ (479)   $ (341)
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3
INDEBTEDNESS - Schedule of Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
May 08, 2024
Dec. 31, 2023
Debt Instrument [Line Items]      
Principal Amount $ 1,133,244   $ 1,088,000
Discount (5,885)   (6,974)
Debt Issuance Costs (15,741)   (18,376)
Net Balance 1,111,618   1,062,650
Less: current portion (6,512)   (6,000)
Total long-term debt 1,105,106   1,056,650
Senior Notes | First Lien Term Loan      
Debt Instrument [Line Items]      
Principal Amount 633,244   588,000
Discount (5,885)   (6,974)
Debt Issuance Costs (8,030) $ (100) (9,678)
Net Balance 619,329   571,348
Senior Notes | Senior Notes      
Debt Instrument [Line Items]      
Principal Amount 500,000   500,000
Discount 0   0
Debt Issuance Costs (7,711)   (8,698)
Net Balance 492,289   491,302
Revolver Facility | Senior Notes      
Debt Instrument [Line Items]      
Principal Amount 0   0
Discount 0   0
Debt Issuance Costs 0   0
Net Balance $ 0   $ 0
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3
INDEBTEDNESS - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
May 08, 2024
May 07, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 07, 2023
Debt Instrument [Line Items]                
Repayment of debt         $ 4,756,000 $ 4,500,000    
Cash outflow from financing activities         (122,827,000) (187,298,000)    
Debt issuance costs     $ 15,741,000   15,741,000   $ 18,376,000  
Proceeds from issuance of debt         49,959,000 0    
Loss on extinguishment of debt         377,000 $ 0    
Senior Notes | Revolver Facility                
Debt Instrument [Line Items]                
Debt issuance costs     0   0   $ 0  
First Lien Credit Agreement, Third Amendment | Senior Notes | Revolver Facility                
Debt Instrument [Line Items]                
Undrawn letters of credit issued and outstanding     $ 4,100,000   $ 4,100,000      
First Lien Credit Agreement, Third Amendment | First Lien Term Loan | Senior Notes                
Debt Instrument [Line Items]                
Debt instrument, basis spread (as a percent) 2.25% 2.75%            
Debt instrument, face amount $ 50,000,000              
Effective rate on term loans at end of period (as a percent)     7.50%   7.50%   8.21%  
Weighted average interest rate paid on term loans during period (as a percent)     7.56% 8.11% 7.84% 7.71%    
First Lien Credit Agreement, Third Amendment | Second Lien Term Loan | Senior Notes                
Debt Instrument [Line Items]                
Effective rate on term loans at end of period (as a percent)     4.375%   4.375%   4.375%  
Weighted average interest rate paid on term loans during period (as a percent)     4.375% 4.375% 4.375% 4.375%    
First Lien Term Loan | Senior Notes                
Debt Instrument [Line Items]                
Cash outflow from financing activities         $ 50,000,000      
Legal fees 1,600,000              
Debt issuance costs $ 100,000   $ 8,030,000   8,030,000   $ 9,678,000  
Proceeds from issuance of debt         50,000,000      
Loss on extinguishment of debt         400,000      
First Lien Term Loan | First Lien Term Loan | Senior Notes                
Debt Instrument [Line Items]                
Repayment of debt         400,000      
Second Lien Credit Agreement | Senior Notes | Revolver Facility                
Debt Instrument [Line Items]                
Debt instrument, face amount               $ 400,000,000
Available borrowing capacity     $ 395,900,000   $ 395,900,000      
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3
INDEBTEDNESS - Schedule of Long Term Debt Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
2024 $ 1,628  
2025 6,512  
2026 6,512  
2027 6,512  
2028 612,080  
Thereafter 500,000  
Total $ 1,133,244 $ 1,088,000
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3
INDEBTEDNESS - Schedule of Estimated Fair Values of Debt Obligations (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Debt Instrument [Line Items]  
Total debt instruments $ 1,111,618
Markets for Identical Item (Level 1)  
Debt Instrument [Line Items]  
Total debt instruments 0
Significant Other Observable Inputs (Level 2)  
Debt Instrument [Line Items]  
Total debt instruments 1,109,827
Significant Unobservable Inputs (Level 3)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes  
Debt Instrument [Line Items]  
Total debt instruments 492,289
Senior Notes | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 619,329
Senior Notes | Markets for Identical Item (Level 1)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Markets for Identical Item (Level 1) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Significant Other Observable Inputs (Level 2)  
Debt Instrument [Line Items]  
Total debt instruments 475,000
Senior Notes | Significant Other Observable Inputs (Level 2) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 634,827
Senior Notes | Significant Unobservable Inputs (Level 3)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Significant Unobservable Inputs (Level 3) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments $ 0
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Additional Information (Details) - First Lien Term Loan - Interest rate cap designated as cash flow hedge - Designated as Hedging Instrument - Senior Notes
 1 Months Ended
Oct. 31, 2021
USD ($)
Derivative [Line Items]  
Notional amount of derivative $ 300,000,000
Derivative, term of contract (in years) 5 years
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Schedule of Amount and Location of Derivatives in the Balance Sheet (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Derivative [Line Items]    
Total derivative assets $ 12,669 $ 19,929
Designated as Hedging Instrument | Prepaid expenses and other current assets | Interest rate cap designated as cash flow hedge    
Derivative [Line Items]    
Total derivative assets 7,223 9,746
Designated as Hedging Instrument | Other noncurrent assets | Interest rate cap designated as cash flow hedge    
Derivative [Line Items]    
Total derivative assets $ 5,446 $ 10,183
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3
DERIVATIVE INSTRUMENTS - Schedule of Pre-tax Gain (Loss) on Derivative Instruments (Details) - Interest rate cap designated as cash flow hedge - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Derivative [Line Items]        
Interest rate cap designated as cash flow hedge $ (8,125) $ 45 $ (7,260) $ (156)
Interest expense, net        
Derivative [Line Items]        
Interest rate cap designated as cash flow hedge $ 3,056 $ 2,931 $ 9,005 $ 8,002
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3
STOCK-BASED INCENTIVE COMPENSATION (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
May 31, 2021
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]            
Number of shares authorized (in shares) 13,101,734          
2018 Plan            
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]            
Number of shares authorized (in shares)           9,101,734
Number of additional shares authorized (in shares) 4,000,000          
2018 Plan | HC I Incentive Units            
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]            
Share-based compensation expense   $ 10.4 $ 9.2 $ 27.6 $ 22.9  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Class of Warrant or Right [Line Items]          
Treasury stock, shares, acquired (in shares) 1,399,674 2,913,520 5,317,183 5,388,686  
Treasury stock acquired, average cost per share (in dollars per share) $ 29.97 $ 34.32 $ 30.09 $ 32.48  
Shares repurchased $ 41.9 $ 100.0 $ 160.0 $ 175.0  
Stock repurchase program, authorized amount $ 90.0   $ 90.0    
Common Stock Repurchase Program          
Class of Warrant or Right [Line Items]          
Number of shares authorized to be repurchased (in shares) 500,000,000   500,000,000    
2017 Warrants | Common Stock          
Class of Warrant or Right [Line Items]          
Number of warrants exercised (in shares) 0 188,350 0 188,350  
Class of warrant or right, outstanding (in shares) 51,838   51,838   51,838
2015 Warrants | Common Stock          
Class of Warrant or Right [Line Items]          
Number of warrants exercised (in shares) 0 0 0 0  
Class of warrant or right, outstanding (in shares) 11,775   11,775   13,888
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) - shares
 3 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Balance, beginning of the year     174,575,537      
Balance, end of the period 170,146,331          
Common Stock            
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Balance, beginning of the year 171,411,000 173,816,000 174,576,000 179,871,000 179,757,000 181,958,000
Equity award issuances 135,000 261,000 492,000 172,000 114,000 274,000
Share repurchases (1,400,000) (2,666,000) (1,252,000) (2,914,000) 0 (2,475,000)
Balance, end of the period 170,146,000 171,411,000 173,816,000 177,129,000 179,871,000 179,757,000
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3
RELATED-PARTY TRANSACTIONS (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Related Party Transaction [Line Items]          
Management fee income $ 1,278,546 $ 1,093,014 $ 3,651,784 $ 3,177,934  
Distributions received from the investees     1,250 4,000  
Joint Venture          
Related Party Transaction [Line Items]          
Management fee income 1,600 1,300 4,500 3,900  
Distributions received from the investees 500 $ 1,500 1,300 $ 4,000  
Due from joint ventures 600   600   $ 100
Due to joint ventures $ 800   $ 800   $ 500
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 240 240 1 false 56 0 false 7 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.bioscrip.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 4 false false R5.htm 9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Statements 5 false false R6.htm 9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 7 false false R8.htm 9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Sheet http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Notes 8 false false R9.htm 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 9952159 - Disclosure - REVENUE Sheet http://www.bioscrip.com/role/REVENUE REVENUE Notes 10 false false R11.htm 9952160 - Disclosure - INCOME TAXES Sheet http://www.bioscrip.com/role/INCOMETAXES INCOME TAXES Notes 11 false false R12.htm 9952161 - Disclosure - EARNINGS PER SHARE Sheet http://www.bioscrip.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 12 false false R13.htm 9952162 - Disclosure - LEASES Sheet http://www.bioscrip.com/role/LEASES LEASES Notes 13 false false R14.htm 9952163 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 14 false false R15.htm 9952164 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 15 false false R16.htm 9952165 - Disclosure - INDEBTEDNESS Sheet http://www.bioscrip.com/role/INDEBTEDNESS INDEBTEDNESS Notes 16 false false R17.htm 9952166 - Disclosure - DERIVATIVE INSTRUMENTS Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS DERIVATIVE INSTRUMENTS Notes 17 false false R18.htm 9952167 - Disclosure - FAIR VALUE MEASURMENTS Sheet http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS FAIR VALUE MEASURMENTS Notes 18 false false R19.htm 9952168 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 9952169 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION STOCK-BASED INCENTIVE COMPENSATION Notes 20 false false R21.htm 9952170 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 21 false false R22.htm 9952171 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS RELATED-PARTY TRANSACTIONS Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 9954472 - Disclosure - REVENUE (Tables) Sheet http://www.bioscrip.com/role/REVENUETables REVENUE (Tables) Tables http://www.bioscrip.com/role/REVENUE 26 false false R27.htm 9954473 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.bioscrip.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.bioscrip.com/role/EARNINGSPERSHARE 27 false false R28.htm 9954474 - Disclosure - LEASES (Tables) Sheet http://www.bioscrip.com/role/LEASESTables LEASES (Tables) Tables http://www.bioscrip.com/role/LEASES 28 false false R29.htm 9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT 29 false false R30.htm 9954476 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 30 false false R31.htm 9954477 - Disclosure - INDEBTEDNESS (Tables) Sheet http://www.bioscrip.com/role/INDEBTEDNESSTables INDEBTEDNESS (Tables) Tables http://www.bioscrip.com/role/INDEBTEDNESS 31 false false R32.htm 9954478 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables DERIVATIVE INSTRUMENTS (Tables) Tables http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS 32 false false R33.htm 9954479 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.bioscrip.com/role/STOCKHOLDERSEQUITY 33 false false R34.htm 9954480 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) Sheet http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) Details http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS 34 false false R35.htm 9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 35 false false R36.htm 9954482 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details) Sheet http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails REVENUE - Net Revenue Earned by Category of Payer (Details) Details 36 false false R37.htm 9954483 - Disclosure - INCOME TAXES (Details) Sheet http://www.bioscrip.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.bioscrip.com/role/INCOMETAXES 37 false false R38.htm 9954484 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 38 false false R39.htm 9954485 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) Sheet http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) Details 39 false false R40.htm 9954486 - Disclosure - LEASES - Additional Information (Details) Sheet http://www.bioscrip.com/role/LEASESAdditionalInformationDetails LEASES - Additional Information (Details) Details 40 false false R41.htm 9954487 - Disclosure - LEASES - Schedule of Operating Leases Mature (Details) Sheet http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails LEASES - Schedule of Operating Leases Mature (Details) Details 41 false false R42.htm 9954488 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables 42 false false R43.htm 9954489 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) Details 43 false false R44.htm 9954490 - Disclosure - INDEBTEDNESS - Schedule of Debt (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails INDEBTEDNESS - Schedule of Debt (Details) Details 44 false false R45.htm 9954491 - Disclosure - INDEBTEDNESS - Additional Information (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails INDEBTEDNESS - Additional Information (Details) Details 45 false false R46.htm 9954492 - Disclosure - INDEBTEDNESS - Schedule of Long Term Debt Maturities (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails INDEBTEDNESS - Schedule of Long Term Debt Maturities (Details) Details 46 false false R47.htm 9954493 - Disclosure - INDEBTEDNESS - Schedule of Estimated Fair Values of Debt Obligations (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails INDEBTEDNESS - Schedule of Estimated Fair Values of Debt Obligations (Details) Details 47 false false R48.htm 9954494 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails DERIVATIVE INSTRUMENTS - Additional Information (Details) Details 48 false false R49.htm 9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Amount and Location of Derivatives in the Balance Sheet (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails DERIVATIVE INSTRUMENTS - Schedule of Amount and Location of Derivatives in the Balance Sheet (Details) Details 49 false false R50.htm 9954496 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Pre-tax Gain (Loss) on Derivative Instruments (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS - Schedule of Pre-tax Gain (Loss) on Derivative Instruments (Details) Details 50 false false R51.htm 9954497 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails STOCK-BASED INCENTIVE COMPENSATION (Details) Details http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION 51 false false R52.htm 9954498 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails STOCKHOLDERS' EQUITY - Additional Information (Details) Details 52 false false R53.htm 9954499 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) Details 53 false false R54.htm 9954500 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED-PARTY TRANSACTIONS (Details) Details http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS 54 false false All Reports Book All Reports bios-20240930.htm bios-20240930.xsd bios-20240930_cal.xml bios-20240930_def.xml bios-20240930_lab.xml bios-20240930_pre.xml bios-20240930_g1.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bios-20240930.htm": { "nsprefix": "bios", "nsuri": "http://www.bioscrip.com/20240930", "dts": { "inline": { "local": [ "bios-20240930.htm" ] }, "schema": { "local": [ "bios-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bios-20240930_cal.xml" ] }, "definitionLink": { "local": [ "bios-20240930_def.xml" ] }, "labelLink": { "local": [ "bios-20240930_lab.xml" ] }, "presentationLink": { "local": [ "bios-20240930_pre.xml" ] } }, "keyStandard": 226, "keyCustom": 14, "axisStandard": 26, "axisCustom": 0, "memberStandard": 34, "memberCustom": 22, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 240, "entityCount": 1, "segmentCount": 56, "elementCount": 522, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 681, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.bioscrip.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952153 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R5": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical", "longName": "9952154 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R7": { "role": "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952156 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-17", "name": "bios:StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R8": { "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS", "longName": "9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bioscrip.com/role/REVENUE", "longName": "9952159 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bioscrip.com/role/INCOMETAXES", "longName": "9952160 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHARE", "longName": "9952161 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bioscrip.com/role/LEASES", "longName": "9952162 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT", "longName": "9952163 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "9952164 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bioscrip.com/role/INDEBTEDNESS", "longName": "9952165 - Disclosure - INDEBTEDNESS", "shortName": "INDEBTEDNESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS", "longName": "9952166 - Disclosure - DERIVATIVE INSTRUMENTS", "shortName": "DERIVATIVE INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS", "longName": "9952167 - Disclosure - FAIR VALUE MEASURMENTS", "shortName": "FAIR VALUE MEASURMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952168 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION", "longName": "9952169 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION", "shortName": "STOCK-BASED INCENTIVE COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY", "longName": "9952170 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS", "longName": "9952171 - Disclosure - RELATED-PARTY TRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bioscrip.com/role/REVENUETables", "longName": "9954472 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHARETables", "longName": "9954473 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bioscrip.com/role/LEASESTables", "longName": "9954474 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables", "longName": "9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "longName": "9954476 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSTables", "longName": "9954477 - Disclosure - INDEBTEDNESS (Tables)", "shortName": "INDEBTEDNESS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables", "longName": "9954478 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954479 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "longName": "9954480 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)", "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "bios:NumberOfServiceLocations", "unitRef": "pharmacy", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "bios:NumberOfServiceLocations", "unitRef": "pharmacy", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "longName": "9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R36": { "role": "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "longName": "9954482 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)", "shortName": "REVENUE - Net Revenue Earned by Category of Payer (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R37": { "role": "http://www.bioscrip.com/role/INCOMETAXESDetails", "longName": "9954483 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R38": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "longName": "9954484 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-125", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "longName": "9954485 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)", "shortName": "EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R40": { "role": "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails", "longName": "9954486 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails", "longName": "9954487 - Disclosure - LEASES - Schedule of Operating Leases Mature (Details)", "shortName": "LEASES - Schedule of Operating Leases Mature (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails", "longName": "9954488 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "shortName": "PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R43": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "longName": "9954489 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R44": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "longName": "9954490 - Disclosure - INDEBTEDNESS - Schedule of Debt (Details)", "shortName": "INDEBTEDNESS - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R45": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "longName": "9954491 - Disclosure - INDEBTEDNESS - Additional Information (Details)", "shortName": "INDEBTEDNESS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-169", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R46": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails", "longName": "9954492 - Disclosure - INDEBTEDNESS - Schedule of Long Term Debt Maturities (Details)", "shortName": "INDEBTEDNESS - Schedule of Long Term Debt Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails", "longName": "9954493 - Disclosure - INDEBTEDNESS - Schedule of Estimated Fair Values of Debt Obligations (Details)", "shortName": "INDEBTEDNESS - Schedule of Estimated Fair Values of Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "longName": "9954494 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-199", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails", "longName": "9954495 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Amount and Location of Derivatives in the Balance Sheet (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Amount and Location of Derivatives in the Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails", "longName": "9954496 - Disclosure - DERIVATIVE INSTRUMENTS - Schedule of Pre-tax Gain (Loss) on Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Schedule of Pre-tax Gain (Loss) on Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-205", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-205", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails", "longName": "9954497 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Details)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-215", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-215", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails", "longName": "9954498 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)", "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "longName": "9954499 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details)", "shortName": "STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-51", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } }, "R54": { "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9954500 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)", "shortName": "RELATED-PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20240930.htm", "unique": true } } }, "tag": { "bios_A2015WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "A2015WarrantsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015 Warrants", "label": "2015 Warrants [Member]", "documentation": "2015 Warrants [Member]" } } }, "auth_ref": [] }, "bios_A2017WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "A2017WarrantsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Warrants", "label": "2017 Warrants [Member]", "documentation": "2017 Warrants [Member]" } } }, "auth_ref": [] }, "bios_A2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "A2018PlanMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 Plan", "label": "2018 Plan [Member]", "documentation": "2018 Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r70", "r674" ] }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due to joint ventures", "label": "Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": [ "r125" ] }, "bios_AccountsReceivableBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "AccountsReceivableBenchmarkMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Benchmark", "label": "Accounts Receivable, Benchmark [Member]", "documentation": "Accounts Receivable, Benchmark" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r815" ] }, "bios_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r29", "r156", "r514" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r13", "r14", "r88", "r167", "r510", "r537", "r538" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r14", "r434", "r437", "r486", "r533", "r534", "r790", "r791", "r792", "r804", "r805", "r806", "r807" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r729" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r83" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r550", "r804", "r805", "r806", "r807", "r881", "r940" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r742" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r742" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based incentive compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r43", "r44", "r358" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r775" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r704", "r714", "r724", "r756" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r776" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r742" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r749" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r705", "r715", "r725", "r749", "r757", "r761", "r769" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r767" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r387", "r391" ] }, "bios_AmedisysIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "AmedisysIncMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amedisys", "label": "Amedisys, Inc. [Member]", "documentation": "Amedisys, Inc." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r310", "r649", "r650", "r798", "r897" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r255", "r262", "r645" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r222" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AssetUnderConstructionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetUnderConstructionMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under development", "label": "Asset under Construction [Member]", "documentation": "Asset in process of being built." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r123", "r134", "r160", "r196", "r226", "r229", "r239", "r240", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r424", "r426", "r464", "r505", "r582", "r642", "r643", "r674", "r692", "r842", "r843", "r902" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r152", "r169", "r196", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r424", "r426", "r464", "r674", "r842", "r843", "r902" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r196", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r424", "r426", "r464", "r842", "r843", "r902" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "NONCURRENT ASSETS:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r764" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r765" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r760" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r763" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r762" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r761" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r273", "r907", "r908" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r54", "r57", "r273", "r907", "r908" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r256", "r257", "r258", "r259", "r260", "r421", "r662", "r663" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r45", "r46", "r256", "r257", "r258", "r259", "r260", "r421", "r662", "r663" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r421" ] }, "bios_BusinessCombinationContingentConsiderationAssetTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "BusinessCombinationContingentConsiderationAssetTerminationFee", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee", "verboseLabel": "Termination fee", "label": "Business Combination, Contingent Consideration, Asset, Termination Fee", "documentation": "Business Combination, Contingent Consideration, Asset, Termination Fee" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r69", "r106", "r107" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r18", "r154", "r635" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r19" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents - beginning of the period", "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r18", "r103", "r192" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r103" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r737" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r735" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r163", "r164", "r165", "r228", "r319", "r320", "r321", "r323", "r326", "r331", "r333", "r541", "r542", "r543", "r544", "r651", "r779", "r799" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesExercised", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants exercised (in shares)", "label": "Class of Warrant or Right, Number of Securities Exercised", "documentation": "Class of Warrant or Right, Number of Securities Exercised" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, outstanding (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r41" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r741" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r741" ] }, "bios_CommercialCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "CommercialCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial payers", "label": "Commercial Customer [Member]", "documentation": "Commercial Customer [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r112", "r275", "r276", "r631", "r833", "r837" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r682", "r683", "r684", "r686", "r687", "r688", "r689", "r804", "r805", "r807", "r881", "r938", "r940" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r82" ] }, "bios_CommonStockRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "CommonStockRepurchaseProgramMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Repurchase Program", "label": "Common Stock Repurchase Program [Member]", "documentation": "Common Stock Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r82", "r569" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "periodStartLabel": "Balance, beginning of the year", "periodEndLabel": "Balance, end of the period", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r82", "r569", "r588", "r940", "r941" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,793,536 shares issued and 170,146,331 shares outstanding as of September\u00a030, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r82", "r509", "r674" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r746" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r745" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r747" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r744" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "NET COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r15", "r178", "r180", "r184", "r501", "r520", "r521" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r25", "r26", "r63", "r64", "r243", "r630" ] }, "bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "ConcentrationRiskBusinessRiskPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Business Risk", "label": "Concentration Risk, Business Risk, Policy [Policy Text Block]", "documentation": "Concentration Risk, Business Risk, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r25", "r26", "r63", "r64", "r243", "r539", "r630" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r25", "r26", "r63", "r64", "r243", "r630", "r786" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r630" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration \u200brisk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r25", "r26", "r63", "r64", "r243" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r24", "r25", "r26", "r27", "r63", "r122", "r630" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r25", "r26", "r63", "r64", "r243", "r630" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r49", "r638" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebate receivable", "label": "Contract with Customer, Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r335", "r336", "r347", "r629" ] }, "us-gaap_CorporateJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateJointVentureMember", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Venture", "label": "Corporate Joint Venture [Member]", "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "COST OF REVENUE", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r92", "r93", "r496" ] }, "us-gaap_CostOfGoodsProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsProductLineMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Service, Product and Service Benchmark", "label": "Cost of Goods and Service, Product and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r785" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense in cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r278", "r840" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r278", "r840", "r841" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company's Largest Payer", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r108", "r243" ] }, "us-gaap_CustomerListsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerListsMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Referral sources", "label": "Customer Lists [Member]", "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information." } } }, "auth_ref": [ "r48", "r822", "r824", "r825", "r826", "r828", "r829", "r831", "r832" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESS" ], "lang": { "en-us": { "role": { "terseLabel": "INDEBTEDNESS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r113", "r194", "r268", "r269", "r270", "r271", "r272", "r277", "r278", "r288", "r294", "r295", "r296", "r297", "r298", "r299", "r304", "r311", "r312", "r314", "r472" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r12", "r72", "r73", "r124", "r126", "r198", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r646", "r647", "r648", "r649", "r650", "r672", "r800", "r834", "r835", "r836", "r896", "r898" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r12", "r126", "r315" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r289", "r472", "r473", "r647", "r648", "r672" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective rate on term loans at end of period (as a percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r75", "r317", "r472", "r473", "r672" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r198", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r646", "r647", "r648", "r649", "r650", "r672", "r800", "r896", "r898" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r12", "r198", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r646", "r647", "r648", "r649", "r650", "r672", "r800", "r834", "r835", "r836", "r896", "r898" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r12", "r35", "r38", "r68", "r116", "r117", "r198", "r289", "r290", "r291", "r292", "r293", "r295", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r646", "r647", "r648", "r649", "r650", "r672", "r800", "r896", "r898" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r844", "r895", "r896", "r898" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal fees", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r896", "r898" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt Issuance Costs", "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r844", "r895", "r896", "r898" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes - net", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r5", "r140", "r802" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r393", "r394", "r506" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r404" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r28" ] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization expense", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r226", "r233", "r240", "r642", "r643" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivative assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r170", "r171", "r445", "r446", "r456", "r463", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r575", "r576", "r620", "r622", "r623", "r624", "r625", "r626", "r637", "r667", "r670", "r684", "r883", "r884", "r885", "r939" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r559", "r561", "r574", "r575", "r576", "r578", "r579", "r580", "r581", "r583", "r584", "r585", "r586", "r600", "r601", "r602", "r603", "r606", "r607", "r608", "r609", "r620", "r621", "r623", "r625", "r682", "r684", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r55", "r58", "r59", "r121", "r559", "r561", "r574", "r575", "r576", "r578", "r579", "r580", "r581", "r583", "r584", "r585", "r586", "r600", "r601", "r602", "r603", "r606", "r607", "r608", "r609", "r620", "r621", "r623", "r625", "r637", "r682", "r684", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r120", "r431", "r439" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r439" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount of derivative", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r879", "r880" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r10", "r50", "r51", "r52", "r53", "r56", "r58", "r60", "r61", "r62", "r439" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, term of contract (in years)", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r10" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r346", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r346", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Revenue Earned by Category of Payer", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r846" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED INCENTIVE COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r356", "r360", "r388", "r389", "r390", "r664" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r696" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r728" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r739" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, basic (in dollars per share)", "verboseLabel": "Earnings per common share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r185", "r204", "r205", "r206", "r207", "r208", "r209", "r214", "r216", "r219", "r220", "r221", "r225", "r419", "r423", "r442", "r443", "r502", "r522", "r639" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share, basic", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r217", "r219" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, diluted (in dollars per share)", "verboseLabel": "Earnings per common share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r185", "r204", "r205", "r206", "r207", "r208", "r209", "r216", "r219", "r220", "r221", "r225", "r419", "r423", "r442", "r443", "r502", "r522", "r639" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share, diluted", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r213", "r222", "r223", "r224" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate (as a percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r396", "r666" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r694" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r694" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r694" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r778" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r694" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r694" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r694" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r694" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r733" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r774" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r774" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r774" ] }, "bios_EquipmentFurnitureAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "EquipmentFurnitureAndOtherMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, furniture and other", "label": "Equipment, Furniture, And Other [Member]", "documentation": "Equipment, Furniture, And Other [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r150", "r181", "r182", "r183", "r199", "r200", "r201", "r203", "r208", "r210", "r212", "r227", "r250", "r251", "r266", "r334", "r408", "r409", "r416", "r417", "r418", "r420", "r422", "r423", "r433", "r434", "r435", "r436", "r437", "r438", "r441", "r465", "r466", "r467", "r468", "r469", "r470", "r474", "r476", "r486", "r519", "r533", "r534", "r535", "r550", "r612" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r246", "r247", "r248", "r415", "r780", "r781", "r782", "r875", "r876", "r877", "r878" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Capital distribution from equity method investments", "verboseLabel": "Distributions received from the investees", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r3", "r5", "r91", "r516" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest (as a percent)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r246" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity-method investees", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r226", "r237", "r240", "r245", "r788", "r816" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity -Method Investments", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r3", "r65", "r247" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r698", "r708", "r718", "r750" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r749" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r302", "r349", "r350", "r351", "r352", "r353", "r354", "r444", "r446", "r447", "r448", "r449", "r455", "r456", "r458", "r493", "r494", "r495", "r647", "r648", "r659", "r660", "r661", "r667", "r670" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r451", "r453", "r454", "r455", "r458", "r459", "r460", "r461", "r462", "r499", "r667", "r671" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Markets for Identical Item (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r302", "r349", "r354", "r446", "r456", "r493", "r659", "r660", "r661", "r667" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r302", "r349", "r354", "r446", "r447", "r456", "r494", "r647", "r648", "r659", "r660", "r661", "r667" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r302", "r349", "r350", "r351", "r352", "r353", "r354", "r446", "r447", "r448", "r449", "r456", "r495", "r647", "r648", "r659", "r660", "r661", "r667", "r670" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r302", "r349", "r350", "r351", "r352", "r353", "r354", "r444", "r446", "r447", "r448", "r449", "r455", "r456", "r458", "r493", "r494", "r495", "r647", "r648", "r659", "r660", "r661", "r667", "r670" ] }, "bios_FiniteLivedCustomerListsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "FiniteLivedCustomerListsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Referral sources, net", "label": "Finite Lived Customer Lists, Net", "documentation": "Finite Lived Customer Lists, Net" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r158", "r252", "r261", "r645" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r254", "r256", "r257", "r258", "r260", "r261", "r263", "r264", "r497", "r498", "r632" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total gross intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r252", "r261", "r498", "r645" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r254", "r261", "r263", "r264", "r265", "r497", "r632", "r645" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r254", "r256", "r257", "r258", "r260", "r261", "r263", "r264", "r632" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r497", "r829" ] }, "bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "FiniteLivedIntangibleAssetsNetExcludingCustomerLists", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists", "documentation": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists" } } }, "auth_ref": [] }, "bios_FirstLienCreditAgreementThirdAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "FirstLienCreditAgreementThirdAmendmentMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Credit Agreement, Third Amendment", "label": "First Lien Credit Agreement, Third Amendment [Member]", "documentation": "First Lien Credit Agreement, Third Amendment" } } }, "auth_ref": [] }, "bios_FirstLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "FirstLienTermLoanMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Term Loan", "verboseLabel": "First Lien Term Loan", "label": "First Lien Term Loan [Member]", "documentation": "First Lien Term Loan [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r705", "r715", "r725", "r757" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r705", "r715", "r725", "r757" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r705", "r715", "r725", "r757" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r705", "r715", "r725", "r757" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r705", "r715", "r725", "r757" ] }, "bios_FourVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "FourVendorsMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Four Vendors", "label": "Four Vendors [Member]", "documentation": "Four Vendors" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r738" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r31", "r32" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r157", "r253", "r500", "r643", "r644", "r668", "r674", "r819", "r820" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r818", "r821" ] }, "us-gaap_GovernmentContractsConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentContractsConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Governmental Healthcare Programs", "label": "Government Contracts Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City." } } }, "auth_ref": [ "r108" ] }, "bios_GovernmentCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "GovernmentCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government payers", "label": "Government Customer [Member]", "documentation": "Government Customer [Member]" } } }, "auth_ref": [] }, "bios_GovernmentHealthcareProgramsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "GovernmentHealthcareProgramsMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Healthcare Programs", "label": "Government Healthcare Programs [Member]", "documentation": "Government Healthcare Programs" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "GROSS PROFIT", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r89", "r94", "r133", "r196", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r464", "r641", "r642", "r809", "r811", "r812", "r813", "r814", "r842" ] }, "bios_HCIIncentiveUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "HCIIncentiveUnitsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "HC I Incentive Units", "label": "HC I Incentive Units [Member]", "documentation": "HC I Incentive Units [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r10", "r430" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "INCOME BEFORE INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r90", "r129", "r133", "r503", "r517", "r641", "r642", "r809", "r811", "r812", "r813", "r814" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in earnings of joint ventures", "terseLabel": "Proportionate share of earnings in equity-method investees", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r5", "r91", "r128", "r226", "r234", "r240", "r245", "r516" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r267", "r273", "r274", "r450", "r452", "r457", "r531", "r532", "r597", "r632", "r669", "r909" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r273", "r274", "r450", "r452", "r457", "r531", "r532", "r597", "r632", "r669", "r909" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r191", "r396", "r397", "r401", "r407", "r666", "r874" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r191", "r396", "r397", "r401", "r407", "r666", "r874" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r197", "r392", "r396", "r398", "r399", "r400", "r402", "r405", "r410", "r412", "r413", "r414", "r546", "r666" ] }, "us-gaap_IncomeTaxExaminationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationLineItems", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination [Line Items]", "label": "Income Tax Examination [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r401" ] }, "us-gaap_IncomeTaxExaminationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationTable", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination [Table]", "label": "Income Tax, Examination [Table]", "documentation": "Disclosure of information about income tax examination currently in progress or completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior period, and penalty and interest incurred or accrued." } } }, "auth_ref": [ "r873" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAX EXPENSE", "verboseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r135", "r141", "r211", "r212", "r226", "r235", "r240", "r395", "r396", "r411", "r523", "r666" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r20", "r191", "r406", "r407" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncurrent assets and liabilities", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r705", "r715", "r725", "r749", "r757", "r761", "r769" ] }, "bios_InfusionPumpsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "InfusionPumpsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Infusion pumps", "label": "Infusion Pumps [Member]", "documentation": "Infusion Pumps [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r767" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r697", "r773" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r697", "r773" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r697", "r773" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense, net", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r226", "r229", "r232", "r236", "r240", "r471", "r642", "r643" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r11" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total other (expense) income", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r642", "r793", "r811" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r187", "r189", "r190" ] }, "us-gaap_InterestRateCapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateCapMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap designated as cash flow hedge", "label": "Interest Rate Cap [Member]", "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount." } } }, "auth_ref": [ "r633" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r168", "r636", "r674" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in earnings of joint ventures", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r97", "r98", "r99" ] }, "us-gaap_JuniorLienMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "JuniorLienMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Lien Term Loan", "label": "Junior Lien [Member]", "documentation": "Legal right, after the claims of senior lien holders are satisfied, for a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes second mortgage loans." } } }, "auth_ref": [] }, "bios_LargestPayerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "LargestPayerMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Largest Payer", "label": "Largest Payer [Member]", "documentation": "Largest Payer" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r111", "r485" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "bios_LegacyHealthSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "LegacyHealthSystemsMember", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy Health Systems", "label": "Legacy Health Systems [Member]", "documentation": "Legacy Health Systems [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r475" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Lease Liabilities, Operating", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r900" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r484" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r484" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r484" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r484" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r484" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r900" ] }, "bios_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r484" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r475" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undrawn letters of credit issued and outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r72", "r73", "r74", "r77", "r78", "r79", "r80", "r196", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r425", "r426", "r427", "r464", "r568", "r640", "r692", "r842", "r902", "r903" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r87", "r127", "r512", "r674", "r801", "r817", "r894" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r74", "r153", "r196", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r425", "r426", "r427", "r464", "r674", "r842", "r902", "r903" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r12", "r77", "r78", "r79", "r80", "r196", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r425", "r426", "r427", "r464", "r842", "r902", "r903" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "NONCURRENT LIABILITIES:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LienCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LienCategoryAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lien Category [Axis]", "label": "Lien Category [Axis]", "documentation": "Information by category of lien, for example, but not limited to, senior or junior." } } }, "auth_ref": [] }, "us-gaap_LienCategoryDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LienCategoryDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lien Category [Domain]", "label": "Lien Category [Domain]", "documentation": "Legal claim on the property of another party to secure the payment of a debt or the satisfaction of an obligation by category, for example, but not limited to, senior or junior." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r71", "r76" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Balance", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r12", "r126", "r301", "r316", "r647", "r648", "r672", "r904" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedLabel": "Less: current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r161" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total debt instruments", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r882", "r883", "r884", "r885" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r198", "r306" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r198", "r306" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r198", "r306" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r198", "r306" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r803" ] }, "bios_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofLongTermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Four", "documentation": "Long-Term Debt, Maturity, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of discount, deferred financing costs and current portion", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r162" ] }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate paid on term loans during period (as a percent)", "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r12", "r834", "r835", "r836" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r12", "r30", "r834", "r835", "r836" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r243", "r654", "r676", "r679", "r846", "r906", "r910", "r911", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r741" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r741" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r760" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r768" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r243", "r654", "r676", "r679", "r846", "r906", "r910", "r911", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "terseLabel": "Cash outflow from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r188" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r188" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME", "terseLabel": "Net income", "verboseLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r95", "r105", "r130", "r151", "r176", "r179", "r183", "r196", "r202", "r204", "r205", "r206", "r207", "r208", "r211", "r212", "r218", "r249", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r419", "r423", "r443", "r464", "r518", "r590", "r610", "r611", "r690", "r842" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r705", "r715", "r725", "r749", "r757" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r732" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r731" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r749" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r768" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r768" ] }, "bios_NumberOfInfusionSites": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "NumberOfInfusionSites", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of infusion sites", "label": "Number Of Infusion Sites", "documentation": "Number Of Infusion Sites" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r643", "r810" ] }, "bios_NumberOfServiceLocations": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "NumberOfServiceLocations", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of service locations", "label": "Number Of Service Locations", "documentation": "Number Of Service Locations" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense in operating expenses", "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations." } } }, "auth_ref": [ "r11" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING COSTS AND EXPENSES:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "OPERATING INCOME", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r133", "r641", "r809", "r811", "r812", "r813", "r814" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r899" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESScheduleofOperatingLeasesMatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r478" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r478" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r478" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r479", "r480" ] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePaymentsUse", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating leases", "label": "Operating Lease, Payments, Use", "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r479", "r480" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r477" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease costs", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r798" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate, operating leases (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r483", "r673" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term, operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r482", "r673" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r159" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit of $1,998, $8, $1,785 and $57, respectively", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r173" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in unrealized (loss) gain on cash flow hedges, income tax benefit (expense)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r174" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap designated as cash flow hedge", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r172", "r173", "r428", "r429", "r432" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap designated as cash flow hedge", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r137", "r173", "r175" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "OTHER COMPREHENSIVE (LOSS) INCOME", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r2", "r8", "r119", "r177", "r180", "r208" ] }, "us-gaap_OtherExpenseDisclosureNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenseDisclosureNonoperatingAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER INCOME (EXPENSE):", "label": "Other Expense, Nonoperating [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other amortizable intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r645", "r822", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r78" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other adjustments", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r741" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due from joint ventures", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r166", "r577", "r643", "r905" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r703", "r713", "r723", "r755" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r706", "r716", "r726", "r758" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r706", "r716", "r726", "r758" ] }, "bios_PatientCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "PatientCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patients", "label": "Patient Customer [Member]", "documentation": "Patient Customer [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r730" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r783", "r794" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of company stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r102" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred financing costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock-based compensation tax withholdings", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r186" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r101" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r740" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r732" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r749" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r742" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r731" ] }, "bios_PerformanceStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "PerformanceStockUnitMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance stock unit awards", "label": "Performance Stock Unit [Member]", "documentation": "Performance Stock Unit" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r733" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r777" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r732" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r682", "r683", "r686", "r687", "r688", "r689", "r938", "r940" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r81", "r319" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r81", "r569" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, shares, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r81", "r569", "r588", "r940", "r941" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of September\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r81", "r508", "r674" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r789" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSScheduleofAmountandLocationofDerivativesintheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of debt", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r796" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r784", "r795" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r241", "r496", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r634", "r652", "r675", "r677", "r678", "r680", "r681", "r787", "r838", "r839", "r846", "r906", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r241", "r496", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r634", "r652", "r675", "r677", "r678", "r680", "r681", "r787", "r838", "r839", "r846", "r906", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r485" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r110", "r136", "r138", "r139" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r111", "r155", "r515" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r485" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r485", "r504", "r515", "r674" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r111", "r485" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r730" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r730" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r698", "r708", "r718", "r750" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r244", "r355", "r490", "r491", "r507", "r513", "r563", "r564", "r565", "r566", "r567", "r587", "r589", "r619" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r244", "r593", "r594", "r597" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r244", "r355", "r490", "r491", "r507", "r513", "r563", "r564", "r565", "r566", "r567", "r587", "r589", "r619", "r901" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED-PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r487", "r488", "r489", "r491", "r492", "r547", "r548", "r549", "r595", "r596", "r597", "r616", "r618" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of debt principal", "terseLabel": "Repayment of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r797" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r699", "r709", "r719", "r751" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r700", "r710", "r720", "r752" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r707", "r717", "r727", "r759" ] }, "bios_RestrictedStockAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "RestrictedStockAwardMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards", "label": "Restricted Stock Award [Member]", "documentation": "Restricted Stock Award [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r118", "r511", "r536", "r538", "r545", "r570", "r674" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r150", "r199", "r200", "r201", "r203", "r208", "r210", "r212", "r250", "r251", "r266", "r408", "r409", "r416", "r417", "r418", "r420", "r422", "r423", "r433", "r435", "r436", "r438", "r441", "r474", "r476", "r533", "r535", "r550", "r940" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "NET REVENUE", "verboseLabel": "Net revenue", "netLabel": "Management fee income", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r131", "r132", "r226", "r230", "r231", "r238", "r240", "r241", "r242", "r243", "r345", "r346", "r496" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r243", "r785" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bioscrip.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r142", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r348" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolver Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in operating lease right-of-use asset and lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r481", "r673" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r768" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r768" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r823", "r828" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r45", "r46", "r421" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Estimated Fair Values of Debt Obligations", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Shares of Common Stock", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r55", "r58", "r430" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amount and Location of Derivatives in the Balance Sheet", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r808" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r21", "r23", "r216", "r217", "r219" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r246", "r247", "r248", "r415", "r780", "r781", "r782", "r875", "r876", "r877", "r878" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r254", "r261", "r263", "r264", "r265", "r497", "r632", "r645" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Maturities", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r485" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r66", "r67", "r593", "r594", "r597" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r33", "r34", "r35", "r36", "r37", "r38", "r114", "r116", "r117", "r118", "r163", "r164", "r165", "r228", "r319", "r320", "r321", "r323", "r326", "r331", "r333", "r541", "r542", "r543", "r544", "r651", "r779", "r799" ] }, "bios_SecondLienCreditAgreementMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "SecondLienCreditAgreementMemberMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Lien Credit Agreement", "label": "Second Lien Credit Agreement Member [Member]", "documentation": "Second Lien Credit Agreement Member" } } }, "auth_ref": [] }, "bios_SecondLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "SecondLienTermLoanMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Second Lien Term Loan [Member]", "documentation": "Second Lien Term Loan [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r693" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r695" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r96" ] }, "us-gaap_SeniorLienMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorLienMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Term Loan", "label": "Senior Lien [Member]", "documentation": "Legal right, before the claims of other creditors, of a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes first mortgage loans." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofDebtDetails", "http://www.bioscrip.com/role/INDEBTEDNESSScheduleofEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based incentive compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r357", "r359", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r845" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r845" ] }, "bios_SharesIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "SharesIssuedDuringPeriodShares", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity award issuances", "label": "Shares Issued During Period, Shares", "documentation": "Shares Issued During Period, Shares" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r106", "r193" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software, purchased and internally developed", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State Jurisdiction", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r396" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r82", "r85", "r86", "r150", "r181", "r182", "r183", "r199", "r200", "r201", "r203", "r208", "r210", "r212", "r227", "r250", "r251", "r266", "r334", "r408", "r409", "r416", "r417", "r418", "r420", "r422", "r423", "r433", "r434", "r435", "r436", "r437", "r438", "r441", "r465", "r466", "r467", "r468", "r469", "r470", "r474", "r476", "r486", "r519", "r533", "r534", "r535", "r550", "r612" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r199", "r200", "r201", "r227", "r476", "r496", "r540", "r551", "r562", "r563", "r564", "r565", "r566", "r567", "r569", "r572", "r573", "r574", "r575", "r576", "r578", "r579", "r580", "r581", "r583", "r584", "r585", "r586", "r587", "r589", "r591", "r592", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r612", "r685" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r199", "r200", "r201", "r227", "r244", "r476", "r496", "r540", "r551", "r562", "r563", "r564", "r565", "r566", "r567", "r569", "r572", "r573", "r574", "r575", "r576", "r578", "r579", "r580", "r581", "r583", "r584", "r585", "r586", "r587", "r589", "r591", "r592", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r612", "r685" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r702", "r712", "r722", "r754" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercise of stock options, vesting of restricted stock, and related tax withholdings", "label": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings", "documentation": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option awards", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r684" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r845" ] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized to be repurchased (in shares)", "label": "Share Repurchase Program, Authorized, Number of Shares", "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r845" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share repurchases", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r81", "r82", "r118", "r544", "r612", "r627" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of company stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r81", "r82", "r118", "r550", "r612", "r627", "r691" ] }, "bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of company stock, and related tax effects", "label": "Stock Repurchased During Period, Value, Including Related Tax Effects", "documentation": "Stock Repurchased During Period, Value, Including Related Tax Effects" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r82", "r85", "r86", "r109", "r571", "r588", "r613", "r614", "r674", "r692", "r801", "r817", "r894", "r940" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r115", "r195", "r318", "r320", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r334", "r440", "r615", "r617", "r628" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Supply Vendors", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r108" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r748" ] }, "bios_TerminationFeeIncomeTaxEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20240930", "localname": "TerminationFeeIncomeTaxEffect", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee income", "label": "Termination Fee Income, Tax Effect", "documentation": "Termination Fee Income, Tax Effect" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r740" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r747" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks/names", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r47", "r822", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r767" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r769" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.bioscrip.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r770" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r771" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r771" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r769" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r769" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r772" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r770" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock acquired, average cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r39" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r39" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r39" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock; 13,647,205 and 8,330,022 shares outstanding, at cost, as of September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r39", "r40", "r85" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares, acquired (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r9", "r82", "r118" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r9", "r39", "r118" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r766" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Release of valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r403" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r736" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r808" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "totalLabel": "Weighted average number of common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r215", "r221" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails", "http://www.bioscrip.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r214", "r221" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r734" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r779": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 74 0001014739-24-000052-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001014739-24-000052-xbrl.zip M4$L#!!0 ( !6 7EDM\M,9Y@8! &@_$0 1 8FEO?;F7HR-]W#B <OT?7^]OA6MO-)]B-Q2N?(Q" M; G/=C@1P@D6_N[Y/^TG)-PY*!Q[_K1>CVZ[\F:OOOTX"05%4K3DLN1;_U(Q MFO+8;%AU358?ZAJ2K#H::U(=F8WQ@ZZ/%>-!$A\O&XJBF_*#7L<-&2Y[>'BH M/YA-N6[)#1DCK"EFLRE:EX9J860TF[K>:&KZ&",T,A3#Q \&/-EL&/2]DQ#F M#/-V@TO[Y;?:) QGEY\_/S\_7[P\^,Z%YS]^5B19_6R[CNUB,N]:?#G\_7/; M#9+ZF7S]@ (<7[YRY;-*KY--T_S\0D:0/-/"]N)"^K@ CRX>O:?/\,5G0K/D M0CRR-E\(7ZQ<. _JCPC-%A>/4?! 7QY_L7(Q>9+]P9QL-PB1.TKF=&D'GJ;( MQD=W1%:UQ/Y88#RYW]\OQV,)GB*ZN\G][+&X!6VD6^32P,_ M7"^-A-#Y'7RY-?#--/YJU(M4EI2XK]"&7#@*AK6&W_F-0:_TZ MP>&(,#UX>L,ICV*_OJM%N*7\#.%Y>?6?_W7 M?_T:VJX15]81%OWZ./OSU<_3H!\]Z;?UJV4]"$+XZ^+>:90NIZ+ M80#VRR6Y$/O1K[9E89?^"M_W0(OX]BAZ_TMXC\>_U49UX)Z+IN1)V+[LN/"Z MURL8G8^5IZ9XR=7<]^$--W8P M0L[_8N1W7.L:%%M-B,C\6PWX?-80SO'Q9KSI"!G,[1!O?A[]*MW#\",1BBV/B[Y,]4!W/GW _A8(SN#7?9X6RS%]()'C MY'-,56WR%Q ?_A[;V!>HD.&-B_%5]Z^K*OC]S8L1K#Y]1G50\A7W5'WP,?6 M(/1&/Z/'_?IYXUL6%%D,IC! R4>WZHY,=O@ M,: TM#^ZD7MDVKS^;B'K,0N,*[O' M?,) Q3NR9[&9E+([S:<*5.1)\[([RZ<.5.1)^[([RD4$*O*D?]G]Y9,&*O(D M?.F=XX(#%7GR@@7?]TA3*[L[6U@,1MO?YF[DE7/#PKXG W10R^XT%A*#*8)1 M97<23Q^#*8)+9?, :3&\W+[H<6$(/) MC?:E=T6+B<'D1O^CNY^EMZ*.1/C2.\?%QV!RXP4+ON]QIJ:5W9TM+ 93P-D" MK>PN;2&QAR(857:O]O2QAR*X5'87EHG80Q&,*[L3?-K80VY'.,ON!Y\P]I ; MS\B-]F7W?0N*/>1&_[*[P*>./>1&^+*G+S,0>\B+%WK9'?23VCKY M%74HNZM].ELG/YJ7W6L^O:V3'^U+[PL78NOD1_^RN[0GMG7R(WS9G=KB;9W\ M>%%V9[>8S8AT1=CR.H2ELY"8S (=RNZEGGY3IB!&E=VK/?&F3#%<:I3=WRU^ M4Z8@QI7=8SYAH$++[Q!-H^Q.\ZD"%7G2O.S.\JD#%7G2ONR.,&"[WN9E]W\+B#WD1ONR^[X%Q1YRHW_97>!3QQYR(WS9TY<9B#WDQ0N3 M.0<]\,/+ ;S1FCNX/XX8\1V'$P\TS!,.PC?V+'^*<0]-<<2F!]L++F_Q(QJ] M?L/("2>#5[A@6AKY,)GUP^\Q!?T=F.&O0Q^Y 1J1!2#X^KK\S7NKR)]Y/GSY M/Y[MAG_ "^=^-?T&DUFWO$1\2Y'OGQO?F'74R\*W8HIGFP,.[0*_9W\&-O@%QY[@B&!NR&C^_M MX.?7U^'K#+]#1#R8M8N/.(JOV!U-ILC_^=[5>,+N'-_XWA1N@CM&X=_M<)*, ML)K+.7.Q$0Y3UF%:A/7"7!B)PY1IF!:TZ#,7;>,P91VF1?@4S,8F]T+/[]X3 M]EWRY(1C0>Y (G)SYWO6?!3V_0'VG^S1:"NAS$I09Q 68M@(^#F(.XW-:$+#&[)+H+1%Z4^G>E3JRV=#+W%[9(E=J M C#XB@)L_>YY5M!VK9[GXNG,\5XQCD$4+&U^?GT=S&?P4.PO\?/&F_M_ ($\ M_YA(6I>J9"@,1-FNO"#LCRD-8QF\M=UJ)LC($G-;:AS-U4!S(98%>;[\_#TMK<;1=Z]8;(>=_YKX=6#8-[U94 M>)CS]1-&?)T'MHN#H#WZ]]P.:,6?Y8R,*;;LX#4 =AY?@AIUI;&G!"U?FHTQ MS'G[K$L0U5\%J#KF_'\&&76VD]X@$= 7%CU@\[+ MR)E;V(H2>:>S>4BWS_KCI);6'?:C;RK)Y8+69979X-'QN0R7CCU_BMP1 MIFS^X2;CJ=RZS&SDJ9)<+FI=/L\85X&R7,BZ?)Z1K@)EN9!UF=EX%T.[;84P MAME U9WOP4S"USL'N6';M4@/@AEYQO*I'\JDKCN>DWOOYM-9:9H.R"JS(206 M*?_NC'\FRFO,AG7VI_SBFYLY+#ND=#E<3INCE$8 -&;C+LRS(5=I8#8PLA<; MDHMO,0KPQ'.L[G3F>T^TJU!Y%@.-V;@%XTS(51*8#2ND8L+ &X?/B&JBY-=K M_(0=C]Y!#B672"Z8C0&4BB6Y2@FS#GLJEK2# (<_7(M6"@A"?UZN!#"-68>: M=2[D*@O,>L]1"N2BOR+)='P+;:P6J!@@!U>S([BL,>MC,\:?@D+\.K.>.&/\ M*2@XKS/KHC/&GX*BMSJSOOM>_.G#9.%C]['S,H,'5+0(H\ZL;\\BDXI:B9CU M_5ED4E'+$;/1 !:95-2:Q&Q\X,9V[1#?VD_8ZKK@]#W:#PZF'FCP]34ZMNR@ MX%TJ>W)<^=8N4]Q,9S8\P#@3\HP.Z,Q&!PYBPM!'%B95+DE%4/I'#TV/85D? M2R:8#0:4AAUY2D>#6=__(';03=_WEY=&-AK,.OHE84:NDL&L5W_E8\L.;]#( M=M8.U=_C)\]Y NMV]:(=5-_[U;>>^QAB?WJ-'\(-&VS8M3V_YX4E6H\:S,8% M"(V[=#N&W+A?,768#"ENY.\ P!XNS=R_V,AN* M.'L=G>M2S&PPXUQU=*[<939*?%U MMZ*(%H/VHX]I\'HXL7VK#;]9Y*\*P.O]UH5>EXP]MRZ6+\T4%6\P&WSB6"P8 MB\W]L=C,!8L&LY$WCL7B7*-E>&5:=@UF8XD<7A7PO UFHZ,<7A5P&@QFH[(< M7D4::D5D#AK,QI Y%HO$8A&Y=P:S 6^.Q<*P6%"RKL%L5)YCL4@L%I'N:C"[ MA[ =B_\SYU@LBSM2PCT,#J_R!%-*N"W!X55-;[=9PFT)CL5J>KO-$NYA<"Q6 MT\-HEG##@V.QFI&7)M\=.;?<2R:68V8W0C@43@T%9O ^&>$&E4 M_?;>>SOXNX( M#R88;^F<<>?C&;*M3M0W(TAZ+%_-?9\HD%+5VH:G<2AR*+)PNE"1F UKKGJ/V>V+8V OJ\E>S'E016)X;X,])A5S($B1 M&-X98(])Q9R94"2& ^KL,:F88YZ*Q&PX>J_FE@F/.GOUMBPU0 I:#V5FX[D< M($RLQ3*S,4X.$";L )G9R",'"!,VB,QL//#.02[I;[JT6=A6)+E)/C_RCJRD MYQ5VD)D->9V6O!N:8.RK"_6\-@3EHX> 4H=6\\,9LY&3]C/RK;?M9PJT;U== M4/_DV4_XAVOO#".6!-2%N C,1F/.B/&%6';,1GC.A?%%^7S,1HW.B/%%F.H* ML]$@VH^]/_X[\GVP8/K^O?TX"=\QQHB_S0T "]>Q\^\Y$./*F\X\%_Y\UQ@> M/I]Z[B#T1C^K:0$HS,: ."P*M \49B,_'!9%+B+,QGLX+ HT*A5FXU1G"XLC M)4(IS"9"<4[GFVZI,!L3W(?3>A4YS81AR&S$D,.B2#>2V7@BAT61AB&ST48. MBP+=2+74LH,A MHX^F2VQ>(O7:9>61,F;#8#0XQQZ&"XC0JLW$:YCA44,A$939DRGUJ_P@[+(-E0+(Z/9U/5&4]/' M&*&1H1@F?C T))D-XY\D_/!V3Q"^.L"JJ>W6)YCX^Y>*F7KUV"&W-:O#_YGN#_Z/7K,VL/JP.TZ#-L'#EP&\^D4^:]?R#SJR+$? MW4N2O8C]6O3$Y*:1YWC^Y9\D^M^7,4R\/D93VWF]_,L0F!T(/?PLW'M3Y/Y% M#("[\!+?'D<7!O9_, P51DW_?(XFHL%S'-O%R<1DA/!](7H>A.F@6X,ODER^6'J+!.*A\#9T$I>'#/C B;P>?US1;W05'/C5]*%O/'S M;8^2C0NCH5?]48T/'_69TMY/OHS1H\["&KT'F$[P\UM-K;W#1>C-+K59* 2> M8UM" N49LBS;?;R4!!D>\9D_X_TS*+T_4YDI2B4(*;5"OJ.4WXW2V#C*'[WN ML',M#(;M86? _&@'G:L?]]UAMS,0VKUKH?./JV_MWN\=X:K__7MW,.CV>\5- MP=QK!G]'P01P&GJN^-]_DAO2E^N+JPM!D73-3#WT3;Z M*Q@8KN?VYE-XTDB([9![/*9EGVN"BXB!9V'[\MH;T>.^Y)A"C9H@8[B@)4OU MOU$SY>TIV^O^,U:9O" M372J,GLA6G7=V%HC@C<[N5114_+3=^3_%/HN_F6!AM#:-:W5I:(H,OP='DT> M'^Q)@+7%)K*E4TO6W^;@N&#? 3\&G)6P)HQ!3%$(MOY+>#FV7[!5#_WY0OB4 M6NN__V0:FOYEJ_SMIO@&"OYK'H"+]LH,DO[VHWT_[-S?_J]PW[GKWP^%NQ_W M@Q_MWE 8]@58?H:PQD3*3%:%_KT@ZY^L7X3^C3#\UA&6EJ?%TM2^&I*O95/5 M5BAU..@GUV;@Q8H]$P:V3VCS:A9CIAB P&HFA!,L_#N1'R'RK@7L M6M@2T@OB';V]$X6R5L70@D_J4WC$A-Q6M]!K_14COX[=1"Q5L(GP+*1!A(@5 MJB0*)#KS\3*9!H([S/+4ZC%:)8OA7O\^)R$LL>:G82R;1+&VJ_XQ*[\3Z;\MX"@2"61J/AP(2B)CA_[WE2(9KW\4UC[+_0V M7';8SW7@)%$-5GU+E.LC1T:]KZ!FWOTWD03Z23, M+]=EV335O?W 352QIX]"X(_ #;2]@%3^UR13E?[Y*%_\:_98$Y #VK!_=_7M MG[?>HQ=]MAJX:\JSET.\0D629B_4Z3@Y\Q1E+^ZEY=(]?K0#(BHA.>>?<*H! M:^T=5:57[?N.\*W3OAU^$X5N[^HB$^.. V?ZP$L[A)>-]@CM?>J\H%%(*2%X M8\%?4$! @1#,\(AL.EF"[0IV& BC";44?]DS4+%Q3^.TH0NC>=%H-M.&+N3& MA=+()W8A2Q>ZFM.CU NMJ>;R*.6B:>;T).E"T;5\'F5>F$8S?9A'5DH8YTFK MFTCUPF@OUB:Y#*1"H#=W0__URK-6?2VRNTA2#T(\\[TG\IPW)\NHM:ZQ@YZ1 MCS,8P'F[4:5APA"]=..=^*AXY.J:WH0U7:]+6M-L-+9[K5NM9E9QO/^2$D4P M*3K):F(O8_:@>&8Y_/2T!.I>W%\,+H3.=.9XK]@75C$E]+R+7]CQ[8N4M[9E M^3@(XG]NX7ER(FMFK:7"6(5;]!,'MH6%:W^[.7:0.UIUAK,;1!2 M(&%/K#39TF[7K1#O"G[M^T/O>;& DOK77Y'K>J.?#W/?Y;3;2CNZ"O3].[!! M8!UXV_I4:JWN+3<^#A;H.P]L.^?_MV>1X1=35:VU&I(DZ^=K=<3D(7;'S ?$ MV3/D"/@%C^:D$B!\#.LK#HJT0EBB%N!'( #:8&BP'I-[B]+\]Y^:BFQ\"800 M.W@V\=PD0"<2T].9$_8(X.H@8)^%+QF(SN04KB+K4AOFM:("-+"(9.6] JCO M_U12$=^Y(V1<=6M(&6M3D^J*IF4(54;R8;O$UB4$.7FA=OAPUS0RS0OF@TU;=!+ MUR]D)9](CJQ< %;R"@K)ZL>/VN$>Q>0FVTV7\EJVY5(JYOJ7K#F:'^KTH1TZ MU.W&:#01Z%GU/1:[LZ&.C^AR,'B=/GC.I[T,@;UHXTO'F ,45?AE- MD/L('[C"\\2&3][T:)J@14R>6*UM)5_E<;G_\APO7:^R\D!%?;$\-Z)]2F ( M/>,F"G^6+F#,LC!#OO"$G#DFF[Y",#DLZLLYE993L:Z)5,V"30;91[SZ5A0' MJJ^GTHM2)U9FT7;O^ST4HNI6MT]("X0>"BST;^%WQWL !W, GLVC/^)/\2 MQ8PF** )$Y: ' >N(,E9Q.+^]]PF]C:8V0\XO@ >')O\EH M3SA&+'+R-D?].9X-K^( G(MX9.R-.4'P I<]/ O@@FXB5X/=Y+Q MQ \C:6L!'0D=+@I"P92B)UCH-;A8R9=)&2&ZBAIE1[EP1 &%*)P'"_":M=;_ MXN ]2%=3SB/<_2U-B34.D M#01M:H14P+$JO NVF1\XX/V'A&H5(($E8[W70VS.68P#W M<[A2DW2B8>[QX]R)-N8&]:'PB4#"^"(H*OBXT17AQ*:I,3.2&K--&0DYZ:%H MP O-@H-?,JF,)2(1&L4:9'%40MJH,H2SUA8]K\#YA%E(NC^*(W;X+TT;G=C ENI.UMI+7?TZYH6FGLTJJW2=UQ>NTXMC#8IF\+ MI%Q:/47G\'4>P(."8.DXJK>V3)[,ZV]:RTK AF<'O= )7T?AWLT/= M?6PM_TH+;!F#XP^,+K+=O]%6M,>;_$;J+8+V24O?[;AU?!:P86I>40O/-D!U:8NH,: THQH#(I%/'PO/Y$?, M\1L_JI HS,&7I_RF6ZA@/JUB0*F!Z(]LL+""WVK=WLV&P/Q;!5):73[HST.Z M, X5R'BSJ=URPOK\0-K0C!"A#S2 C!ZK24;DB@W95%1FPEHDK&VHFW>(-$X M_GJRW/)>L>"]#>0B.S/S @5_#A//221'I04O9UYD%%WZI%RH_8372F"^[5?3 MC6KI[1;T$'C./-Q^"],E,>5-]3S3EA4U%F5%)XO2B3/TB.L//D8_ZV@,\[M$ MSC-Z#4A2V^;:HYIR860L/KJ:3ZAN25C< QVK#Z*D/#W#-F?2#MM?;SND7,55 MOS?L](;IR@&>-ED3F$BR=5(?458N3#6?DI^&?F%J'Y?\W/M1%TWY6(7:*E>(E[67'D/G% MHK>!WN/QL>0D&AL8Y_&AYLLYF%0^N0J&A%@9BC#QB6?RISUJG3=JK6Z(IX(, MUC_:5%F-LXQ!EMTL(HV+%AC!,?FWR.H\[- 49VX:YFI;.'GT&H>[.,_YFYV_ M)LG5)VXXV3" WVBZ-=V+_8H:R7A$L-+BL5Y>_>GI91\%$N'&\9[Z: M5P4!!I?PZO*WF5K"Z1[JQ'/@94&\ORI$O2BYQ%<$$4TN\97EKRK76CTOA"&% MGK!3]'G0K<(P,+.).8^#GYQKIAQO72A\ZZ)$+/N.7/1(E>W:#D;SJ,D" M.;C6=I'S&MC4P'K3N40I1SG9Y)I[',R=R ;KSW T)*Z,JX(11>+:F(FAI AU M*XDZ5KDZ+A//_D9.HM@A3>BDJA4^<)*_B69VO&!.$HK;#]X\*70CW-O!3ZYN MJX(!5>'ZEHFAI.&;%NM;C>O;,O$,[-C0![9077OG>R-L$?7*E6E5&+Q+F3*> MEKE7#NP14';\'-E%DFSQV=5E P5?/EC0+JK$DW69&$I*GMWB1^1$:SVM!L<7 M^\JP5E6YY\3$4-+P34W4:)OKT3(QC02=A!LT"CV?J]#*<)6K4$:&DH9O#;[W MRL104O+LA[O4]&B G*A.2)2QMEQEG<2F?@2TZ4=LMG*%6QD0J!D/F''A+8!O M9JQP=:YPR\2S/BT?UW6C$D_P**Y&J\):KD89&4H*OFE*K$8;7(V6B6>=EXG] M8/-TZ^IP5-UQ+IIOB'$@[0:27FL-NK_WVL,?]YW!\35Z\1O'7-NQ,924($VI M[62->767[[FV\HC7*IVVMG-\5Z[SJ*53CYYDLV>55"6/*JFRQ&295$*"@LCZ MPW5P$-!BSG'9Z:0?7"!X)+SP; =8A,_&V,?N"#ZUW:@EW=_FB'27N+E"/A:^8>2$$[%&!Q+? M=?6N[53\\3-^_\D\V-"9RIO[R:=T\.25&]Y(BJ1#N1&LJ8OQD. M(GTS.:S@V%-ZDL%SQ>6! M 89&V(\&-/<%_#+#H^@RTFKQ$:9#OK)=:QZ$_BN%WA2-? \, =>;VB,A!$&S MHET2\@ O.H$&]\ O--('S[\0;K:39@0,?,"@$DE_L+$==<%]]DB7$-K8$067 MBVYP<,7(GL&M[X7*=DF_DO>?SASDOO_L 3LV?EI[ )">-*I]_S$.0GNZX7T1 MG=Y_.D5K\A\ \9VU@3W;CK.L!0)@CH/\9<5%VNS.P[F/X[XK; GU9L'X@,M$ MB;G8IB%@$)_0\XG)(XS1"+YT21O!()C[B$X=8/PV]3<,==T@Q,BBW0E>Z0,? M$#F8[KF@U4$0"/Q&4<].@7)Y'(BK@":D)N^9SMX#G,A:_$YX.WG20]P?2ER, M!< 4/8+T$ CQ(\BA*,2X(8\CG143?%JD[RJ=MVO%(B)&C76HW$2"1%>LY/&C MY$QG<"%\Q2-$.O%\H%"H\80)2MZ&OD29I;[+MDN:.0!-YD320P2B0D?NV\'/ M:'Q1'Q:Z5HYL?S2?DBX(%(.D!RMYG&6/Q_9H[M 'SGQLV?#L2!>XKX1BSQ.; MB"HAWSR$=6A!1K),^YX#W!L+\;4P2)A;]'HB6[X-!MM_,&TF:2^N(CC,[)DS!:PQO%FT0T@LG1VP(AD+("F ML>]-89P>C'.*+/) @;:I?00RA9&&HF3_0*O!O('440><<&7! %I,B0E"NN>, MHPR>B-(CHBJ$B/5T^NMC?VNKM, +8^,M;\NC+6HDSKM2[580=]MYR]:#Y'V'W9T MVOK3DBTWZ%PEC[L0V@Y90!\GPC-9I\G!P!"F/@NC%L3QLO4JV N>$F0GC$U: MJ1"8P2(72?SR!;3Q%DA4 (\!MOUTO6X,B V?"38]$#[ZP=/%V-%$ZVJ G("VK@: MO"'Z.GCWOT#+T>"MZ#D]AX1.O.X<\1W#V? MT;L\ZB-$[=8^IIJX:-V%2*^N"!!D!*1EF_VV';M8Z59@ N]9\JSPRPC/0O*@ M&-&+=MPP<0<];S=2SC$*H.82!5"/'P7(+938W(,N)XIJ9AS*_E%- SQ"VB6% MEC0ECLC&S;E]NJT4X8F3 V'1 MM-X6$PT][FIMMK]ZZZ[5NAV[OIWW]O#[O] MWOI$]I2U1BWU[%<[?9]Z^O$9*&%;M\"CG/-[&QM]XJ4= BE&^S!K8]DPOF(L M"*3ELF*8?,6HTHI1C&;IWQ%-*ERU[SO"MT[[=OA-!!5[M6[A%3.\JW[ONM,; M=*Y)7[-!_[9[W1["'U_;M[ <=(3!MTYG0ZNS8L;ZJ=L3AM_Z/P;MWO5 %#K_ MN.K<#6&(0-J! )\)=YW[Z$^A_;W_HS<<_%*])FV-QD6SJ>3264W6+G1-3?6H M[9_KZN:7'#2HCYO0'7T_>7,_KD5^0P'E!@;@+M(8CJ!*47?90S:8*T"())8E M)&&LW2W84A,D%OW0FUW"=0+='!3(S+XP2JK-B0B?YDGYV5_R \M6VBR39]_, MCP[#VUV.:C$88@]5Q:.91 51N#P;+*^1V N^<["[*G^S^U%P;T__* MQ+6K'_?WG=Y0B+AW>1#[WLTZ-?F/=7].0B>0?XW(>6&9DZ0C!MU^([^0,.H3 M3*^B-"LTN"C[9KD7\Z;^!HAU?(]\ENR1_(F8/3&87O M?ZO9+^&E.Y_6+8^ZI^2Q(#E %4QEB$0.QG52W5MKJJ*D-'[]O#K4+>E_A\C> MWBS*9\G@\E%-^= *D ]R&D-3Q:9F,B(?.9DT)5D3VZ,1S(6FMXPPL/3!P:+@ MXG"KF:.DH\1&\2^UD.Q81!*"WB_HV2#NT;9Y (H5!#4-LZ$U&@'1>CD?7):F)'DD4/TBO[FM6E5H<=NC5 MA(:O( 5IX4_.0,F2J)NLV!AYAFW.'C@[]&@6X#1J+<701$G2& '.>1FG=SZ> M(=NB*>5N$*>2QMF%<=HY"@*\'L#A1L:>6C6F<"]=6V+KK-/E;YQX*YOMY)+\\Q[W8WJOWWN7KB#L79/H[)).2N,$ MDQ/^872 F20MS*(C9GR3)HO;&]'TSD%N"&Y*)R%K^AB1)L,BJ.BB*?--F@H" M::?#FQ^0% (D26RH$B- .J]-FOZBCHJ#$2V7 -_5O7&='NTF9C+?NSE0W2Y( M>TLH>T]>TA__"#!U/M**B5IK-4U1D3-+"=_+80](.]1MKD#2 $B:*.NL; J> MEUG;=4/D/MKD&%445>06[2$J]L'V@LL;&V[$M_83MM[(&D5VP [IO,2ER:[F M 4P5^[=V$ 9II44'Z\00C0;?UJD@N+:HW9.!B^RS2Z)D*HR Z[PLWWM2 \]' MCA!XHV;%41-DOFFBRI/ M8"H$$;][GD4JCW*S]L#(04+ M+BG^^&Z)HF*EOG<%3=8V8/-CCC!@;#1)?9@ M7\91M05A5^3U+?^NMR!J6JD@1UA)9A$W1"L(H%T1USP I)!S M;*):R2.>IIIDF_J:; [)7&>;BLJ.#VB[+4$%5=SS]HR! MMU1LN6>=3O+X))DD(&<#WR4E%J5TI,?UT1=DIY<"J.6E.,% ME7$M*;7.:T=K46!OAEY)$2]>:_8\:FGN62;P+D+%80>P=:/6TDU9-(W,9\_8 MV9KC E%-@=BSW&$V@6B2G<:&J,N9]TX8W&HLQ6+GSS&9Z914 (I::=)SR].9 MX[UB+#Q@%X]M7K'KX(6C$U/RGK:CMFYM]& [M-'N@2)CUEH-26QFCT'Q/#GV MP+1#Z>8-IH94:YF*J$NLG!(Z.U^#JM\/ZB4Z;RSF276'G/"(:1R7N N2&G>Q MO"Q)4%K1D6NMIBPV358L%YYE=Z+C'D=#E%)K&;HH,7-2_KQLX9A_PLSS*3R\ ML>"]*S&1*.-7;@WG4EDBD977 ZT7DGNG@,#DE7C'36&&D)2JM$16)&FUEMP4 M%8/;P8RH7L=S'^LA]J< @@=^N/E0?7L+9!P"%:^!B >*AEYKD0!=YJ/^W,QE M#ST[=&P.Z&D0],!\&4'/69XDR2N6P%/Z=VG;S/$X US ABHJ2E[E\YG(W>5G M28ZMJ#,#KPEZ&BQ@50%8;0--%KUB;D'G(,' M?/!ARP:M3R-+.CGIRX@KPQWA8ASA@T%D1.U7](;8T*OH#[.OD=^7#%_LYRR4 M]L!TV%;/X6!2 $RZJ#6KV*.0?2U\ MG9B]MCORIE@(T0M/;CI8TR;4[%)B#M'+4BPH?0%20ZVU-%V4LB<$9#L73H$ZGR-,*D$F* MFDJ2+&IF7@7]F5#?/ /J=.H[)>::=%O.,'51;92B@C-/?N+)3Q5+?MI>Q>]R MK8XRSX!*P4O+?DJ>'3^B3JZ_;-#X93',OO.3#: @]$8_OPA__F@=N,/^8()\ M_*$-TNW=K'=ZC]\R("^Y0W[?'X2D:,(?R)GCMZ?&RX&T6 [DC]>E;>/1CC4> MI=:2+H AZR6CUCX09L@7GLCSO@A;YQ"0]P39AD_'&K3GX<3S@?'6?DONVYS4 M#VB\>7SIV)UU?.0X("F+(6T\NK).]VC, EJ\4#P%_?OS, B12Z1Z9V#Q;6[Z M26A_V-@:M9;K[4]O[^TE @I(_LX ST(\?NM\I[JLOV#W$TCMR WWVYF#SH[7+9LT&FR!IU3F^DLFG97 MWG3JN9GLNET+8?2*M$:4>9A1MVOE.V@PIG2(17>9UJ)(,?:,YI+YD6ZV^ MW9,A)KT Y,4TG3%-$4])%75_/#LG.M-3SR,"T!F&: M)NH&3$9=;S>TG6FYV^)GD7>RPQ9?XFQL3;VWFDRR/DG0Z6WL/:#09 M@@8/D]9:0Q^C8.Z_)M9TSFMW\GB*B1@>\8/2K0'D:*0J-C1#5*3UFL3'6,'R M&CK0N=9J@KD!EJ&RGBVT8?42!132,[KBP?$F48!GSC"\X@D[K^<8??J4XY*W M 0H; @D[]X!EB?9,;X!)MHZ#7W@0JLP(VK$RYH8@ZF>2 ^+K=O#)$71>1QWN MD&W5;5<8H9D=(H>?;CBTQPW,G3P#.82B7?2[9A:*%2:CJMHHK3!U^5N M1^D1M:M)3/Z(TBBB)$U4C+S:GC/BK91$V][C$,&'EH"1[\+P^='=0_5M0LE. M3,CV:#2?SFEGCVL\MD=VVOQS62+%6B43Y(-W):@@GG9HVR/@J4&.@QN\/U=Q M#6(2#B9]8;SIS,<3[ ;V$XXK*'"#]_"FC@EYHQ8>R\2-3L'?>@$Y^]X?#]%+ M:NDQ:BU3U+/K8F[YL@>MW>T1CPHM$JW71+.2#0M*T.3G@QE1Z-FQ)TL1]F2Q M48ZSZ6=P\&C8'[9OEPLN"^W>M;#].-*!!P&C*5ZJP 3+FS\X>,&C; +'&CGW M;YV=/WTJHXCV/UW==JTT6] "CG8?;;UGBW@A&A?V\Z4YXN0?A]7>95$L_R6B)3-B&:F%D-)NZ MWFAJ^A@C-((ES\0/AH8DLV'\4P&1B6^:^&\)@8^X_N!C]+..QC#!2^0\H]> M '(9?0"]=W1_3[*MA!F/#R%,]>=WB#Z;="_[5ZWR<>#(?SSO=,; M#H3^#7SU_>Z^\PVNZ_[1(?/H?^\P,I-/W9XP_-;_,0"?;2 *G7]<=>Z&PEWG M7AA\(\1O?^__@%G\LE51;E)>='EY4XAT.8,).6@6X,ODER^6':%W+#W/B5 M="%O_'S;HV3X0M52/6K[Y[JZ^25\4$<=U,=(V!'&^3!D:*Y=ML%;B62G&+-\ M33-$81U84;#P':Z;!$('%AIK0Z;V'H5EJDB;'GR2BC1[XJ<$;NS^9:6VN3$? MQ3;98S4YBI#+;'?5/ZH,N=2L2J&*1.$8RH"A,ZC6U^L,A?O.'YW>C\[1]J\J M%B9-/?W*1$'U73F,3]B=XQO?FQ('GSSQ[W8XN9H',#OL=UY&SIQ0I1T$&/YG M'9 [(T>'$HRFJ&MY-7-D8C_C@QP +H=<#E?EL%&\'-*C')*IBI)XM/PZQIUMWY05A?_R[YUDTN07[3_8(!P//V;-^VI*4T Y/DD): M-N25KL9 PAE'TIZ.28Y(:M9:3;4I&AHKAV@XCDYG6.>((]JTR)0,6+M9*4G MD70ZTS _)"D209*FJ6(SNP7(UL$^EHV\W^_[@X%P=]^_Z0[YP;UCF'^_^UX0 MW/G>.'T) D4F=;4:L$IG+B!4DM@$AUP>=F(6R-%2;IJH-,YE>XA#+@^3,@OD MU%K+T#2Q<38[(1QR>=B>62"G >14390W-$5@$')G$&S,T/5R'S^.WW_Z^\_ M>^K?=>[;PV[O=X$$RZ,#])U_W)&#)8/++"U&V#'H27? M'[&+R4%,4M,=65/;M8/0IP='A"F)JA^=_)$R17D=Z4U2R>V@<4^QA:H=K?R1,&;66 MUM!%7>&8JB"F=OCN1\)4DY3L-<6&Q@JFSJL\^C6>^< <6N,@,AFG'@SN/]$' ML<'(2Z8?:"\N4Q=^=S#YA8C.$I%32XQ):ZDVLG>HX#73V0/4#F/Q&(!22:%' M790VM$/C@"H]H'98BD!5 *!90F9\Z@9;"M M0VG*AWLS3$Q]]S&7..(9;Y+N,!K["9UCERI(+2[DQ+ A@XF85Z8P$[OS.3GQ M9PR\'<9E=N"1([(&J>*95R"; Z\2P-MAA&8'GEYKZ9(I-G-K"1PYJJ M)$IJ*0ZF\?SY/2:[%P>*2B[G@SO-X,[!IQM^Z]S'_ISP*<[6_X5GZU?I_O/* MUN^20M X").M-%%P<7A>:?F?<@Q').0\, E1DVLM61%5;3T#YA>>TEIFW.P( M)F3%C0*X(74HU[TYCIM2XV9'*" K;M1:2VV*LKY^E)GCIM2XV>''9\6-1G'3 ME!G0-^>5)A_U-!5L5\#(=V'\ >GI]R_/=D/A";OAW#\P&^HL4@9W6F]/(!.D M2V@4WNKAU-4A-'*$4E1SVTLJ6>2TVO#9:<1EAT\CZK&A\LR\V8&2 M=,NM3J+]HKE!Z? B%J5'TJY$FGR1I-1:34W4FJQT]L@S*%>>"?U M%\&F+.5YW\>U]))0]HH +4O6 8Z0KM+]-%U=EZ?]UW>>&%DI/.YK21X%C^0\ MHR2:#87CD>-QBZEZ2CR2UI>*J&SH \WQ6!T\'F'#.5<4-L %-T7#R'S6EB>2 M\T1R/CA6!G<&B>1Q"OG7SDW_OI,DE _;_^@,>/+&P=ZR".-R9!<(.#IN 0TF4FKR@8@5QN#.=A!T0/W"F)H+_LT.X;(D3-5-'CV0A4QM)=MF1U#*BE:)S8;F9[BEJ.%Q-\A8H\.?CS?]RFB!'19M#X>'EY)J MD&J[JMC4SZ6(&1(+?LI>7;\B#JY_K)!EY1BX'\U0>XC)D6OYJZ/8<#_P9;PR0&; MX!?A$<''8&6,4# 1QH[W+$RP]8@#6DB!U,:*3N$)(7H1'J(0,_GTST.[@>%](Z/['09-/FR/0^S?XY&#@L > SO(4(;HY0[Y MV$T?"C?I>>(-N[IBNOFF.C2?YWS7IF1(M5;FZ>Q[4J9@]AGT.+BQ(5F/]D-/ M->4UN[HX#BJUEKZ>;2,*/@YF&/YXPL[K8L4"[7/83DW%/,)-,V3:Z3M>$9?, MZ&R[UN$RJ=9:#5%6LIP#9F=OF@M4>00JSTY51Q"C=4G1R%X<(WOP7%;.2E:. M@>N1D=T9*LE.]1DC]42.QU[X7(=@,P\O@X.0 M=1">W*(_AKHTLYOO'*F50FH>IO)ABK,I9;2+2Y0"P[+13+;I5TWF+;9R+B5U MJNM+GV&NW(Z3%!O41:(JTJY<3;G6T@S14#)WZ$[++49C4US8SDW8=G@V>0J; M$IVRT#,7Z>'"QH6-F7GG>,HB3V$CA;VUAJC(7-JXM)VGM.TX ,CSZ$!.Z=-\="<;W1D$:SKM^UZW]_M N(LV.K_W M>\+@6_N^<]@1BP]6:7Y_@?>?60?QI&_X#/M",$$^%H4'%-BC+*4/*V8<;IIA M:>V_.^P/")L_C"JTS7%?;=S+^>#>(+AOYM5RA^.>X_[(N#?RP7VSUI(OJE8WO,0^ MBV4[\Q!;&2*('T0Y*BCKZ>=?.4V0SN.YC@"V21>8^=A^J5G"_AX2EZDSDZET MWM1VF3(E+E-1 MJ4IE-!@\HX&/CFTREH4!I3"01O'@8A%BHG=%7*#&:Y( TI1$7RJ#1S[@Y;"*ZI"_&95GE*VB0L=6J9 M(O_1=J-CL5(!75H4@H[A! NN%\+S0@^@@>:631P"P(1%^GO3W^B!740^'MLN MPN/66)?:-8%C8SYOP MA)E[4+[QKG_&TD\R6B(0MJ%:&!G-IJXWFIH^Q@B-#,4P\8.A(8EOI,AX?0I?F M'F2)A OT@^?3PL&7(-#8)U?!D! K0Q$F/E&6?]K-'W"KAD3\B3Q<$3T+'G6OAJM^[[O0&T6^#_FWWNDT^'@SAG^^=WG! FJE=M0??A)O;_M\'C(S_ M4[O!+UMUX":]1)>.-UU'%RH8MH-F ;Y,?OEBV<',0:^7MDM? M3F_Z$J\NL8(DXOUNF:+OB[Y^D_P+*9+^..X5OSG^^@*^^KS^>:-QT6PJ&[^2 M+N2-GV][E*Q=Z)J:ZE';/]?5S2\Y:%#ZAX_:$2O\T& UUR[;8%5&B& IA:,' MGPC?X;))('1 ,UK" ,]@I0=S,#+45$E:!OE5V$EX6W2%F_O^=Z%_U[EO#[N]WX7VU;#[1W?8[0PR MM3C=JX80 RE+>PSNO$Z!]7 8=_/,U'FEDJF]U4C>31D9S=(>7I%(NTU=%AM5 M2D+@@E!-0=@12LTF"$I4I<^466G?=UX%F=K6O^9!& 5 0T_P,;!^9(.S[B[6 M._(Y^8LVN9[YWI--O*2'5\&;X2BD%%2KZWN>AHVL7"B,0^ :SX#M-N4D;?:, MIJ2[PW^B#_#+C 30>2KV@6;",G7;2X1MNU9[-/(Q^1TT:&J]J=9:6D.4Y=;K(Q@NK^R@X& 4DG3$@VRV'9RQ6 M6UIV:.!^0LU;0LQ[\I+^^$> VT& PV7QZ41+76JQH0GE8M.L4!E"#JX]5?'1 MP47RR36Q(6>.$S!8^ZD$.OD:C['O@[^3^$+H!9Y=)PX1-XD/-HDCFD91@R%Z MB67C*W;QV$YOMI"<;TF4LI<%Y*8P>UC::0KGBR629RV+1B.OLB7D6(VG:M:SL8 36-X^8M0YC:H8&/ABF%8$J5,X>LN)E[4$GI?\_M\%6PP=!-BDN#1OZ7 M9X.M^P2KZ]S'9Q;O3=7)?H. E/N%XMSNUQ*A$8DQE M_5QYZC;VW 1F"4P[-/!QP$1VVD196G>J3@ZF,[."!Z$W^EE_0$$4T@7FV4^T M7@B)&O&,ASS4;]+) EM72V1-+2)ZK:488D.I4((DA]">2CQXDE412RPHIEB0VM?5 M\/Y>(S>&2Z> CX8GA10I$HT&*RGDYV8>3Y#["$^SW:6$7T3R!@-Z#,.QT8/M M4%;S\S5;UUB3;2:W1]$E9A>TG4M)$/+_DP9RC^S[)M;W&T;]=]WY!VM3F MIR+76CIX-N;ZD0>^II8:1;O#^CFB2 $4B9+!@&&6ZQK*N&XEWJ@;>K[--TOS M5*=+9$TM"&23M"'J9A9)X#$B!E&46IUF09%6:RE-46VL9Z>4>WN4<7UZY^,9 MLJUD S3R0CP:(1K-?9\D8D?N"3=>\].V,=&3\Q T98(Y(E0UJ H,RMY5(9Q5;T(*\S0*W%9SLO^/:I"3DA[%U%V MZ",K]:E=A>R7-C31T#5&]K6X-7RZ@/V1,-6LM71)-+(W1>2F\2'ZUI_3+@)+ MB8+$/,;3F>.]8BP\1 =.N6V8:65RN1@:@< M=#)-54GD0FRJW#ZN&'Q2%;([&#X:P$<5)7E=K?)4B*/G<0.Y5S?JWN<1C, M]UWH?=!0@:2!+[+\LQC$>_5S*H^(Y=N\AQR?N(N)__7U1T!J2&XX99%:I@R2 MO&2(BI'7P?6]N5@"&_N,$;F[B\ZQ$-D$4T*11#7[SN$I$'EFIX#V;\+)6PKN M:P2PS._W'2:[O3\Z@UPZ3.ZCHHNX_\P::HW^/;<#.ZFR">8=:/#P-4H6@*]F M)*YR7GYXGE'.)# U]"BA?7P7$_C.0> 7N58GH7'J9=($PTT7E<;Z*LG/+I0: M4CLLK^-!2I, 4K)H-ADH&GA>W7J_S@/X+ C D5ZHXX >O"5*F3K>*&*V=5X[ M3L=4Q0G1:2RJ/R;N3/R-E:)0N";G5BB<[T-50!OOC:H]]+%2:\F*V-09.!AS M7E9QM#\5%7I;C6\*YV4+'T'_WG@^6"Q $(N6J*6D[B:4WA8V^E@%JZSU:N & M<0$J^"!@[:&%-9+@UVQF21%@T"@NTZ;3/"I_O%$A'V7#J>H2M6_ZP)8H?QY2 MI><0ODC%QA*8TF>+QWU/"A\1CXU:2R/'U7*PM8^'QYRL<#:4OG'J#29V=Y?X MUE+_NW#3[;5[5WQKJ2I.]'+OBI6#J"%Z$9[M<#+Q'#*M,TOS/,;V4GPH<.@- MT*2HOE%4Q@.WI6Q\=8*21L6AJZTEHI7:RV5?2]W@6 MLSCI6BS,?-L=V3/DG-=64YYZ^8VJFQK/[B$.)CFB;>@Y.,U;Y?B^=V8J =*A@R288JF MSLH!:F[&GBY9?5\8?;C+J"NL[3*>EZ5ZS1O 'REZ$(E"(ABT6?[,C-.Y/YJ0PB4DE]2;P@!>803>Z.=YV:7'4)TW MG@\^6TS?_OC*FTX]EP:^4QNH.JED(HFRPL#I9FZ<%I._E!>6R$%Y0Q?E#:V$ M>3SU!)FC;R9J/HE*Y1.0(P4!EF2%4OHF(?3AF1^Z04J7:%+FTM?!\]C30904)Q#>!V\B2Y(V1KGGYDE?0+'0M*L@].U1B"UZCM2U5C]8NO(.1N]9ZY7X1LZ<4+3S,J+MN^]1B#OC M,1ZEWD!MR*14JBG*&_8 ^ YJZ;&Y(T;%.#9)<71%5*7U*M!\9_8$B?RT/H5K M17X6?F.\4!<>\*/MNL3;\L8".-/"C(*!!\.V":)V1$%,+5>D/[*FBDTM<]8, M#XZQ![4F2U C391-392;>55]9"1.QK3BWF;#@^+NP,?]&^&N<]_M7^?FNNX5 MA6"-3'\^WO0KHTM4EG2)7FMI3564LV"[D8R#C!YV!C^GD@FYWW]>TDU#,S,$VA'8"4P- ML0]:/8LK53$+8=,,*V,$[.R2&L'A#O!Q0#N>AD',;+&QH813:8-#7!*J*0D[ M.UAEDX0F2$)#5+-OC;$5NRKI(C?RII@4F5G/Z\J\Q\?:U%.[PM44[]WMP $2 M0X*(0R6<%&30145?S^LI[>8W%X9J"L/N;HT9A<&0:BU=%1LF*V?IS]FG\U:; MD^^_Y'&+MM12?E![]1\!3BWL,FT*TVRL-X7A7AXKP.$R<7C/^$-D0@&9D$3X MEQ&9H O@YQ ].!C^M>RGUJ_P(WGM%/F/MAOMED@TQ_NT?%0('X<3++A>",\+ M/6 BFEMV2 N#NA9VHQ*A+MW'(74&DT,ZR(%1P@=1@3KD8P&Y-(KYZ,-7,^2' M<5I9@)U&GITB?5#>TG_.79ML)) KRE^R)*7TIO MMZ '&.P\W'[+$O-&F(07\B8[8>4>=#=6B;'\DXR6(-HV5 LCH]G4]493T\<8 MH9&A&"9^,#0DF0WCGTJSEMPT61P;F*%'7'_P,?I91V.8X"5RGM%K0/"X##Y M7CP@38ELJVTDBW$:$_MCJ(['A]"LN0?)(K$#X??\:/L#Q!7[Y"H8#6)E*,+$ M)SKO3[MY9X#L$<5 ).6*J$N7U,Q!K4VXH#^.B]*UJM\4I?V[8;=/#A7<=X1O MG?;M\)M(3ANL2W(QP_O1:_^X[@X[U\)5OW?=Z0VBWP;]V^YUFWP\&,(_WVGJ M5/\&_NI?_?5;__:ZO!+UO5Y28= M1A>9-[U(-U=AV Z:!?@R^>6+90VBY].;WIRZI\$TWP;D&C[XN^CI6$ M:5X8DD'T1.S>Q2^.5<@%3.;S^N>*!G/@!H5%D4%(D4X3M&M8:*19/3S;TR M<699^CC0O"Q@D6"EJ)9JY-[-ENG*-ERNN%PMY&K'IN8FN5J7'XW4X.&BPT6G M[**3KAJ;LF?UJUV+TQ[;GZ1WKZAMJ+;!4(TK+E].LC=6WO#HE87/Y"1&YP7[(SMJK$0; M*@G>C+ E$(4G'(1QU4-_44Z7/0;^J,?K3O)@F2U76N( M7OZ^M*ZDM3N:I)6!:$I9NM%QK'%-P+G#N<,R=]+IZ2TG#(O4TS(S>OJ\JLY0 M?M8?4-16C.3ZD2Q#TE\7NP$]KG5>G5 .4W/LE$/AW.'B!QREJ'KQB<9!A/D8[JP7"VM)O>DL4I@AWB _2=[ MA*.N.O=XY#VZ]"G4Z$AM/BBD,:G9K%!=JVJ#D:L*SAW.G1,H\AW%9)A3Y"I; MBOR\=@+OYOYH@J*=0.("(OSR+U9)U/?>! M&M%*<]CRHM5:ABX:JEY\G)%#B0LZYP[G#N?.V7$GE]VZXRV2.CN+Y'EMQO5P M&#=^X)MN/-[$N<.YP[G#N<.YPT0D?4[- MH<,%N\32%[3#T[83I*RYRLN:\UI& M6Y>J \HO[UW6W)1X67,N5^<"UAY!"R5?!V]\+*ITKKF34DTSU1!X:7)^Y)!SAW.'\HJ,*8(E5M+DZ]O MUP%Q\2CD.W4\R,6YP[F3\ZJE[CH(_1:*_*@F:]<=.7-"IOM(<0W12R=26YM6 M'KG64C,G'7,T<5GGW.'UUX=KUS.PU&<.YP[G#N< M.YP[;)EBZHZ".%D*'*L2.1(ERWF9HAT+U%IYV/Q*EJN2P4N6 M<[DZ3[DZH"SLNOPT>$Z*^': M48,C!^%2:BU%%B5IO>H6ERTN6U66K1T;"#G(%FUEHQFZJ#;S2NWB)>WI\9KG M/&S%N<.YP[G#N<.YPU9 7MM1\BU3961%JK7TAJA*F7O-<.APP>;[HYYLYB+4ZZ:S J9SYF(2 M'$OL86F'PW4$**D,0>FLZI4/\"S$TP=PPGC1H\Y6JM\/(!1<2 M5AX)2R5@1R^KK!BT:KEIB$V#%U;FXG5>XG7TPLI*L]:"<8JJNMYL@PL7%ZXJ M"]?1*RLK9E2UO,';;7#9.BO9.KIHJ;29C:9)HL2+EC,F'9NIGV;>2YQ08=J6 M-W]P\"HK-N[.9=W=XT/C0^-#RWMH9[5I>HU'\9ZI?-B>:?6-H6J://J.XGV9 M]C]5.>_]SQ(X#%P2V)E:*DG84DUHX='V&%6U MUE)T790WM,%+O<]_KEQ3JSIT\ M/#E6>T1J$ND1V=APNIV#D4DP.M2 MK:68NJB:ZRT7>:=@+F'ED;!4 G;T,I>Z'-4$U\6&R7Y+."Y>7+SR%*^CEU36 ME5I+EQ11E7@;;BY^V*:2Z0ZPD>]^\1@1YP[G#N<.YP[G#N?..7(G MW;[^6MW,+;7_,I>S7C>AU5JKN>&0$=_'+S6B=IYL.R*B-$80=5;%S_]G[F)! ME7CM=EU^6GPVN=<=*H@.NG\G[7: ML4>K?=XP:BW5T$2YL5Y$EM<^YQ)6'@E+)6!'KQ_;:-)R);(F-B2)+V!0K9AUEJZKHNJ9G#AXL)U5L*UH^A&=N$R)%B[=+&A\H6+R]9YR=:.[*P< M9(OVQ-%D^+^:N2LJKWW.:Y\S14&^!\^YP[G#N5,][J2*WS9WUJ7(H7SNNFFA MU%KFAH8J/'6%-3!Q4>?TH/QR'I8940/GUF)*H27GM:W(T,5RCG$2+.'J MQAZKGG0Z^[HIU5H-45;6D\[X)G^I ;=O1Q MQGDTG4L5"&YYZ .LY[UT=O*D>JCYZ)>6P7(N,2 MRR7V8XG=$<#=J_(Z&+BY5U[G0LF%LDI"FJZDEM- M=RZ[7':K)+NI1/?HY:R;.JT6KVBBI*]W"N.++A=<+KB'".[12V7#JMYJ2*:H M2'FU7.=BR\7VW,7VZ%6X845OF:+.A98++1?:?(0V8QO-/626=E32E(:HY%TY M_^1R2_>J/M.=-_C7LI]:O\*/9+A3Y#_:;O1>"03UU+Q7".^'$RRX7@C/"SU@ M/)I;-BF8 4RWL!M$OU&*T#H:8]M%[LA&#HP2/J!E6 3D8P'&;0-,'GWX:H;\ MD-3C"";C]EB7ND>*1V,^;[H27>Q"^N4J-Y9]DM$0:;$.U,#*:35UO-#5] MC!$:&8IAX@=#0Y+9,/ZIRK7DIHF?S&"&'G']P$;YWV M[?";*'1[5]M%.0U6CCKR7G_8&43+Q; O_.BU?UQWAYUKX:K?N^[T!M%O@_YM M][I-/K[I]MJ]JV[[5A@,X8/OG=YPL#[)/:52J^U%F2]'7@'VI)1\(<060&\^ MA4>,WBWY\OM%_NL\@(<$P34.1KY-:R>W7>LK"NR@/[[S0>N[(96+(3SDJP,6 MP=OJ;D8&A>W.L=4.X\_(*^!9:$;TLS\'@>ZUAS\ S*\V=$ M]6"A[S\BU_Y/-!-2\2KAC9!,NHBU+=[K%Z*ZVL(5L1"^8>2$DZ@LEPU6PS-8 MB=^4-@6S;R;1R(PLSWGFP+AF.[8Y@./(%D.Z'9*[W9HX<;B!GB M.,A_%2;TP<*(O"2(2KN!,3,!._!Q(B" ;E0A3G!Q^.SY/XFZW6KPSB8(;-71 MZX=6;[=WLU*B &#V@/W^.*XK=^N-Z"O?:H9+"_B;$CBDZ[LUPGCN.,G@A7@0 M0 HZWZV##<"\Q@>-M!O3=0 /V#A,D 1SW6DFMAS8ULCQ7+#XI@]SL,X\X,"" M371$P85 C,JKN!H;&1YY0$#[)0F +3!/K(A=WA)Z@>_AQ/:M.C$?7\&(? 47 M0A0F7D!K^A%83%X#&XQ/41.GDC6Q>G-Z*.=VG M[X!W#Z+GK)[D OD>$9<,Y,("I;T)"4JM!=S> (7H>>(2\V/96YED3)Q B!IM MV8'@V 'Q)"*A%GHHL-"_A=\=[P'H-, .'H7"=^3_Q*& B*KBQ2X:"U/\N N MUI1ZBO4K6JG:HQ$ @!#G#ARIU+@9A"<@*1C4699$P1K8/(PTW2- ;"1)G M5R1-ZN9.2)D<:1.JQ>CP4# 1QH[WO%!DP++ITD. 8B0_V'V,Y'7SD\BM9"S) M[3-:=R=(ADM(Z=/XP6(V !JXVK)'U'&/PP [GDYZ.,!C7C'RZ6 "?" @+(^. M)>( IJR)!V"[D=I+S*1%R(-\N?%9/BD72R#U\"H01-#11HM'N.46\N!@XLT= MN(G,&25X_-?I2*Z>ZO'O3!)%'_C959I3F>YUPF)@D M\A'&:GCN1J*YR5SONJ.+A%R>VJ=BBD!)DJ\WG4N/M MO77E36;U6DM? M;P/]?X3(/2.\I%'>""P$5Z ,89*8OK0^I6]=GO(6(W!"K?ZQ )K>)0:Q,/:] MZ?:G$'LQ!JN5K,2$\G3%"!WX,%ZRH\F32Q9/AK?\RP-X"F"^AW-0C_&2GCQG MI^@L"4Q<7/KM,'U4K.P"C%,L1.^N1Y07NDNC)]H>WM8#;2THXK&5"'WB)?$W M[-$>>!W,IU-B?! 3VWYT[3$LV4"M-Z-8H H>$%ND\A,ITL9SG_I4EAV,Y@'U M-N)U_3W"M@-R7<4L1X'.?CO"S&4[PN#;$6>R'<%TGKO(@&@\S:8 MM8WUR+796(]<#WY\_]Z^_U\2FQYT?^]U;[I7[=Y0:%]=]7_TAMW>[\)=_[9[ MU>T<%J:FKTQKMH,OV'8M\@]9K)Y@]0?F;K7?C7+:[V1ZU%*AORQ-E#7KG9H9 M-LF0H![J!*X&I]FQ8<2KU@_U%CW?!H*# 0_>Z]R'527R3T(0;"Q,X?T3&G1T M2,P?_%EP/*GKC]_F#Y;Z1Y$T<>V&:(!1F&Y,WH%?X>TT)C<&U;)I+6787-_F M[>$9 GIW7DB#F#BF$]5-NIK[Y(PT4"W C*"GNV0$S^*1X^611S'G43QR%(V< M&-ND$0X)%OAXA(&_1,%3FWLU-$Z?,<46_3V8SV8.X;@['X,C +:S3_'SY\/S MA/0-D02Z*T!ZK%[- T ']N\70VP3.P'<2^^9N(\WGG_EP]C"_2N1-=ZT6;/6 MTO2+;=GVP#,GB0FEFI_&ROQ(I37E8MUW>S>_CS0 G?TUC&[I*YE^I=(0XPR/ MB-GKO&8)NF_V3^-5*)D.2$$Y%Y_M3B +ZF.3+_X^/H%]&LZ>NRM.,'6T[3B" ML^K^4R,SBM]&WG?D=$6>?QSY>4L#^\"K7^R7O5-?L:.^LE&PQ5=/7A=,,-ZY MX'T(]W!M\*M+,@A2GGIPBU2L"[HF@=FGJ!?K!16%8^FP%&-38&S2!B6;C.V= M&MD7(N T$E:#60->#-T:W.3SCZ*N;]%.,ZETLH@_XHUAH3>>XF2W7MC:3>(EY_'QT7$1_+#I9&&RW/Y/E)=##:R(!5GNRK)(\9(=^G[.H&@Q)&ED/PQ$#8<\DEH,NH5.'R81$EH36L.2FTK#\X5<) ]1K5 9PJZXD_@1S&P@\KY%/K*?(H">LXR*)22 M%(J>HJXHI%RR J/>%:"!4>3W)5D=.RCP1SLMLUY8]:J?EE7O"M!Z*%J#M9Z6 M1@TL(-)70CT*G#R7T"]U/80D344=424=/PW,2.G^PF0%9P-\285\T"J%84W) MW/JZBSF[&U+;]:(4V'E*T*"6N_:[#;@0IDRMK2K]:%XU?:! MC3GL/*:B61W[M%JQ3P4C4RG)=6WD>3-R/>)I53ZL7KV'I6S$*IIY=DOX5Y9R MG\O)8+PLKU!',U;5D7[-6!F6__#+J%I332RK>GVF(2ITZ(+TBOIC,D@\'G)B M9EP671H04.TFKL_J6UB)#OOZ*/\I.!:__]:1OCFO_#5DA%6?U'R=LI"QZX^. MRDX 7#E.GP&'Z;:LUI,6YB3/?]"H7<"*%D!E915Q-%KL\!(EF5758-0+(.41 M!RP8_,V) I\>U#2((O?9]3 (QA5F'AP#8X=R5[1Y/4_J@]H\(JGCVB<.:!8 M\C8JR'F7P"" ]V)LDM='T;J0K&8VJWYEICT"FX8LL7T5HA?6Z=+2 7@3"V'" M,Z\\H6 4H"F1QV=>QPO"F&5F45,$*(4[L#""\ Q'+R,3FK$5ZOFG"352B%X5 MEK:-'N$ W5L#4DJ!M#1U0F,+ U NEEBU RP!CO#PX2/9MA&_4F?&5Y:K/N]& MGM4@9O!+:Y0!3T)\'VH@6$3\"MH-/%VLQ8$O#FG.8*ZHQXDP3X^&KCGB4TAF M"Z,8.B$DSO([!F1(J1Z^.L"Z$("4B[5]3AL1\WB6F]*MUWNDJA>71K$/^Y;J M>KU^)56#M14GOVRJKJ_/-)PF(5 !9A]0/P7U,0ZQB!'T_$% B>J(=EF]CB>U MNN-)Z=;K>5+UBTNS&$XKJ_[:WXE> 4>CQAJ3M]3\RA@P@P-^GK[/I9T@\OST MF<#%EU2A82*'OQJ AP6X*7N-X)4>R%[X>Y"@ERO@M7@A,QE!),-J_IZR72$$T=8#9+\DQFK%_#(*[3.2%N;@YK[9>$ZD1)5"+?9"Z M==1 ]311 W7V-5#Y'I'8\L$=OATIY*A5+8OBX1W,,"I+8B\&8]5B811<*Q9& M/=S\?G/WV\W:JJ?-E_K%C9S1"$Q2>N+W0[YT>H0EZRS6-9776+'5MT0%1MML M&& I ;5P*/;2[&FP WBO"9_$F3S")#IF\_=!'1H%(3=D,$;'@SI,?=I"I:9W MT\86[ZC5&R2PL4'T_N-2RZ*,\_,MI-*$MF:EUN,T(A_3?WP""W *^SG&6?M=!EWY3,%^9?YSQWXZ6_%ZSVKHQAVZ4_=CE)Z M?=FK%/A!ZU5ZU?+KNE;^$;&HO2YJ-2:LF5BY@:;L2W(G"12#3SLAT!O.8KV?IB\S+O^7\@7,>GW$V S*4[IJQ M-FL,[)N?O-,?MA_ &->3\[/B#(V>2F=HP$IDVZQYAD:KI]L( CP' E2ZQR= M^^+2UDW9Z KR$^1W9N2G')W\M.[%I28#FUEG%$& @@!/E #5XQ,@-BN1 M34.7=:7FX8O[&M-6Q83EB:0M,F%_S65(EIJPV;[5:OLNY1DMIY\U,PX/03\J M%H>9K2#WEN+HW(;7PN5*_F$ QI7=\%,-J4;4G*VHQO5Z@V F@F'Y\ M%.M=7/8 Q;K:SCJ 0+$FHIAQ?!33P=(SN[+1*R9/'P?%SB >\H.7%VRE0Y9L M]Q1)PSP^:1A@@RFR;M;E 6F GT-@V S#K.-C&-;T*[)JU^7D%AC6* P[?B!3 ML[#T2%8-@6&GB&'J\2-UF@TVBB*;)051Q\&P,W!&WLT2TJMJY]P)S%.\M2G6 M4268,)XN>N-,JQ,+=M0/GY-A,\=WA/2PY8BLFI:L]XH-W+>S4^L[Z2,Y4@2I M"U*OF]2/[Y#J8<,:N6MKDNY\@=4'J@M3K,1Z.3^HJ9AD9.E@/EB!U0>J" MU/=$ZL?WI6-3!TU63%.VM=,@=>IF^!NMFUX^$[ELLN.&73",K O&ZC)Z?HEN MLE&-$Z1>UKUBMX1>K]@MX?;N^O[[C?1T];_; M#8KE+RWYE-J6U@8U3VQA7?IBYV:%K7[ZH'P];)1<'.K7VP=QGH@9;W'L:.>1&@'))S^A6>& M_2OQP"KVSIH[LH+DN$D_D6W^ 3YSS6@&<.^>M53*#RO)]='JF1>7JM&IJVO; M/E=JP4KUD@E0OY3-XWIQ0I>V%.2]*PLS[AI_,'9;#D;O+CN8W8:LL0YGL^$, M0S*@O3=Q/%828]>7]-A4!7# Q:YDL,/0Q<'+O:>)(@4SR1^ M)<3/7DE[J^+4K0P;(IFB4)!@HTL?> 4V7G/Q;>G(8ID^-==KC;[AQ?&X$'/2 MX;ASXYRV9OX>:\!6C5^J!8X9@5H"_UK$@=_396_6E/0E7?6G)""\'4]_IDJL*?D5= M,N.,#C)*9_C !Y_Y6AC]C^!;UWS6.\,/Q(7&O5Y_8QH;'^-<<1[GDIU08IJGCMFFJ)BMO!E0 MI56U1+P6.&?^8!8&&RW02,9$,KY22F)R;CYV!<:%O=K@1L9D/Z0K2>4FT\_R M:]UA-M ^U&UCG[J2L<0NVDJK,_>Y4I-J=24S)HZF;N_U8*S6'(R][&#J&X%[ M6LKW2=B#1G>I/3A_[-6-JP:1H:$L)<--=IFI+G06R0PC^3"$C;#EUL^]KTP- MVLX.*TS*/9(=9H#NK:]3%5?;82T/$ MH^(95SY%#8<,K[.FG1%NX?&EE(+(22.Y_[;X6-B M "@#O@W*(1VZD7G2Z',S,0+%FM!V]FZ,DF$2A$3RW#^Q)3R=?H*C0VC3^P@X M!+9]!^"GJF7)5]@L&GSH.5T6CE/!,TT\-J\F76TZ.J7L+0,RQ0G.J.KBA_A< M6/[ $#3:D#)_-DB%,B_@&YG!E$Z)!# RLR$>!Q&JQ9-I$#H@#V<2+N+3B5*I M18$[=CXL2D=DQZ7J90,/E M.B^.Z]%=T3$V&,NCTI/^!6CWZH2#='LR=O;'$4/L SE8,(D+USY,/ETNA-^R66X44:M ,ZAX^(W*7:W)\>SFP5Y4 MJ7T<=$2-Z!FEE&O!.<+&65&OQ,,Y2=0',_*1_+)HEJ6C6)K+>U>D'JCS>N/8H6,/DTG"'%HI M<(KZ%!.MV*TF-ZTP-[LO\*G60_6B6XQ:^/":="3Y=3 @F6\;_\AB#H^$(;AF MJ6S*$+.CD,91RW+>V-7R>8WIN+] 2F(7-2@Z]&[Y'DA4/-'ELO4L1^THM8S: ML<6HG;,?M7.D]#"]:G;8C1.B/A[](.'CV"E+#3.L8KZ68153PVZN'NYN[WY] ME'[W1-+D94D6M$!#J4_EZ\!%KC>@TVT0QFB221%" MF2H*R*U!.0'E -8-$.](G^FC);>[*("\/A=3SVB:@EV51?Y(G)JW\Z/QTB&Z M;!,8:P8!!HPH/\D.WT^5C/Q2I"")<8 G_43!9.Y(7Y;OS(T6IO@Z YHQF;Z! MC9F#[5.Q2BW0G5>8JEW,0J;W,HL4Z==E TYQQ6B01J0/^T%5J:UV909T!'=" MQ\TR]P(UT9E'869HIXX;O('Z$R+N'YF#)D[-!5N<(O KG?GWC/IK['Y( DOXL%P24K, O1#L1[0\^!TR!W-$EH.. M>HE23.-QDA(:R0+O;"!5E/FB.@46N3DG?^3.I?OA%9Q;NHK'#-U9PCD9L(3T M[!COAQN( +LPHZPUU+(XA2SCTV4Z]=*#96B'(T$)!R.;'HHO23DSIXF2\V:( M\[:$LL0@LG:.UQ*+VG118A"9&$36QD%DK9N!M-'@J#657RO <#9P/,1@LM8! M9:>I9.>.0V?0?_,Q9VAQFVF75IP[#(=H3UDQLVJ+^2=S\=[NHJFWHX%7)FZK*G-'T@C4/5PJ&HU$%4U.K[3ZLI:"U2 ,VA8^E >RA SE%92EMU MRNI=7&IJ#U3KG?45,9&DF6BG=1N(=MC2Q0 MN:[>40+KFH9U2@.QS@!F9^BR MI8DA*=FH#T]^9LKF[>BK0 MKJ%HU\"0E87-]"Q+-JRFS$5SBW,"GY>5E5"*WAY-41N6J(=RRK/(%%8M8Z^=DG<=5&3C:'TX,G]J*$6V[Q+U.LU99ZUQ3A!D3T!1V<)AVLF<6[&QWT,,= UKK+ MVK@*.C@^L@@ZV&10[6YT@(F%NB(;]L[!#$$(@A"..L9U-T(PT"2W95O9N;I' M))UMZ@_X0OR #K&ISR-0,@:W0>:M6-U^5W=>[H%_+&_%E[;'*L2<1V$3'.!79O;L_O%+ARQ M95JRI0KL.DWL6F,E[A>[;,0N5>Z=DA4IL&MSTVNOV&5W$;O -&N,T_H,3+.; M?!)C7IOI9V7<;:4@&26)ER59W%(\^S<16#OT(&E:8"K[.RL M!3+M%-9)-$A3\U?:LNJZ81)<,!>*'6SEXK+;T>J*DM5Q5 T-*@CZ%/19A3Z- M>NA3I?195Z&\H$]!GX(^B_Z4[>E30_JTELU2%/0IZ%/0YU;T:=9#GSA'MZ/4 MU*PM&4O[[ ;1Q\]) M!)^.HNM@\HQY"O VG#4(1P6 NN83P]DT>9QS_D1G>=&_OY+*<^5M_>+24-?. MW:5C/7%$.!M:%<^^*4V=-QQLCE.KB/L"]\"U9S)VO"'&A*\F9.!&;Y$LT7F+ MV=-1.HON>Q(GCB?E=B%=C4)"V+!T.J9T*$U(. (D3E?!Y]%&Z83R]@YKJU3I MO6)@H*CUGKLN:KW%HD2MMZCU;DBM=\,V7ZX/ERN?91;8*954'[=ZN(T0.T01 M>AOA(C!)E*(?MQ2]8;%YL;@]+NZ\\AI$3?HYEE[MLR;=-D1-NJ"#=M#!/FO2 M;5/4I LZ: <=[+,FW;9$3;H@A)80PCYKTFU;U*2+FO0FU%6+U8F:=%&3?FXU MZ7JW*VK23QN[CEB3KG<549-^VMAUQ)ITO:N*FO33QJXCUJ3K7>U$:]);HF;> M#(>D3_-1T_E/4I0-@!+C*FO6)_FXIP+I7 W^2*(8TX,KTP_FWM%!0 MJ*#0AE%HM::B*RA4IVU%:_8^B;:BHJUHY;:BNF*<8EM1OAG:QL?ML[_[%(8) M_<0/T3=6TR;/9<[JV8?Z?#N8Z?V@< MIEN8.B/RX3DDSI\?G"'L\*/CO3IO$7*,/'L 1K ^&4P*W*2Y4 ;#KAM.8ON0.W_:.U(5( D5JHR/]YQSA%S7L>9']#;@L(?=3RD[]T3?B M %-Y@@<^>T'_SQF/M!@#!^Y!!EKQY+.5[<.^ M4B; [8M+JU/4):54=..FJVDG]2Q,[5YQVQ]+KR0DJ>XUD!Q0!##N,0U\5$3@("("7\ <.U"9 M8+4>!8(S *'C1G%(I?KLX&CK;0(@<>#KJ%X . ;X$_T759BIUA'%\#\3VO2; M)?9-0S*&^_!E3'?L2#NAG+9OE#-J.EG@ &:)RK@]RBU1ARLO#/0153TSE+NB MOZUD8J\\H>)#FI\:DHGC^C.,HOM^A4VM%&&%1(WYF3-. M@*OW/PZ2\(TXX>P$-13C^J+@DO FKNZ7[0=,C#Y8QF"$ +SR&REB'TO-741 M+8^ O4K[_,*__0"?!MN_3[.W.6I^4&<[Z^'.>G8!-W_I%,3R;AK,-]=Y=CTW M?OONQ%CS]D;UO*)NH>H%!::JHM<427\_SR$C:8);)TBF;'!#-#]AH=&C%&R[ M8^E:U4D*)B@!MEY;4W^UGJ;^5DR/351:J7_@FLBC>E_T+Z MW%^D[-RIO_'-ZLN!\AU$P"292#^8EVB^^G;;[+9MFVLWS2^_:3/R*BE5M<'N MQ"(;E;??VO#%2MVFJ,2M5"%2LF7*W #3@L_DA^,.KO!\MJ8JY>*RI\F6:+=_0*H*8L?C,JP4:]FRY8IO(;-0!H\Z8^2BX$F$L5"VE6!W;M#4=QO?IH2 M008W/_MPZ]4$_ZI,?AK8"K9L6\4FF3M-=Q3RKA0_?@!)83[1B^,E-#.7B3Z/ M'^NJ[L7[#1>6%Y=T5]67G%4\L0[X-)ISU^$XUS:;2()2^4G6Z;B8GO&WK!JQ2D2)8'[5(1>"B8#Z6R M91WJZW5FFS_@>^^'OT6$%KO=/\<.?&]PZX-6,W;\$?D:A$L92B%!6--!G=$Z MQ=!-FB#:Q<1TRN$^!,,/282YEW!>C#87[\OI M,W,I\ULFR@O^<,+\84UI0,W\P0#^8'2*W4T$?S@:?]B@OB%E! -0Q_P@EL;. M"U;>O$D1J%CN$-0MK-'(/A*$TI"6W>42QN.Q@\^QY]](/&,J):7%\Z7$HKAX ML;A8JZ6XV!+%Q:*XN#'%Q6;5XN(?(7*<^.V'!]SGRA_<_"MQIZ@A8,&0%T1) M6%*3HY74^VHE];X_'NY_W#P\_5.ZNOLBW?S/;[<_OM_"K_R%:+6EV%M6'!TRD5 14:YVQ2]7** M@,@7A%&*KZ4R.KDYK.OJ5$ 20])$MK%I:*8LJ4V MI8A&5&C5BDUKDM1JQJ;>Q:5MRZ:J-P29SD"1Q:!P$I,03(!A_$JG84V3L#]V M,'<#%5J:PNX[GO<&F/!"/#CPG88QGSK%] Y*,?K%I:[*>F.JK81^6RLRK1G? M73,R&8!,75DW=\X4%OKMINAPQ=)[6-=_SE_Q (6&NYPHULP/KYDHL#&0(7>[ M0L$]261:,V2Y9F2R+BXU33:,G<=\-T3!K7VJ]T8!DU:CW&$M*FP:8ZBRW:MY MT-EQ0W4""W?%PH-:*3K...CU9+U;\T#,AH2OVJ=VLNITI]]/)@E+3!^0:0@' M2',>STOYK+/:_&H&T2\Y@,*_/4)'D?F#JTD 6_\WO;Z4S"I3F(+YY*;3I!\>X,_#3EJ=4T]%_M4["[)YQLX+Z MX=-H-G0(J^6.5.;8?:-0^ FXZUVV3#YP0T;5>".U&X"&3:&9G.(/)7 M;N,5]/#:Z@E/V;M4;>\GXSE2>FNJS?,X5N8.PJ3EVE*@-H-^VPK'!=F<(-FL M*1E?1S;&Q:6A[+WE@B ;03:-(AM]3<7X/-E4C$R8%Y>*;&IU%9P)JFH&@@FJ M6DM5:TKG=Z(J'/XJ=[O-EU5GD#BTS. K!EE$5>=R:EE35;\3M=B@U\E=0Y1P MGB3FK,FFWS7],G:BWQ[2KVT)^A7T*^AW7^K\'ND7)SUV957=N3!#$+ @8$' MFPQGK)> #4K 1DD5=AL)>$EEU2:3!#<;EX>.KXTFJI66:+'E'G?"FE5UPMJO M03!X=3WORA_<^K'CCUR +NL[MVK&FE$R8\THF;'VZ_W]EW_[9 M=\*0%J7-BJ)&_$1VJ6KJ%&"X.48\]L=DD'CD?GC5_U?BAF3PU07V1;ZY+Z2 M(Y_?OCM_!.&UYT11"998[9Q0]U1R,G3^<:XECI/KFX''YF:02:>R8@FCR_)F MX[F:.#':3HRVVTLA54LGNHG1=F*T'0, ;2!79*4?-RE>V6F8T;JJEJW:4]6^ MN)H2DJCB;;*9S@U&!E!02!@Z'D E"?O%#*2=P[A-VW#ESB6G:1 K^AJ?] I] M=*L.E(9]<:DK/5FS=BX[:4["@Z".4Z6.-0ZCNJG#[#:-.FI2A%HB!I]"9T# M!/LS^AL>M!AOM8(TUI0>UDX:.$#0EI62OJJB_?\)H-.:DKS:T4EM&#J=E[UQ MC\-9,[\>6I\%0U0402PE%F--(=YZ8BG2@W9Q:8LDY--$ES5Y"]N@"QT0V!1T MJ5-)5=2.VG#FR9*01^7^NUU4UC,>P[&F.*AV]0,[;^@XB,-NPQSY ^NZ9XR' M:TJ-:L=#@^.AT@H\Y(P^740*Y1Z-7M>I-&SP_'YB'4=9W!E$NZZ6I!/L%.XZ M=D1+!*U6!JU.VP2H-+MFESA/CG3R VPJBQJEY#_GCHEE!G3)RB\FPE@[J M91=,]ZYY$I-A#U#5(6A:T/3ATCNVH6D#:%K39.\QICUA@> M.U(4^QQ@8XN_;M\R4E]$N/RG[X>+.)?AE#'#*1,;GQ3Q20*X>+@8;*E0:85* MW2O$F0=ZI^B!SI:X0[,/60I)-"7PPA?BO76D?1Z=43=@[+J/SJQYA7:7'MV* M)6Y_=-K"T\1Y M!I:8Q,L?*6LG<@R>I/06 )3[;X4F3[VLR=,XR]J;.B/RX3DDSI\?G"'L\*/C MO3IO$7+X//L&1KT ^&4P*W+ZY4 ;#K!$=999!N*3A'@7K,9I MRE(D(!R@W;^L/SM@]$\TD!0,I6LD>Q]#2,YE&5YLT&FH"1V[[*H=N[Z0YWA5 M:RY;*;;FLI5B:Z[;NR\WGY]NOMS=/&[7@HN^=.OF4K@->I8E.U#;V3;J6^"/ M/@#SF( $>H[3_D_ _2MV@#KY-D]:KZ-HU7HSM:_-DUC4IHNR1$.L>>O]1^CZ M?7?J>*C+)W[!LWLF8$ I=\[;1R%R&T6)X_<)J#O1BG29TX;$'8FESXZ'<#BW MCF@/Y"7P8#W25Z?O>F[\MK>(VXDY?"MO_V3\N8JQ=A[ANK5U<_L=?+%51/[6A3N]P[=\%K0E:*Z>UWWR> MJ$4&J7)3A>!Z@N $P0F"6T-P6(!)FY:CODC5YD*<1NUIQ(J! H*8A4*WXLUS?6XLT1K<+SB>+BTDR_8Z*IU M&]("EYJET*U%ICH4.J.K75R:LJGL4L0O$*B%S&@GA:YW<=FS55FUZNK0>FQ' MW18U=F?G#:^\_9,AIL/Y_(RN?G&IR$JM7K]&A)\$P9TYP=79BZ5NQZC1-6IS MC IJ:Q+6"6JK@]KJ,35,$&VZ;-;1,*SI1%;%LWQBW8UJ1+R=;!2+*E**(AM* M78,KFY5KT#Z?]#<211^E?@+,Q(^E*WJ-MA[[D!*&C\<>Q2"6-TY>6?J ME+AYQG?-R*4R_[,O+@U95VIH)7ALYTR[NAZS%FW>7"WP5CQN$_5"/+]/&TBT MT1)MM/;!TN\"O[\=5U>Z5*OMZO!_)]M JY4-LZHV?_A"^OG>#PIK"+38^T$2 MS1]:V=) +&K318GF#Z+Y@VC^()H_B.8/HOF#*-RK(>]'/T3S!T-16E7()XID M!:T=F]9V2_A5:D_X%037),03!%<+P>W8_,%01%,C06:"S/;1_,%0VM6_2#1_ M$$6R"W1A'"X17-$O+G7+JJ-84!1<-S #I"(RU9#CK!B8$6+O-&1=H%([4:F6 M!%[%O+BT9&]>4!]SA;- M'P0NU>,+5KNB^4/+<*FB0K<6F6I1Z%0%NWD9]BX*G4"@%C*C710Z5<7F#Z#0 M=8NE!:+YPZEZPT^K.K;&\H,?-*B^8-8W^.V^219LZ]&3: M .(ZF,!*WB1:8$L&DNO' ?TA'KOA0 )\\0?HT)+X97H![G/\@122*':PF40N M8?<:7N+&TM4H)(0^]PZ?PK"PVOWT1-]YE;Z37E4^O>](3W#/PH\R? KP4PK@ M^1!7XX\B&3XY2/H $7RI2Y<,'PYA$5+@TXMEN:K?B9R=RHT?ZY7O_=R=T$4=QW4I&F!_4&67: M%YF3*J$38[83.ENELXPM HU[\)?,J6D2O'#47H9CTJL; MCY'NIJ1/23)*^N-2G.\L;=%2PJ\:PI^>*A'UJU,=:4VE M+>\J4@GMX,AP!Q M]X7\("$V(W!&I!1SU8M+LU,B!G^A1UQYN>J>EZM=7%H=M=CY]A?>#NB13.-\ M/Z N$QUT,^6M@N04.^'CWAOC[.S046@ UX6E+!RRRS2/0?VGK:T$7U[]^0=? MXA5;81Z6*"H0S4L!V*/G7?0>;WG>O;TO6,<%6\68TB_(V;C@!]%-E^\#A4H@ MA.-Q)#&IOP0?&G7H^MYA:"#5E,RFV?+0C;TOV,1#-\L6O/VAEU)Z*??.I_UN M=Z1S>4-KA/4V;-!:858M6Y.UYS6![M;K:"7*6XW,>BM*W?TX[96@JP'A>]WJ M!VIU][XJI<*1[L"-CW.JEK)W^*E;G*JZ]U5I!SE5K:T*?>I@<"(PVB+8W^N8 M<).>@ 29.F_4L.']*$O5 -S(,YR,#R] H9-X,?542/2W*'F.8L>/7<<#0 [< MH=MW*&X K.$&@ 38B(D;C?/?(3_="*^SMIAX+,0!2\ICGZ.W1&_^('T5&)CH MIYKB$QX>4Q@ATV7=,Z./TCOWO?2-7Y\ZZ%9RIPY]/[P,#F:\?'.(!'GB^P0O M@[>!Y??B!F"7IY^+QTZ,RX:M?Z(/P6UPGP\GQ6]A=)_">T#0U0]',F"/5C.0 M+6VU@?R0'EQT/]P\%#XSC'N@.'<[RT9)<;MX)5(@CYJ=+1FPW9?>.G8&*_ D MHL<_!^;9$3(\HR=(,<7-9'HD R:[_?$\0DI])QK#OX: %\SM-,S\2[C%%S=V M"976%<^CM_H\[DA\#5_^$08O+C"1SV^_ :G=^IESZRK[=N63TC=Q8:1$D_A. M,D @PI_! (%%H(JP7DS:1312CIZ]PZQ:RA7\,@J@X4 MS.3H+&MUG(/)D!! %-@IPY7];V?C)*C<9DRDQ:)U,+\9I+>^,W5CQ\.L1M3^ M/0?UV-0SO)2[(4N=P'I A@#I.=21EI)V3".3"*79F>.7?!)3W67D(,716^LE M&*"4/B&#Z"O0:-K0#"5G GKG0UR(P M%V'VV =9G'A 2]^=. DI2M\/\WKV$_K^G^ 5G[V@_V<&&QWL+P(0F\++0,22 MBY:@[4*']0GNFN2UP\7FZ0WNG6[;'4O7JK9.-ZV.8>NU=?%6Z^GB;8%-MKJU M^(9=O!N5+%'>C/BKBZQ&^B=Q0NF&&I&IOT?2%/E,.S1_=WUWDDRD']Q0J:5- M>O+B:D[RT-]>S[)]5'?+?^';SVZ95X+^0[=557ICQU MV=@_T6QI?\1EU"WA3[M:XEC$A:+LZ36H3%-:3335K)**AM.4*016:V@*@ZR5 MJ:HG)-7AJQ]949-36JU,(ITJELT?RE&Y1_G8^?M2=@7/J3&@?K>!TDP[Z MUC19[2T+8Q_I/$6AYRPF_06$C3_:-G^8WLTR_.2 MYT[<6')CS,N;!E$2TM2@_MCQ1S2]9SX#.>K ]PG->904^'**-GN"%WWC1YJ] MU-\$@O"B%Y;>-*.=:,]K7+DBF:8I#I.0)L\.W*B?1!%073W)&BE;^-WQ$A)= M^8.;*'8Q9VOPU7%#=I7EO.3 L2R3PVIG)@*%323#9.)K0!MODIXKE)S\!Q>);IZB*-]B2)@(#J=)F0JI(EHFF= M7K=:;L6(.6$?Y*8E3_^M/$P ;AY$J8!1+O_G!,OAH[T7BW1P7KS#;4B3BB42\FD9O5 @# M919?9>^0C6$>6]94NPT9=H+2!*753VE6A:F%2RAMY90MH_8I6X+(FH1L@L@V M(;(*DZ2V%F>& N),Z\D6)GT)2A.4=I:49NU9G*FM$F=GD#>TT91>D3FT,V'9 MAQ!AV)S(5F75VMDBJREE2"!1G4AD=_?,G7NU<6>!/TW$'^403$@')F3J#V9"1M.84$UYKZV:'K/8_JP].;%G99R*^2?;U;YL+]U82JRBR(92 M03%"1$5P6VN[B__#1O8A]']D"WQ/HEQ^,0@5WE=!*R*DV2*??BE M7 MY$&:A\^H#>.CK:0=O!@,WBA)..<'L8S(?3\%'D?@DGLW-E)P7Q_6<9WH@ M^&8^E*5P6%L@H[4&.L!#4M"D7^%#Y3^GR[MVIO!+_%8&*>WB4K/U3C&HG<)J M@8WB;;A$UT\<-ILGQU@Y+^NIS!,_#2(7[_F8#CB8U3W^,E_PQ%EQ=_:(\PRZ M0A(O?V3O-5(;LFQ%7P!0[K^X7 2T:VH#XIB6I>N&U=.'Q''ZIFK:Y-GL.5W; M,/\/?9_\H7$X*V(9D0_/(7'^_$"[SWQTO%?G+4+5)R_-0)0M 'X9S(J";SG0 MAL-M@&9M #,F; &I@Y"BT$=*,'@7K,9IRE*D<8@D^)?U9P='1^NWD;BOD7JI M0N1!L5Z=YS:R9D+&5S%_!I^;+X*_LO-P^WO5T^WO]](MW>/3P^_?;^Y M>WHL*/^+Y?QYOC7[)+R^)=IA?JY'@H.;![/>"L.LIC476:3J5=9B CM7!&#M MA Z=OPWJ G#;?,.)LN+[? .*V<3H0@L*-L.&:1;8M^*%3Z9>F)6'H<^.]%M$ MV,R1-:O/]<< A7$4.I,(5)KG/TB?MQ%(@8'-,W@* M9!DOCJ5I!?,#,LK,4C!)5YC%S@)SPF%;#,79T'E[+1J)E!%8N;,KF*",FY#C6E(0X0CBW@ ('6A!S96M;(NM6C%RLI]-0J@U%R006#"^)N"^,4CFR;-@R'VFZ5E0L M:")<')7- 7MV/!QZ)P&/1AQJ3P.B[:94:5I'MU?WBCG\E"JMVS',JA_?^^BL M7DQMEL(N(&\3O'^$A'I.R,\I MZLT1"ZK14'"?!:G0HB)'JX$X\_2K<\JN4KMK*O1FB@W5XRI/9C.MBTM35I'C M-K_Z7I"8(+$]D-B:^L6=2T@<3.H,'%(=2I32J'3PNJK$TJ8'<- M*I*HN]Z(;ZT=_+$;W[*Z%Y>ZW-N=;XFJ_29BSYHJG)VQ!X=M=V7%VEFS;%;1 M?I-Y<%JIGT6#]F.F'OMY4<8DRI@./D1K1VZH C=49<.HN3.RJ$441"R(."7B M?:LT&A"Q+=MUMS<7A8BUY]:\\X(H>B^-,+FV+/MI/L-T-LXKS;"!TR%]JD)- M@S"?>I.FQ,XGM(:8BS]@P_%XH""83$,R)GZ$+^'+<7VX3*HFJ:_)G?H5]O@- M7K\DAXJ$%,G]?DGVE%62N6Z59*ZOG8P&?WR(G9]S8!^&P6199A+":^3#F6X& ML?2<%O.>$M])!F[,,IO*9\P0]:3RRJQ8OJK7[5 7*W[':F;CW1 :[? SJW]6;)W-9=DYI: M"IL['&E;!30BH>T\\HEVS<#*;_B<@*8)9!+(M!]D$DE\1TWBJR=Q[Z1=:>OV MWF@WV;MJP;]"SRY$1?C7HN^!1O6O\W;S+36;T>%P#1C[%1 6B^5)ZH7X3(9! M2!Y(WW.BB(X'Q=5<^8,GYV=E?YM^<6G)BJH7W&V%F:NUY:4VV!4N:+.EM%F- M--?,#ZR9(HM$9UQ<]HH45W.JFB [078-$XF%D8*-%(DF3=K)]=Y6D?+0V MQ6-E0L*2YBEIG@*/_<^G(>PKPR#7CJQ"\Y;V]&/9,M- 53N665^;D7I"U; H ML^*KSCBH+Q:U=.$*<@SH82YYH.C$OSMX6;)-.@MVE'9K!W5LE^U]LR._CIKS#:9G7XD.3B7EN#( M2WAD@&.#)\Y/=^+^FZ8#XYA@-JPY>(8/O_ QE],D9J-Q._<#X]UZ<6"OYSIT!K$+3[W[1EZ()RES$'A/-S*B,]QP.6 MSZTF#LKVD[Y+FW\7VR98RF0$3\,;L4U>;O@R0Y\9&!CTHW[H/K,(,TO%CI8G M*7/+]@-Z9SYJQ@*"?3@BAF$:MFID=OSAE_!I#C8XYA!AD9XYS1)7/TFW[/QX M"OFPE"SHN7#$VP7CEL]9%L>XU3&JU8Z1C<;>["@C8&2>$Y8?I+SPBOFS7_A,N@-1IT\&3NHV^R1%SZ MIH$;\@G'L&(__:O2 '"!JUOAJE:=Y90)FB#,28Z8],>^^Z]D%6MIK@[RC[$+ M^\K/;7\FGDOH]-0XRFUS0N)Q,&#*26YL/:43K!ER(]3660]:1C"I>H 3Q?LN MO#N.Y)Q*L@)#AL,][UHZ'GI>7 [D;/[JQ R;2)HIVR;SW8V+ 1ZJ2%OLREZT3&S#3(CH0.[3IL",]A\&?0%]4 M%J%FSE1D6$]:YQ>]@53A=8'O4BG->!>HPX^$2'?XJ"WOFPXJGM,MX,XSR%>? M1-$QST>F4GR8A%Q<1_TDBG)MLOM.&+XAB>0*,3<[S=.@IT?B@R5&D2CZ>%1> M6DY'^?6MHQ]!'\>BC_PIG09=9(G3#Z@973O3)A*'6TBH7Z20PET1EI;#2YC] M1G_GRAT]V20&'8(FB_=CARDO]%M!5'A/D=J>_7IS=WU[4Q(DVR0H MIKC#8Q$MN"E*GO\ [0*=(DP'<$=, MTY#1[8&*!_N#]K.A%X$]A=1+C&_(7,'L/F1XH^"%A#X>,9)H MI*R-W*3NA& M; @2Y6H^IE1ZZ%$)HXS?+K*ZYR1"M06U#"PV9W?![5&"7K2)\R9-DQ"Y+;(! M_/-Y+L0'VWHFC-UF:X1U_XTZB"EXF!L-#B$BY$]<'6QG1&8WI2^C+CFJ=5,H MH*^=,GS,4$7U FXF/\ED"H^#ON5,G%$*(UQ52";H4TI\$.3L4*@;'AAT""!X M(P[J45^I- &,H-Y3^%]YSG^([W&\B.YHS=G"_\>H(V@.[G#(;Z9F UP 2HEB M>+/S4Z8TA9FI,E4R/ ^..V'OFI(0'>NX_HSKQE3;PV193HR<QX0>]1O_ 7@67&ZI'.)./ZJ"EX <@Q7#F. 9IQY$!!YZ!]T^.@OA3$'9 M'[@(;?R%J@U!%".ATN'7[##=E )!&_#QJ(%"HQ@/SO%D6,/("0<>$$1*,$$2 ML^E@<_I^ %O'H OW.?. "OR2$="4^!2!^;G"FC!]AWF<0;W)>E\YTRGH<]1) MCYVR0G1@X_)I4G'$^,: 3/PL:5J67EW/D\8.#I+-">L!X'J4CDC;2;-I(P+] M/7A%8I?SQXF1?Y^Y\'&3\#-B!QS%$%D>PY(P\2A^(?$'?<"3CG2%U,V0L<@@ MAHL\A&&7]$X=>!(8$QZD8+%B=#N33K@:-;WE$^ MPR 4"$E_# P8%,]@FO>8KT<'EPYXRT@,.1!? 9<7<,$-*)&\CMW^.->PC0=/ M^GU0 @89ZXYS->P;OV3JN(L,2J03+JI]9BWIA(9()SS[=,(&V3):55MF9K#< M#Y$%@]RB$'U@C1NO4;8_CH&I?$:'V@_GC?+#$N/&*#%NC*)Q\_AT?_W?'SY? M/=Y\D6[OKL'(N?W]!DR<[S]N[AZOGF[O[[:S<(PF6CCEAW0#QD?\)MWZR/]0 MZ_[A873NF'ZC-._A-R2C4IU&[2J65+IRZ1W>3Q,[NI_H;7B5_JU\>B^S=( 7 MYLJ@@LKW43V?@!*$\IA[ESZ[P6,_=*/O2R^GKP/ -:- P_623U+ MWT%=T&2V/!3=@-RT?QM5.PCM4#I([U-LZA!1Z(_T@LZ<)T4-Q(VB!--\)@$L M,3X@,6='3! :$BI]5(OJIU>7F;R? ]"W\,+2DLD(>4]4K)K4\E63MW=?"X.#,YZ5W\U5&.+L8^1AG]\*;.WJ M%=8,;.>9A/=#^FMTQ4Q_,/@VJY[LSABBB:7-2E>13:U7J*"4V+YXWUS ,G[: MU$GH9!]E:6N B_S(4^K,CK0#Y))"M(=((F%Z$WX"X%H9J+U] _4J6]S.X+4N M+GLR<$7\OZ7@K0I.F2OOW,&S"X+JC4=0&_6%RABZ!)KSIOO8*3# <6I#USZDH2I^1?33JCXDX_94[ W[/M)EO3]3"4$ MQ02ZO \LN#@3!/T\P^1ML?(NI'D^NWPOK["9OU:K'I^?F*0O8MF51UN DT$Y MNMVPM6;88:38 9H+8$>W4X(7H'YXN"Z$7\7%FOM:+.A^JMDI]E]*%TO1;\JF MVGMO.R*#UEADL/8%7Q5D6:?8!V 77+#WM58-<$'MV)OBPB9ND@U] ?9VH;!C MV8J]JK;B8T[W9J8 )DRL"'F9W6(U&EQ;8A7^_?[;EYN'1ZY"2C?_\]OMTS^W ML0;9)UIB#0+!F](_G)"J^8TP G>5E*]L,U)JI0W<067U2>TN49^>W2#Z>(VA ML/LAA]I]^("[R/0BTD]8L.[F)PG[;K2H&@W=GV3PX=\D#(I:D=G55_1O6;98 MY5B+-2XN_2 NL+HB[R,>CX\2_AD:1WE-T0[#.DG8'SL8E"S5^W:7F8MH09?$ M!%^VJ,J05_<'^;4:M-DUM\"598;K85:,,[PL2];THLU41)I*Z'$UKX=+&R2F MR+RD */*B%J+&(*A#%2J8H^A2;:&RD!?9]B6POU^9GY4AK.]!6:LLQCK7J0" M*KZNR)9F;8 +2XZ]T4',I0)7/VV!F[)3]()6IY4YB[)[*%&F*%M0C'F6,LJ"N$E&+#2?]$*"4Q=.M(#R=#L1QB,0F=R MU,SY5!@_;13,RD4UV3%ANGRZG2G;#FVL,D5Z0C?U:(0Y2#%9X2=;AI/+C)PH MC)E/9@9*#LEE,8*GX#.9W;RA^3#SK2E@\.@X\7!)1]#4';@8,YB/$79R8>9E ML)-SUW)Y8S0H X;KC'6FA><#DN8"8E*>.X%_R6G% ^;CN5D88I1X#APA>EXQ M"SA-')LEB?8#S,6E92KY/$(>35UZVO 'IOAC"XFR3I[4 MN7@P.G594TQ9L;2-XWE#6LTC.9C$/4K1FU4 P:TKG?H_2$A7O/+ U)4[3O=Z MQ3Z/Z4:SMQ9VJ&(O?[MCF^5'L]5BE;TM%BP:#7AE,1+!XT=(696")OKJD,G< M6FFWMG3!N-+OE%&6,'45S)F>LB)@4CVZH^QGH1HV@2R3/GL+\]7!OHS#<0"U M1V==@#ZIJR50VH)]F0=DA M\+RO08AY;307OYA"@!Z9Q10"32FF$-#*=]J+DXI\FM@?C;%HIK1$:XQI=K2@ M9H5@V=+NR;+.I'>T8"=( /*#Z/W'K9(9Z&;7EM#P#:=E.732!N"&YTPC\C'] MQZ>T$[GKTQ.F#WV:)P&L0UF8LD&_QWZ>E:ATNJQ,A;>/0W>,#J6M7H: M_,:#Y7L=O:UK<""_?!?Q<^5YG_G@^R]&I%%ATK9HHAKN,@2TW*;TM8Y>-"!'D[ M+ED"@G8@_KNZV.1<64HNJZ&, "JJ&9B4(ZMZD9F^KZI?M$R//0=T6L)(]XA. M)H;E>B4Y:@='IYJ4TF:PUY5N!FS*VA]+FB+OHH2>L5UGK!E,7:M=AT$\4Y,M M96?/0J6#:X%F>\88J!X2 VEPUI9-O9AA=:ZU*J;@DO8Y/Y,P9Z* MIJ!A%-7N3KNNUT.[3I%[2EWZZ_$]"R)G85<,7.<#KA4#=>99L,SF8^!YJLU5BDU>_%N(C(63@-9+%J1183&6E3$ES.RPDK M23-LD;/0?G1:PDCWB$XV*R4N.G)%SL+^' MS79UJR%O@-5T:0'T0)%@A1LV$ M,[;\K#4NWSHM/QU[J)M=6>G5G-6PT[&V0#,6V+L$>WN'Q%X,Y)FFK*C%UB#M MPEXJ0/Y&BUVK#D'F6SK+ 7E6'0/R+%T,R#O[ 7G'FG"@5YUPP*?>_7#"^.TI MA$_S<KKY\N''U,QGR3W@?5*D6[IT&X<7]:$=LSY04;8Y-$=T!:$OL/F,DDX M/]CM$S8V.(ZD/P(7KK[ 3PDVDJ##8W%X=;^/[4QH(T(<7NWVV?!JJ@IY?"8Y M;6C(AV+A^P;.&TC #_ __(MTSFR43-ET<#XM>395EE])!XR3:'X.$XZ=";%3 M16[Y0T+'Z?+YMY5ZN]AK&GL]$(!"0G $./(+?.4_X+2ODP@PDH0W/_G \2M< M*9BI3\[/DF8O.A9YKACF4[V?CZT>9-U8@-WBM:I:W_2%KBX?\?>X\HVPP/3UL8!P^B7'8->XJ M&PV-7(>B!3*;Q'=@2S$;1%XVDIS.QV03KEG_FVE(QG ?SK%BZ%/#X+1Y5"4N M=LT=N#@-[CEA7(S-^Q[C-U-!4#=K8@*'R1LF;G#;7USD[OX@N@^_Y%=4=O"@ M#75747?M7&GW)5NK:6R?[1+W>-)K^-/N8,-2@'I/>@UKVGG)1A=%S\:-Y1K= M#:U<.5N<+IF.NQ\DA"%5B296%;-4;<-'E MRF/M2[YB6FCTPWG#)=,=7"=AB--$_<%=X/?9'V5;47$K)7WILZVL:CA8' BZ MER/K=7<_,@WW64S.V=>1K5OR+D?66R>DZ'K+IT1TI!R'M$XG)59(D"\LP#']&8P),=B>^YY//P-C"C5W[>,Z,R\3=PG1/ /DS&3O>,+74 MYI%'ALM#@!D^UB=A[""\MXZUI24-',QXJGLYO/B@9K#4PU\[2<3 1D["O;D30:AJ"'D+5 *I0 MN"CIJ2L6E("+>SK;7KI&O\S?B>/%8_F"OA*16.U^XK)8IG\JG]++KV3Q2A*E M%Q#5^<4@"=.K=!GXR9(O2K=^OT.?0]UTWKN3/$?NP'50=\A[DS(:&\S3F).C ML6%&8_T\C:$=F>)1S@W]CJ_Y^Y?_<";33U=\X>^QT;B+O'/ VHR#@@B6+)]& MYN 0(!>591Q"QJ/4;"'4!8=_1: )N$-0A$!W27LVXQUQB(9Q?G@Z@&O)XO#^ MDNTP V76,GH9,*)QD'B@V+$EXX+A%7\D/M/T:32CK,/T6M_;;$DY+QS=&X4. MVY@?Q(2B:4C0^LCIPY2_*[A5C%9)MTS/@_7^3P)_@[A[PPE;-&K@2U^#$&[N M?O@?Z1V]AQ]7=CD]KXYTS;70W)I2S&<2I>2+V6O8%*5L<5=R^J$'-_I3^NK0 MT5DI4L^]!T_OR@?MTRM9]7]G3E5L%,N]4.4VC/0.W[2PO?].MR?325)])P'] M'N^#!>$7.=K(N2-)-5:V(ZKN9_] /O$"AA?"9D1\Q#,\3K1HE;SL1#3/0\)WR3QO3%@'SP MD5GP<1P&R0C04O(IQ@'2^B1^#4(Z^T"Q=,D+^BD'I-DXE()^\RE/>D1L6P@6 M]GE4A(=H631IP#X;A"/'=__-WH>>7A=0=XIASQ^R@&Q8/1&/$PZF7KD)_U?7#]"$:W'E+RFL!I*A,@= M7%P[6+=!@K/@/#!+ 7#<"9#>R'DSK!0Q !YBZ_(#/UT[@#?&B"U YA[X0P9L M-E2&+I5+@" $:>5D(H#M,\GFV@WHH$ VF$+.+R*3#QF,V*[TQX4U\]EV?< T,@ 8_2.#"H7I#)LSP-$)>E', M>WV#%'>!:(?,$4T7'H=,M^ A;ED"DXL,N#RF&6&<-"C=N)-)X@GC7;R .(S;#]@W50HP>Q"UDJE?H=",O+M RR,P!R[TA [FX9QG';Z:< M]0U!P_@;NT/Z%?C>5*;.,N"[H,;3T<I.BMPA$ M_$Q;WO0(9]K9HXN.2AJ@<]GGZ!!-^EX$5)A,F=92E$MT/B5R!*:'HJN/P1?6 M#GH/;,4#-<6G'CVDZCY-)\%?Q\2;2C@+B+DG&4]@_(+2'8Z3\KR<[M/&^%*% MX4ELT&&:XFHZW0G70?Q!=O($^9GT+Z;RX]72F'O@^\!R&6/_D[SA\%HPD[ERD)XL M$;<]$VHO1< M.'_M40U<:FWFF"4PP-1TR5E&+I-"E2&82K'9FU)KW4F=*F2P @TR!A3%(--' MDN>"&3:@]=L^B(:Q\X*;Q7=.F+H-E!@Q!8QNY(^ +HR 3X_ YY[[I^$,=><^<=AEP-[7J5#WI F\N6XJ5SJ MBPF6>#N6(^HYAG%P"N;N81S8GXCCB#C.<6P 9!2<[G +&_KQ&R^5)/SKGA!P%P2!" M)^6 _I;[. HN5&__,2:+&3X+WD4Z>Y>_59Y?=C\8^=2>3*:PY:>RM;>3#I:8P%QJYJ@DSP),X])'D5@F0G8%&^Y MV)L[>4:/*K4JB?_B@L%!_YVYAN8RK:C 0N]DFL&5(E0*0#8;FHU9QNS]#/[, M+I<=UX< MU\,U=Z1'[C1&"TCF$7?JV.?FV 2!F*>N9\Q5Q$AP&*+Y-1\837P.9?;P_%EE M!(NNWS20F<*%4G&69,IKE$6OF+QB D9T#1.C&]XJ)3B"&:6#9 + M82&=SM4! @$/DGY,/X"<96$Y7#..I%>@=IPOS=);Z;V\"4SNR@ UIK[+*)1G MCC)I2?U#0?K:#SR:38F/IO+*635C%MJ9)I,I7A^[TVF:KS&&_WBY#^*U5R?- MU4CE,OTQ4\J7!K"H+YDEN0*;"-X(2<.!+#R)D@K=V&'$HVSH6/%? N\ES5-& MWI>3?JD(X,!N*.UN7/W 4XTC";:<3,B'9VSX U>?F<1!G00XW73F%\4 2DZ1 MR0$"P@)J#((PRXOF;UVH1D.) '\ASG)#-70TFKH]E32SBM+CA8U 9Z"KI2D>YE3KS*\U2[[E,P (!O^].J8( Z!LY MWLS]L/ALQM&HOI7Q+Y8VE?V9UGO/%WO+4M#O)P"7_EO*: $+_B04=>BJ0'ZP MJ@+7CY*0#=OF#&%(J#<<7?FDD/[?4KSZDI=K%*I9)B5.>H>L3<$C$5 M(TVFZSO,B<5X6\2BL#_)(*VAH8B7WT[N1@R$^",7ZV0ZTMP79MRSBBQWH[G, MPI8[4)8P6:I1W+*2^'<<-]ZW;&O+G" QF'AP9GQ7,GPJ/BX?S9:4:IN9_KS M+-WT1IJD2W+J!0\7+J;5!K.&5M)S$(;4?QSE,J^^NB&\[AMH>M(3"2?2M\#Q M931Q4$$,,0D52\3 $GTDO@L<^BZ@MOL;G M(NQ=LQ>%DA?0G!YJ!I#T4VFY.4OT?@UFXF'ANQ2QN>>,Y["L00XYGM12ZX*?.O*E-1TI(JCJ%#QPU9D(&J0+"K%VJW8G845F*ESG]< M"&,R8-DF3'CD.%&I\K-T]:OP\BQSEI3E.4LB^Z@12SF?[*/33#>BK8"E+(VD MF$^42=^YBLWR+*4ZLHRD=Y0#@RX 5R*L6.C#$_35\"%D1QA->?]Q*>3+F!?; M9<80:7=E[%GB3"/R,?W')XQ'><[;1]>G4*,/?9H_2&0;"\V5Z??8SYRCV';' M[)K(5'BK?OYASF\Z< I_*UY7M8YF&:4_=3M*Z?5EKS([5J]7Z4W+K^N:5M.: M=+WJM_>_)@$G :?3A]/J-:T9*K)Z@H$R&V$PU])^==_Z3P4FW:01)$]4?'UG M4NMFB=1:.I+DG"%WA^*^"N VQ+U&S:TI'U]1/@-KKASLT^ZA1:=N M!M;OMI0Z3A%9(>;GZ_N?OMINJTVJ6GOX@ MI0,FFP:(O^YO^XV>JZG(JFG)>L^H.*FR*A1:,![[E,:EPG\[W9J/=+?S/ H8 M?ME$#%;!)\$4SX,I=FU-[BH]P10%4Q1,43!%P10O+C79T!79M 13%$Q1,$7! M% 53I$Q1,4W9U@13%$SQU)EB97?HD/Z_-KE#K^\?GZ3[K\MVN"39$5653D.[!9&[5R*@@W?- #57N]339JFSZ"](] MF-0]4W7Y#/*6?GVX?WR4?CST]6C;JS]@2Q[_WS55MM>3C=JST02Q'T"R M;WEH@MC/E]BUG@S_$L3>LG,#R7ZF:OP9) :LZ=^QJP-./"^>%\\?]ODS\)+> M_[AYN'JZO?M5PL2F1^GJ[HMT\[\_;NX>;QX_[DU?$\^+Y\7SAWV^)A6,JIXF MZW_<8+Y69?K4F>5PZH9LV\>(>XJ0] :GHU9V_IY(2%J@QEK"M62ULHM7$.Z! M3J?7T07A"M0H 5?/T&5=%83;S-,!B2M2KP5JE!*N;LM&3Q!N,T_G?"5N37[) MEICRA='$<_-%R?S@NFTR/-N(^K*A;YG&*:*\^SZ<A MJ!VUX<;[4Q [7CKBU1_5$G,_I51NQ53 E-^R+R"V'MR MUZ@:]Q'$?NQS \DN.D"=?FW3[=WU_??M>C6?8/FXI\L8]?%YU=FZ3*NW MB#T1EZGH%+$]J2MRM[;>J]Z#8EGA?/G\KSY]5MZM:/24BB.$UOE26?Q.?55NJ=HLI:3W\O MRN0;=S"=[F%/I0'VIL"*M5BAR*9E"')MWL%T%$&N BL6L$*S9$4_,!\7Y"JD MJR#7;,WR?4EXH0^K#^2@J'T1^#ZL?1" M_#@)MZP^;6W449&U;=,]141XSVAX@NJ/0_,L'IR MSSK&>"Y!MAM4H9[KX+0Z ^HMJ&;D/9S10)?>\0SW]Y+K]X/)3G.73JDB&_-I M=A;Q=0>)'/S(AQ06)5PGUV[)I5NW*+LC\V,>F=+;L;-=V4J\I"Z#)_@71 M+4ETOA&0:<[S+8+,&71+XGV2/M]\O7^X2;LF/5W][\WC>54QF9JLZV(*;S,/ MI_J K!-1SP1FK"/;KMRUQ,S[9AZ.Z#TM,&-);+^K@KBM.@A-T.VAQ.TQ.*J@ MV^9CAFKBU$E1R]3,T['.54T^ R_FS#*7>$OC\RID4FS9L(\Q)EFD:FX2/JFJ M,)Q(JJ; C'68HX> SD$V6Y2SU1U.MN)D.T91-'O;IZ63('?8_)CTX#PUSWMO=&HKFNR MI8NQN&UCQKUS'959 V8(EG;B+,V0M>Z6Y"%8VA&CMH*E"98F6%JIRT179,/> M,M]$\#2AI@F>)GA:PQ!&[=JRK6S9PU_PM"-FQ8I:PU/-TJFUUE"#,QX$R;-' M&EH>=;S",0$: 9H3!,T91$KNG_Y^\R!=WW__\7#S]YN[Q]O?;Z1WW^X?']_S M (HL83#E_BNF.G[<6W:V>%X\+YX_[//G-7'B>NSX(X*#(A,_)+">?Y.!],X+ MHNB]-'+@)7&9# B$1U0@?,D6?=+*79^2L_$)T.77OVK(MNV M)4M_Q?_# >NZY/@#Z:^Z*4LAB::D'[LOQ'L[K\SP=X:LJ!5:8XI\EP.=2[>C MG]TP7($5:_,E1'I:(P]&S+<0V+&"F>MRSSPP.Q=4NY&05820%5BQ@!6V&"#5 MN$,Y:P$K/)O?;R0QS6([BUW$K(]^8I5L^1.)5Q\8*TZ)PBM;^8+$CWUDVZDG M@M3/G=2K>@8$I1_]Q"KY# 2%GSV%5_$F"/(^]G&=M2 _@QQ33(^:]S(L<2]L MF!G']E)(CCO+\H Z(=-HJNF9LJG:V_DBZX".\##OX5"U ML,R*\&DTXF%QO+YEM\OZ8"389R,*Z 7[K(5]"EWSI'5-I6?(JK(/GBF4S6.6 MYA^C/ZC@EH);GC:WQ+)^2]FRB:?@E@T]U>I%_R?"+:E#]F^Q T@(_SMP7R[_ M$_Z3+HD_V%-9.=OJ0.$[? M5$V;/)L]IVL;YO\I7>TB?6H1AL-2XLP8?E6:M. M9U> M;'XR=4+X+0ZD39[0YB&T%#;J86&SDMZ?QD0:!IX7O (?ER@GC*1I2")8EQ01 MC_1C@N+/I_+887\@6"@'Q,+.Q(LC1)5@2AC21=(P#";2_13_D*X!@M+?B>/% M8QK[,S]%4N([R<#E+P8(1(N?&+J^X_==QP-PP(4)HB L,Y1B6&Y,CV+"CH(L M.SRL/<4SZ6QX*,U&V%_#((JD'V$P=..E&RJ3(?1$9W*)JEBP#<^91N1C^H]/ M S>:>L[;1]>GGZ8/?9J'#_+A!3E.O\=^YBS:MCN6KB&7YE%._F'.P#NPE;\5 MKP.;UZQ>Z4_=CE)Z?=FKE%Y'48U*KUI^7=?4$UX4_*!7>]4!%M7M&,IJ2*V) MH;_8 M$$\W^^9&,9=FXP4*Y4T\59MLN(9N2^V'IK8K$=GK@=XNH/SNA"ZHC:0LYVK! MIM>H;K\=H_ML/7G; M MO:A&U=6Y.[E0-9 ML$MFV!;98NZ]HQ9@6(BI0-3L>LG"LBRE':HAU>!Q%M M3KE$0SSML#Y(.5613?L8>?C./DVKZ$0*F53= -%8E?E6A4%#;7>! MPJ>!PCU9->H>OBU06*#PX5!8[EEU]TIK" *?N$]+N+1.UJ655XXEEJ.YBUMK M@PED[<%[M=M1=JI-6@>&-M+$@7T)IX506F?+D2 "H?8_(S$/S&:-25Q:4U92 M"<(O456I894AKM\/B1/106'^+-%&>G50 KFP.[$T=H#NX&>/?!BX(Q!__#MI01X6ZN '86E!*+T1)Y1>QRX@2W\ZZ/Q] 6KIS?--LU^G=6(3"-O@F3=R?L@1/ MOQ+/P__%)W@I#>*S"__JTT_U@>YQ!%M,)@ I)WR3ALY+P.Y*7P;BOY^$M#!& M&KSY;8@%00B8()R.'7_VCO<,7.S;D3/9 CR;@84A MTP ,$C^($>L Y1($#WP;TY0[TM,"Y-ZDYW11L&F. %$RG0((^V-< MW\"-PH350/$5."^.ZSG/KN?&;_F=W/XN#;W$'61+]>DB23CI2%? 7? =CN>] MR?!=WQFQ[3FPZKX[=6(2L?W RO7Y5;ZZ@&G/^+J1PV;OS5;,C]G!5R9#N ;[ M#6<4&@;3 *NR(I \[A"DD(_$/TCZ^?U$4\"K@03?!BH#1,G1>GH2$7SA3_*6 MX6V>4@=A MA AB0D?I^>3Q_N?R: DSXB"GP%X "+QIV=1AG7/:N1@\W=_)QB MW5O4X&(N$/V=+JNYK53-I71TN_RG+0JG])Y66XW2*2\*?M"JE= =8%'=CM%= M_2I1S=7LG'-1S56IWJ#]>%JE&J,5&+QKW=G^BLY:!T=1<28JSAKU'5%QME_T M%A5G95!Y)!Y<',G2B/A@SGG4/> ,)J[O1C'OBT(6S3M1DM:^L@W=D&U[RQRD M!H2X!:ZU"=^,Q77$2P.+^S2YP3?',*M-ZLJ&+TIJ&'HXN=[M;-L07A[-O(:'UC,V% MA#B5 YV*VM$.>RIM%-TK5!:3-7INL!1_"F+'2YO<^J.M/3S;CUDZ R.J+N T MFHH44P'MIVKU:KT0:JB;0!"'( Y-5I7="C\%<9QST=W)#WE\I\BZH6P[]+SA M\QW/V?M7?9#]29@0&]9** VNE:@2$I8&28@&Q.:C+#!!/TV"8 M;)]+;/\DC8-7 J(KWC MY13OE]*Z**=H:N5"(QHF;?R78((NU?\).4!'&-_X(7#^6 M7D!+QK929U8N(6OVEGU-1>KWWL]&-;=L$2K.9M]GHXCA2LT\&7O;MKIG)[_; MY]"AD?E2+\YIZZ3O=*M"$9"P% YT*KV>L-^:=RJ*UA.GTK134>W*0_6$6=W> M6D::0?>.AUW>8POO8%)H1+!A/%Z4;.T3.(VF)'3$ZYI9N?ZY!=5:*^PS01>" M+M;115>V#57014V[$Z11$3[-I@[=K) B4#MPA%=O#V>J=]0S]NJ=X,PGMRPW M:[L"QMF$(2>.0_$17QSB2\]D7 B?0O@(7BCCQ-P M/.G9\3!M5)XK0]RX^+ #UXAT%\1$LF4I/=<]@9^^L:S*J?Q ;F'-SS$9^"2* M]KRRE>N0^:@N*?&=9.#B!*%^@.@:L7]11NO@Y:'KPUFX<"I1#!=P5E%$'OR:TZ&T/0WU431FJAZU$XS5H3\[/=*J/J$)K7<%7(Q':IIL6E6S7 6J"53;(NXBVTK5@0W-P;33 MSJGKJ9UCC)!K65"LRAV[_3%;2+D&^+4Y@ M :*\<>U&N[WU<^]CIQG/,1T> VQZUSCF'1X%8TN&U\ M]L =B=,NML@W65M;Y @A&0,_1;:7-KG]%D21Z'#;OC!^(Q"IR"T1N@<@M$+D%[?Z.R"T0N06'%ZUH^U6LNA;1M\9%/71-MG2CM>$W M@6HM0C5#UKI5:^P$J@E4VV:DO=SKM;*[\FGG$[SK=0[<9:PIJ02GW?66.?[[ M^U'>BL33T@E=I3 8CS"K@V#]+O-FR"W1[.;\A*VJ%-DM" M(A_*_FNM0G[:!X,$8W5;33![]'>5IP[0O1W)&_9]+QTN](ZE;_#]DNPH=.9^ MT#K*_V_O29O;1K+[*Z@I3TJN@FB"-\?)5LFRM:/$U\J>W>0C"#9)C$& @T,R M]]?G'=U @X=$4 [7[SXW)#^,[$AP6LV9M9*242NL6WR:.S&; MAT)=JX&=ZG"B(J*[*!0JT,WJR&ZTL-"OK[3L5UI47:C:C3ZC^*EUB3+I$M4, MA.8UB?W"HG5ST1>#3ZE9>:=O]EM[EMU5H\?H(Z)L-9'41**"R=T]RX9K(JF) MY"2(Y&Q@]EK%P^"5IX\C]PQ;W5.-HA]!03Z82=BNV9@+&\?#3A+OZ?L(/_LA ML/(Y*QKVTTQ0*B_>5*8]L9TX""-C+"('OJ0>!/2%/0K 8(JP1CKPHV?HJ?SL ML+C:LQE"G(/A(X/)!'BRU[/:^FSQB>V&!D#P!SR(-=A"-<1^U<:J1T,5:J<= MTZE.W;$7_$I#_!1.$O.E?8&+E!7@5A6O:YNU#JC);=P)?J\Z_48_AM+6$UB<">!"V"$F\6"&ZDZ5M:-QJ M[$9.$N&5,QN"!^^$Y^%_\P3$+&P+$:T0:-W1(-?1H+N]HP%NUQW_UR\/E]); MS=XO=1^$N@_"BXD06K% 'P3X9$O=<";Z+S6QL,,#[1V%:ZM$PA7UPDF O5UH MQ@K>.K:;H?Y.H.1YH.:MCMQ@84G\3_+L"!$E6 A&N8%/-1L^Z'U*/*6FM M:*.+>\1/W>?BZ>NW*X$3N[:.>/YB\ZJ JVX$43>"*-5[3J$1Q-P=CSU1-X(X M!%2VYS^%XE;X2=T)HL(UTVVSU[7,_J!3V8*@&MNJA&U6OV\.VS6VE>9*CAC; M.GUL<].L+*X==T*+U3GI*1//7VEW2.WP,H@H"KM%0RQ2LE,]S&Z9PV8?)%U1 MSK/YFLM>4E7%^^ET0#(4UD+J^WDAN=UKF^UVT?9T]>V\D-P>-@[!V*HHMZOG MU>'X\"(?'RZ60'[BY055KQ[H=SIFS]K30"][B4"-PB>!PNV."?^J4;A&X:JB ML-4TN\?*A(_MYJ%$;\8&*I( M$X?K;G0$"-5N6#5"/2-"%1O?M*$@O)Q-B7>L%FZ5N%H8"RI+9M,/$B".,)*(2!+&,+[86+Q:58.>%&,=9O MP!2R$'_%49?W(3CZ M/78N$QV9/EK4QYM"6_X*8<[TY'& M83(UHF2Q@#6<&9;:CMTH3*C*Q%PK!.0:%<1X%_[ET'X>#,JR2&95+,P'VM0&YI MC-2FX- 22[9<>UJ2?FN[GCUR/3=>ZB>Y_JSM*1_/AET[[@*'C_-Y8.?=_"[O7,"T$2XWM7FD?;9C>['@=^/!. D-C# MP <8--XLN.HC?K"Q6=PN ]R+GR)*Z3J MP<45VM1Q#RZN2Z3J$JDCK_FI2Z3J$JFZ1*JZ[ZE+I)X7O>L2J4U0^28\^'!J M&E/A@VGAL2-B/'=]-XIE\PNQ:FK4-535JS/H=WE=*Q^?3FEO)PSJU6@;7Q]*R]T*\TBS?SK^JFUPQ>T.]8>F%:WN7M61WE296LTJQ::#:Q>C68EN(LC M1K->KVC_]?+@V7''!<^L1O]EJ;\L,<'GS_H_Y($_< ".&^M@CQV:B/YGX/JQ M<0M:,C;L.:VD_[8Y;.W9 K!.8'[FN\$.VW7*?SGOYLP:%- /ZUMYH5OI-+IU MRO_Q.7(H;+S1>W/<>JAE#@>'J$&M;82'[V;0,3N#/1-"Z\MY;D$P:)G=9J>* M'IPCOYAAOS:M]S6MJU651ZE>9S+T\AH39(/Y[G/L\S'YS:GSS5,MNGABX)2: MDL[:+;/5*6YL/1%P#F2GU711T\4#WJ&AV>\7+5NM:>/>T]7D41 ^I:80- *: MK0)&P)/#IW;R/8OKM==I#$[3S7.9E2T1__ RKU;V\-2'=-8V( B.(_$"":3 M"#8[6JY6 &ZJB+MR0WCC1U?XQG<1SHV/ 3P$V_5QBHEGC&P/$U3-7%'>KJ5X M#?A,&)^#6!A#TU!X\TS72RMNJOG9?.'7L.<1P-874?3,.[MW'Z:O#5< 5PQ;A QPW$U$RY20)R:IU??AK3B5@N\YE:968 M!#/W^OYTIY6"OK*:O4;3@(U[V$QO82]I8$\H'.'>PC+PV4C,;&^"%W(Q%V,W M6@)942T=+8"3?R)U6Y^2.(&;0)*!:Z'V?!?34-"M\)[AAW,13D$B4PTHO*%@ MB:]&1@":D"=A^8$^?LEV8O<64]?M M5:Y$KI2;JNOVJE)G4-?MU75[^];M[5]V5Q?TU05]=4%?J=Y3%_0]+WK7!7V; M"_K(!(G!!-G2HOW1&1-E._(1U[]TF^:@5]WA%S6J50?5>D-SV*PG^I3F/HX8 MUAB!8"HP+"6YK&W^%8@:< 'F=:D#[,8BBNOML]0+&I=Q4'<6NBG.]CF+7 M4>PZBEU'L0\/E#J*74>QZRCVB46QT4 I6 U=QWE*YV:WNI;9&];AZ])MB#JYY_X^2']&S)VT'=[WFY8&P+R(SL2G.IQ9JVD M"9RZ;OJ8*0F/:[]51@942%H7A4(%FD@=VXT6D?/U=9;^.@MJ"%6[T6>4.+7Z M4";UH9JASKSRL%_@LV[I^6+P*34KMSH]LV5U]PN$5:.OYR/":#65U%2BPL4# M:\]RYYI*:BHY"2HYZ[7-[AX>WAU4ZGKQ';B((R,L8@<^)(JV^D+>Q2 MS11AB6[@4P15=;&NF^V^7+/=9T>8JT?T(8ASR+9O@)UN8:490+;JQ'9# \#W M Q[$>FFA\.55&RL44^Q+^ZI3J;=C+_B5@"+"26)&ZR^ ZH@&L'NKBG>US:61 M=M0F^+T"2[712@'SR%8$_K9W8K<+T/8;@R)OTHKVM0I\X$S8BB+Q8G6Y3I:W MH?$P8"!.$N$QF3G!@W?"\_"_>:1AQK8%<5:0LJZXSU7<#[97W.-VW?%__?)P MJ;?5'/Y2U^F?>IW^LZ/PYB+\C^Y?B3M&&8Z2ZM)>8/F^<2.B( D=+9^K.GQ_ M/QE-&A;PQ]N59]Z#?J8]8IF:-%_MT<),>FE(V"%*>"EX[U"%VCJLA 1$9]#6 M9#2U0FIWVIG,6&U!=$&/;15,VA:-F8V+#;N-8;H^/ H&8&,N76=CU" M9-8X7=@3B$G8.BJ]K@><&4YT)C625YW5=D7P5&C?^88G8F!6M#'YN!M%"0HA M.$Z0Q%$,_X WOE;;WP' :O>=1O]I=M]MM!^]^_=[J+R;T285L9&<:K,0S) B M1AH7?NZ@4C9:\O,LN7\'_3&>.:!Z&)=+>!48'[ EP+1KWW&1"'G6# OQ!9D( M^,I6\^T?BS%U^&'1?TW+*WF_Z^*TE/56M;"2AI ;&4!^<\-JGO\C-XA%*B,X MAV4?R&TAN'L@)WQ$!]S6+>BY/!D&MKB8V>'<=I8FCH9)<#]&E+BQZCJDS8L! M>\N9^<"SIDO\.+2C.$R<. G)&(R2Q2((8V,*&!A+D@99#5#5IA873B"W9$"C6Q?N!B /^$!@&JF MLP82 >F%,[;1Q;A$&?KEF%MNQ_@BMR6Q$/Y%!P*VP2B*#]A1%#@N&6]W+FQA M$08.DP,NBNUHT&Z /\=A,L415D!Z@>\+;J45R"2O"/O6K:P$%W3K.OCH E[. M [ T1%O8RW1'J?6'?#1C:@:.?\HN@LS-[%0,UW2-[$BZ:9+?D@(^'/)/D%HY MNU6[.QVT"'?@=R$8+'2%N)NYC1OVJ3L:W 5B@"+CU2O,7S[^<@M%1\L(V(QV M/#E*JLCQ<*]_)78(P(1OLP%ATK43,7C#-1##O7B PA(! E09<805N<$W)W07TJ^7 M?_W)"NWBM>'.QP)MQ.U M;S/ Y7.:4XC@^PB,A?_*#+L;AOB<3=,RGKFP"J&0%C!O;O\0&O-E*2#EF\Z) MD4@TBX'M!!H@N68GL+(?ZF]!8C86G@VB>+Q9J2"< Z8F_+%B_-KS:G#EO!.J)DA"(U6QIV XPOF+N.F8U%9.>DB%VT&-%Z MG"8@@+'%IZY-^&-%V>_(*RIWK[B$)\#:)!:8:=?V ]" [6,S4,\5MY)X@C!+\^TLE"C!P,4#>DN .@:5DM9 M(_C^D5@"<$BH;&&O!1 *["D1^N0*1:;%H9R4C\%?8,Z= 7W\+&3=,D.ZR:HM7.U.O+[DIG%5*D^&!E)P MZZ+VCRJ;SC@7%(?K8( RYY5C!7=](;#F2.)*_Q7YLDC&N&Q9"!OP#'GQQ#AS M7Z<.1J-/KJ0!<>,S%[Y9>WIHP=]+\E $H8JN4O?I,;^58MUD3RP6<+_IQ&K0 M+4CI>D?#HE&2K@J&>.-1I,RRPTQG@9W8')8%<4,6D8F?X?-!SAR0$#<-X9(@ M/Y,GHHU\^W)UD]LDJM6HIWL) ^DB^^Z&G(%A!A/XGW^N/8QJ ?]JV^-*75E= M%8Q9.J"I*RQ*G7'L6V''D=H;N2LF@4=B'@\#1H2+*I4'HBI<:N(R/^\9KU,Y M%A F'O=1O\0,(% $<:G%V\9J6SZ!.&& :%@B,7TV"ZSO^209&^9,F_B2'CB"1 M< ?FQBO:\!IZ>&W=$:EQR4(2R/< U3,,AW\$=2($T8>_=M&^,G J.JP;SY3Z M.0\B3DKQI<'-T'0T:*8I*](??3$&0>F25H+PNICBLV3%VZR#K66O2 W)5ADK MQ4,9G8:EAP**^N]-&4%GQQ9%S5..E#>+[Z->#"7D8BHE-2D?F/IN? +E=AW. MI,61!UW-G)BYH8;[BO]>$5%]!(6;L1.1D%GWR@,F>@;07T/L*IXA=S2)TG.B MP?9U#1MGA#3UJP9#CW5W^'+3JPU7&V.?$5>(@P:DZRF?_7+/,=C&R&CNC#U8 MA"0*P:(%$"T@V/C/A'7WU\PE6T3< +KL VNQ'D%<0]1)+,=)>VGV(2FR\7G?,TFFHU>OD@ M'X%?W;W)D+5)IJ0^6_+U@W2 JP$)Q?&&S'F;;76<$-ZD*5)2M6"TO]IBBB1 -DN07#G4 MZ[>IQF&3O&):'(N8,AKY.=O!\4&$$ZE7= TXM%\KW=>*,"R\KZJ2T3?AH\[Z M.8AAW6T:)=Q@I]%&OI1>./LF0I$B3R3F[CE^18YLO(40>%(8Z?C>MNBQ"\!O MSV@W<5UA XR7\$.E"H[$%""!>:GR5Z9$]+7=LCZ?7Y]^/*SB95RO.Q^5B\D) M0"FB6T!W#CMS*.86C#QW*MU8,6EK.)4JBMTY:;6OVLVNIN^,E)>.65?.,(E6 MK(,L5+[JE&H8ZSNU*47%==&,B:G %=U;UBR1Q8<)*8RUSTM#N7:S]GG5/J\*^;S0G7^%=GXY M^7O!X]PSI<1(5Z)%LTAQ *H6( D2_;85;9:=$=5%' M'QSQ0*;2;JKW% .9*E!ZO+D /3U3/3UJGU$H)X,>)SMB:I?R\9,9RO7HF5%' M!Y1Z9M0+O>CKBWGFB[&Z9J<[+*@* M/-'EG)+MIGAT5LSW2!Y=W5:(5JME#EHO/#2P;E*YR\V@$3HMO+]FL!PQEBD-[:%K]_GZ:0RF:$==S:3;=Z[!EMIM% MAWK7UUKV:^WTS$&_://]E[C6$S "+K=V #C'S''7Y^*+"2:JN\'XM,R!=J=M M#CI%+=!:\7RAL-2P8UJ#ZH8*COMV.D.SURLJJVNSX"GX-G6^V<:Q=Q2H];"7 MYX=/N>EWT#:;A0.Q3PZD VGC-9745+*3ACCHF9W!GC&*FDIJ*CD)*AGVS&[[ M<>ZX Q%)A:9$T8K[U/ZI&C"5M'FQ'ORK5NF;FBN3NLO3Y%1LGK A.76OL4G4 M)DF?.;/[$!D<'92U,QXGXA"SJ7',R%5O%FQJ[E)_%\D<7\&:&Y;.NM!3D74PG^.\C#AP M?NPW\8]ZOSP,N\?1[P.P?F7UNZM'W7[.#52YXU O:_#+7JK;@>9 788NJ:) MIR09\0*^@D[KJ/[%'V0[FJJ2KVIK1PH"30&)=V@SL+'CY(;65'^_N/BJJ$OV MB8YRW?14IW+5U4O/<[UX MLHD%I"V%+O8EXTZ)OG$+Q!0DD6S6I^:>4J-46H1[>_,H#VP):4>!KPU@HG9' M;N@D<^R>Y@@YVH.[+I*FR+#"3MCT#6V=.G@!F(@?Z-L>!4DL)QF%(0TRH2&% MM!#\4,@VH)[+;1L)9^.LOZM43+>V#^6MX50(;!4Y9\T0'@KAB'ZB=2.G\:FJ MFR@[NE6'"S'.W6#6JI[;(:F38R/QL3N9(%"17_/L@O2"33D'!G] (QKTN]:; MM=-"2U=X^J_394JJ3#Q$I(!8,_L6L4OXJ%OA64*\+Z6Y;^'ICF)>=L:\%CKS MT@@HRBY,S8A1(ZO^1U$P8CCN9D0S2X)P$7#+^1%*%X*U4T_"S+>@LIYD$F;+ MJB=AGGSCJ@-I0-<@$8QVPV#5[7OC1C^.5S3PC)$%'9P5+CIT"(=6PC8@^RT;6;B1_8,BL@?W MWY7%=2IE%Q!5=*I"%,Q$D$!E#\0F#^POB][7&?T:SS^1"4B M8FU:F>OC#("(!H/*HSKZ41?I4;>W\&53XR8!F6.U[7.K>R:HE_@\\:9$L9DM M\N&G="!>./'KS(P9BPA4)S9C0+DGOD&S(+2I@>G ,C9UY(:U<:SR3-+AQW8$ M#EX$>\.CP0I1,IJ[\9;=<$MKM";1/T/'QJ'M.#%ACAZ-?\ON]:E]HCD70:E5 M9@B :"$<=^)FK8V_?;A,->00@,2 I=E#:M8:355#CJ>=UT6;!0PWV026_.O! M?)[XU/U_JU\%\ /T--6P6K5)1^OUI82:_ MHR"'O0!H+$*7)G0$V)<[N*,CHY,6SAJ1'12*J1V.M;E.8PVG]+;:4;+ $9F1 MBB6D+:7)&X9MNC=,UWBNXV7+I:;^.#]WPI?#^C;Z"Q\FF@>:]*:3O@@'1,I] M-L_9O>^(&0C6CHF;DZ(VG0&VP]9IZ'$V?^/^DY2?M5]F42?JN(P]FU.N3KVA M,\#="#GGMIK\'>Z-+@_#(MFI>0RK/+F\=#YXYI )U<%UYV\,ML=#WM^.&B[) MZB".:27,00Z*PR1"S3FU-#SW!W*/.%A_P"RVS]K\SYG_K:!VFY6ST"U MJF*@?@1MU6,[3J &645#[@KEJC1/: B61X=:9( MBR!KLY\U[VYNHN%7,.V-:]-0F&"@2=MJOM5A31]9;]>\P0WC(AM#AUMF3I'X M,J%H+5DF=T+[P5C /MB/Y,Y3\& HU_:BO%$R M!L,C$JEYL@-T8'=O@OR@:X*5B1-VP&Y* ]?)@CE([AY&P@ONMD]/J%(2VGNP MM)81)S"Y\Q$.72)/"\%Y$UP]]Z_$!2@N37W4.'O=-J!;1:/K*]"0KL84*R+T MCCGD?U&9R^@+I"&@XN?*Q,PQ@W@DXCLD]M09B6/?<:;MA'4$7E)"TA'N@B;L MJ?QBH@_']FEJ.VC0-& 4IX'>Y#:JNX< X6FB)]X(F!CI3/:$F MND5RMCF>[ M\\B8XX87'N\MO= %CG!%%X#ZULX/,,4U183#Z 4<0Z3;)4L#=X4P3 MZ37L]O@]VR7:'PA\[4UC'_-7)KPE[Y)9O9$F8"MNE _H.25D'*D^*93<$7;X$7SD!W2Q1*!*3Q: MCA(-'V/ 2VX<18'CVLHGCEI..#Y';^X2[PSGP*KD'N"61&.V[: M#'SBC5FBV9DLDPQ$.BC1A;J5@YCWL!"4,\"7;20N4WGL>3ZQFDF,\Q8I 90] MB')$C@-P-TG_'D7P1JF"_^&CJLB_,/X>!LG"U)*ZQCBN=#G"?3L\*P[G4HY3 M&AR[49@L*",&-YKN$@^#(F)>,.W-P\&_:2Q&;8)\FQBK 5;U[RS.$O%0Z)7%.<8@4FSF&%.69S=. MA92"(@8@B#&K6:3Z5, 9W.ET)MVB.+)R]2SEE$E%X[=YKS&[3.'\,W<1,9$O M9C;P.DS6 ?TGMG-AYFI7X$(#AM0DR>) 6(?& -%.:0F>Y'T>IQHL3L]!DQ2&3 M!A7*X:/,2AW2.M@4B-:6D)%)4I%YB$HCG/!CU\ALCO W36UH MS),H M3N/,P/^F00#T&(0_6#/.SIT& B.1/VW#^(3#T"6_R@-"?KAZ_COD!B#"Z*1L MZL %D-!!.4A,T T9:Y?I34C()_Q?3-=!MLMJ$T^DG[JWQ.M\> IUE3G<#)@> MP W!2O&7*P863M/5+U:C#1,0.R:KQ7/G+H=S.>;G!1QOM',GS2UD,CE%,S"O M0%V(*,*2J[W*T15?M[]%8CY 8&OR,9VUO#:H/"U38XBL'R*-8[KDED8]"2=I M9QHG50W@?'#FYW((=RS3@?1WH4S@^&K*ME'KL1>R[@#U1Q24"*KR(J^!?-5 MVEFA+QNT[/F"*(<0E8M!$HK\L9P&V,I8?QRZ@-1I>CI:>3+S2UT14RL0WLH[ MX3;AUA';_D5Z*]*%,GU6E-<[J9R.1#;)D/40? /^@3BQ<5\Y5X#MR^'B6W^= M):Y)!IEN\L)#[@!:P%V:@*_63,/ER""$8!F6"D=) ,KV(,O!E(_N=F;%BJDB M,Q:Y]Q'SXCH!N5 HK3$&/NQ$13092CG8R-'1J!V3K1'J)_Z28.V!Z\F$OD>O M6$BGW^)CJ91/H*#^=27@\BB/7A9>8%$%<*V(A0#1EN24>6<"3X8FY7N*(7,? M/^4IT,H.VZAF50F6#XS])CD$H,"24:"N2S#70Y1O,RPYL,F.T$&9&C#IH&S4 MD#(+*B4EME+>)>,ID+5,'*'$,=+\+8MSI>:4'V%F[@4;B &= @XFAODR00J) M0$X9UR7>1%X[)M8Y;B[#Z9,8N[2?3:O #I(%KM7BB?(3L ]A&2J:Y<2BG[$@ M$YRM%Y!7?5DEPSX)-.O2-_P'"/NW\D\74SVDN7Y&) M5J*-.T@WA@2PXI>T+- B\< )V.J7I#W@>\YP$74T]6EZP$W:"?LR MN#[)H"KWT3)[.6Z7] X'M-:(E I/FIDJH<9%;8HH,W5: 7Q:HG,MH$B.@C1 P%JK!\I7[GR^N72175YWJ-\7E132H@MO]U(3DK;8E:&W(<= MQ0S@["HE5:YL#GYZD4S1M)"N&=@9RM#$5]>C<31TIH 6!UHIP_MA^XI^@2Y* M!).,EH 4@C5I-NF"48L!*T_S6=,\4[7A/B,!GQ-VA[$IX\#(B!ZFB^JXB M+2_UVI]([G23TE+*:5JM',I>WUPH9&W0B]2:A!J]WJ_L+4H(D=@;A&26TX%A MT9Z9UL%Q,:\'HESN,LW0S%DD*(53S8[.I&7$KF8N8K;6)/#<0.J H*F[(DU_ M75D9[0=*H$VB58M#I@7';$*,HT(&!#O4'B\533(,KW82!##-)QIHMI(S\Z&'+Y:A$_94,F)"8X[3$]R#Z.2O1 M4LU6+)!(4@659:14IPZD1K8J(7V>CXT0I"$Y5Y4:YLM!YTJRR$1X6"OR- MDIFKD1.MPI0""*2C9_I9MJJ+"X_^E'>.KT15>BG5W2FF@N.?>?MA-6R2>)S[ M03F4"]354RV!BC&7Y@8!M"$F19$)U&1 T[$Y!UB)$GO\)_!>^?ZEP"7B4A\A2J9UCF7AO;/P2"7RQT8X,4%WLJ5*Z" M\,&8\;+5@?NY"U"H)/::S71K:0[)E H#0R_!'(P''K.446B/C*BT9\PX M-0G(9[K^L;0F3,TBTD@A55*[GZEZ.Y7]BJ$"'Y4!Y&'AZ3K*8&SJL>G1@*J6B*FUF39ES*TK'%L M34CFC0B^#]*%)$ZG?#_5HR/METASZ_I0^@Q)Z/6C-=!.) 2'K^(^>6(XFH27\6Y0_ M;+51FPY[U'TV7/!&;YWYH+LN\PT>M[?N0@7N52>HO&F)IY\3'7A9Q"D?\-34 MS_3SA^&F@IXR!X"H=H*/@H8U#E9#A=NBHFGH ME/1V#DI[ O[@C@,@-+@P ^]093 M H3_4N>66AZ%/WX(L3 B>R+BI6SQE=7$2NDFDR24?V="K$0U_N'(HHPJFFE5 M*H($KKIA?)LQ[BF0:JB;N6&X!$O+U0E&9.:3/=JNP*SI^1>4T/9%,SN8S$.@?'%+!H^GA;'WIC+0=6NJ8MC8R1SX=G*L\:Q#6*JP(P!(;%M$]6- M(6Q']E1KVY2LURWK_C"-'6AWH.Y;_'1EJT5*1AL%-FR=PN\I'GU']X;.E'9S M#&1V"H6/R1Q!]B[+):'9W4YWHF5XY6F M:IHR]EL5*=WXPP_1B([)*?_-]K@QW8>_2&)^XYQ+U8KL#VXR*4O *M":Y!KS MK4/C:ZH";3I:!97&3*M2>/1\]DT!L=5+RRXD6H,PZ=;_G7@RV$B!'(Y%;VDHL;T"9I-P MYQ.D"@--!,#TJ!:6BE''JV)@&)VK[>/X-R_4P;Q^WM='3F+&4Z_/< PSR?T]3+;S/J MGJS4@5,%RX4,9'RER/M7\M8#@ @Z)PJ2AS %(Y:4HH+J;S("U1K$\D6:///5 ML[G)L0QA;)\L?MQ@O,C:V^J#:'B'>UISHV&ZTYD3'S8FL5M.$%YA6O^BD MUV?'WA,8=2[S_#,]47[P*$WQGJFV._'G#6"L!A?N]RVSTR_*A3=CS2%F#A_W M[;2;C7Z[OIM2WDU-.66^G6'/; V[IM4]T 7MZ\BID"#.>GYGLGB]#_@A'3?5 M0UMKV#';O=9^:F4)3)_COIUVJU%X;GU]-S7EU+ZEQMS5L#(NRKBK@ M;[3UG+L'I3++H5J83X0H7&UUD&=_GK M&R[&P8(;5GP*QE2JE]8.?Z--D?=ZF\HEZG\.9"\:;E\9R(&.^8(%*E'X3_?G;W[@?T[F\":'2D7A"#=8 MIN2<=W\Q?'L.^Q;.^#<$'T+/ M@0T,7XRK.GOQB,+$"[/^/?)NY/,88S>9'X MA0AZ+W^S^8'_?)-[X]]6_S:-.:$+M];8>WO?P[D? M[[J[?A$X[/V6P2]_BR7B/PP&P\Z1!=:E4I^=P#_7/X\E6=@9612>]%C7>.9J M/#MY<.Q9X]EIO42-)QS2.0? 8;?KW^3DL+=5*OS,'4#\G+DC-WY[Z/T]>S7H MCM>F:V[8G\N=+ ^I*_6J,@SP ^-1MF;.LQO")2J4&W<:@?_]2QU,J)3%"5H%LMANK7J#Q7D1.Z"YRULTN-169 M.=P&FW<<)$@&:K<%[QA6.5!HLF'M$FE_^K,29WE2[>#! Q]8.WCD_J1V,(OC M1?3;FS=W=W<-V&9C&MR^N0B=&:C%T1LQGMKAF[$=VV^LIM7IMX=O8+ORGZT. M[KUCO0D6SNQ\XD[BF6PS#F8O]MFTX\8L!B*\PJ^,"_Z.;.(;^A;^>+<\_TA= MQR;&%VX)0WVVN6V=:5S[3L/,A@E@A1A6.:6J?UF5H MV=J)F&MR?4%R)5H3/]N6]1-1L E:B-7\^1<3&KJ:,@\5ZO(S5TP _X63$/U\ MD7X:O;.S-6 Q_$?C6^.R@3T[\&G^S&IWFSP_@)T>N0=SOVPW6\K[\\T.1[8O MHO,O/SVQS!J$-UO'3R^M(Z*79LGIY?[]K=)+:W=ZN4I[O=7T\LQI;,?OST7M1S@1/_[[N8C MMG"/J8/[^\!),#Y6Q+=4E9/BW7V[_/W8[NZ[_1/'$"Q!4L8X[0*="\_7)W U;X7$]=W3^MF/UZ\.X&; M_6B/A!>=SJU^O?EP K?Z-111.C_L1.YVE]K6JIR&[O6*4M#0TKG$F3'&5WLJ MUJ]N[P3?3G>_!-_UL/.!TEB^7?_]\\7W/VX^?"N<&G+XU-&O*U,E]0EQJ?&: M]43_\).' BD+UAJV.Z9\<$KSA>1$KS&VZ9-3-6B,9LBQ/'@-#F5W:6X9CH2( M/Z M\V7C83&S_[&?@3,_3+C:F9]1A*8W>I]'\EF/^-Z.Q6]JL&^^\?L&A]F]N2V* M\^[*)S/H3_*W(< M59!!H[,!5@>"RC9W-F;W9/&@?U+S:U#)7=0ZC+.OH0L_7\#O-S_Y'D7N12IR MU7>OMWFKUU7 4\[X[V[/^'\S"L9+^,\LGGM_^W]02P,$% @ %8!>66$ MME6_#0 :XD !$ !B:6]S+3(P,C0P.3,P+GAS9.U=;7.B2A;^/K^BUZW: MG5NU3-2\3)*=S"VB.*'6J"MF7C[=:J'5KD'P-I!)]M?OZ08$!6Q(G+ONQ?DP M%:'/T\WI ^*'7Y^6-GHDS*.N<]-HO6LV$'%,UZ+._*;Q,.DIEXU?/[YY M\^$OBO+U=MQ'7=<,EL3Q48<1[!,+_:#^ OD+@KZX[#M]Q&AD8W_FLJ6B?!1B M'7?US.A\X:-VLWT6#XO/LNOV^\O6[.K"4LY:IU/E##2E G[QKSUR0 M)4;@FN-=/WDWC87OKZY/3G[\^/'NQ^D[E\U/VLUFZ^3K?=\00QO16)LZWS=& M/TV9'8\_/>&GI]@C\? I=3?!^0&3T=4[TUV><'>;5Z?->#3'HCO0J>/YV#'7 MZ);/%/]Y1;Q6OA"RF9$DI7,$$ >,=_-W<<3B] R>;D]G/]1)1,W0(AI M5=$9#^=_Y.C$CN/Z0IX?B8ZM5M29N>$!.,13YSK.GS&9Q6MI9J6.UO76U=75 MB3@+:Z$0QLQDKDUV#SY9,7=%F$^)EU[E!<""D=E-@R]@2KQP_;9BY!U8$@_) M*-B+)["WW[B4 S!\^"FX0$/-@E#=,C^6V16U7\0H0[]4WAOXVE5 M[T&$V/_WCIO8KNHXB)B!_9*LY^(3.(^H==/HN%"DCO OWAE](7\9= 2]D_?R7[H D)54>.' ME/6+U[&>5OFWOUZV6^__B4+5-6_Q>B2YE_S_=5U#-MUPL8@0^A(LYJH@J!+I16QD^OU:62 MH49T&P_W]^KX&\PW_=- [^D=%6+3Z0P?!A-]\&D$,Z6C:Z7I+8DFI?-RF\X( M6,S2!!HEV"@&KQ%W8^VS-G@H78S'PZ71O]J.?B19H]"&!=]$_5H^]],BLA!? M-+=#'%680KQ&<=;4\0!FKP%KM'&GCDOGC4:&[+,61T_P"Y3-1[&E4C(E95RD-D7N1"O7]9*Q"^G5$9[-\"ZA 7LI$9OL<02D""Z7!:L1'N7[GR+6I28FW MWR[J&G4W=V=G6>[*=U/1VUA-G>YV1OW."9[:Y5G;%)*2DNF51/+H;8A0IWAO M=_.J!;Y 6LI IG.2[0C6D8RP9U>-@@T9:> S;9%0O([!SNOY50O]#@0I$9GN M2'[OL([$R)I_U4@JB28E+--2*=-0K"-]Z39?-:IR)*6T9+HL:9 ZAC^W8UB- MAUT04D(R39;\UF,=JV-" M8#X M*-*"0C5H^HQB1._W3U2'9]:U Y\ M^D@,8@:,\J^L:D^F'5C$FC%WV7&7JR!TUYWQ=*;.W!L19BPP(Q4Y_$G:I7F0 M:<'D]+Y@%4Y9@Q)S4&P/X@:AE$5\*L07AY&]_L0*;N+-;[%$3 M.U:71Y98<;SZKN>],GLJZ9#F2*8[E)LCL4Y.O="*0"V*]";)\):K_J66F1!V M-_=1MY5 DK*::2%%S==CS96A+)E.PQ5A8)(S[Q/L$>\>^T'EI;X2II3&3,MI M36-Z0JYUH% )"K4<.97$_[?6SV 54(^\[IW7O!L@%:?F+@@I8YE>8]%-E!IR M([OOT<&,/4,:JTLW "<=2S7-8,G-)A8<8S[]3U3IZOSTG$YMHGH>\:M62C_? M$&F>9-J?I>[=*"@V#86VB?(J91U*F\?7AL1 %%I8R\Q+WX%)5N7!Y*JH4K9S+X_*N]1 MPV.1L)/89&'M++ SYU=C<3L?BO:.NURZCN&[YO=7,UU-C93Z(UCDA/S6X]I('\H/:_O^Q8#XX>,\U)EW L]WEX3UJ><#OW@*E0HV M_9O&#-O\;?W\)SMN&B\#[;QI0_? W__.?*+I>05WD6A/Q:O[PYV/\ M^-0TK+!O&A:94CCJ!6 .]0/NZ"?F!JN;1C@0C%DV4/AZ__ (S%M( _:LPQF. MG?P.R*[(;!@,GI0)0%;F0/U431/,L;2G%7$\XJF.-81M#.L$C+_1N$_QE-JB M,5;H=06$E\? 9,3Z>4$0:[GN>>"&Z &-"7A*39]8XHSX;[@2G2#MB3"3PHP$ M/R?XZ0OU%PO7YGE='*%]P$ V.R"IBYP&![-V!@\$C8)1S6 MG6CNCXFX-PF>:;,9,7/9 P+LGRREA M:6]#$T-G=PC\3)\L=PF[]1(.#0)NS'!F$/9(31*WB(JSNUB@PA)9(4>IXY,Y M815<@6U/P'^0T0 PN1];H__73O3YKP!ZOOCR@"2S1$K!596W'+TQ,0E] MY.;<$L=<+#'[OMNC$H('X> G_A-'#C\6SFL3]E&[#/ MQ+%<)O$H9^!!.,"WNKP>P79"P0?A MB+J$XMY[]J"DDZQMV8$'X4!<>T'^3ZDCM$%]QI_#Y2&'ZSJU2&B$V [SYPZB M83U""B^NKT0]U")XTTZ@$O)Q7;P7!D,B=:C.;FWUU!^86;MS?)?$020[[,%$ M1YS?>N46/CC4EZP].R0.PJ4^S#)"-A_1CQL7SQ/WEHPPM=293]@W@AF_6A?F MZ4N@#K4M$E?UHV"YDE0PN4,/@EOM]X"NQ$^&!PSR+F D[E#M]D@N=Q#N]2CS M_#YQ(ZDTBX8?A#,&,5W'*N]-\?B#<&<=[(Z8INJ<$3%BLJ#,@EK& ML?BGDH25POAY;K^$Q"V30R/+,KI3^!#\S'E:];GD-4(N>:B7!+7=;%V.;-G$ MS P[B/EXU]%UT36ECX37())K6N'P@W"&A_C]%\P8)('$D=RA!^/$>7DG,D,/ MPHG4TPC)#8NH(27OE\@D#V&IZ]C8\X:S*/I#-J;SA9_TL)/7440WKXKO6E0& MVKO[X1%//,Y1YFH6#A0W[]+WH,+CQ;>O)&)_F%OB20#/7) E_OCFOU!+ P04 M " 5@%Y9^)3!%>D< !M$ $ %0 &)I;W,M,C R-# Y,S!?8V%L+GAM M;.5=65-;299^[U_!>%[GE'-?*KJJ P.N(H("!G!7]Y,B5Z-I(=%:;#._?DY* M"+,(T)(7+IZ(*@Q8OO?+/%^>+4^>_.O?OEWTMKZDX:@[Z/_RCOY$WFVE?AC$ M;O_S+^\^G7T$\^YOO_[E+W_]#X!_?#@YV-H=A,E%ZH^W=H;)C5/<^MH=GV^- MS]/6GX/AO[I?W-9QSXWS8'@!\.OTG^T,+J^&W<_GXRU&F)A_;/ZWPY^9-C1; M%4%0[D$X$L%E07/[]___7KUY^^^6'OI\'P\WM&"'\_ M__2[ZX]_>_#YKWSZ:6JM?3_]VYN/CKJ+/HB/I>__\*G]^.MF_\TK?'8S"L'OY4QA+]S=+B[=WBZMXO?G!X=[.]NG^WM M?M@^V#[F'2FT[0 ?Y\_>P"KS+X]&V<^C'-9FO^]MX@W/E0K\AJ,)S_ MRY[SJ3?];6G;(RK!&.:RKA[$9^*N;K%[PO<_D^]<:C^6^FLSN=V<7:3B^PA7='V_WX]Z_)]W+LO@/T[BCC?99:@K)A Q"N0R>6 K9QY!"T$X: M6GE\3^&Y.]9;[-D>AJW!,*8A:K=W6U]3T437BFX&S@W# UK=7637GW@_FEQ< M3)\)W7&ZF/_[/!Q<5.3">-"0$&92Q[&L2XNRUCH?NWT<_$'W2XK[?=1IG[N^ MEZX'G,9[WT)O4FS'SF0T'ERDX4%W-!YU NILK96!E#E!W9T3.)\9*GM*B... MXB0\IS[6?OLRS&!OB1DO(X>-Z3(?\V^#0?S:[?4ZA'$A-%*42BEPK 3?[I*! M("SQ+!E&1:BL,>;O7H8#_"UQ8*/)K2;:(]1,..3^YX.$[L=)F;RC_&DTXV$G M.\)0#1% YPS'18D&SR."2R;Q;!/J*%59WD\"6H8$XBV2H)X8ZC$#(X+A@T$2 MKV*,C("43J+^D0Z\RQ'QB.Q41M^?^-J,6 1D&2;(-\F$C:>]NI=PQP(5G\48 MI8,T#I2-:'J(QW@O2@TB)I\INBS"R%6=@?LO64; ZBT)N.JL5EOE!UWGN[WN MN)MNC\\%C12S 6*@%G!D&:SU JB@.<6<24ZY\BI?"*2N=9N_XNKV2+,U4B<* MUHD(@G,!QG(#C$L3+6&*VMHQWK.@VA0(;SA')\W8BH 3511PK56+&; MT&J?N6^WL:'U5DQ*HC F]\&BAR:T ?0"/+KL.6BGK#>D=C+M&4AM"I;J\Z.F M/*J19.8H=E@042F#C)06OT2;P05C\-V<>(SC0XZQD<1Q'?P[U^*10<44+A\D"""H3."(MR"2S\BC/P)?;:%WZE2W59.L( M_TZNM9DY;VCG[28/-A\V8@J,Q B!FI($8P9LUAQR(B*&2%2RM9WOIQ&U5.UM M0I,&1%&-'GL7E[W!54HGJ5>*]!:99J:<$=8"8N$E;D#3;-%?I0*Y;(PTS)C* M#'D65$MS4C5(4E<@C>2MYT"\]X)HBF&E+,,,(F/(01P0YD,.W!HE:NN.!3!: MFG^JP85-)[U>0!_"8-(?CX[=E?.]=,/$$-#]TXC%10W"Y@C&HBM(.0N!1<-M M2)4)L!A)F[;I*W.@PM0WX3.CFW,Z'H1_G0]Z.+NC4FLXONK(X$10(D),&E$E M3L%EJD E0WB2S!E7NVSC.4R;CGG!*"GEN-(4 ^5*=8QV"G#JT5!S0:CT4>-O M*H_RN7&UQIW>G!?W%\"& F@DUY4%ES0(#X%'C(&E(. C^O11IB2X"#R9ZI9O MM4CJ%5SD^J)?=\HK)[)O3&]P-)/D@1B&$++7X$N*E7AF@H^2,;J-B]='L MN-$Y"JG\483SQ?7PH:/M\8X;#J\P+/F[ZTU2AQAMF)<:!4881JG"@C>!@V+9 M8?#*A(RUN;T4L#8IO/5Y<9_B]652W>D[22$A,'0^#M.-&TJ$R,;BF#D59;N! M:'#>K)?.T9KB;CXV&Z=-UY0G.>S[PW0DT2 ML\8BVRQ&-))1M,8T@]4L6!.93*1VY+<$K#:E NHQHK8\JA%E@;=7RNB\0@@^ M*(NQ*2+R 0-4S0VQY<0N"[5+4NJ'?-LQ=HN$7>\8YWV_O^,NNV/7VQE<7 SZ MT]=U#&6"9N,!HXU8CM,)L#1*"%*2;$B*3%4O:'@659L\I VY\< 2UA5)35TY MJP^;8I@Y:]9PH;W&-Z=4CM%D"D8$C<&J5YQE(;2HG019 *--'E%E,FPZZ=6D M?S9,;C097DUQS+AX[:\7PHE24,PT+?XZJGM&+5AA8Z0N,!]J[R0_AF5%+PG> M$A&JS'_->&ER,9GNVLQV@ <7E\-TCD:[^R7-ZDV[8[_8_ MCVXQ=3?E;NB..PR-G-%6@;41U1LK.57K,V14;LG(DAVO76KY/*HVG:2L3(S* M(KE'E;^^OS]C!_CSNBUY/AUN?]K=/YMVM7G8WN;T#+_^L7=X=GKT<>?HC^.3 MO=_Q,_M_W]L_Q!_W[B)#[M^,B[9 MO;/!L9M51$9J@X@!C$4?%AU;BVRR^)WP"?\S2MK:.PT;0JYR&NZ1UY?D^,?> MX.OO*7Y.O^%*++_V&5M4"4-R!(SF!H MV2S7BN6(BU)4/W10?Q1MBNE?DM4+S^F]'C\J)M 15AJ-9^BO6'\>5ZVQ7S^]$YE0)E*<<8\C M%,$I\"2CBYT2.ETI1]+ _L$=""NNKF:#X^K4>+BUL/[\5]U!&HU+6[+9.*?; M'(1H(U$Q.&'*(4JEP1J9@!+&,SK<5K#:D? "&&W*F+T %S830]UC\+='=F?( M'9X)44$QT(*6OG69@A5" %>!:I:-]$0T8<0?1=2F7:1_I?4GZ2/*->=07\\ M=&'\9W=\/N_8<].:KVSUX7_%=>D$K26N1 .$" QC-;HOCCH*E$ME74B"5J_. M60-FF[S6=?GR, G0K+0J9@U'Z(N7?G_3DKPT_-(-:70ZZ,4.RX$:9P5X$1&/ M8CA^)C)0)E"W4TYUKITX>AS-BO:V6>>K%DLJ37XU,J %^!XH=6B)=P)A0+17 M(!@.SWF,P/BT0B#&P'5M1^L.@,V=Q_F3YLNPVY_@FKL^637HCSZD/!BFFVX= M:;3W#93 ].1I6<"#7F]JT68VM*,\)9KS!"H%%$]6"ES"<) P M&9+B@G-)JCNAC0VG31IX?0X^]%K;(?^*T= UT&N7ZD/JIZD*$MGE8!R@IX:A M630 MSD&T2G75EOEF4]Z@Y(7R1L@DP7,B0+B,#J\G!+(BQ'NC.-&U^Z<\(_DU*EO3 MU#?X#8W"T/70D=^.%]U^=S0NK_ERD_](622T/0[#.\U!6*+!L)#!>'3H2\]> M+FJ[C,LA:Z6R6XLA#TX#UI=,Q=Z-E\,4NM-)P>][Z7K+:?NB;(K][_3W'2\U MH\GX6?\/$449O(] 9!32"<-C]1!L&5QM2G[794QUJ51V_IN)9CP73%I73HYH M R)$#L[%"*4_$W.BY#%JGU%^L6BVCH/-9?:48I2G&4.3ZRRR*^6$(B?&"B6$ MKUZF_:R#_;J:NBU\?-3565-Z+[MYCTX=B9ZETGX1'?# %#B#46EVWN=@D[,)V4RSZ1V&/E$POIUU7,M#MQG M_?HS7K<(8(/*LBAQ K@S0#Q^$2K%4EEF(5/T_"G)WOI&J@1JU4N^KCINBE@O M*=6VU%1OG_[^\>#HS[7N/5WG-2])6JIDMS SRL!PSQ9]U@4#=9II$5G'(,"-'H@Q,QE6XP.D26'..U%_SRZ"K< MIAI2BE/GZ-A=E2*MT8WL*)=&E1W/LHY2:4!7 MT9:F)10]2/R1:I$I>A$QZMJZ^3Z&5AUZ?B%^;"2'ZAKENGWMV0!]O%(F5P[C MX5B1O*?GZ-U]0.[&XAJB7SC+P)) HF&20I8*ATZU!8RJ!22&8S8\,(SB&](S MJV)=\5CT#\&N%Y%KQ;8MI%X[[9HK@U;HT3JP3)Y1"-*E=O ME8,U!*>!!2LRSXQ4O]UV>705]BY+\Y6TFV9_[O>_-RD<=90/7% O@;CI[DQR M8")A0)773B61\$O]W92?35B!_I/'Y M('X_ +G;+1/4CZ.CX6XI)"IYZ+('V2%>)8D1%!"#YDI(*<&[:($K*H.T MW: MVN>35T/8IK.(+T2W!D78H)J;-W6=CMY%9Q(M;HLM5T%9AAZ+49"UY#Y)XT-L MWC;> O06HMGFE=:Z$FJH&&PQS=&7CM+K4(J%$04(0FFYJ5R!0KU) XNQ?O2Z M%+ 5 ]D?A425)=:@!IJ?Y+Z^;S4@UX:N'IR'\AWON::&XXAMDB HPO"1"HA,\R@B M3T0V>^7@',DR#-(_&(,JR*21>OG;U=BE.#L@P\":$U:/<>OTZQXP.E-@8*6@A2KE C&'WZ M#,%++YRF2O/:)RQ7P;<,M^R/Q:W&Q%=19_=[_CM1J=W.5Z,(R[&)'ARB<, M(J9W1V)8RDMWV:2#E+[V5L(&<)>BW"N7>[V09UY=N@TUAI%4,2XXOI.5/!D5 M"IP5 :BF005M>4BUCXNM7F?_4O70+T29]270H$ZZ1]BSH8NI$Z/$L!%'*:UV MI5%D H/C Z*LLR0E3V3M??#ED"U%FQ\L ]Z S!J*^$_*I!]EG(9I6N)VM# _ MIVV$S(YJ 5241L!>23 B&J!!1%+4GZI>Q[TJQJ4X]E*W8+Q*EJ"R'.N>&EHP M]'D_Z-,QQ@PEO]$Q.!F4\'+SFO0@I$%X,E/(#B/19#@-I/:9S*7!+<6O5RX" MJ\ZO1B17[R:?6PP_RCOV1R462*,C-*QEE)/NZ+RHP>L"6>X- M-\A<,(K'H@QQI$HG\#X;PR@S5->^%N194$NQQOQ@NRAU1=5T<>IL._I>4:X5 ME+ERM562\KK&P2'#(^7KL_^)G9T0G\B,0Y>*5SKSF7\+CD(%&?!!4Y5KMW$:Q5\;Z%T=5."/5;U M75U^U4\-W"#$*4$=,[XZ[KG^&'V-4@YR.?5@9= J"B9 $?1;T998,!HU#HN6 MR22T(;[V-M/RZ-Y"Q6KC[*HCNR8.Y=X^+#.-F1;-16"J^*T61'3E]B*JP'HA M( KB/-52.E%[>WQ%B&_A.&93+&M"BO7:"N%$E/\+X[^XWNR 7ZF?#6/TB(N6 M[<>[O[CUR>,T[)9:M_OIR.M[$/:^A7/7_YQ.,)3?PU@]C#M.Z\@SB< \09?+ MHUMM/ 9@G/%HE;/450^77W:$+WBZ* LJ0[8:;% 91+;HR"9=IE9H%0(-IOI5 M#NN>+GKEMDGMY?B"':$FQ/\:\843,F^>.7F2V^>GIN*OVEZ+CJ3ZCA&]VC0RX4!I>DKH^ UY:"B<4SEK$7UYI_K M]@]ZW6,];Y^>FXJ_T]LGA_N'OYT>[YV<_KY]LG<:SE.<]-(@?W"C;G E M:=V;C+]?/5V23KOE.NK>Z"[ Y5J,;?2^&KW&Z@VX4M.Q/Z>K*,7M+VAD/Z?# MR85/PZ-\C6*:'QX=3<:C,4)#/!WB"*?:<:1.N2"$* P)F=3@*4\\66^"K&W8 M5H2XJ1I]Y'4/WC,56,=12&2J;U]L1+ -KFB M37+MOC9L3HK5[/5"B(]-QG;\G\GL3%7)K1/)E <773D[+*;-2@/02&@H#@;- MM+-N=I(XBUE,9.3!6(EL3')B< R@=-$:XR05;^]3] MLM@V57A/ON<3+H99?4+IF1#PH]L7Y:>.\)1PZ00P%TPYPT[!J<2!6^M%),Z+ MZM>DKP6T39:V$;;=UW+-B[.APLP;D)VHJ$Z28R"D5%&XTH,/R8/F,1,GO&7- MW3)W%TJ;3.6+L*>&2%IC SNT:2N(;WAI.WA_4"]M":4GTFE4$HZ4!FOBA ]++=\(1?[/Y(8== $#D]E"SAY#%1(- MX)J(H)Q.7J:,2^Y5_(.%:-^D35R%=RO9Q'J"K688EYV40US\9U]3[TOZ8] ? MGT^/GZJ4+0,52K]N7HZ?>M354J"V3B9;HVKOOZV+]4V:UL9)N*E07YR"99&< M?1UTA#1&$!+!*.] I')7R^P<-'6,80 =?.W^&2M";-,&1JL(MXX(7X=G2)S4 MB5(D+[@ F[Q'5U19L($@8",H33FZ+&L7B:X,# M#^G8=>-V'J?A#4C))(T" W:54 4+Y00X&P-8'A/U63MJ[C'M8>BZYKM7;%KV M=AGT$K)I-/MQ?')TO'=R]L_MP]V]__ZT?UQNP-H@X?_4XVKD-9:&6RF)\6C- M=.G]1$S,/$0"N=Q@)*)"1R=&!=HSYE3FGH4&[EAX%$^%VR06/_NW8>G<$(DP MQO$ P97V'3P1=.N2*A?6>1FR9/7OWWP:49N2#M5XLN >B5I"J7=N.(3)Q63: MJ6J96\Q5) M-VKO?CLZVOUS_^ #][)_N'9]N'O^U_* GST[VSTQTW'%Z5W?KI+I:; M-C*:3\'MH0[R?OGKS]W2[FC:C70#J]D\J!JV]X6GKI(%_]CMX^(YZ'XI19)W M7SOMWZAP;01G0 G!2WL]#!J-D."R22HYI5GU2R6?1K2IX+ZD6 MZ<"$<8DKKV@FSU5&VRD*_#JMJR*]1:[R/8=R'L[W=P[W3 M6YO5I;/ !M;T^8?6L(8K0J^UJ3[H?SY+PXMI\P42,KK^,8,+I=NYUN5>&:HA M9R5-I%805?M$[.WW;]YDUH_W^Z/Q<%)0TQMG:MZ5'EH%/3TI73W: M?/HUS=F+%897R7X\&418R944QH%4I= PHR+P/&A(RK+ +'Y;7?DN'\5MIF>^ MS^Y)NKRYOOMXV.V'[J7K+:[]-5H%1JP"XHG%^8@!3%8,OR-!:>N")TT:HW4P MM\ER5>/:4[JL<<$V8O:>0;W??U $S(NZESF#$A(5MDVJPPF%KFK640-4.5K%1Q3HT!YKAQSJ/'6KWU^'I(VU3D MW2*ZK2S$UR/?20-M4Y]T> MNJTLPDH%W@]Q7MVM&59$\:R"Q5DH74.$3F TCT!8D-HB4.'NT>JQ>N[G7M6F M\NWJQ&A@MI?,8US_OGSQ;I1^_UXM* MS$.MKCY+EN4L]7%*;DF9U?6DA2$@L5,B?4C*F3Z__@8X6+(HBMPB0,ITK>[E MTI1[?XCX"$0$8OCW__7G[^^3_^'#C1_GP?"6D/^8_&>'@X^?A[VKZ_$/G'(Y_[/Y;X=_Y<:R['0BDHE MI*>)^"PI\4[GH%3F)M#_[^JOFG/E6% $-,,_"R&0X"PCB6D&'B1WUDX>>M/K M__[7\D_P(_@!E]?S3V_7C_ M GQ]&G_Y#Q^B43]-?XE_.NK]=33Y[]\/HA]/%+1R"3\L_8OR'9G_&2D_(HP3 MP?[RYRC]^!__]L,/4\GY81P.;N ,\@^S+W\].UY$VNN/?TJ]VY]F?_.3O[E! MQ),GC#]_A+_]..K=?KR!^<^NAY"7HI\ON8!2!<[_6Y[VT\:8KA'(,-X%(/A3 MZ!>*5\3XU-,WQ_SE621!]G_@UO=J"GCAT1703AY$;N$VP+ F MU*^>^P#G'.1CA.61H3<8Q6'OXU_BX/:G";Q?3PY^?7M\2+ M\]/WQV\/\(?G%_CO+TG[\XO3@__]]]/W[\].CL_^J]?CR_^N7HUY7VD M[,'4"3J!O='['JP2Z=3K]\H.]1Z_G;VTK&AKZX4_Q]!/,-W(YK!N!O&K/[HI MV^C@B]YO?(";R4\O[T;DRON/E^=C/-/*\8;K@&/\N//AX/;CX,^?CLZ^+.'PLE)1&$E02$P% XN MRRFTJQAS&?!7W$!H18RG %7DR3/&P#.\>8&BEW%F8X$_1:$-V? (T]O),;86 MJ,M'YDDE-CP)J"(+EII7SW!@<\4-6DE]:Y20'$+44I.D..Z:G%OB4G"X=7(K M6%0VJMH;PQ:I\)7ENGLF=!%V P9\0/W!< CI?#R(O_\RL6DOM7/"4@4$: (B M$P1B<<%$V$BI,Y[3)"H3X"D<-?7_E"^PJ/P**AI4EN^BSNFF.L?UW0[Z#P&E M0*.,BA+G'"42 (BU>'J"4"DI29.BNK+"%T#L@[8WDVR#C_?%$/SH;OAY FF* M;@[,XJJL8L2%A,N$'(E/:.9(F[PP5@4N8F65+P6S#ZJO(^E%"O!-*7"0TD28 M_N:#[Z7C_J'_V!O[FQFXS(')F/$8 ]R T-H5Q$:640+*^F2MULQ4IL&S@/:! M"O4DOD@'L2D=SF",ZX-TY(?]7O]J-$-E,B@3D)I#2.F3<)0%J+_U2/ M.SY&L7T>-%7<0AQR(ZE7=$3*/= 4SO%H= ?I-W]S!V*F<-CWAJ@E7$LY\4VI7"FG@^_W,W&I>M=W0Q6&*4GU_[(90DB50.83R!)[D7 M9X"R'/7&< [#3[T('V#8&Z0SB(.KJ8XG4KGDUD?F WZ()"O10"H(&G$&[3O/ M#'[:$JZPNO/4=DW[2>I7R8@&SMU$)X=*FID,8Z0,C"$)F3)TX&3W+$KT-P63BV_GG\,A#[R9VMJJ:! MWW@"XZD;^WXP&EU""I%:7+?Q95.,LFR* DC4C N(67)1.\;X%8#]Y,CFLEY4 MO-Y4\$:+ M$ISD8ZF0?0A&? B<4N$!4&DY8'X''&/ M9,[AQB@R'KI;BC[\^T^/./,>OWUI.NG)P<6O9T>G[TX_')T=7!R?GIP?G+S] M<'9T?G1R,?G^]-V[XY.#D\/C@_?WR99O2Z3Z9O22?-+-7E@AH;3BBBMEE+ZY M&_7Z,!H=Q*FS,%W2+.CGM=<*/P;$ ^['TH$FSF:#GPR::<@@M'XB(WDCXCV' M9^./5KR&='<#I_F)MXS>?'[PW32O3D:T986CA"J*)Y/2F@25%(K#FG(+%B+4 MM@*Z8MQ6IFHUGBSX&BV5LNNLUM%P_&"!TXWT%QA?#]!W_P13MW[QIP G_A8F MR5O@I)(A.A)C,8JMX01=*S2*E3=!QF027^MV H$\8!]^=\^\33'N+ >V*7$& M.U!@Q1AVP;T,U^PV33;3:'=KE8'356R7=)D&0)ETI*@E232 M2$6< T9RBI%K8(Z[&OO1+LBR),GVM7*EBR9J7XZ]ARL?/_\=_,WX^OSSJ-@ ML\M_116GF@K"P>-B4\+%)L\0FLG,:H?HU"HK_?E7;,]YK:V$074)5KS\GJ Z MN2L03O/LPF!>UCNZU#P:&I5%V\[BT4DMKM-$3H2.V4@K=11V+;4N>\/V0Q+5 M#=IZ$FREUN-^OBM[W7EO#*/+)!/3R#02."Y/"NV)I8H1:F.2E%DFO>FDTZ\> MOV\*?;GL&J1(ST&=HKF,_.I?G4_=%#QLP N3G2-*E$Q-"I0X83DQT3-F&$M" M^MIQZV5@]H "=07>(%_@:7OD](\^#$?7O8\?T)W"[_T57#(KG,"U$L^T()+% M1 (5BE!M(S=!)P:I2874&N#VB"EM%++TWKUJ//;\UU]^.3C[Y^F[\^.?3X[? M'1\>G%P<'!Z>_GIR<7SR\X?3]\>'QT?G]SD(N"<.AK>3 VZ#H&R%MU:(S-9> M>Z7P[.&@7_@RG"9T]$:_W[/4^JRXY(H8'A21/C#BC<4C2=&8A'5.FMI;_7(T MF]=W/7KR-&03L\T.[2."'Q8TAH.+>.+BDBV/+*'-#>GQ=7W]-6XUS%I)WXM% M7AN+=]>AU/M"A4GBP <_''^^&/K^R,=9P._A;Z:5KQ:,"B81[V(F4@93Z+\)\#E-YON$G>#>=%3;A(R-PIXG GQ)5")C[@FHURZ!0$IJ*J MG3;]#)SM^TN;:FO!'JDCZHJ1LA+M_<7_SV!X>#<:#V[179M0G'LK9>)H9IGH MB!0E>I^@F%[>4YN5B,RNH_@5%QZ+;]X#^Z""2"N&3 J:$KH_S5]AFK%Y'5 5 M;T.7 MG^1>BF&AJT$F_EF\UGP($10@ G"7$0:1SBTB80"=)Q 5XRLU9?B=>E M\V?N,[>C\@Y2K7Y!Z8=7,!I_\)]A.#M6/&6,2V4)526H)QB0($0B)@:GA/,) MG>GU;B87GKW=*\E*$A_4$U>3?C^/3J$WG]] /U[?^N'O$[[B$B'8D(EF :T/ MJ8!8:031V4GAHHS6U/;M5V':@Q.[B?@;%(TMXINCFWT4UL'7R*M?A6TW/GY= MC:ZD2P5U-/'P5N!$?\8Y[SVB*UW.(#-B8]*$,\6I4BJ)ZG7^NZ'+BAC ;MG2 M10M-HD&?H'\'[U J"!5QQG$I$9\?MO.&>#FA@\L4$6IRQ*+5Y$VI@'1>!2Z] MR+SV]TJ5\MI9Z MXF42>!)G14*(&@]F[SAWD48=UC(]5[YJ3Y3?0*Y-3I/1^#3_/!BDT8?A(-W% M2;N<&3;0("QWCG#.2Q/%*$GPG!-;HELZ>NVA?GO*Y7CVA!C51=\@)>>)L_," M_]/)L1F3]]8R27@4I3>6B6B.Z[)M9>9XEL&KVEUJGX&SWP[+BX3>H(?=XFKQ M/YQ]!M:!MBTWY1[6J_%07J;"E;D/F\E_&W[) XC*(OO!&F)*@JFT2A"+NQL) MAFH?&(M6U6YZNW5J=/=&FC.CB]A;,&)FWRY G/?E%#EF7XK7O,3#DV;<*PU/ M1/NHN7#&:%L]_/4\I%=@8;Q4?8]I45'V#4*C/P\^P;!?4JGF#M%H&=),M=%< M1@(:S2$)7B-F[8@.*D3IM;&^MA&Z/KK](4PCC3385L[O/GZ\Z2VG-I,07 :' M\+C&W13_L19]*TXC9J&RT%LRGM0H&5MR*/O7N/7!,JHBU8INK!WA&!_TT0S2: M=X9> U3%[(>E0+:?_;"YCA857DG E?,?EH/S#CG2 ZE MR5:I)?"NA$^-S$"U]E8^\B&6A*57OVN[&1*5-#)H)\X67GB)"R* M:S\9].'VX\W@,\P[P(X>Y/.^^3PW2";L=R89DZT@(B:4#'> 9USPQ!@1ROU) M-*)V9'(SQ'M@(^Q =0WZ)W9%/\<^^TBN@[Y1"'0SY#N:^KA%KFQ(TPJ*;N$" M;[8*ZI--Y7XYA!A+O%$1)SDE3&G*A'/XR^KCEE\A35=-I/QF6=I%O[5MMG># MN^%OT$^#X=RFR"$E20>N-)IV3C(\\Y>I)9UD1F M)8@#'HGU2E%JO%.I03GTR\"^@L#=^UJUTUM05P.>/=V*8G2IE0A@I2"YR$&" M"L1E3XE0* =T8%BLGCJ]!,K><*2&J!O8.O>-KTO^W#*0TK ,UI8TJM*?2EA% MO%")V"QBEEGC!EF[O?1:P/:&'?75L+5.0F][GWH)#\_1Z?!M;S3MEEZ*@2]! M>>XC&F:E AC1*E6B';+0VPTS=7;TV]')KTALY#"YT,_AJO!\/,@3TK1-F@JU?45%3I(;;2J2NVB<"OP5U=#N)HP MX33/D-RSC+L0?)FF"*FD2R6#9 @4C5,\>'*4'-##JOP)7(5ITQUGR?.G85G- M2O%CEH0QC8>JI8EXGSGQ 3="YV/6U:>[/H=G6VVDJO+@\6Y33>"[;BFUI!0Z M6T@HFB(1EXA4D]HF9PGER5L?G QAK:D7WTS+AWH*?;[Q0Q?!;JWX?QU0WTWC MATX:6JL+P$O$NS7=BY %4]Z0C$86D3$[XM @(DD'X7)643_N5OXMZ+Q;XX?Z M*N\BU=HA],/![6T9[NMO'E4(6JNI=8C'<>F)I,H3RRB0H+--B,SR'%<9E<^^ MX;4T@>@D_4%MT=4NKGR06OL(E,E11:%($.#*T$!#K$?_QBNET&V*"'I+T<7!_]]M,D R">>4B'RLPI; MI>#.]!JA3$S^T]_V^GX&=$81[0*#S"*Q2:,=!V4XA<=]1CF7K +#)=2.[#P+ MJ,[=U=T1Q0RU''OB(6@F)!@LJH=15X*9EL!G7JZ?_IR M:E,Y[SJ4L[":@[OQ]6#8FS6J=1+Q,I#$"-S*9/)HO5JI\>A56B1&C51MKC@? M(]E5B*>2EI=QY^72;G;K_1#5/ -Q#5R-4DV78=I-$FD-O:VDP@9"WR8IF)=< M>%W92J%'(@ H_,:1PF4_3(; M:LB[043C*5CERR',R[_7 =C(@%@);C>61!55KD&/S?70X#Q9#508"32:0%(H MTP%]],0Q8 2HC4((A%B]W]>.B++"RM@-3[J(OW:D^^ 64F_T>81;Z+Q %!*Z MZ3H39DQI\ ""V%S&"JJ8$:9UPCUR0I>U@7S\Z%?#@$/R( M="]M*%'"XTN06GD:-;&1&2)-PB/0B4 RVLE!>1N4:!AQ>PAEAV9BRWC4BZ7= MHI@B9T"3]1-\P7>&-FT)J/?Z=[W^U6PR;,G #3SE9 %!#ZZ/:)*HUTTL!2^,W?W$V0?*D4>@L9AL/);4NY>!D?7OO^%2[D MX+8TO;VTRBNA-2<\43_=/8-$1QQRXAH,X3DYKJIZ*K,CD@ MYV?OX> VS*0PY?S5M /9J)=FO)\@OX#A7%CO "Z= :JE]<0JC9\$(Q,)S"H2 M44J.61G J[6LD(U@[ -YMJR,BL4:$^1?0[D7SV13O53!*&IL1FY;4>:_:.(, MLEPG/&]M]%EHN19-GGW-WM"@GC ;="!^O)>-%K>[2YEM"A3/QBR](E(B.@O4 MD*00(TO!&EU[//P:L/:!'ZVTL+0Y7-6\BZ.#LY/CDY_//QR=G?_]X.SH />V MU+NY*V;7.<2[(;X!1M,D$DAYDF1R^_%N/%G8()<:&-P+1Q]@.*G_WR!WHQ&2 M"OD?VY!1I1R2YZ&]^QK:Z0*T!Y^$(*CERA'O#%K5%K#@823(D4-%(Q4+U M6Z>J*]A6#LQ.N+MPE;4[Y;^6')L-%_[F\],/F,2#*43O4F#$.EN*X*4M$RB! M9,>EB\DP*FLGZC1AD"L$($%Q7D.M5O[[(9I*ZX;OUFB M=5%@DPRI0?S]]..#U)QD3:3>,*)L&79AT?=UB(6(S&1& 0B0M7-@%D!L/PI0 M5T\+V5";"+EVA=T9E.XQ<0QI@NO@#S],\PHCJ9GF49!$2_3>[U'*@1 [&D](6J/0KU,11&DFT M ))%KP6OO==7 ?Y:.+;E4,3VE;Z=4K_'X=2Y-SO(;_RH%WT_O2VKAC1?4>FL M5S&PW.E]#<+'+U]OI2#Q@CE<8-QS%B35,I1M+KB,>QT#9 Q^&T12)FM3!N_6 MSF]Y%E&]@.Z3[WGSN;1&&/0/;_QH-(V(@)4!]W=.HE."R,@C"-];]F64(7/>PDRWP=@/\J2^BLRL[IYB_1PTX(PX%:!8P1R*"( MY%&BU2D<@3)K, <5?:I=0?]ME26TY4D7\;B9. A37 M@QM\UVAR6!Z$T:3WRZ5.>$#F:G?N?B'4[?.G MH2V[#76U9MFECB#0G+)$:9!E1FT99B$\H59[Z:)2D==NX/05@.TS8BMJ>XXJ MG63>P)KX!_2NKL>0#C[!T%_!R5V1UVF>?#Q&IW?CT=CW2_NH68SB;6]4?*>[ MX?0C\T4>3!H!20+1DT!7XIPX_#21A":YLSH9JVH72]5!OE>;T Z4N4-*3@1W MJ61(.BA*A"E]\H)SQ F52;:.[Z MEDAN&?!+GKBBTDAB=+GN-).AM 9(#,$:)15UU3.U.T+\%_LJJ['!7)\GC9(O M@A AH/_L*+'H1Y=X29E]K0/!?=G2K%W04#MM]UE >V6TU1-]B[%A3X&[E$X+ MP%V2!$Q6T&#/V+(VMC-*\,/9Z8>CLXM_'IR\/?JO M7X\__')TM,HQ DAVMFN\!JS=9W35I,.@K5H:^$W+5X\/F*4J MK .Q45K7&O!VD]A57;7K4F=#O>R(0C9S1IT):*89M!.MPD\1]Z$,][,TFDQI MJNU^[XPZ*U*]7@-SNJBCMA]VW,]W15 ?[FX_CF893$ =M=D&(B*+I?U8Z;N. M7B>:^,HK::A:L\#OB8=OWV>JKH%!1?'5+MO\LKAW=^@ICN^&I;_^Z?CZRW@X M"%1(AZ=R]NBP(9\-KM0@JW&A5$1CI#=KZ7;5F_9,T54%VV#;?P]^!"7EZ/CV MXW#P:6+0S@DIL\A2:R QFD2DI)8$RQ0N6G,KTB2]L?)V_PR<_2%&;=DWN(]VL?'U;"@.@]/QS0PH!EKDK2H?&22.$B>F-)$@7@ ML\Y>6U:[8. Y//M'DVK2;] ^=)J+.IGA,XD+E?]@7B@1P"3N52":Z]*Y@I>+ MBB )9#PEO9%10NU>Y\_ V>NH1BTU-#A\ED";?2[6 ==T[-X28+NO1 M8P,=-)O"MPPDCXDJ;LM,,6J(]-R4"TOTIX3D3E/')=2.QN^ (&O-X]LV/[J( MO@$OBAUTFL_]#2AW#C[P$&A46SX1S]J]F\L5,\V"6"LMD<$KYC/5,M;.5GT: MR3XIOX*LMQG _GE8ZIZ,="Z!522%X@\QQ]"A!H9&L'2@4!1)U0YF/(_H%7D= M=>YF*RJ@P09Q$./=[=V-+_G7\'$(L3?].,#'&YB(O9\.;@?#<>__3GZ^=#&7 MQAIID\C$:8E&-PV&^"R0]=Y%KY0-OOH-;"WL>T>YG2AUFWO7"8POF7.X6WM- M8BXG*YZC)!C0!'T^W%=+P[_J[16>P[-W)*HF_ :N\$-67TJ:!),R$5D.;BEH M&?1C,ZY9")>S-U;5+K5_^/Z]4_R+A;LT7EHU&?'GT].W_SA^__[@Y.WIQ=^/ MSHY/+@Y.?CY^\_[HX/S\Z.+\T ^'GTLMV:3SGL>M[GXW?+CK#?)Q^?55+]S M=%3,!BF-[4%52(S^*VN%][U/D!Z_]I[O(-",EBZ1Y$KS?)DX<9PJ MHJE).B<5,M1V9-?!52_%\IFW38.>F:O@H\S$@BVCPJ,K&>V21!Z /&D>O [?1149'J+NY MVFBF^O4I5DUOKX!NU'.FO07B2L,+*2)#Q((3DT)(#(SQU9,W7P7-5ER0O%:6 M=5%7BRN4N]%X< O#][W[E!(MO(G,:))2R4C0-.&.[@7)*@$(JIR%VL'T)V!L MWPUMJKK'%RL;RKU!Y/1BZ!/<^N'O(W3!)]^4M7X!9XWDD 6N+I6*<5RV52&B MS<$L&L0SGQ'#])8H>^ZX5(D87VZ)N(O$&>E)1@)3G;)- MLO8UW2I,KXHL=;S[JFIH<.0\@V])J.Z2BI25 T-428B3'BGN%6@"4EED-K7! M;3$PM@3E]T6E&JK:KN-4;GQP=XTQ:UT<5$NDH:4?6['Y0XR.N=*98(M$VLF% MVRY)TU4%+<9?/2#KZ<(5P*7W0H=,.1KAA;[:H)4%VA"N>3".(YU%;5/F>41[ M2)"**MC.9=WQR=NC-Q=';T^.SL_O)RZ]A3#>X+)M]4,K7)9U1%[ILJL\_WA2 MFO#U?:X0Z-(F'E"5DXDKLJ01!D48>*6BT8REVA4 2Z!L?G7_\+'32#BCWCNN M-+)5,EP=GH'6>D:H8""R8)96+WQY L:V+JEJZ'CQSGXSJ;Z6"ZC#(:3>^)V/ MO9O>^/,T'3LD+61F!*@N8Q\$$&\S11/<2>L4M3+5CJ0LHMC5==+&>GT<1]M, MOBTBJE\AFA=2K(&IT1W04WAV<]&SJ:Z>5?T&@MX6"1S305E'">-E!+C,@3B: M%1$Y<9Y-+D-DOUGEK[A^V8;NN\BW@<[/X-/@YE.O?_4UN'F=KM&@D_:E]UXY M# 5N=T+BV1@C\\)YSW7M@->S@+;O3&RNLT$K@3<(;;T?]*_&,+PM!]Z73C$N MN!"4SP1L0F 4)/$A^C+ /7+#*).L=A']4SCVY?#?6,8-@@J/,EL2&!T\3EK=2+0-#ONO#[9I4[@DI(E6X:I,"5U.Z@QB(CI+B[:' M#ZSZK.]%%/MRT&\HWP9];[Y&].!"?QUL/1^'T/ M^J7S_?N!G[=@4B9DB,R2Z QB0D\7K1J9B3#&FVBD"GF](5 M95>[3>8YQ$$_/0&*6? J24>2489(8&BPX%J)!LJ45]Q*O_*V[]DW[(-&JTBO M^1;]=7'@)0+@IC3)X1FM4!DTVJ-),R)TIKDD*HC'\\PK;]-?X]DU#UK8V^Z]]/TU%F([MFP#404F#UBDR/@8B7;(D&*V(4XH&:H)CIK:_MA+4/O)B M4]DWV2HR#(>0WO7ZOA]ATG"S9"QI]"PE.$-B=*7CC>#$F>1)EL(+*@5^7;LI MR!(H^T*$S>7<*(A[,8M97&HIM$7.$0&^C"\2@G@/N$AO!4M*2)9JUX4^?/]^ M*/K%$FW@NS_$\)&/NG MZY?(MT$SVH>03@;].$<5=9".261>0H/49" .*$<3)#JF5-91L89:OT>R?XI_ MH907=:\:9W$>I#1YGK\Y[N?!\';66:I*,N>SSZZ?(H!'5L;:Q\4 MKS"ULXN.UTGM["+5UY+:^41@DY< "3><<)X8FJV2DH [)O%,:$\I \5K3ZA] MW9<^G?2Z^M*GBWRW&>-?!]?W>NG326?K!OM?(O!M$@)LLM;)1)@MEYT!/P%> M,T-T=E1&;52&^G&"UWWITX0'7>3<[-)GFGYX<#6$R0%S<=T;I@/\*I7O9J'O M1+4$FQ,QW&LB72Q3EP4C,05K@\^6BKS*LNS\UEU[%2]5U)/70[6E7/O.:-D] MEIL, R2*%5,I1 XL=0&(GG2+@D/3J=NFG^U-T:;*WD#V=7^>-_?8CUBWA3; M?*Q;8HQR!<1$!H@P4F(%RX3G)*EA64O+UM+N6J_;!UW7EVN+ '"!Y\=P-1A. MBQ5*TKAUC)-$,^*!..FC'PAH'C-W>+B)VCV1'F/8%[M^(]DVUO6,W.L@:I6M MO8!F1YG:&VGI&95O(.(6&=J+R#A3AH>@T#PMJ<@@)''.&Y*4""F[8"2OGIV] M):6ORLQNK/,NDFV6D5UPS9LD,:IB#)30:$H.,EH63O-,I!$I16.<5VT2LN\Q M[" ?>T.]/)F+_4*A-DCK^,^[1WBR\1JH3\0ECY8C%1Y/*2F)D#X&*516U3MI M/\;PS2MY(Z%NH:YFLEDE+R6Z"Y)0RR9SB2CQ 2%29HW3&4+BM3/N7WMQW49F MVJ8R;G1S_T0MR3JHOM?BNDX:6Z^PZB7BWEYQ'9,):'*.1(&8I#.,N.P5T=;[ M*"EWE+:XTW_-Q74-.-!%RELIKO..HD5*(QY!((EDN%!+J2 V@ /4F+'5IX"^ MWN*Z3MI965S71;0-++JG6D<(0;-)M.B$$C16SSFP$M;QA"RVO>LK[N% MSB8'_8;R;9"M]71GES4P?9@L=3Q%4=II$B?_(!-Z_0>>-'O='YQR&>:*?]W_RP5PZ^,S\&=HDF38A) M:1)8.?T<1#1WLD#KAYO J8A,MJVU7XYMUS=V[QND[%721'/&()MA5FO&E=%2 MATB\L,CD9%P9K:$)RL-;+JFBJFU.ZCV6?63$"R7=/"/KN(_.$8S&A9Q'.4,< M]S[!!S2U\7?^"BY#RB:&@ %]82# R)5< MF3F$^L;KUQCV@P@;2;9!L.($QH=^=/UA./C42Y#>?/YU5+KE3RM:2[5[V>!0 MSC"Z]%$!+_EK6JA I$:?S9=Y7U1D+UA$([YZ[I$$NE6? 9<9LY9; MXF/QZ;/P: Y)1Z)FP;&48V*U:\Y??9^!V@3H*N=%]9M-U8_;5 1(HWG=>#3V_73?2,GGH'2,M,R0+!EW M!K]*C!,%/B>1P4I5FQNK,.T'-:I*_HE@U^9-YG&9@* E1IL92C_9.\MIEZ[.KG]>\/KX]H4PKC3Q!'[:U M^69'HW'OMLQW?.=[P]_\S1V,IJ/#3L--[VK2:6)4??Y9EYGU8JA7%?!6*8QD^@Y(HX<)HH2WD, MJ&'NZKL_KZ[)1A<=K]-DHXM47TN3C2?S&8.*.BK-B:2QU!ZJDO90K@@<#3DR MD?'T_V%("N6J M61G<&D/R)'G!7$Q:Q_R]97HWX$ 7*6\ETUM*R$XH2502D4A.,PD@,W[+(5/! M%->U#/$EUY_?PR>XF6#SSO-:Z^A2U]9#MBT'00 \-,C6^0/L%_.AN.+$[1XMX MYQ/!U@#;R'+H!'0W!D4+C2\C53-U-3A]NH&VB?$(LEPF\D1D\I$X!H)D36V( M3H8L:X]Z>07<6F&GO#IJ==%22TH=]S_>C4<3";#YS!/&O51>*R=JWZ,W"V;^0T5.0RRFRHA996T -H?#Y!)64I0')<8YEL*R7: M]Y %$=0+X0UD'9J9/HMPOC>"O$0+6]I!Q R:"<($[3U1+E%"O$0+#2SC)[IO2JDSEZ4T3)52'I$RL0(L"59:+IW1/GY? MXR@W\8\VE&^#=..E;?K6P?6]=B;NI+-U.]*^1.#;[$RDD9M5SZE$H_M4P8L.(TE[OB%- 0#=P) MIZ+-L7I7TJ> [%KQ[ZOCD MHOH8F^XOJ9"#L^'*JN7<#'N??"E+O.>52P!,<4M$%J+TGV9X/.#'/ZF0%90T MP%P[,O,$C,VM@ODCIT9P3,ER4;HL!\/PTQ+0"+:F-)!)5 F3@//:39,>0=A> MCLUF.ET\]U\NR=>26_.$*62MUC*Y4#J%X=FIT2ARVGFB@^&E3"89VC:M;+=N MX@8Z7>TB=I'M-CV"=7!]KRYB)YVMZQJ\1.#;)(1CC$KA.'%0<@J<,<0I*@CS M%GAI\*%4VUC1ZW,1F_"@BYRWY2):8[*5I=9%%TSE0LY10+\)P"M7-KW'96?? MK(O82?SKN(A=9->D^SN)2U*C%*#!=H C$524@,+2(6O/,4#\SJW1>?!+(+"Z*6K@:U!=W MC/@[I*M>_^HMC'I7_4FL;9J?E90%I#1:P&44C"USP8/EQ$K)>/ ^!EM[-W@: MR3Z8#A5DW. 2>1'5W%)> U)MK=RG:+AE6F ;;Y$(763 (!V,9ACOS:%YTF2* M21KAB1 B$ZE%($$9(#FBYZL"M4[6[FVV!JSM&PMU=+A@+=950*,+ZH5R-"$% M!6"22!/*FJDFSEM(!%$' Y43T^./:G;=?>Y%N PYTD?)6 MBG2- ^EX$*6Q'@(J@P8=8B#)1Y9\\6-4-S7\,;?E$Z^-A%IZL2'[M(\K4D/BX)W5E/58Y"$98I'JU>IE+R MRPE(ZKUW!A=:VX!YW5<U&P.B MCO;6H,0&HF]P@#R#$%TM+RB51' \-*5Q0/"4I"0H&XWD+B#H;YP4*PR);7.B MB\0;<.'#$#[Z7CKZ\R/*!T8'_70ZOH;A; [ P6@$X]&7FH%8F@\HDA1-1 IG MB:4IHBAX$"IP"Z9V5N7ZZ+9O6M32Z<+DGR8*:6!C3'"=#/KQ*6@"%RVR0RP. MSU0:#+&.E^'O-FD9Q/+LYJ\F[1X>B8+?1UL_RKIZ:S%+D4;+U'!MDMZ M>%266B>(2*67B0%)@K>!1&X,@M7*0_T(QK=4TM.,'5TDO[62'D!E2993:9&# MUC;'"W2O#2W ME1(-')O+X,N MM<"RE-$Z72YU& I'@\"C4@AB1$2Y, M]]&RA_,Q8IKT 'YXKV@#SZ'TXL#%\>)P(_<=^O&@HPT&$'BJW:[U&3C[8$34 MDG:#O(PET.9)AFN :V1$/ ML-U9$-36N1X\-=-#DO'@.)'CN$8(AR@A>>G M8FDVN)WI8&6V2E;O?;L#@JRP(W;#CRZB;VA'S/(#9L<;5Y2!LGA"VHB[91") M> B&:$]SM"(;/#8;V1%? =F^'5%164L,B9=+NE7.Q>'@]N,0KLO'I-C010 E M#'CH1]?O;@9_E)14F,<&WT >#.$,XHT?C7JY-_N,]-.%__-2ZQ"BM9F8TB]6 MAIR)IPJ(,)9Q#2S+ZDGC51?P.@+SF\3(=J?/UT#.Q\N8+FZR$C3QT"9/A&KG M2&E'1&QQ WTL RY2B%37[O9?#_UW2,LZFMQ.&?#YQ>GA_WYS<'[T]OCD\.BD M7+(CD_.#B^/1D@TND-9]?[/_G@/T\:D__AA^F>FDD$+0R>FDPS361BC(1R#\DYV$@M=U[6 MOE/9'/7&C4=FMW>G^6DLDY^.#N[&UX-A[_]"^A5U-3P?#^+OIQ_+[S_<^/[H MS>>C/]&I[HW@P[ 7X:R@GSK,0K,R[!4(]267S)=:$\L-L8Q:Z1Q:*]7[5[5= MT;:NO;;,YX6F*:^'%J_ETJTLJ32_GWAR21ONO6;$FY+6ZA,0RT7I7&LDTSQ8 M/%]J9YT_>/^NXF&OB1:/,]1?JIX6Y0LS+// \1IH&@70OD:RFXC9RS6S1,4; MB+6]LK-S1@>7"5J298:%4<1[M"R%528EKRG5M=MX;D/)*Z)>K73<19H5=3N9 M4G+ *;,%SRS(DE)DEFF)GH)'/]9(=!>HP%5ZISWED PUJVSQIQZ\?<=L$R$/ M*DFH@:<_L7^^- F,+$D5C""0M"52,4H"TI(XYP7^S@>TCRI_$+\"\*\S>N'# M_7(%-;CT6FEACY:9V/?+Z*=''Z5UUM3HJ&^QGMT8#!O0Y+$;\UITW*)E:(NU M\3)OB_%,-$1.).#1[1)/Q/IH;. AQ% [$^C;X>T*&^B5T[:+:FN;4G\_/#[N M1P39^P2_HBKFU:') 5@;4$@>T&!P-!*;0R",^6QB!I$U6\ND6O*"[9M6NU?= MH++<&QAJ+PYNG=P5^#/+YH$-<^E=Y"S%1,"4!L':9.+Q\T="!BZ%,T'RVO&8 MZHMXA61M'&3<*0U>(Z_O)[4O+,TRQH(3D8B8#"XM!>(S;@D<[7$0FAMN:]\] M-ES.O[B^(VHT,$0/;B9_ ^GI-_(__[Z?NW1V?G1__UZ_'%/^\_%3M.L-KPK M7_\-M>[,7[BF2G?GAR5)XC3_PQ<"CD^'9[VKZ_$]U7A4,C-;ABAJ0!X8B=8G MR\2*:&(,T4=5.Y#V/*)--ZPGGSZ-;KGD;<0=DRB6<2OE7I(0#9#DF,HT@3:A M=MK[U6-HP=!DRWSXLN0F]QG6QFJ.9Q M.*?07%?9$0V^W+P*( YD(LQ$9HW13CT^-9ZY4G[T\.V[-=4D__B.>1.Q50SS M?,&C'N.)62O--6&T+$ZI@+82KI4QZEW6VB>STO-8]O ]4N,F8FMQ@38OSSGZ M/W>]\>?B @_Z)4(_V8)8SBHSA,1C]J0T7R?69DT4U0Z2\XQI7SO>]AR@/3/J MZ@F_06K (TPS[J\#JI%)]R2@W1AS%14W:"7U!IO%T^"$!Y.<\X0ZJHC,,A"7 M;2(0+61F5$)KY=NEP@KS;=M,Z"+L%L;\X/9VT)\D2LW/KP3>9BF)=&52O?>. M>"8.U+^MO@ M:NAO)Y1VTC@G !>55&E/J!RQ4C+BO.$\J1C\>BX;ON:!KO&[>ST_CV!/;("* M8J[8)GHYJAG%U\'5Y?Q_$0UV#.UVY$BLY[CHJ M$@*CN%<)/.$@Q9S7ZOS[ZDBPY-#?!0>ZR+AVM.;!F;0 ;SY,RS@>5>D"Y74F MTF2$)]&;C7C8E3GE2;GUDM=6OVM[IWQ=I0S:2;1V7.?),^Y+HA'$NR%*'$;S MM/ATF3*74'I!T2S1XHF9$1O*(![EA$G*"L[6*P?I^N97$A':[(*POV(3 MD'M!I>VJJD%P\F((?G0W_#Q9Q QK1)]\6/9'H:4UT:/;34M$G0?BE4_$2$]9 M*.,75.T.;,_ V0N^U!9[@\%&7T&;@SKX!$-_!8>#T?@##"> +Y7/68,H28-4 MHGT5R_J5(8E[3@5ELGXWCG6Q[2]7:BEDD3BR*G%^\S=W, =;4/X"N .F2P4R M)28X"4Z4@)S+)<)#2?0ZE:[(">WTEJ19@FM_"5-#$8MD4?5MF_LC\N!V<-GX@_L(0=44[FZO;)+3O<&JZR9Y3]YSSTB:9(I:E2ZDT1(I M\)] K2$NZ;W$7B?;#$ M99$E\YY%5WL@RC-PMIS4O8&^G^D)MI&,7TLR]_/WUYJ"MHZC?'S0*"[MB#4\ M$9V=Y6 IXZYZ)?QKS/^IIO5."4!=I+^U;(]U0'WO"4"=%+=6VL=+I+XU2H!4 M*F<+I>2@(0HTIX*0)1B>/^ MQZ0@SBF*_^#_N,!!Z]JN\:M- .JDG)4)0%TDVV8R3O'(X2U,__=X"NYZ<(// M'TT%<#:XN7DW&):RW$M$$V693!M8F8)*(R,>DB,I&"<35PQ<[7N?CA!WY@M7 M-$!;:J7%;>$]JZ>^WL.+*@79:$8CT5XP(KU1Q"9&"2VCA())TD%UQ^L9/#L9 MD=%.F#2Z@_3V;HAP/L"P-Y@6YH\NE32<>U.NEC@>H4:G MLOJ2%$&%,)#Q(_.H(_F2%(/GW[.?RJ\MX!8M"+^.ZSV%T/D8?$YX$$8N\"#$ M8S5DIQ&FL\RG@,=C_3*45:CVDS"-M-+@PN_9_4PZ97U6DQR98HU!(MY:3IS, MS@%N-5CZP0 M%.Z$NE+0]PQN2I^7#WXX_GPQ]/V1CS/@,W-,)^-]IH:H+/'PX\J5UD&,E)^B M]2Z2=[7-D%68ZH6"E[QI].;S5[^9A++P VVL3Y)H!ZXDL%IBLXTDYV"SXH+J MZD.G7@1T6^'CJLQ9'DENI:+7$F->;WV3> EDQJ4-0 #0#)&,X7$B7/%[(TT\ M2G28:E]3K(]N]]'G9DP9;$5C#>)1#_',@S!K(&H4H5Y$LYOP="O]/4.3#82_ M'5IH$2BZ-('0)"F1X!RQ JW7D!73PI2(6NW6>]NBPXH0]>[8T$7F38+5PX^# M(8+ZSP%*[S<\RNZ&\VFA$E@IS&,$%.-$QM+$H5174H.^@2_IBJZV3_D,G.T[ MDYMJ:R&Z5$?4#4*09_ )^G?P#D4P'VC_C][X^O!N-![_1YM)*LE3R6NZ)M2FA9+1P*;EL0NTDT1? W"UKJEO$K175@%O3 MH,LT-_&X_PE&XV(PO^U]ZB5T74>GP[>]T7C8"W>3#?4DL2 M&#R(:20I4<.,MPS"6O6U'>CR&,.>$6(C$3<(?A_$6+)61Q_\YX)G.MSW;C@L MO8[[Z630C]-O+A6E6?B .*4"].:\(2%DACAC:6\=1:P^:W%=;'M&D28J61K_ M?F%,>"+!$<2_7 T^_00Q_?1E<,9I_^;SZN#O5^1X^)PI+V*ZI\/73^X4 ^Z" M&@4)"48L$8L][- MZUX/IGGRRK6&2+ON&;,?EW\"PO^/?_O_ 5!+ P04 " 5@%Y9=)]F^A/ % &)I;W,M,C R-# Y,S!?9S$N:G!G[7D'5%/;UNZ&4$6(("!% M"()*!^E%(" "@E(4!:1*)R =3*@YB!A!) HBBD)H@H 0:=)"DR8"TD% @02D M2F\!0O+BN>>>^]_[W_?&??^[X[TWQN^7,<>>>^VYY]QSK;7G_M8*Y0ME"CAF MI&^H#]#0T "WJ#^ @C^VI8> N0& L3$@ 0 $T!'3DA.45U167U<\K_M(W*0H 0P!?P M 0(!*4 (T*%J+D X I0&0E P;,(>00%^:G+ROH$RCBZ^#JYRCC[>LLB'/UD MY63.R0(:4(2?H[.7:Y"0DZL[S$=3=+6V050(YJ(I:JED?,[83]?5 W8I-,#5 M/-3DNG.HE[.:BRA4B_6(!D(=X>WG[1KD*(3PONT3J([0%/[=NSI5_]DL*ZRE M$>#BIG[MHOX?%M0S3>$_G@4.A\O %61\ ]QEY=34U&3/R(LZWK; MU=O5)RB0VAMRLL*R_]Z8U"[Z,^@_[7YJCE0;==T 5\<@UXM4T?HYQ-+G5*3E MY:[_=8AEE.3E-&3_P4Y#]A\>]/]!;VEIN#BK._]\)M^ OX0W=_7_/QOMVS"M MOR/5?TF3VOH7A>J?.OF8F9DU9/]CZ/_<%[)_S#VJ]N=,I=XI]'\!OX+\"O(K MR*\@OX+\"O(KR/]?0?[&=EU]J!073N6RE'% %V"DIV>@IV-DH&=@8F1D.L+. M0N481[C QXZR\W#Q\?)P\9S@%Q0]Q2]P1N $C[",\!DQ<4DI23XA6059"7E1 M"4F)GTYH&)F8CC ?X61AX90XR7-2XG\;E$: G0EX2U,(HA$&:-EI0.PTE!8 M @ T]#2_XZ]+ QI:$!T] R,3\Q$6JD'%,8"6!@2BI0/1T]/14:]&4*\#=.ST M'*?D=!B.7W5D%/;GE(]ZDLDDM:W]II!:> N\Q'N$_P\/*=.2LJ)BZA MJ*2LHJJFKGM13]_@DJ&1^?4;%I96-ZV=75S=W#U@GH%!P7?@B)#0Z'LQ]U$/ M8N,2DYXF/TMY_B(U*SOG=6[>F_R"TK+RBO>55=4U'YI;6MO:/W9\ZA\8'!H> M^3(ZAB=,SWR?G9M?6%S?V-S:WMDE[NW_S(L& -'\%?\T+W9J7K1T=" ZQI]Y MT=#"?QJPT]&?DF/@T+G*Z.A_7%@^BHGSPI/,DB9F$85K:UQ. 7U'N$\KXL^L M_TSM]\S^M<3N_I1PC4'YY>\#H)3/[ND*L]_'.7:##., MZ^O3,(C 'PREMUWCQ*0+1UH*3N\/7/G>.L/Y->3=2D^9%BJK5$.-P._ #O." M>S:J&(J(/O4U&OFX7:"EY9>LIMIQ,R,K3DQ(+"L.^'=+0DCV^YC9=+T$U<&R MVI/TH&HEPH3B8<:MTJK$S@\6"W<6C5Y6EWV/)G]H\>IT]\LYGQ&\*1&:O2[:IUR8%8^TR?*(& M4U5OK;99AFX_K-X(V[LW=)JWD DW7!I_K0+M .X&QWSY4K$N0.+AJ$J+.!FX M-[R<7L:Z,061,5ELJZ:W'?S$)!1]]_P(EY&?>QVJS>+^HV\"2897Y,.&;]S/ M<+UZLGU. %QD(V^I(HUV4QJ<#KH-4^\>?G&'KW_6"O1*Y=F,6VV=0OM8W4.: M@*40B+\HZU[O2[>JPN1VH^9T] ;[BQ@G,5 M'^=:3I&JU-)5^C3!NMELU= XF!4GB5O[$">60?OODK)PO7Q62'/H_:RO$<^^ M?9\;-2R2^%Y_IF4S7&&=]J*6L_-9J,0;R8ZSHB7K3W<#)A>/VWTM@;D%BI2L M&':;"IBC7C P&,Y+YO9OY? DSOMH7MB/\%KPE)8*66^]<"_D=;5U_X?9)<&+ M4M,C)R.#*WSQ#]L/-O0@!.N*Y7<% #6L?:K-"*\Z-&88T<&ZJ9K<=;I/$WD MU2R]3JZX$,;_4+FU2QI2S0M)"TU/PM<96#WA&!/(;$@P?>H\7(,E7B_2..]3 MP:6V6,AML.B5$("R".61FA0(^Z31N:(509?-8,^DX51Q+6*],'3$;AI[;W>" M]YVWR2?7VG+S@Z$;I[(@$^W^I,+HBJ3=TZ%\GSJ*P%5-A&2K38-\9*17;K^- M>I##HP#^C= 15U=(DCL'_(B"O?TMK+'(MZ9*<65KAMJ&^Y8_4G:5+Y(2TF\) M$JJ$O(J(?CG$[(3>]UX?FT7Y^DK4RCG?!38X#\]GQ>V+;)I1WS7@WR4%8X]2 M/?F\6U]EBVMX\TIL%(%E M2;*BY7V9HA=&&P%-]AA79;V.#68.UC0A[. ?7O8_]216*T^1F+/@8.PVG;]. MC%6['J RE5C'_V&"UVHJ8?[M]:\.$BK-39T^BMSGE.D*HW$XYZ6B8B^Y?F8BHS$F M]8*N8%P=0"K, BJ7J\";GD4OZWDA,-=. M?Y"WR=\2K%BJ![/ V$O1*Q(S$6$C:49UJD[9QBL]$,VBSOM!T[63O8O4NK=_ M?.K?]F+^E&IT+#VJ.0+>^7FUQ# ^0C*OP+KU[F*JTK?X5T4MTKPD?8FLY=,= MB3AK+=$XHXJ3R3972S&7AHIORSQ].]Q??AM9.2M,!(ID!&M M&T(!XF"F6A]JKU>WA^+#C_M!\;R5H#)EI/J"Q5Q"!<'BT:+\*?,47>R]D8H@EB!MMO-;693U[2/.=9\#H\QCKY7/!KKI(# MDYM2,K#H/ M_X]?N&U+$Z-943*QT3,5!UOC*5Z<'M^1VM]\JF3V, 6AZCPP? MG+ZVT4%,D+C8G^'\F0(<+):'O%:NF^GQ?.KA.-UIHJQO;%M6!N_EGD%#>LSM M3%&!A_GMNZR.'R1SUH:JY0W5%AYEX7 -Z>_561=7 V?EMF5-3.Q,$N+$L'W@ ME'_YB_\OBH;"-+I9?%4 9Y[QP>6)Y:$RW-C(!Q^S F"[G '_,I=AS6L.4N\F6VRLJH+B)'/SF(.M) M]F.N8-5;!D(#!7CQ";:Y'H*8R=,*FR1>>;4%0T&%]QFREQPF<%_=CO"\N3F_ MK]#_22%NS]7>P^M$C>)5B2[837\'1<2$"OH35C=_C +PRT?H(Y/#?42E6J\A M64>>[%M 'KQ3?3Z)2=X)Y;LJ:U3)T;_ ;>[%M)J7E_K&K[L71!PQ=,6KQ3*L MZ.E\,T^R]VPD%%Q.UDFQA*"^SYJ;]GY^5_YLQ36!/3$48[2\+'WM\Z@3.BNA M/C>QOXU%[+UV5(1IH(7DHOS7"L<3BA5)6H%<<<'?DYKVK_NX6& MMUBTE7R$W.]>W]]H4XR%Z(@V#-=Z2F2+G@ARM8Z7-'AFT)-RS!2FH!O(KR?\ M2EY]*NY!95'8-S+:N>#L^('5+,]4Z0:4KS$)WW9OM^. KZ]3:O5JLF*1Q+CAP'1YF7%)!LEJ/[56CZLKS%"L4(A:^'FN MZG$"_T6AT=GNEM=T5,R7=;39M5ORL9D3&8'$.& %AZ S55DPI?M'S+R_O@R%T]9)_.OO M1MPL7MK;M2KEO/"%9;2VPK4A 5^RM@H%V%X6)=_UH$7=(]GE(3HO)U* 2YOA MSV?/53ZO-9FB(5?4VIL?:%* CZ@P"N#("]WBPEK\IRIY%,Q-;#=>\XX_$=KP M\GO/N1B-G*_P6Y@%&[\KE=SK72_&A>_S;HDH?8>4BY+B:DP/[UE2 &W/;0%9 ML@XW9KL)NL6N?:RU>"')BP-VU?[#R'KQ7"7KYIOM]FD+7ZS(P-;!PX[-[S8M M_?5]23&\T$^XI L4("EE&+G42P%^5"RDBU. )P94EUC>ABV0]C$B]=N%C ]" M+DN+=FUH-$-63\ ^[I"\ G"U.T@*D.B#7%JF (^Q5_^6 FZZ',W0\$0=D3J6DB* M^=>]2\L=9@'=Z*[(ZT=K%!OB7VL-!S\Z9SCRHU9?"P.'%,&($,*-B3RL(1YS MXDOQRV*#M"B$X;OS[IGM6MOSVX1) >^&TF!3,"*]GOAVY3@&>#:Q XMSW1PJ(OL8H@[4)C//M*)'[=&; M:H+IG+:@:>"T[P,,>"4SI>W]G?UG*2(QL.7&3X<\\!WAVD.X^4@%DF74$P(6 M_ ROECR[E+3Q_",YI C#OJ"\/X?R+5\J!Y]<*]U0/^F'!-D''D 7K_7@^9>5 MW41_G' Y:ZKG^"KR5B\C:^@$=>+$='CZG#"E /<>_FCN! E:= G6'WJ-DKC# M/2)'* !SS1=T]8YOJ?/D':01(=AT3ZT;2L:E4 =SQT^8+,!A!BP6&=$XPQR M/!F.>^4I"XT*\J^R=ZRV!@FJK!>AHK9$D.%'2VMO5U;J;AJ1TYL'1S D2>H@ M5T^;[C;L9!:0)4V)1A3 PUM$K^;P>]H])XL'6ZK7YK9I?UNT*:TB5A-J@P>E M<]_U+KOR9\4,S(I4FIG.Q3&V@'D0X!N5[XD/8?3#:7[CEF;E$+_]5WZ1SQGJ M?@,X@7.:A2E$=%9S<3ATJ"A7NUN@MIM79*6&M9'\E*:_20.NO*#!5JHG?-_ M_''CEC#.OGGZ;-EAYMLOAC"NPWV[E][*PYP25BLB4A$ ;8UOU'YY*J;9!C'K MU.TNJVQF(Z ME@!B&I\;$P^'?V*G.AE]DU6BX5J@_'"JV](,O3H^5HL=.6DF@EIW;Y4V,N6 M'$70-@6S7N(H_3PMSKX:-9 PLW[]Y15BSY&(HF [=1AC]XYO"L:W%CV<1V3, MRM'BK!J>I5G99AX/0B65"V+2C4.[01JK^-V6%SB]-[8>6B)E?'>JO=+ZCL8\ M9LL!]1Z8DX5(%ZO7=K)A&<2 ;M_MSLEM_\IO\8(S<*4OR _0UTAO"N!U>!^R MS%H;V52YJ=HCDMGC)(F\2<1.+;./ MG7]DK_;:_NB= E?? ?0PKL%L/3DEOEZ1:+][I;RF,HY[H_*KD+EHEXGV5@;8 M<7VV HY?I5M4SWUE9CO>7LU2C'^U;_D*YL"!DIR7UPL&!^ MVZQ$0TQ 8WMKT4^A&Q7K.:Y_:+@TRR[S(?5+2R>$'U='F M)JG!":9L\];)%* EXD+?-(KC]&/G(U4S?HQJQ1? O"1M8K1&S]1#5<4Z<9Z" M;W81URD)\ M:;KN$\.6_[I:SK!9)&)^O 83.OV:.#Z5CT?D>K4_:K*P*'-BTM0+@-)N7T2U M\7G#'Y@-]ZYDY#7MXFUK:G(Z"!>)4WCA*$]Y]C(+>RH M7DA>;%-&Y6-2BW&6;UZ ME7Y^#*4+DUL<^ESZ;T$Z-T0+PD]=S5T\86',O Z MQT 6X=GNJMOA>6NJ&>!K ]LLWN8F=_?;;J1.!('YL?H,N/$6"G!L>UFW=8-H MCM_.4;"W60^&JXBSKS#ZG$^:*"3WC+W=C62K&5AA06::'N 2XII529MV4!2) M/QL!-A]2"GS30+K"'UYT9Y&6U)H %BRGZ=2*78_K8QVT)F,"A7B5O^N#WWTB M5&KQAU^L7K<=J=&O=7MO_3D=&1[[N%CAKK8F=:2A%L2>J6YY_5@EQOJG_J6? M142A]I@BOP;6X.?!%"!A['.>MZ]TN:5R,4'\/D] FG8&:\_8<;*>L2CY [7Z M9B@%D4]1*W[/ ?\EZD'DAPWNR0ZZPCEW:!P]7(W^.\O0A!<40.BEZ?X49I\Z MC]+*>XBF2+S?(L2%W$.]%_51*_)'B(WJPFI_G><(F:.!J*U$ 8C&D1T[V#+C M[Q$I/*/?T^OWBFW^"270_9,2"'*MC;19UZ&C'==6H[>VZX?=TV;R[*)$TK)[$L2@?G34HYAXWK%WR% [$#ET[:J*0$,P1PU1F4O.T.:^%[,,B>E6XUG0AS MC!.S*IZ4'@JXQ#CK-+I7;R:W7>R+U^:>Y,;!W(^-+C.Y^ M^LS/^,#J.U#+SNDWO,?U16U M;&;;3?R&I.&Z1%Q>&P2\772^%;.60H(^X=@KVWEIH'JSSG\\G1"57F0OM[XS M[Z 5E6%-VH6?./^!K0HJ=FBZ8-& =PJ_Z!'954_WU&Y:$";J%A$!M:Z>PJ+& M@L4_\3BQ5,!(MBV$G M_!T\AN$6*X)JF0;7SM^E#[%<9LO$:6:+S_LR07>[Y9DTPM96Y+PRK%C#='W3 MOS%W/8[^//D:",4\4%)51((G/4^84"L:;X-:A[-O3?'R:Z=7D2S:U MN%/;8VJ'QBZ+ZL@6A[CC!HZ%7UA9#-CXS+YRMU>:DPI'%:7Y!IK'!(I3\G([ MPSP^B*U$&.Z*I@(;R^9DDT J-<&>H=8HZ[J[.!1!.89@!R68I!$HP%%8^S7V M"\*)G(M,HF^VA$8,5.'E3B+;VYR58;2_V'NSBX&9&?33>*&AY,T*#:^32\.!OG0(<<^ M$OU;.Y,F9)^]$B/QQ?U>J((M/>9A_5F$#[MC(?%&Q9T'WI??L,&COCZY,;;)&; JP]LWET_.)]X]E1TQY1_-**!P@Y9?+R#+K9XWNRT6$!/%E'P/(W M\()5 SURQG\=>1@!.>096AJ^XP?;.3=VLZU$AY;N$:=?@2J5'^-]8RH>@5HF MSE0/O>TZ-F%[(NHA".?KG*[Y" @-1@P74@!174<*8!]+?:](7V94-G2;:Y7U?"L1[?_9'8KRZV/.NU0\]1YL@!);5"Q MVW.Z55 VS2>X\-44Z EWZ.;2^%@I20\/X22:MJ?82ZQI2$9P[5@O=J-/IU<) M[,W^=E[S.!YUKYS+W"NG^?1#"B#M+N@<6=%(G-CH-T77K4V!R&,J>& MM;]8GU-3X^EQ[/]-$T1H("6QNI.K*,!58Z(!!3A=JT\!BD7W4GN&I$DW".@8 MOJ+S-GQNQ;^-?>P7$"$& MBC[,E#I-[NH+#C;N&[/C3$H ;K/O%TOV;X5%B)CW>&>7N:).YX=!E<9((FP?WN)P7VK'VCB5&*W/9GV&<4YG M:U$,] 5:&C2YM_:> C1(DKE>9"^E\]8/^VP=?<4_@:73=GCLYDF9/ MQ!#0L00O5LEF=SV.1]A N2;ML+NAD3=&2>IKK U16_!'.0?ZF0'PKU^=\[<$ M!VF^_-V2U7/[^I!CV"/!#1[+H$3MQ>S!9"$SD6ZH>\/>L57D#Q&J1<5B&VYW M:N3^MNE1A/YBC\W[ \4->US!RZA/R69@B*[]/0]0&XZ%.G/9"3W[N\A#5HF4 MEC?9?9&JB$#K>CUE\Z<&,O(XCCSH;J]2/]'T0TU;VGIVB_JW[YEH4US,,]Y* M4%6*[@!6V^O-^N3='R1?_/# RLM/+\ O?%5/ME& J5 ^AMLRR;FE=]\KYSC? M/>6PEI-BW)\9F_/L4Q\[C9M;K#8 7["_G.?9<)P$IH6E6/.,+#OR.Z:?[?1> M3AK9Y.PV))\-O_A@ ?T:BRH?-1$-8>--J=J&&@%;:9"6>H%!19ONR\U)-CV^ MM]_V[S%7TNNHBH#Z<7D?[/EKB$UA(00P]Z3Q#M.1+#EI&4F[.IZL1;0KMV_%%JEZATEWU3OK@+@S* M.4%S75OP9381W*Q."_ZQ+#RF?)5<,A 8Z88;:%)YYT#NLS^5.C1$./PXBY/0;F;WB+8>"J8(C\+ M/Q.?/&JB=7MN,+Z7 ;/,3 &$^7=H\P![^S'COUG+ 3OT6@+7LZ@ M !V=2]#M>63B2"XBCZS'ZD#&N5'=LH8@X\I]N1'NA&8BMCG4<$BHYJ%S&RJ/ M1V@_B%%I>+Z'T!W8%#JZ+AU_)P5^]=*S9V_T;Q@=H]GM!IQ_4I$-XY[#B(8- MKD6E1I+ VDH>'D,7@;*N5-Z%>,"_6 DR"29/FC'&AY^C+CZ'IGWW%RG OG)= M.JZ]T9YS6!$9)R@^%,QB*O%YWT!YPX<1(>_BOX4U^7WW04>/TXPF[N?6)6HG MVB*"4?_+ZX8!4QT,'FM5!IDWFR.'8#?R!<5F@$MQ4T%?%4Q: 9[_^#]$ZS]N MK/'\\0>@W$^__S/Y&>^(W/]BIXHR^C\ 4$L#!!0 ( !6 7EG9N.]S6-T M ,=G" 5 8FEO&ULU+U[<^,XDB_Z__D4N',B M;G1'"--\@*\YNWM"Y7)U^X3+]MKN[IWHN*' BS9G9,E#4J[R?OH+D)1$O4@ M ND^$;L]+IM$9OZD3"02^?BW__W]90[>>%YDR\6__\7]J_,7P!=TR;+%T[__ MY=?'+S#^R__^C__Q/_[M_X'POS[=7X//2[IZX8L27.08O$/Y']=K%\O4]SYZ>2^ Y'EH_MOYK_C_A9X7)"X)( ]=\1@A!)(D=B%S0Y=CCKPDCJM% MY]GBGW^3_R&XX$"(MRBJ?_[[7Y[+\O5O/_WT[=NWOWXG^?ROR_SI)\]Q_)_6 M3_^E>?S[P?/?_.II-TF2GZJ_;AXMLF,/BF7=G_[KZ_4#?>8O&&:+HL0+*@D4 MV=^*ZI?72XK+"O5>OL#))^2_X/HQ*'\%70_Z[E^_%^PO__$_ *CAR)=S?L]3 M(/_WU_NKDR23G^03/RWXD_QL[WB>+=E#B?/R&A,^%]Q7JY7OK_S?_U)D+Z]S MOO[=<\[3X\O.\WQG5F- M-78?A87@PS/<(G,VR_47ZG+!QOKN;DB=S?KP'-OZ6BQ+/!_A:[$ETV)Y+G]Q M+7YJR,B%.HQI1:2+QBOK>7.TB!C__X7\=-L5< GC%]GMZ\\%R9[ M\73-A;6]SC#)YEF9\>(.O\L]L?B\XE-2E#FFY0S%84K3!$'?XQY$+'5@G! , MO3".&$+% M_^-KMLA>5B]@3?G??MHR;1G%^8=B,]>"Y9H7!><3L.$&5.Q,P)JA]PDHEX!P M 5S&)N!+5E \!W_G. =?<;G*Q1/@CS6?_]])5)=TAZ.Y]".6^3X\2WH6/%N= M+00^%38I+D@%4+/N3]*?^XG/RV+]&RA_4RFN$>F?#KX\TWPM*\YISR?6//$3 M70I'Z[6$.Q]>FB]?S@>E7)[_O:L_-,'L7\ R9SP73O<1P0^T9LK^L2K*:M'' MY3V70F9S+C;X*^&MO_#K92%^?X&+Y[M\^98)>_;I_=>"LZO%AL*@1T3'Q&K0'MMSWE]?3Q\O/\&YZ__AW\'@_O7F8 M7CQ>W=X\Z!EC'335;.Q &.F9SH8)4'$!VFR +1_@#\D)J%BQ: 0- +!DVW0H MCVJR#"#9MT0F2Q@ZF^(@4_XJ3L7YA5B_S%<5H:_\A?!\1OT$A6X:0$Q\1\9K M QA3[ D?,HT3)Z6NDV(MI[&#V-#.GR1=@)4D#AA_X_/EJ[3TFMY<%UJ*7IDE M##2]*TFUD;Y-%_Q14[;I%BD(:,N]Z2(UKINB(/2!NZ'RCIY6,Y[-+I9O/%<\ M*AP\/]PWL")CU0\_R?R1;U?!Z5^?EF\_B7?J+Y;X8?M].EQIE"_/20'6WY33 M#Y@9>^F[RO^__-\-SZ>C><[%R1L5F(_\P7;#=7[2>K"/?PA7.903D,Z__ M5_Q[OI)7B)??Z;/XO/F]V+@NTY2+[QX+TXCXH0^%[XD@$FXH)*'8/J*0A C% M4>BG_JS>X[&MM2">"XQWZ<'/Y"*YN+NXOIP^7X@=P,7WX!4QO/M<_ M7/[GKU>_3:\O;QXU7=R1/V*U/>_/^\%IVC#!V:2./;08G( M[Z!^!"_8_B]W MWZB% FNIP ]KN7Z<@(UH8"T;D,*!6CI[&_7'?"J6MOZ1F1_5F?B8#V;?/?D@ M+LQVMOI"YGB0_GU]X_*(R;P=+R$N#K@3P=##(41!',.$^S%T,451XHF1*"EO-.5BFZVLG&0P5_ZJ8 ZUKC-9=EMZ&8X*\VJXQ,)[#WOAM M;_DJ#L$@P9HX;_8[S' M[VH08 M./-\Y#$&O<1/((IB#K'O/Z[5!Z7W.S >J;ZD>\??IJGQ>2F/T>?F"L\4LC7V&TH1 BE-7G,/#%,:> M3V%"4C? "8LYU;H8.D5H8.O17 (+NF!#&/Q1DU94M%ZHU#P3&P#H69>6[/]' M[#,%RYKP;9_XVCY%GVR6'(>39$;U#OJ$W7I_7#]<^YEB>B![>7\AR/O.1 M'T21CV%(?0Z13PF,.6>0DSCUQ(F$TY2IJ.K!R@/K9D,+U,34E/%0^OY@M;%, M>NJF*(Y6J/HHZT:AZMV51@M5'Q6@':H^_H#99B9C"<*KYD+-V-7BC==Y&;?? M%N*[^9R]WG'QP0EOY8G/?$9<$B(,?0<'$'%/J$P8NY"[*4\3YJ8.=G1V-V7* M ZO4AB+(%N)UP0?X 1< @]>:@Q_UMCQU0-7VP$%@TM/2F@50\P"V3(A3^@:[ M+1_VMDAMT2WMF>IT1]U$M>'8WU7U%]"S*9RRV70^;\S35+K<3[Q*\VJ.60K6 MH6^-H=,7YG.PWI3:Q-5L0"\ W2IO4W8]#3\EML6CIJIP'3NU6*)17\JV6MN[ M\"A*JBK>6B>5GS>(:%WS)TS??^%X7CX_O!9*Q7@IWX6/_3^D[ Q?+E=4K+%9[/ MW^4US6_%)KE[>SFEZ RHK#6PP9$L\$51?5G!FI?J_@F\%7]M%4ZH>PE*"/5[ M"[;!T3-,RKA8SHG6E=S(I5 B,)IKH2-NV\70>D]?T6^6BQN^U'3O=UX:6'4% M+7AS>:OAO^^*U*^"QM+HZ=I:$,L>^5'NC?1E=Z71%..H &T-./Z 6;!LG>=Q MFU[B?"'\=IE_\_",<_X)%QF=+MCG;+Z2U?6[>1@T#BE#PL]&7/XGQ1Y,"!<. M>$JY%R=>$$=:H3-#/D;,@JGXJ-+S&D[ FE,9*0(5KWIQ-5/LU:)L(R"JI^]M M, ^AFQP!>,@$F#/AL127,^5BU"C=F5#MQ^S.74Y_3[\7U%R'!.XTSZ=L^2K6 M_C+'3ZJ[^XG7![8]DBJ09*';#F"!A@/U[?^4]/V.@ 7!]4Q$C\S@#TG>DI_0 M(YR1QW!JS=%\AQZAVEY$WZ,&@?)O.&?%Q7Q9\,?EU\5K)FL.*R56#I.?7&'H M('E%&%240;8 CUG=T>'KS=U5JQ)6)VA^&@R%D+D5'#0#YHH0-+NRK?AYKZ1F MT?/3RXX7.^\5;2=RWO^TF8?_F>?9&RZS-WZ=+?B5C(;-4LZH2^,(.FZ*(6*N M!TF$.,2,)H&?$"]VJ8[W?H3&P J[I0C^D#1!150SE^L8-&K.]9D"ZVFFKJS: MOG"'-);\W&,41O5A.T3<]T^['CTSO5+V?,IDP\59&J6.+[.U4C_U(/)P"G&8 MB/-SY%/'P21F.#%*K-R0&#J"7/4YDH'1=)EO>B!)^H;YE%MLU%3P/(GU-'"; M0RGVO[I*0] ;('/R0!;;.9-; A^3+7D@X,D\R<,G;::#%3.>1#Q)7 >Z@>L+ MO4L)3##','"FE M!1STE/-4+M=IJ2VE;=G>)$]1^1.D9)W<+/L>-^PVL"S*V_3GY9(5=_F2K6@I MM^+F B-@?D)3%$ >A6+KY&+73'R>P"B,W12%V'-2K:VSB]C@U[!%*<.A%?$J M]/G \[>,\@EH6&G_$GSB"_K\@O-_:A;V=Z&IIM2V,-+3;%-X!FA-HP* K?KT M+E+C5I,K"'U0^ZWRCGYLZ0Z__R;CQ')F@.R1OPU(J![=%%<9[MLLB(.WZL9C M37ZGQYK5DYVFL$8Q%I7U1PNV: C;CKKHO&;PI>4\_SE?KEZKUN35% MO2\7TY=2-2K:L\S >Y2D#BKRH*(/6@R >UZN\@68OBQ7J@W15(!1T&1[F&AJ M\?EPZ&FQFJ!F&MRS]GC:JR;DCN8JOG)FQ.;R.W[)%E4^V':C\;S C:.$09?001 M$O_!LFZ=^ %VP\AWF:>4/Z!'=NA\@IH/P!M&JCC%4K(":,T+F&^9T6GUHHQK MM^8.AY:>0J^!6O, !!.@X@(T;+1;C0T"E$ZGG"$ ,ZLIZQ-9&U[B M3.;CR:P/NBSD-(UG7 +A68-"<+<2YO-=7C(L9,,J\8;\PV8MX2<)8U2UFEV) M4U&+WD18#8"I$'(UK[B1W7Q+F5TBZ_#; M]/K72_#U]UDC"._K>@#<,DIRL9I21W)UOYK7MC+M.R$\91 !]6+)Q_4^VX5>7DDK9SS&_S"FU[KS$L#X/B![T&, ^'F MIRX)4H^EQ%&JW>@G-7CVS;;SK"2JV91> :IN?;0+@)YBZLNNK(SJ8G7M$6*5 MUOX@_K75304"HRBINJ!K;=5X0W]+J*Y(9#KM5XZED=5(;2:FV!'3(9;8#'UAMM^^L0IKWY=3UF=FK:G11U MA]^KH]NO!9^A@")"$Q<&B1-!%%,?QC'GD!+J$S],DXA'.B>FDY0&5K[=\N'E M9C3:7+*A6:]X&BVU Y,5##2U<7\6W)KJ1&8RV#LG]8IFZ8QTFLZHYZ->(:N0&5N5K.8=8 M,\[1@X^:WMJ36D]Y3PQT'"K6H2;F@%,9/RK:H2:XRJS%L^,=V^K&EY?EXJ$4 M*U4E)\7MJBQ*O) =[V=!B(.4Q D,>!Q"A%,$LP**BOH$++?TP0_9HOF]YC293@@9<2*6^CY,W)A!Q ,&XX &T/-9 MG+K(2R(WGKU6$X(?2IR7XP*Y3U@9SN9V;0((?\H658YEDTCXSG%N$S]*2)(0 M'T;<=2&BF,(XBA+HAV'J4H;8%K_+!?L(]-9D];'C,H6Z1JU>RB)N:AN.+23T MMIM&%Q]J77QH=+%%VF:5>[^ UJK<.TB-7.7>+_1AE;O".^=F0ZQ[HG+6;DM? MTVNF"/XW9[_*%.B*D]M7^?<[\>4I/KU??N4W\OLQ+J@QW-=AD.' M0A\A>8",0A@G#HG@3ZO,Y(EAH31>N[$(,Q^4"K%D,"? MSJP8E*KAR62.B^(V;<9"W^;WV=-S.?V>%;,H37$0103B-$ 0)6X$8^%9PX#$ MOA.([TFJ%VPX26GH,XFD*SW AK(L!JIH@S\D=4T[?!HO15_0!@J:CJ I /I^ M8)]PMIS DW3&]0#[Q#UP_WI?L!'W7Q<9O=\L%TUEVU]V3%AMR M %?T]?3[ !0U=3Y'5#WMK2D-HZFGI+"DF ?+CZJ'IX3;5[N3SYEIV3U_XXL5 M_R+XN6C*V7_/RN>+55$N7W@^)47UNYG+$I1X<019[(A].&0^C(D?PH Z-'6\ M)/1BK7U8D>[ NW'#!9 ?!UCS49?&KSD1OF;#BZ;#K8JLF@8/@)>>8EN"2EOI M-06W9 M4J8YJ(C2AV+<KN]3N\@.;!TG,)$WU!!9JFFXNH9Y":PBGK;3'9;"DFWN+CZJ"QP7; MU[033YDIU.]<'K8YF[X)?_N)WZQD!6HS,>[@+F;*_K&JQX,60\I!!QZD#,.('8B[ GC)>+';V\WV-4 MAH[U52GH9Y[XC\.C&,4[5VC-R%TE[Y 1@$Z!;,7GCM(8-R;7)>9!'*[S83V= M9#R;72[*K'Q_Q-^OF%@H2[.ZCT)M#691R!F2W6)YB!D4WCV!B1]$$$4!1PEU M21@'*GK92VEHOZ&B7;4^WJ7>;'UJ2MJ/5[>B6D5!3UF- 5!66F7A.@IEQ!JU MSHH?MJK:O_(HZJHLX%IEU5\PS<*7N;^;R!+Q8HS",(9N$'&AJS+U*6 QY"3% M 7)]&GI:)X#=Y0=6T'6*N6'T;0\*M?W27$ ]W5.7S2!Y_I@(UI+E=Q8?.3G^ MF&"'R?!'GS+LY9$MLI)?RT:L5POA]CYE9,[KG?;G?%D4,]]!V(]# J/(E0K& M&<0\;47>8G\/14%MM?CH(S=NEP]%X0\:?:B^=VYB<@>A.@LUH0EF@9S) MEQ!9QI$2&*?,A]2)8D:)@TBBE7*F3GI@D]!NYM6M$N=F!_=BK&8QAD%.SW;L M8S/9A6[ M%Q5F:VGV/82_J!T655 3J>^*J]@9F0>\ZJ&_KU56C&E_UIE.6>S M (5.PC&!Q!=./ I]%^*8>=!-,4EX&#E>JF55.F@-[5DTE/<+['!#WCQ0WX6? MFL6PA(J>B=@ LE?EM*9LSS@HB&?)&G11&E7]%43>UW>55PS3V,0A?WTU];"Y MF6K="B=)@%//B6%(60A1RGU919O (&5AD#AAR!*M4WH?P8%5O4T>;.D;M7M2 MQE!-TVTBHZ?N9X*BGRFG**FMS+D^X7%B4T-3#0N>+MC- M\;SYBGLTIH@[/DP2XD$4( \FQ D@ M]:GKI$XB?(50ZXAQ%CM#'SL:8H;VXDRH%4\:HP&H9VO4L=,_:%@1V=;AXSQF MQCV06 'NX)!B9U4S'$#BXPAR!^,X\2*7^8EQ M?*1-::SH2$7XC/C'#CH&T0]3F<^+?33]7GJG!IT7^C@FVQ"!CQTZ'Q?V."9N M9]#CZ M#NP;;5(64I\Q)*:0>01#%B,$XC2E$;IQBXE&2QEHWJ?HL#*SC%].' M7\"7Z]O?'\"7^]NOX/;N\G[Z>'7S,YA>/%[]=O5X=?GPMZ'IT/"_ MZ?A)P"L/ 22 B.(;$31$DPL>@#O:C*%0J?50C-[2O\/=C*KBR]NT^VM[[IG(9LASR%^@ET82I\?84H@1@Q!-_*= M.'#B$,?JX\]UJ0^L]-LJWV\U1P7@:]+Z*5EF^"J<'(9$3<](G.Q(.&E73&_K MSS@?WJ\6K*ZO4-2H8^\.?C]:D6QW/B\F\AY T,_> M,K;"8BE(;*^,I$\\(P4[NN!HVM4E3ENU.I\S;9W0.7@E M=KC+$L>'*4TY1&[J0ASY <0)<@*'(T1W#HAE%.!,1@^8*AC-L5#LL?/S<&CU1#WLM##"[1MJ.JT61B2<;$W*WG&=4 M^+QW^5)K.+S"*L-]6QOB8+W=K,D# 8Z\<*><#30Y7D-LH^U'9?W1=B,-8=N; MD\YK9N'M3ZM"K%34I4Y%)@_N3=73NK"&8R]*/>Q"YL2)V*ZB$":<>Y A%"0) M(YS%3"?$W4MQX!UK31^T&-A4W9F6)_7#J!;YM@J.GB4X%Q?M8+BRK)8"XOWT M1@V**XN_'QA7?]$@.-Z:EEYME[\NLK+))L6(IBF)."1L!63]/N 4HAGVQ%?3\';DE=$@:3: MGW2K);M&)-H.!F8QY^-86 HH]PO6&3KN>'V\('&_##OA8(7'#0*_[!^/2WGO M-WTIE:.]K7>&#O%NVI^"<@G:4]'$MOFR7'5TO>P652',:RBE9FSWI(!]\ND% M=X\(8Q;1;2\T7ACW"/L[L=MC?S=L),!8M=WC^1W.V-7B K]F)9ZW3KR+9I@372X#;1?0J/MM&/9T3;7 M?M':6ZW"TV8;[R7.%V+10KBY5?RXZ8B_*:KBW$T]PGSH!#(-U"$Q3!(70R]. MN$N3%'N>5NU:#[VA[W0:ZN"5YX#6.TR5!C:I)VRHYC*IHJ>V!5O$1/-"9PV' MH%Q?Y&S&7PQ29Z8HJ*6MMX_:J/NNHNC[FZ[J:P9'T*>G\N)Y\72W*!:_X?G5 MXF'U\E);E:)D[577CHP^S34\Z?<,G!Q7,U.5YX MF7?B>7GX$_RMJO:?4TI7+ZLYEM_\3WS!TZP$XM@/IG/AFHJM36YLU<1OL>G) MV;55A2:0DN']_:^Z9]YZ(V>-'!7F,$WD M^&/Z7L/%\H'/.146^&O57H-KG-"/O3O"V1POQ)>I(0P:RMKG]*-R]V_$YXJL MISFFTFIMAETB&>UW1Q<<;4OK$J>]:W4^9UB\C-^KW-?;5)9'7Q7%2EXR72R+ MLIC%/D&1DX8P#9C8I$CHP)BG,<04^<0/9&4FGRTJQXH]:I0TGR:I]+5,ZJ_E M 6'EK^AGGO)<]L1.LX4@+:-(5%+7+'CN0$[MR'TN$&;7U U1Z?)*LF!-%UQT M8J!?'=TOG:UBZ0Y*X]9.]XM\4$JM\(I!^0$FXB237V=%69U%M*MZ3BXP\%[9 MT 62\$3W%'M:ZOY-THK >IK8EK6I-0#62WMZY3*K/3BYZG@%"'V"[50A]#YL M.+\*9WD50+A:O*[*XIJ_\;F_SN=BA/N^PZ#K!@@BCA)(?"0GM#N)XS/7#U.M M3B =M 96RH?L:5&-T5N4X-?%DA0\?ZN^K34GX(>*%^!K#I;H D]M [4$B9[: M2J)UU&C2 # !#0 #=%A4$-'6Q*H.2N,.J^H7^6!.E<(K9AHN5ZV">M/Y?/E- M[LUK[_$1?Z^&U-0AQ:M%?;Z9N<([IE[L0N[$L6Q9XL(DHH%L;H!=-W$B["0& M3K,N'^-XTO?B.(*+*GSZMF80X#6'>N9 &VDU&S$(<$:&8\,)V+ R 9NSB!P3 MV\RRNEK0O(+UA\^\_NG'WI0W;<-BBHLE:Z--?E039 K.OETR7N?< 1CMZXA6 MB>NG]^TCS#3Z9=LRTKMMO/-2R"NF^"W:HZ^YA9 MG]-AS- 'S>HX%\#3\SK.7MFTG9VP#??\57REGR6-SZM<5A;R/%NRRD&=$1\3 M)TH]Z"H2TN0DH]'ON]\.H M:-ZLH&)FO:I=HD4;U,1!37U2'R%M]KY3%-5:_[L^>B/WP%,4_[ /GNJ+^F'8 MRW^5[]-O.2OL)39I+#E:2M//55NQS_+';7!$6H"FXV.]&=<>KOW<)1V0^^/ M ^&K9SN&A=9R8I(!8D8Q9QTZHT6A#81OQZ5-7K@"&(O()"Y+'3]($$!56IS996KH>U<>[)H ML>V3R!LNS2"-8- JAUHL5C9P".9X[;#9%9Q&W08 MK"Y/?X*)L88PJHV5-5WYY_)90ER,B1_ ( XY1 'S(79( M"",OB:+0Y2P@KHZ]/$IE8/NW'0!4Q_IEJHR>G3N.C9K=.EMB/3NT%;:B)P-[ M%45[!J53($L&XCB-416^4\Q]!>Y^V$PACW;0W89'O8"Y#L9RSK,K_I-@#C&G M 71C%B#QQ\A#6I,%NLD-K*(G6SR?$8+NP4]->^VAHJ?&9P*BK=1J$!#J^$T(4NQ@F$7%AQ!R4 M1#B.0[T*TF-$AE;RBB18TS3LI'84'45E/E-F3176%5=?:3ODL:6JQTB,JZ = M0AZH9=>SALJ(BV?Y_S)<]8;G,M/UGA=EGLDD=OF'Z8+M_J+UY(PBXE+?=V#L MI@Y$H5!=S(7J(DP#/PP#)Z#I[+4*U3Z4."\5=?<?0?7#Y7_^>O7;]/KRYO%!?"27XM>W M7\#=Y?W5[>R2Y:D[H#N'!GF_]5*?BP@J3.#*M!$36<8C4(LIJ3K(QQ MZ9YEI;_LB-.LC&7>G6=EOHR!#?_EXNJJHI>]<=DJM6BN_Q,W=-/4":#+4U^< M(J)JTF *.1/^K!\@RF-?V5"?(#*P-?[E ER!#=VJK:Y.6^53R"C860ORZAG3 M8Z*:M%,^);.&1;0@NYG9,\- SZSU"-=INTZ].YZ!ZN%^QPKU/6N86B'S^(N+ M59[+;-)UU[4X<2+?I01&D8PXIB&!2>I%4"*(7!IRZJ=:J1+'J SM^OUZ?R_. MN&#Z\'#Y^/ WS>R&H["H'5G/%E;/TM3DQ&&T)CA(V[E.D6PE!ARE,>Y%?Y>8 M!Q?WG0^;:>//RR7[ELWG,TI1Z!*"8!"P0)S*"('$=WS( IH@'@=AP*B. JX7 M'ECGUF3TE&TCM9I^FX?,3??\_*Y^?E7'9Q_;+,CU=,S"BB;D YARD*Q>X5Q"DD.!7N,L?,<=TX M]!/OC-8ONOPH?4_/+EZH4L&;4C#:3ILM\7?P;*G6MCK'?O,94U L=Z;19N-#VM:8@G6JIXWQ>H8I>.4SS^5Z.7^6 M_3K?N'#VER_\>ED4-[R\304;=5W'NL!Z75Z]\4[=A% ?\0CZ+L<0T="#Q M" MZ.$4^['O)L*AT,K7.YNE@;V-V\=?+N_!Q>W7N_O+7RYO'JY^NP0_7-\^//P( MKF[$KR\GX.;R4=YN/4[_2_, 8.'S4+. XZ*L9PLKWL .RGLDL\G*_\.TN7S[E^&5;[5ZG M1;LSW\>,>I3!!'LQ1-P+((X=##D2-M'UPH@QI=LM#9H#&[VZ-#/?L %>:SXF M &]K_;%&]1I]KZ@U@W:J:J>9ZR(NI(UA@)W*,E"8<"0M M0Q@A'*5>$&OE4)^D-+ ]6-.M*]6%%2BK(@?SPJ[3D*DY-%: T-/Y#0;-1/6: MZKH)BCUOI%ABP/7TW+!US-[/J_XX_)S5OQK MA>=56[^Z+$KX&LW8@T*CG[;)V@.K<\/2=C(46W$Y87&?K;73O>9,?ZRD$;#= M)F ,3/4LPV!P:E69GX.)4;FY$<'1ZL[/@:-=@'[6.OIG#N&BL!45JRS8 \_? M,LJ+I@2!<2\-8]^'OBPO1XR[,"9!"-/4#7J'.. Z<7GNT T"O>&V7O_]APPE\+Z_SY3NO MITO7K>W4^]+T+C*PWJWI[G3FTYRA=U)^-8_=BN@&I_33=RF3=8="^SV)>X6U M-3OO))UQI^;UB7LP+Z_W!3,E_(Y8"V"@/>4V??CH::GIE+JJ6:;BCVU.\:[)4W; M67I4Y3HFU+X^'7WFS(;]PLFE\Z6\1*F523<16SH,_"V65B+N,K]DCYL:IIG"PS-PZLQ#N:=^CL$M-VJ_QBI MC^G5WR'TR6;]7>^8J?85 7-Z[0$<%@4<@]CF%"*<<$AW"XL=@L[%Q)*1,69C5 -T M+EC[QNGL]0P3-?,EY9P5LEG9FLJ795XE"'Q93ZF;TC)[JWJ;S5*/^L)*Q9 3 MCT-$A:DB0>1!G^"0)ZX;I(G2_%A#^D-G)55),]OI?'A#6#/S4A-5-9LU(%;: MH;>*D;HYX@^;R7[I,O\1U!AN^ '3?@SULRS-D+"57*E)?=R<2C-H#E(I#9F9+Q:K/\,PC41PAE\'(Q2Y$GLP<8K(N/@V],$ZBB'"M$BB[ M[ V=9-0P6XV6M]/=M!D2J#M+Q.Z'JF8C/^ZCTC.AQSZ9]\GV@[F\>P 7>$Y7 M\_ISZ?L$]-OV#P*4K1[_=ID;=R# (, >3 \8AHIALZW#3-)U%NF,,(^@P$

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end XML 75 bios-20240930_htm.xml IDEA: XBRL DOCUMENT 0001014739 2024-01-01 2024-09-30 0001014739 2024-10-28 0001014739 2024-09-30 0001014739 2023-12-31 0001014739 2024-07-01 2024-09-30 0001014739 2023-07-01 2023-09-30 0001014739 2023-01-01 2023-09-30 0001014739 2022-12-31 0001014739 2023-09-30 0001014739 us-gaap:PreferredStockMember 2022-12-31 0001014739 us-gaap:CommonStockMember 2022-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2022-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001014739 us-gaap:RetainedEarningsMember 2022-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001014739 2023-01-01 2023-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001014739 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001014739 us-gaap:PreferredStockMember 2023-03-31 0001014739 us-gaap:CommonStockMember 2023-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2023-03-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001014739 us-gaap:RetainedEarningsMember 2023-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001014739 2023-03-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001014739 2023-04-01 2023-06-30 0001014739 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001014739 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001014739 us-gaap:PreferredStockMember 2023-06-30 0001014739 us-gaap:CommonStockMember 2023-06-30 0001014739 us-gaap:TreasuryStockCommonMember 2023-06-30 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001014739 us-gaap:RetainedEarningsMember 2023-06-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001014739 2023-06-30 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001014739 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001014739 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001014739 us-gaap:PreferredStockMember 2023-09-30 0001014739 us-gaap:CommonStockMember 2023-09-30 0001014739 us-gaap:TreasuryStockCommonMember 2023-09-30 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001014739 us-gaap:RetainedEarningsMember 2023-09-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001014739 us-gaap:PreferredStockMember 2023-12-31 0001014739 us-gaap:CommonStockMember 2023-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2023-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001014739 us-gaap:RetainedEarningsMember 2023-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001014739 2024-01-01 2024-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001014739 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001014739 us-gaap:PreferredStockMember 2024-03-31 0001014739 us-gaap:CommonStockMember 2024-03-31 0001014739 us-gaap:TreasuryStockCommonMember 2024-03-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001014739 us-gaap:RetainedEarningsMember 2024-03-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001014739 2024-03-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001014739 2024-04-01 2024-06-30 0001014739 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001014739 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001014739 us-gaap:PreferredStockMember 2024-06-30 0001014739 us-gaap:CommonStockMember 2024-06-30 0001014739 us-gaap:TreasuryStockCommonMember 2024-06-30 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001014739 us-gaap:RetainedEarningsMember 2024-06-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001014739 2024-06-30 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001014739 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001014739 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001014739 us-gaap:PreferredStockMember 2024-09-30 0001014739 us-gaap:CommonStockMember 2024-09-30 0001014739 us-gaap:TreasuryStockCommonMember 2024-09-30 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001014739 us-gaap:RetainedEarningsMember 2024-09-30 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001014739 bios:LegacyHealthSystemsMember 2024-09-30 0001014739 us-gaap:CorporateJointVentureMember 2024-07-01 2024-09-30 0001014739 us-gaap:CorporateJointVentureMember 2024-01-01 2024-09-30 0001014739 us-gaap:CorporateJointVentureMember 2023-07-01 2023-09-30 0001014739 us-gaap:CorporateJointVentureMember 2023-01-01 2023-09-30 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2024-07-01 2024-09-30 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2024-01-01 2024-09-30 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2023-07-01 2023-09-30 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2023-01-01 2023-09-30 0001014739 bios:GovernmentHealthcareProgramsMember bios:AccountsReceivableBenchmarkMember us-gaap:GovernmentContractsConcentrationRiskMember 2024-01-01 2024-09-30 0001014739 bios:GovernmentHealthcareProgramsMember bios:AccountsReceivableBenchmarkMember us-gaap:GovernmentContractsConcentrationRiskMember 2023-01-01 2023-12-31 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2024-07-01 2024-09-30 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2024-01-01 2024-09-30 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2023-01-01 2023-09-30 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2023-07-01 2023-09-30 0001014739 bios:CommercialCustomerMember 2024-07-01 2024-09-30 0001014739 bios:CommercialCustomerMember 2023-07-01 2023-09-30 0001014739 bios:CommercialCustomerMember 2024-01-01 2024-09-30 0001014739 bios:CommercialCustomerMember 2023-01-01 2023-09-30 0001014739 bios:GovernmentCustomerMember 2024-07-01 2024-09-30 0001014739 bios:GovernmentCustomerMember 2023-07-01 2023-09-30 0001014739 bios:GovernmentCustomerMember 2024-01-01 2024-09-30 0001014739 bios:GovernmentCustomerMember 2023-01-01 2023-09-30 0001014739 bios:PatientCustomerMember 2024-07-01 2024-09-30 0001014739 bios:PatientCustomerMember 2023-07-01 2023-09-30 0001014739 bios:PatientCustomerMember 2024-01-01 2024-09-30 0001014739 bios:PatientCustomerMember 2023-01-01 2023-09-30 0001014739 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-09-30 0001014739 bios:AmedisysIncMember 2023-06-26 2023-06-26 0001014739 us-gaap:StateAndLocalJurisdictionMember 2023-09-01 2023-09-30 0001014739 us-gaap:StateAndLocalJurisdictionMember 2024-09-30 0001014739 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001014739 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001014739 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001014739 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001014739 bios:RestrictedStockAwardMember 2024-07-01 2024-09-30 0001014739 bios:RestrictedStockAwardMember 2023-07-01 2023-09-30 0001014739 bios:RestrictedStockAwardMember 2024-01-01 2024-09-30 0001014739 bios:RestrictedStockAwardMember 2023-01-01 2023-09-30 0001014739 bios:PerformanceStockUnitMember 2024-07-01 2024-09-30 0001014739 bios:PerformanceStockUnitMember 2023-07-01 2023-09-30 0001014739 bios:PerformanceStockUnitMember 2024-01-01 2024-09-30 0001014739 bios:PerformanceStockUnitMember 2023-01-01 2023-09-30 0001014739 bios:AmedisysIncMember 2023-01-01 2023-09-30 0001014739 bios:InfusionPumpsMember 2024-09-30 0001014739 bios:InfusionPumpsMember 2023-12-31 0001014739 bios:EquipmentFurnitureAndOtherMember 2024-09-30 0001014739 bios:EquipmentFurnitureAndOtherMember 2023-12-31 0001014739 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001014739 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001014739 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-09-30 0001014739 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001014739 us-gaap:AssetUnderConstructionMember 2024-09-30 0001014739 us-gaap:AssetUnderConstructionMember 2023-12-31 0001014739 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001014739 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001014739 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001014739 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001014739 us-gaap:OperatingExpenseMember 2024-07-01 2024-09-30 0001014739 us-gaap:OperatingExpenseMember 2023-07-01 2023-09-30 0001014739 us-gaap:OperatingExpenseMember 2024-01-01 2024-09-30 0001014739 us-gaap:OperatingExpenseMember 2023-01-01 2023-09-30 0001014739 us-gaap:CustomerListsMember 2024-09-30 0001014739 us-gaap:CustomerListsMember 2023-12-31 0001014739 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0001014739 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001014739 us-gaap:OtherIntangibleAssetsMember 2024-09-30 0001014739 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember us-gaap:SeniorNotesMember 2024-09-30 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2024-09-30 0001014739 bios:SecondLienTermLoanMember us-gaap:SeniorNotesMember 2024-09-30 0001014739 us-gaap:RevolvingCreditFacilityMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:SecondLienTermLoanMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-05-07 2024-05-07 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-05-08 2024-05-08 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-05-08 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-07-01 2024-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-01-01 2024-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2023-07-01 2023-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2023-01-01 2023-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2024-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2024-07-01 2024-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2024-01-01 2024-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2023-01-01 2023-09-30 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2023-07-01 2023-09-30 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-01-01 2024-09-30 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2024-01-01 2024-09-30 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2024-05-08 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:SeniorNotesMember 2024-09-30 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2024-09-30 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember 2024-09-30 0001014739 us-gaap:SeniorNotesMember 2024-09-30 0001014739 us-gaap:FairValueInputsLevel1Member us-gaap:SeniorNotesMember 2024-09-30 0001014739 us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2024-09-30 0001014739 us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember 2024-09-30 0001014739 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001014739 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001014739 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001014739 us-gaap:RevolvingCreditFacilityMember bios:SecondLienCreditAgreementMemberMember us-gaap:SeniorNotesMember 2023-12-07 0001014739 us-gaap:RevolvingCreditFacilityMember bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorNotesMember 2024-09-30 0001014739 us-gaap:RevolvingCreditFacilityMember bios:SecondLienCreditAgreementMemberMember us-gaap:SeniorNotesMember 2024-09-30 0001014739 bios:FirstLienTermLoanMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2021-10-31 0001014739 bios:FirstLienTermLoanMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2021-10-01 2021-10-31 0001014739 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001014739 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001014739 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001014739 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001014739 us-gaap:InterestRateCapMember 2024-07-01 2024-09-30 0001014739 us-gaap:InterestRateCapMember 2023-07-01 2023-09-30 0001014739 us-gaap:InterestRateCapMember 2024-01-01 2024-09-30 0001014739 us-gaap:InterestRateCapMember 2023-01-01 2023-09-30 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2024-07-01 2024-09-30 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2024-01-01 2024-09-30 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0001014739 bios:A2018PlanMember 2021-05-31 0001014739 bios:A2018PlanMember 2024-05-01 2024-05-31 0001014739 2024-05-31 0001014739 bios:HCIIncentiveUnitsMember bios:A2018PlanMember 2024-07-01 2024-09-30 0001014739 bios:HCIIncentiveUnitsMember bios:A2018PlanMember 2024-01-01 2024-09-30 0001014739 bios:HCIIncentiveUnitsMember bios:A2018PlanMember 2023-07-01 2023-09-30 0001014739 bios:HCIIncentiveUnitsMember bios:A2018PlanMember 2023-01-01 2023-09-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2023-12-31 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2024-09-30 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2024-09-30 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2023-12-31 0001014739 bios:CommonStockRepurchaseProgramMember 2024-09-30 0001014739 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001014739 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001014739 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001014739 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001014739 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001014739 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001014739 us-gaap:CorporateJointVentureMember 2024-09-30 0001014739 us-gaap:CorporateJointVentureMember 2023-12-31 shares iso4217:USD iso4217:USD shares bios:pharmacy bios:suite bios:segment pure 0001014739 --12-31 2024 Q3 false 10-Q true 2024-09-30 false 001-11993 OPTION CARE HEALTH, INC. DE 05-0489664 3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015 312 940-2443 Common Stock, $0.0001 par value per share OPCH NASDAQ Yes Yes Large Accelerated Filer false false false 170181238 483026000 343849000 428951000 377658000 310599000 274004000 98798000 98744000 1321374000 1094255000 125911000 120630000 89210000 84159000 17768000 20092000 291839000 315304000 1540246000 1540246000 41379000 42349000 2106353000 2122780000 3427727000 3217035000 591971000 426513000 60835000 92508000 81893000 75010000 22013000 18278000 6512000 6000000 763224000 618309000 1105106000 1056650000 87879000 85484000 45008000 34920000 279000 0 1238272000 1177054000 2001496000 1795363000 0.0001 0.0001 12500000 12500000 0 0 0 0 0.0001 0.0001 250000000 250000000 183793536 170146331 182905559 174575537 18000 18000 13647205 8330022 416552000 255107000 1224059000 1204270000 609203000 457513000 9503000 14978000 1426231000 1421672000 3427727000 3217035000 1278546000 1093014000 3651784000 3177934000 1021797000 838748000 2907170000 2443834000 256749000 254266000 744614000 734100000 156999000 158214000 465524000 459644000 14659000 15005000 44294000 44417000 171658000 173219000 509818000 504061000 85091000 81047000 234796000 230039000 12345000 11786000 38150000 38816000 1391000 1273000 3921000 4107000 -583000 -449000 1983000 84487000 -11537000 -10962000 -32246000 49778000 73554000 70085000 202550000 279817000 19698000 13783000 50860000 69904000 53856000 56302000 151690000 209913000 -1998000 -8000 -1785000 -57000 -6127000 53000 -5475000 -99000 -6127000 53000 -5475000 -99000 47729000 56355000 146215000 209814000 0.32 0.31 0.88 1.17 0.31 0.31 0.87 1.16 170636000 178826000 172490000 179956000 171941000 180528000 173848000 181286000 151690000 209913000 46029000 46423000 17892000 14610000 10088000 11767000 -377000 0 3465000 3312000 3921000 4107000 27620000 22908000 1250000 4000000 -1845000 1769000 51293000 5075000 36595000 28362000 3175000 -3197000 164754000 50726000 -31673000 4197000 5560000 9829000 16833000 13019000 -3880000 11762000 287270000 320326000 25266000 21981000 0 12855000 0 5889000 -25266000 -40725000 11235000 1940000 4756000 4500000 49959000 0 77000 0 160122000 175108000 3404000 -5750000 -122827000 -187298000 139177000 92303000 343849000 294186000 483026000 386489000 48666000 46377000 45258000 53699000 21861000 20272000 0 18000 -2403000 1176906000 190423000 21159000 1386103000 1902000 1902000 5988000 5988000 75735000 75735000 39208000 39208000 -3443000 -3443000 0 18000 -78138000 1180992000 229631000 17716000 1350219000 247000 247000 7685000 7685000 -32000 -32000 114403000 114403000 3291000 3291000 0 18000 -78106000 1188430000 344034000 21007000 1475383000 -209000 -209000 9235000 9235000 101099000 101099000 56302000 56302000 53000 53000 0 18000 -179205000 1197874000 400336000 21060000 1440083000 0 18000 -255107000 1204270000 457513000 14978000 1421672000 8182000 8182000 9605000 9605000 40289000 40289000 44791000 44791000 1551000 1551000 0 18000 -295396000 1205693000 502304000 16529000 1429148000 -1299000 -1299000 7608000 7608000 78768000 78768000 53043000 53043000 -899000 -899000 0 18000 -374164000 1214600000 555347000 15630000 1411431000 948000 948000 10407000 10407000 42388000 42388000 53856000 53856000 -6127000 -6127000 0 18000 -416552000 1224059000 609203000 9503000 1426231000 NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Organization and Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 92 full service pharmacies and 93 stand-alone ambulatory infusion suites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. The Company’s stock is listed on the Nasdaq Global Select Market as of September 30, 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income. See Equity-Method Investments within Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company’s equity-method investments.</span></div> 92 93 1 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2023 audited consolidated financial statements, including the notes thereto, as presented in our Form 10-K.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div> 0.50 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of September 30, 2024, cash equivalents consisted of money market funds.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $45.9 million and $52.0 million as of September 30, 2024 and December 31, 2023, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the balance of the investments was $23.6 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $3.9 million for the three and nine months ended September 30, 2024, respectively. The Company’s proportionate share of earnings was $1.3 million and $4.1 million for the three and nine months ended September 30, 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% for the three and nine months ended September 30, 2024. Revenue related to the Company’s largest payer was approximately 14% for the three and nine months ended September 30, 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2023, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 10%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12%, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, approximately 68% and 67%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. For the three and nine months ended September 30, 2023, approximately 73% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery, losses in revenue or decreased gross profit dollars, which could adversely affect the Company’s financial condition or operating results.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of September 30, 2024, cash equivalents consisted of money market funds.</span></div> 45900000 52000000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the balance of the investments was $23.6 million and $20.9 million, respectively. The balance of these investments is increased to reflect the Company’s capital contributions and equity in earnings of the investees. The balance of these investments is decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $1.4 million and $3.9 million for the three and nine months ended September 30, 2024, respectively. The Company’s proportionate share of earnings was $1.3 million and $4.1 million for the three and nine months ended September 30, 2023, respectively. Distributions from the investees are treated as cash inflows from operating activities in the unaudited condensed consolidated statements of cash flows. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div> 23600000 20900000 1400000 3900000 1300000 4100000 500000 1300000 1500000 4000000.0 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15% for the three and nine months ended September 30, 2024. Revenue related to the Company’s largest payer was approximately 14% for the three and nine months ended September 30, 2023. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2023, approximately 11% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 10%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12%, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients or other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, approximately 68% and 67%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. For the three and nine months ended September 30, 2023, approximately 73% of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery, losses in revenue or decreased gross profit dollars, which could adversely affect the Company’s financial condition or operating results.</span></div> 0.15 0.15 0.14 0.14 0.11 0.12 0.11 0.12 0.10 0.12 0.68 0.67 0.73 0.73 REVENUE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957,601 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,160,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,765,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,278,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,093,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,651,784 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,177,934 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">957,601 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,160,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,765,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,278,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,093,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,651,784 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,177,934 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1109971000 957601000 3160490000 2765513000 147005000 124122000 424033000 370648000 21570000 11291000 67261000 41773000 1278546000 1093014000 3651784000 3177934000 INCOME TAXES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, the Company recorded tax expense of $19.7 million and $50.9 million, respectively, which represents an effective tax rate of 26.8% and 25.1%, respectively. The variance in the Company’s effective tax rate of 26.8% and 25.1% for the three and nine months ended September 30, 2024, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. During the nine months ended September 30, 2024, the Company released $2.2 million of state valuation allowance. On June 26, 2023, the Company entered into an agreement to terminate the merger agreement (the “Mutual Termination Agreement”) with Amedisys, Inc. (“Amedisys”). Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys (“Termination Fee”). During the three months ended September 30, 2023, the Company recorded tax expense of $13.8 million. During the nine months ended September 30, 2023, the Company recorded tax expense of $69.9 million, which includes $22.1 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. The tax expense for the three and nine months ended September 30, 2023 represents an effective tax rate of 19.7% and 25.0%, respectively. The variance in the Company’s effective tax rate of 19.7% and 25.0% for the three and nine months ended September 30, 2023, respectively, compared to the federal statutory rate of 21%, is primarily attributable to the difference between federal and state tax rates, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 26.8% for the three months ended September 30, 2024, compared to 19.7% for the three months ended September 30, 2023 was primarily due to change in state valuation allowance. In September 2023, the Company released $5.8 million of state valuation allowance.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a valuation allowance of $4.2 million against certain state net operating losses. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. In making this assessment, the Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income, and tax-planning strategies. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s tax expense of $19.7 million and $50.9 million for the three and nine months ended September 30, 2024, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense. The Company’s tax expense of $13.8 million and $69.9 million for the three and nine months ended September 30, 2023, respectively, consists of quarterly federal and state tax liabilities as well as recognized deferred federal and state tax expense.</span></div>The Company has accumulated federal net operating loss carryovers that are subject to one or more Internal Revenue Code (“Code”) Section 382 limitations. This may limit the Company’s ability to utilize its federal net operating losses 19700000 50900000 0.268 0.251 0.268 0.251 -2200000 106000000 13800000 69900000 22100000 0.197 0.250 0.197 0.250 0.268 0.197 -5800000 4200000 19700000 50900000 13800000 69900000 EARNINGS PER SHARE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three and nine months ended September 30, 2024 and 2023 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855,323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,180,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,941 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,528 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,848 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,286 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855,323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,180,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 779876 984567 855323 1180376 324877 16564 365835 569831 0 0 257735 288680 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,856 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,956 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,941 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,528 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,848 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,286 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per common share: </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.31 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net income for the nine months ended September 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.</span></div> 53856000 56302000 151690000 209913000 170636000 178826000 172490000 179956000 0.32 0.31 0.88 1.17 62800000 53856000 56302000 151690000 209913000 170636000 178826000 172490000 179956000 1305000 1702000 1358000 1330000 171941000 180528000 173848000 181286000 0.31 0.31 0.87 1.16 62800000 LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, the Company incurred operating lease expenses of $8.6 million and $25.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2023, the Company incurred operating lease expenses of $7.8 million and $22.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of September 30, 2024, the weighted-average remaining lease term was 6.5 years and the weighted-average discount rate was 6.49%.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. During the nine months ended September 30, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of September 30, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div> LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, the Company incurred operating lease expenses of $8.6 million and $25.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2023, the Company incurred operating lease expenses of $7.8 million and $22.3 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income. As of September 30, 2024, the weighted-average remaining lease term was 6.5 years and the weighted-average discount rate was 6.49%.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. During the nine months ended September 30, 2023, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the unaudited condensed consolidated statements of cash flow o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lated to increases in the operating lease right-of-use assets and operating lease liabilities. As of September 30, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div> 8600000 25300000 7800000 22300000 P6Y6M 0.0649 <div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7464000 28646000 25880000 20554000 13517000 43813000 139874000 29982000 109892000 23000000.0 26100000 PROPERTY AND EQUIPMENT<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,911 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,630 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,631 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,981 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,671 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,911 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,630 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2024 and 2023 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,006 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,631 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,981 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,220 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,671 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 36476000 36943000 30124000 23593000 117827000 99725000 52513000 50572000 26007000 33668000 262947000 244501000 137036000 123871000 125911000 120630000 568000 616000 1735000 2006000 6063000 6365000 18485000 18665000 6631000 6981000 20220000 20671000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in the carrying amount of goodwill for the three and nine months ended September 30, 2024.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(244,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,607 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $8.6 million and $25.8 million for the three and nine months ended September 30, 2024, respectively. Amortization expense for intangible assets was $8.6 million and $25.6 million for the three and nine months ended September 30, 2023, respectively.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(244,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,607 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 514388000 514388000 39136000 39136000 985000 995000 554509000 554519000 222549000 199084000 21874000 19698000 479000 341000 244902000 219123000 309607000 335396000 8600000 25800000 8600000 25600000 INDEBTEDNESS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of September 30, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,133,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,741)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,618 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,105,106 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2023 (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2024, the Company entered into the third amendment to the amended and restated First Lien Credit Agreement (the “Third Amendment”). The Third Amendment, among other things, reduces the interest rate on the First Lien Term Loan from Term Secured Overnight Financing Rate (“SOFR”) (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25%, increases borrowings by $50.0 million, and removes the credit spread adjustment with respect to such First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on the First Lien Term Loan was 7.50% and 8.21% as of September 30, 2024 and December 31, 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.56% and 7.84% for the three and nine months ended September 30, 2024, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 8.11% and 7.71% for the three and nine months ended September 30, 2023, respectively. The interest rate on the Senior Notes was 4.375% as of September 30, 2024 and December 31, 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three and nine months ended September 30, 2024. The weighted average interest rate incurred on the Senior Notes was 4.375% for the three and nine months ended September 30, 2023.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed whether the repayment of the First Lien Term Loan indebtedness resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the First Lien Term Loan and Senior Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $0.4 million of the First Lien Term Loan was extinguished. The First Lien Term Loan had insubstantial modifications for lenders that participated in both debt instruments, which resulted in a cash inflow from financing activities of $50.0 million in the unaudited condensed consolidated statements of cash flows. The Company incurred $1.6 million in fees, of which $0.1 million was capitalized, relative to the First Lien Term Loan and an immaterial amount of the total fees incurred was netted against the $50.0 million of debt proceeds as financing activities within the unaudited condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a loss on extinguishment of debt of $0.4 million included in the line entitled “Other, net” in the unaudited condensed consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,628 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,133,244 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024 and 2023, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of September 30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,827 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2023, the Company entered into the second amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (the “Second Amendment”). The Second Amendment, among other things, provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of $400.0 million (the “Revolver Facility”), pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company. As of September 30, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of September 30, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,133,244 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,741)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,618 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,105,106 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2023 (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 0 633244000 5885000 8030000 619329000 500000000 0 7711000 492289000 1133244000 5885000 15741000 1111618000 6512000 1105106000 0 0 0 0 588000000 6974000 9678000 571348000 500000000 0 8698000 491302000 1088000000 6974000 18376000 1062650000 6000000 1056650000 0.0275 0.0225 50000000 0.0750 0.0821 0.0756 0.0784 0.0811 0.0771 0.04375 0.04375 0.04375 0.04375 0.04375 0.04375 400000 50000000 1600000 100000 50000000 -400000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,628 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,133,244 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1628000 6512000 6512000 6512000 612080000 500000000 1133244000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of September 30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,827 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109,827 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 619329000 0 634827000 0 492289000 0 475000000 0 1111618000 0 1109827000 0 400000000 4100000 395900000 DERIVATIVE INSTRUMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300 million for a 5-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,669 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (loss) gain associated with the change in the fair value of the effective portion of the hedging instrument is recorded in other comprehensive (loss) income. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,056 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 300000000 P5Y <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,223 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,669 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7223000 9746000 5446000 10183000 12669000 19929000 The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income recognized in the Company’s unaudited condensed consolidated statements of comprehensive income related to the Company’s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,056 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -8125000 45000 -7260000 -156000 3056000 2931000 9005000 8002000 FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value at September 30, 2024 and December 31, 2023.</span></div> FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s condensed consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value at September 30, 2024 and December 31, 2023.</span></div> COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</span></div> STOCK-BASED INCENTIVE COMPENSATION<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip, Inc. (“BioScrip”) stockholders on May 3, 2018 and amended and restated on May 19, 2021 and May 15, 2024, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Compensation Committee, a standing committee of the Company’s Board of Directors. As of May 2021, a total of 9,101,734 shares of common stock were authorized for issuance under the 2018 Plan. In May 2024, an additional 4,000,000 shares were authorized for issuance under the 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance. The Company had stock options, restricted stock units and performance stock units outstanding related to the 2018 Plan as of September 30, 2024 and 2023. During the three and nine months ended September 30, 2024, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $10.4 million and $27.6 million, respectively. During the three and nine months ended September 30, 2023, total stock-based incentive compensation expense recognized by the Company related to the 2018 Plan was $9.2 million and $22.9 million, respectively.</span></div> 9101734 4000000 13101734 10400000 27600000 9200000 22900000 STOCKHOLDERS’ EQUITY<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— During the three and nine months ended September 30, 2024, warrant holders did not elect to exercise any warrants to purchase shares of common stock. During the three and nine months ended September 30, 2023, warrant holders elected to exercise 188,350 warrants to purchase shares of common stock. As of September 30, 2024 and December 31, 2023, the remaining warrant holders are entitled to purchase 51,838 shares of common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— During the three and nine months ended September 30, 2024, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. During the three and nine months ended September 30, 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. As of September 30, 2024 and December 31, 2023, the remaining warrant holders are entitled to purchase 11,775 and 13,888 shares of common stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company’s Board of Directors approved a share repurchase program of up to an aggregate $500.0 million of common stock of the Company. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, the Company purchased 1,399,674 and 5,317,183 shares of common stock for an average share price of $29.97 and $30.09, totaling $41.9 million and $160.0 million, respectively. During the three and nine months ended September 30, 2023, the Company purchased 2,913,520 and 5,388,686 shares of common stock for an average share price of $34.32 and $32.48, totaling $100.0 million and $175.0 million, respectively. All repurchased shares became treasury stock. As of September 30, 2024, the Company is authorized to repurchase up to a remaining $90.0 million of common stock of the Company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The following table shows the Company’s changes in shares of common stock for the three and nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance March 31,</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,816 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,757 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30,</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30,</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,129 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 188350 188350 51838 51838 0 0 0 0 11775 13888 500000000 1399674 5317183 29.97 30.09 41900000 160000000.0 2913520 5388686 34.32 32.48 100000000.0 175000000.0 90000000.0 The following table shows the Company’s changes in shares of common stock for the three and nine months ended September 30, 2024 and 2023 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance March 31,</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,816 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,757 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30,</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30,</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177,129 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 174576000 181958000 492000 274000 1252000 2475000 173816000 179757000 261000 114000 2666000 0 171411000 179871000 135000 172000 1400000 2914000 170146000 177129000 RELATED-PARTY TRANSACTIONS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Equity-Method Investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $1.6 million and $4.5 million for the three and nine months ended September 30, 2024, respectively. The Company recorded management fee income of $1.3 million and $3.9 million for the three and nine months ended September 30, 2023, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income. During the three and nine months ended September 30, 2024, the Company received distributions from the investees of $0.5 million and $1.3 million, respectively. During the three and nine months ended September 30, 2023, the Company received distributions from the investees of $1.5 million and $4.0 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had amounts due from its joint ventures of $0.6 million and due to its joint ventures of $0.8 million as of September 30, 2024. The Company had amounts due from its joint ventures of $0.1 million and due to its joint ventures of $0.5 million as of December 31, 2023. Receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. Payables were included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.</span></div> 1600000 4500000 1300000 3900000 500000 1300000 1500000 4000000.0 600000 800000 100000 500000 false false false false